Applications of Allyl and Alkenyl Zirconocenes and Progress Toward the Total Synthesisof Tuberostemonone by Pierce, Joshua Glenn
Applications of Allyl and Alkenyl Zirconocenes and Progress Toward the Total Synthesis 
of Tuberostemonone 
 
 
 
 
 
 
 
 
by 
Joshua Glenn Pierce 
B.S. Chemistry, University of Pittsburgh, 2003 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
Arts and Sciences in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2008 
 
 
  
Professo
Professo
Professor Alexand  
Joel S. Gree
 Dissertation Adv
 UNIVERSITY OF PITTSBURGH 
Faculty of Arts and Sciences 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
Joshua Glenn Pierce 
 
 
 
It was defended on 
November 17th, 2008 
and approved by 
 
r Dennis P. Curran, Department of Chemistry 
r Scott G. Nelson, Department of Chemistry 
er Doemling, Department of Pharmaceutical Sciences
nberger, MD, Department of Radiation Oncology 
 
isor: Professor Peter Wipf, Department of Chemistry - ii -  
 - iii -  
Copyright © by Joshua Glenn Pierce 
2008 
  
emplo
synth
zircon
functi
the co
transf
agent
again
prom
Stemo
 Applications of Allyl and Alkenyl Zirconocenes and Progress Toward the Total
Synthesis of Tuberostemonone 
 
Joshua G. Pierce, PhD 
University of Pittsburgh, 2008This dissertation describes the development of several novel chemical reactions 
ying allyl and alkenyl zirconocenes.  These diverse nucleophiles were employed in the 
esis of a variety of biologically and chemically important molecules.  Initially, allyl 
ocenes were employed for the addition to imines, thereby providing rapid access to 
onalized homoallylic amines.  We were later able to employ alkenyl zirconocenes in both 
nstruction of C-glycosidic bonds and the addition to chiral imines.  The power of these 
ormations was realized by a rapid and stereoselective synthesis of an immunostimulant 
 and its analogs.  Biological evaluation of these compounds showed encouraging activity 
st malaria.  Small molecule radioprotectant agents have also been developed and show 
ising potential for therapeutic use.  Finally, we were able to install key stereocenters of the 
na alkaloid tuberostemonone. 
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1. HYDROZIRCONATION-TRANSMETALLATION-IMINE ADDITION OF 
ALLENES 
1.1 INTRODUCTION 
1.1.1 Hydrozirconation of Allenes  
Cp2ZrHCl was first prepared by Wailes and Weigold in 19701 and subsequently 
used to hydrozirconate alkenes2 and alkynes.3  The resulting alkyl-4 and 
alkenylzirconocenes5 have been treated with inorganic electrophiles, and transmetallated 
(from Zr to Al) to increase their reactivity toward organic electrophiles.6  Zirconocene 
hydrochloride, also known as Schwartz reagent is a reactive metal hydride reagent that can 
be handled in air and stored for several weeks in an airtight container.7   
Reaction of Cp2ZrHCl with alkynes proceeds within 10 minutes in both CH2Cl2 
and THF; however, hydrozirconation in toluene proceeds much slower and requires 
heating to provide reasonable reaction rates.  Hydrozirconation of alkenes proceeds slower 
than alkynes while the hydrozirconation of allenes occurs rapidly at room temperature.  
Unlike the reaction of Cp2ZrHCl with alkynes and alkenes, the reagent must be added to a 
solution of allene at -78 °C, reportedly due to the reaction of Cp2ZrHCl with CH2Cl2 at 
room temperature.8 It is unclear where this hypothesis arose since this side reaction is not 
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problematic in other hydrozirconation reactions.  A more reasonable explanation may be 
that the lower temperature allows for a slower hydrozirconation, thereby providing a more 
regioselective reaction and fewer side products.   
Suzuki and co-workers were first to hydrozirconate allenes to generate 
allylzirconocenes (Schemes 1-1 and 1-2).8,9 Targeting the synthesis of  three-carbon 
dianion equivalents such as 1-2, these authors investigated hydrozirconation of 
tributylstannyl allene 1-1 as a selective method to generate Sn/Zr-bimetallic species.   
Upon successful hydrozirconation and subsequent addition to aldehydes or ketones, 
Bu3Sn
•
Cp2ZrHCl
O
HR
R
Bu3Sn ZrCp2Cl
H -78 °C, 1 h
64-86% yield
R
OH
SnBu3
elimination
1-1 1-2
1-3
 
Scheme 1-1. One pot diene synthesis via hydrozirconation-aldehyde addition-elimination of stannyl allenes. 
 
spontaneous elimination of the stannyl and oxy functions was observed to afford the 1,3-
diene products 1-3 (Scheme 1-1).  To further drive elimination to completion, protic or 
Lewis acids were employed, allowing for a high yielding, one pot synthesis of (E)-1,3-
dienes.     
 Furthering the scope of this methodology, Suzuki and co-workers hydrozirconated 
a variety of mono- and di-substituted allenes to generate allyl zirconocenes that react with 
aldehydes and ketones in high yield and diastereoselectivity (Scheme 1-2).8  A chair-like 
 - 2 -  
• OMOM
1. Cp2ZrHCl
2. RCHO R
OH
OMOM
77-95% yield, > 95:5 dr
ZrCp2ClO
H
RR
H
TS =
1-4 1-6
1-5  
Scheme 1-2. Hydrozirconation of allenes and addition to aldehydes. 
 
transition state 1-5 was proposed by the authors to account for the anti-stereoselectivity 
observed in all known cases.  The high reactivity of these allylic zirconocene species 
should be noted as they, along with acyl zirconocenes, are the only zirconocene species to 
react with aldehydes or ketones without catalysis. 
 Since its development in 1993 by Suzuki, allene hydrozirconation saw little 
attention until the work of Huang and co-workers in 2004.10a  Revisiting this process, 
these authors were able to readily hydrozirconate trimethylsilyl-substituted terminal 
allenes 1-7 and found that the addition of these compounds to aldehydes was analogous to 
that of the tributyltin-substituted allenes previously reported by Suzuki, yielding 1,3-
dienes 1-9 in high yield and selectivity (Scheme 1-3).  Interestingly, since the allenes used 
in this study were 1,1-disubstituted, unsatisfactory results were obtained when the 
substituent on the allene was bulky, or when ketones were employed as electrophiles. This 
result is in contrast to the rapid reaction of ketones with mono-substituted allenes 
previously studied by Suzuki.   
In light of this lower reactivity at the γ-position, transmetalation of the 
allylzirconocene species to copper was envisioned, followed by reaction with enones at  
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TMS
•
Cp2ZrHCl
O
HR' R'
TMS
ZrCp2Cl
H -78 °C, 1 h
64-86% yield
O
R1R2
CuBr•SMe2 (15 mol%)
R2 O
R1
62-86% yield, 9:1 E:Z ratio
R R
TMS
R'
R
1-7
1-8 1-9
1-10
 
Scheme 1-3. Undesired elimination to yield 1-9 and transmetallation of allylzirconocene 1-8. 
 
the α-position.  Wipf and co-workers reported the first addition of alkylzirconocenes to 
enones with catalytic CuBr•SMe2 in 1996.7c Applying these conditions to allylzirconocene 
1-8 provided a conjugate addition reaction with high regio- and stereoselectivity as long as 
R2 was an aromatic group (Scheme 1-3).  This served as the first example of 
transmetalation of an allylzirconocene to generate another allylmetal species.7c 
Subsequently, transmetalation with CuCN has been utilized for the addition of 
allylzirconocenes to imines.10b   
1.1.2  Additional Methods for Generation of Allylzirconocenes 
Taguchi and Hanzawa reported that the reaction of zirconocene-olefin complexes 
with allylic ethers provides allylzirconocene 1-13 after ligand exchange and β-elimination 
(Scheme 1-4).11  They were able to react these allylmetals with aldehydes to furnish 
homoallylic alcohols in high yield and moderate diastereoselectivity.  However, 
preparation of the previously mentioned allenes or zirconocene (II) reagent is, in many  
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OR
Et
Cp2Zr
ligand exchange
Cp2Zr OR
β-elimination Cp2Zr
RO
1-11 1-12 1-13  
Scheme 1-4. Generation of allylzirconocene via reaction of zirconocene-olefin complexes with allylic 
ethers. 
 
cases not trivial, and the development of a straightforward route to allylzirconocenes 
would be desirable.  Addressing this problem, Oshima and co-workers proposed the 
synthesis of allylzirconocenes from readily available terminal alkenes (Scheme 1-5).12  
While the zirconocene-olefin complex 1-15 delivers both a hydride and an allyl group to 
acid chlorides to generate homoallylic alcohols, reactions with aldehydes generate 
mixtures of reduced and allylated products.  To circumvent the hydride reduction 
                
R MgBr
(6 equiv)
Cp2ZrCl2(3 equiv.)
Toluene
0 °C
H
Cp2Zr
Cp2Zr
H
RCHO
R OH
R
HO
+
PhCOCl
bulky
ketone
Ph
HO H
Cp2Zr
OR R'CHO
R'
OH
1-15 1-16
1-14
1-17 1-18  
Scheme 1-5. Study of the reactivity of zirconocene-olefin complexes with electrophiles. 
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Table 1-1.  Aldimine addition of allylzirconocenes generated from zirconocene-olefin complexes. 
Cp2Zr CH3
OCH(i-Pr)2 + N Ph
R H
Toluene
CH3
HN Ph
R
1-19
1-20  
 
 
entry imine      yield (%)        anti/syn 
 
     
1 
 
N
Bn
 
 
 
67 
 
 
11/89 
 
       
2 
 
N Bn
 
 
 
73 
 
 
17/83 
 
pathway, the authors envisioned a reaction of the zirconocene-olefin complex with a bulky 
ketone to generate an allylzirconocene reagent 1-17 via hydride reduction, followed by 
addition of this species to aldehydes. Applying this method proved successful, generating 
anti-homoallylic alcohols 1-18 in high yield (Scheme 1-5). Surprisingly, when the reaction 
mixture was warmed to room temperature before aqueous workup, the reverse selectivity 
was observed, yielding syn-homoallylic alcohols.  Extending the addition to aldimines also 
was efficient; however, these reactions favored the syn-addition products in all reported 
examples (Table 1-1).  This report is the first and only example of allylzirconocenes 
reacting with aldimines without catalysis to furnish homoallylic amines.   
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1.1.3 Allylzinc Additions to Imines 
The addition of organometallics to aldimines has traditionally been limited to 
strongly basic reagents that do not tolerate sensitive functionality.  The much higher 
reactivity of allyl organometallics reduces this problem and allows for the synthesis of 
homoallylic amines under mild conditions.13  Among the many metals employed for this 
reaction, zinc stands out due to its reactivity, selectivity, and ease of preparation.  These 
points are well demonstrated in Williams’ synthesis of (+)-negamycin (Scheme 1-6).14  
Although various allylmetal reagents were screened with a variety of Lewis acids,  
 
Ph
Ph
CbzN
O
Ph
Ph
N
Bn
H CeCl3, THF, -40 °C
BrZn
CbzN
O
N
CeCl3
Bn
N
Cbz
OPh
Ph
H
N Bn
H2N
O
N
H
N
CH3 O
OH
NH2OH
(+)-Negamycin
1-21 1-22
1-23
H
 
Scheme 1-6. Application of allylzinc-imine addition methodology to natural product total synthesis. 
 
treatment of imine 1-21 with CeCl3 and allylzinc bromide provided essentially quantitative 
yield and 4.4:1 diastereoselectivity.  It is assumed that the anti-stereoselectivity in this 
allylation reaction arises from chelation of CeCl3 with imine 1-21 to generate chair-like 
transition state 1-22. 
While treatment of an allylic halide with zinc metal has traditionally been the 
source of allylzinc reagents, there has been significant research on the synthesis of more 
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complex allylzinc species.  Wipf and Kendall have recently shown that hydrozirconation 
of an alkyne followed by transmetalation with Me2Zn affords vinylzinc intermediate 1-24 
that can react with CH2I2 via a [1,2]-shift (1-25) to generate an allylic zinc reagent 
(Scheme 1-7).15  This functionalized intermediate reacts with aldimines in a 
diastereoselective fashion to generate homoallylic amides in moderate to high yield.  This 
unique method allows for the preparation of allylic zinc reagents that contain functionality 
such as esters and ethers that are not readily accessible through traditional allylmetal 
chemistry.  
 
1. Cp2ZrHCl
2. Me2Zn
MeZn C4H9
CH2I2
C4H9
Zn C4H9
I
N
P(O)Ph2
R1
MeZn
C4H9
NHP(O)Ph2
Ph
NHP(O)Ph2
Ph+
71% yield; 85:15 dr
C4H9 C4H9
1-24 1-25
 
Scheme 1-7. Tandem zirconocene homologation-aldimine allylation. 
1.1.4 Synthesis and Reactivity of Vinyl and Allylsilanes 
Allylsilanes are versatile intermediates in organic synthesis for a variety of 
transformations including C-C bond and carbocyclic ring formation.16  Significant effort 
has been devoted to the synthesis of these reagents; however, the preparation of 
allylsilanes containing complex functionality, especially heteroatoms, is an area of limited 
study. 
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An attractive synthesis of β-hydroxyallylsilanes was performed by Roush and co-
workers who have demonstrated that chiral allylsilanes can be readily synthesized via 
allylboration reactions as shown in Scheme 1-8.17  The resulting allylsilanes can be 
applied to the synthesis of 2,3,5-trisubstituted tetrahydrofurans by [3+2] annulations with 
aldehydes.18  Additional work relating to the synthesis of functionalized allylsilanes has 
been reported by Huang and co- workers (Scheme 1-9).19  This approach entails the 
 
TBSO
O
H
PhMe2Si B
CO2i-Pr
CO2i-Pr
toluene, -78 °C
4 Å molecular sieves
75-90% yield
>20:1 dr
TBSO
OH
SiMe2PhO
O
1-26
1-27
1-28
 
Scheme 1-8. Synthesis of chiral allylsilanes by a double diastereoselective allylboration reaction. 
 
condensation of α,β-unsaturated carbonyl compounds with γ-
trimethylsilylmethylallylzirconocene followed by an anionic oxy-Cope rearrangement to  
 
•
Me3SiCH2 Cp2ZrHCl
Me3SiCH2 ZrCp2Cl
R1
O
R2
R1
HO
R2
Me3SiCH2
74 - 84% yield, 93:7 - 1:1 dr
R1
HO
R2
Me3SiCH2
KH, I2
THF R2
O R1
SiMe3
82 - 89% yield
1-29
1-30
1-31 1-32
 
Scheme 1-9.  Allylation – anionic oxy-Cope rearrangement yielding functionalized allylsilanes. 
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yield the desired allylsilanes 1-32.  Further reactions of these substrates with n-Bu4NF 
affords cyclopentanols via intramolecular allylsilylation. 
β-Amino-substituted allylsilanes are a class of reagents that have seen few 
applications in the literature, however there are several reports of their synthesis.20  Brook 
and co-workers utilized the Claisen rearrangement (Scheme 1-10).21  While the overall 
yield of this process is only moderate, good diastereoselectivity was observed and the  
 
O
O
NHBoc
SiMe3
1. LiHMDS
2. ZnCl2
O
O
NBoc
SiMe3
1. Claisen Rearrangement
2. Esterification
MeO
O
NHBoc
SiMe3
50% yield
25:1 dr
1-33 1-34
1-35
Zn
 
Scheme 1-10. Allylsilane-modified amino acids from the Claisen rearrangement. 
 
starting materials are readily available.  Further applications of these products have not 
been reported.  The sole example of a β-amino-substituted allylsilane undergoing further 
functionalization is a report by Panek et al. (Scheme 1-11).22  Utilizing BF3•OEt2, an 
intramolecular aminocarbocyclization with silyliminium ions was realized, allowing for 
the facile synthesis of highly substituted cyclopentenes 1-37. 
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OH
NHTs
Me2PhSi
p-TsNH2 / BF3•OEt2
CH2Cl2 -78 °C -> -35 °C
NHTs
NHTs
85% yield; > 30:1 dr
1-36 1-37
 
Scheme 1-11. Asymmetric aminocarbocyclization of (E)-crotylsilanes. 
1.2 RESULTS AND DISCUSSION 
Previous methodology in the Wipf group focused on the hydrozirconation of 
alkynes and alkenes and subsequent reactions of these alkenyl or alkyl zirconocenes to 
produce an array of synthetically useful products.  We thought that it would be worthwhile 
to investigate the hydrozirconation of allenes as an efficient route to complex 
allylzirconocenes, and were inspired by the work of Suzuki and Huang.8-10 While previous 
studies focused on mono-substituted allenes, we initially explored di-substituted allene 1-
38 as a test substrate.  It was quickly realized that the hydrozirconation of this moiety led 
to complex mixtures of products under a variety of reaction conditions (Scheme 1-12).   
 
Bu3Sn
•
H
CH3H Cp2ZrHCl
O
H
O
or D2O
Complex Mixture
1-38
(CH2Cl2,
THF or toluene)  
Scheme 1-12. Attempted hydrozirconation followed by aldehyde addition or D2O quench. 
 
Due to difficulty in the hydrozirconation of 1-38, mono-substituted allene 1-39 
was prepared.  It was of interest to see if the increased steric hindrance of the TBS group 
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prohibited the Peterson-type olefination observed with TMS-allene.10  Surprisingly, upon 
hydrozirconation of 1-39 followed by addition of anisaldehyde at -78 ˚C, diene 1-42 was 
the only observed product.  Performing the reaction in the presence of TMSCl did not 
prevent this elimination process (Table 1-2).   
 
Table 1-2. Hydrozirconation of allene 1-39, followed by addition to anisaldehyde. 
TBS
•
Cp2ZrHCl
O
H
TBS ZrCp2Cl
O
O
conditions
Conditions:                                                                       Results:
CH2Cl2,-78 °C, 1 h                                                             85% yield of 1-42                  
CH2Cl2, TMSCl, -78 °C -> rt, 1 h                                       60% yield of 1-42
OH
O
TBS
1-42
1-39 1-40 1-41
 
 
While hydroxy groups eliminated under our reaction conditions to form dienes, we 
felt that aldimines could serve as potential electrophiles and would not be prone to an 
elimination process.  Treatment of aldimine 1-43 with allylzirconocene 1-40 in both 
dichloromethane and toluene did not produce any addition product even upon heating to 
90 ˚C for 8 h (Table 1-3).  Although this lack of reactivity was unexpected due to the rapid 
reaction of allylzirconocene 1-40 with aldehydes at -78 ˚C, we felt that this problem might 
be solved by utilizing the transmetalation of zirconium to dialkylzinc.  This protocol has 
proven successful for the formation of vinylzinc species via the 
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Table 1-3. Attempted addition of allylzirconocene 1-40 to aldimine 1-43. 
TBS
•
Cp2ZrHCl
NP(O)Ph2
HTBS ZrCp2Cl
conditions
no reaction
Conditions:                                                                       Results:
CH2Cl2, -78 °C -> rt, 8 h                                                     No reaction                
Toluene, 90 °C, 8 h                                                            No reaction
1-39
1-43
1-40
 
 
hydrozirconation-transmetalation of alkynes; however, the transmetalation of 
allylzirconocenes has only been demonstrated with copper (I) salts.10  Additionally, 
previous results by Wipf and Kendall have shown that these allylzinc species react with 
aldimines in a diastereoselective fashion to furnish homoallylic amines in high yield.15  
Initial reaction conditions involved addition of Cp2ZrHCl to allene 1-39 in CH2Cl2 
at -78 ˚C and subsequent warming to room temperature upon which a red solution 
resulted.  This solution was then re-cooled to  -78 ˚C and Me2Zn and aldimine 1-44 were 
added.  To our surprise, these reaction conditions yielded exclusively vinyl silane 1-45, 
albeit in a low 18% yield.  While intrigued by this regioselectivity, we were interested in 
improving the reaction yield and first thought to screen solvents, since this has been an 
effective solution for other hydrozirconation methodology.23  Although hydrozirconation 
in THF or toluene produced complex mixtures, it was found that a solvent switch to 
toluene after hydrozirconation was an effective solution and provided the vinyl silane 1-45 
in 80% yield (Table 1-4).  A solvent switch to THF after hydrozirconation was complete 
yielded no desired product and 90% of the starting aldimine was recovered.  Additionally, 
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Table 1-4. Optimization of aldimine allylation reaction. 
1. Cp2ZrHCl 
    CH2Cl2
2. Me2Zn MeO2C
NHP(O)Ph2
TBS
MeO2C
NP(O)Ph2
TBS
•
H
1-44
1-39
1-45Conditions
Conditions:                                                                       Results:
CH2Cl2, -78 °C -> rt, 5 h                                                     18% yield               
Toluene, -78 °C -> rt, 4 h                                                    80% yield
THF, -78 °C -> rt, 12 h                                                        Recovered Imine (90%)  
 
Et2Zn provided the homoallylic amines in comparable yields, greatly reducing the cost of 
this process upon scale-up.  Significantly, Et2Zn was ineffective in previous zirconocene 
transmetallation methodology.15  
Encouraged by this result, we sought to investigate the scope of this process and 
determine if the unexpected regioselectivity was universal or substrate specific.  For this 
purpose, TMS-, TBS-, Bu3Sn-, and Ph-substituted allenes were synthesized24 and 
subjected to the optimized reaction conditions with aldimine 1-44 (Table 1-5).  While the 
silyl- and stannyl- containing allenes 1-39, 1-46, and 1-48 produced the expected vinyl-
substituted products (entries 1, 2 and 3), the phenyl-substituted allene 1-50 yielded 
exclusively the terminal alkene product 1-51 typical of allylations of imines or aldehydes 
(entry 4).13  This product formation was expected based on our previous results, and the 
regioselectivity and diastereoselectivity was confirmed though X-ray analysis (Figure 1-
1).15  To further probe the cause of this reversal in selectivity, we synthesized t-Bu allene 
1-52 and subjected it to the reaction conditions.  Although sterically larger than TMS 
allene 1-46, this substrate provided a 1.5:1 mixture of vinyl substituted 1-53a to terminal 
alkene 1-53b. 
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Table 1-5. Hydrozirconation-imine addition of allenes to aromatic aldimine 1-44.a 
entry allene aldimine homoallylic amide yield (%) 
 
1 
 
 
 
(p-MeO2C)Ph H
NP(O)Ph2
1-44  
 
1-47MeO2C
NHP(O)Ph2
TMS
 
 
78b 
2 
 
 
 
1-44 
1-45MeO2C
NHP(O)Ph2
TBS
 
 
80b 
 
3 
 
Bu3Sn
•
1-48  
 
1-44 
1-49MeO2C
NHP(O)Ph2
SnBu3
 
 
81b 
4 
 
Ph
•
1-50  
 
1-44 
1-51MeO2C
NHP(O)Ph2
Ph
 
 
83c 
5 
 
 
 
 
 
1-44 
+
1-53aMeO2C
NHP(O)Ph2
t-Bu
1-53b
MeO2C
NHP(O)Ph2
t-Bu
 
 
 
64d 
 
a All reactions were carried out by hydrozirconation of allene (2 eq) with Cp2ZrHCl (2 eq) in CH2Cl2 at -78 
°C followed by warming to rt, solvent switch to toluene and addition of  Me2Zn (2 eq) and imine (1 eq).  b 
Alkene geometry assigned by coupling constant analysis of the crude reaction products. c One diastereomer 
by 1H NMR analysis of the crude reaction mixture.  Relative configuration confirmed through x-ray 
analysis.  d Ratio of products determined to be 1.5:1 (1-53a:1-53b) by 1H NMR analysis of the crude reaction 
mixture.  Only one alkene isomer and one diastereomer were observed, respectively.  The relative 
configuration of 1-53b was assigned based on analogy to 1-51. 
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OO
NHP(O)Ph2
Ph
1-51
 
Figure 1-1. X-ray structure of homoallylic amide 1-51. 
 
Further investigations focused on applying the aforementioned reaction conditions 
to aliphatic aldimines, as these substrates are generally more demanding,13 but provide 
products of higher synthetic value.  An initial problem for reactions with aliphatic 
aldimines is the synthesis of these labile substrates; however, Charette and co-workers 
recently published a versatile method for the in situ generation of N-
phosphinylalkylimines.25  Applying this imine preparation to our reaction conditions with 
allene 1-39 (which simply involved adding an additional equivalent of dialkylzinc) proved 
efficient, yielding homoallylic amide 1-55 in 79% yield.  The regioselectivity of this 
addition is consistent with the aromatic examples, providing vinylsilane as the only 
product by 1H NMR analysis of the crude reaction mixture.   
The scope of these additions is illustrated in Table 1-6.  Analogous to the addition 
to aromatic aldimine 1-44, addition of Bu3Sn-allene to aldimine 1-54 provided stannyl 
homoallylic amide as the sole addition product in high yield (entry 2).  Interestingly, 
reaction of t-Bu-allene 1-52 under these conditions yielded only the terminal alkene 
product 1-57, in contrast to the 1.5:1 ratio in the previously mentioned aromatic case. This 
result indicates that it is not solely the nature of the allylmetal species that dictates reaction 
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regioselectivity, but it is also the steric and/or electronic nature of the electrophile.  
Furthermore, reactions with the aliphatic aldimine 1-54 were noticeably faster, reaching 
completion in roughly half the time compared to the aromatic aldimine addition reactions. 
To explore whether trisubstituted allenes were effective in this reaction, TMS-
allene 1-62 was prepared and subjected to the reaction conditions with both aromatic and 
aliphatic aldimines, but in each case no product was observed.  While 1,3-disubstituted 
and trisubstituted allenes gave rise to complex mixtures during hydrozirconation, we felt 
that 1,1-disubstituted allenes could serve as useful substrates since they are sterically 
biased for the approach of the metal complex and have been used successfully in 
hydroboration reactions.26  Addition of commercially available 1,1-dimethylallene 1-60 
under the optimized reaction conditions to aldimine 1-54 surprisingly yielded only 
terminal alkene product in high yield (entry 4).  Under these reaction conditions, 1-
methyl-1-trimethylsilylallene 1-58 yielded 81% of the allylic silane 59 as a single 
diastereomer (entry 5).  The relative configuration of 1-59 was confirmed though X-ray 
analysis (Figure 1-2).  This reaction was of particular interest since we planned to further 
investigate allylsilanes of type 1-59 (vide infra). 
After evaluating the general scope of this process, we desired to explore its 
extension to tosyl aldimines, or more importantly, N-tert-butanesulfinyl imine 1-65.  
Addition to in situ generated tosyl imine 1-63 proved efficient, yielding allylsilane 1-64 in 
85% yield (entry 1, Table 1-7); however, extending our methodology to N-tert-
butanesulfinyl imines was problematic.  A variety of conditions were attempted to  
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Table 1-6. Hydrozirconation-imine addition of allenes to in situ generated aldimine 1-54.a 
entry allene aldimineb homoallylic amide yield (%) 
 
 
1 
 
 
1-39 
 
H
NP(O)Ph2
1-54  
 
NHP(O)Ph2
TBS
1-55  
 
 
79c 
 
2 
 
1-48 
 
1-54 
NHP(O)Ph2
SnBu3
1-56  
 
79c 
 
3 
 
1-52 
 
1-54 
NHP(O)Ph2
1-57 t-Bu  
 
80c,d 
 
4 
 
 
 
1-54 
NHP(O)Ph2
1-59
TMSMe
 
 
81c,e 
 
6 
 
    
 
1-54 
1-61
NHP(O)Ph2
 
 
76 
 
7 
 
 
 
1-44, 1-54 
 
 
no reaction 
 
-- 
a All reactions were carried out by hydrozirconation of allene (2 eq) with Cp2ZrHCl (2 eq) in CH2Cl2 at -78 
°C, followed by solvent switch to toluene and addition of  Me2Zn (3 eq) and sulfinyl adduct (1 eq). b 
Generated in situ from sulfinyl adduct 1-54a. c Only one alkene isomer or diastereomer was observed in 
each case by 1H NMR analysis of the crude reaction mixture.  d Relative configuration based on analogy to 
1-51.  e Relative configuration based on x-ray analysis.   
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NH
P
O
Ph
Ph
TMSH3C
1-59
 
Figure 1-2.  X-ray analysis of homoallylic amide 1-59. 
 
Table 1-7. Extension of allylation reaction to other aldimines.a 
entry allene aldimineb homoallylic amide yield (%) 
 
1   
NTs
H
1-63  
NHTs
TMSH3C
1-64  
 
85c 
 
   2 
 
 
 
1-58 
 
N
H
S
O
1-65  HN
TMSH3C
S
O
1-66b
+
HN S
O
1-66a
TMS
CH3
 
 
 
1-66a: 36d,e    
1-66b: 45d,f 
a All reactions were carried out by hydrozirconation of allene (2 eq) with Cp2ZrHCl (2 eq) in CH2Cl2 at -78 
°C, followed by solvent switch to toluene and addition of  Me2Zn (3 eq) and sulfinyl adduct (1 eq). b 
Generated in situ from sulfinyl adduct 1-63a. c Isolated as a single diastereomer. Relative configuration 
based on analogy to 1-59. d Absolute configuration based on comparison to allylmetal additions in the 
literature,18 and relative configuration based on analogy to 1-59. e Assignment of the alkene geometry was 
based on NOE analysis (see Experimental Part). f A single diastereomer was observed by 1H NMR, and a dr 
= 96:4 was found by chiral HPLC analysis (Chiralpak AD-H column).  
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improve the regioselectivity beyond the initial 1.3:1 ratio obtained under the standard 
dialkylzinc transmetalation conditions (entry 2, Table 1-7).  Unfortunately, stronger Lewis 
acids such as ZnCl2 and BF3•OEt2 provided mainly the undesired vinylsilane 1-66a, while 
copper salts yielded higher ratios of desired product 1-66b but at the cost of lower 
diastereoselectivities (Table 1-8).  Rhodium (I) phosphine complexes were also  
 
Table 1-8. Application of allylation reaction to N-tert-butylsulfinyl imines.a 
Ph
N S
O
•
TMS 1. Cp2ZrHCl
2. Conditions
H Ph
HN S
O
TMSH3C
Ph
HN S
O
CH3
TMS +
1-66b1-66a
1-58 1-65
 
conditions result (1-66a:1-66b)b 
Me2Zn, Toluene, -78 °C – rt, 3 h 1:1.3, 94:6 dr; 81% yield 
Et2Zn, CH2Cl2, -78 °C – rt, 6 h 1:1, 94:6 dr; 20% yield 
10 mol% Et2Zn, Toluene, -78 °C – rt, 12 h 1:1, 94:6 dr; 70% yield 
ZnCl2, Toluene, -78 °C – rt, 4 h 4:1, >95:5 dr; 78% yield 
BF3•OEt2, Toluene, -78 °C – 0 °C, 6 h 5:1, >95:5 dr; 57% yield 
MWI, 150W, 120 °C, 20 min; 180 °C, 20 min Imine decomposition 
1 eq. AgClO4, CH2Cl2, -78 °C – rt, 18 h SM 
15 mol% Yb(OTf)3, Toluene, rt – 60 °C, 14 h SM 
10 mol% [Rh(COE)2(acac)], DPPBenz, Toluene, 40 °C, 18 h SM 
10 mol% [Rh(COE)2(acac)], DPPBenz, Dioxane, 40 °C, 18 h SM 
20 mol% CuBr•SMe2, CH2Cl2, 0 °C – rt, 12 h 1:2.3, 2:1 dr; 40% yield 
50 mol% CuCl, THF, 0 °C – rt, 12 h 1:2.3, 2:1 dr; 20% yield 
10 mol% CuF•3PPh3•2EtOH, dppf, THF, 40 °C, 18 h SM 
a All reactions were carried out by hydrozirconation of allene (2 eq) Cp2ZrHCl (2 eq) in CH2Cl2 at -78 °C, 
followed by solvent switch to toluene and addition of  Me2Zn (3 eq) and sulfinyl adduct (1 eq). b All ratios of 
1-66a to 1-66b were based on isolated yields.  dr determined by 1H NMR integration of olefin peaks in crude 
reaction mixture.   
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explored to facilitate this reaction, but with no success.27  We finally selected the 
dialkylzinc transmetalation conditions, due to the high diastereoselectivity and ease of 
separation by silica gel chromatography even though the regioselectivity was less than 
ideal. Further unoptimized catalytic asymmetric additions of 1-39 to 1-44 in the presence 
of 15 mol% of (-) MIB 1-6728 as a chiral ligand gave allylic amine 1-45 in a low 33% ee 
(Scheme 1-13). We are continuing our studies to identify a more suitable chiral ligand for 
this process, mainly encouraged by the enantiomeric enrichment obtained in our first trial. 
 
TBS
•
1-39 1-45
MeO2C
NHP(O)Ph2
TBS
1. Cp2ZrHCl
2. Et2Zn
3. 15 mol% (-)-MIB
(p-MeO2C)Ph H
NP(O)Ph2
1-44
70% yield, 33% ee
(-)-MIB = N
OH
O
1-67
 
Scheme 1-13. Catalytic asymmetric addition to aldimine 1-44. 
 
Mechanistically, we propose a cyclic transition state for vinylsilane formation 
(Figure 1-3).  Hydrozirconation of the allenylsilane 1-46 leads regioselectively to 
allylzirconocene 1-68.8 Upon transmetallation to dimethylzinc, two allylic zinc 
intermediates are formed.  The terminal zinc species 1-69 and the internal zinc 1-70 are in 
rapid equilibrium,29 with 1-69 reacting to give the terminal alkene 1-72 (not observed) and 
1-70 leading to the vinylsilane 1-47 (observed product).  An alternative reaction pathway 
would involve a direct 1,2-addition of allylzinc reagent 1-69 to the aldimine without 
allylic inversion to give product 1-47.  However, the exclusive formation of the 
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vinylsilane with the TMS-substituted zinc species in contrast to the formation of a mixture 
of both vinylic and allylic products from the t-butyl-substituted allene supports the allylic 
inversion pathway.  With 1,1-disubstituted substrates such as 1-58, the steric strain should 
position the metal away from the substituents, thereby producing exclusively the terminal 
vinyl group in the product through allylic inversion.26 
 
 Cp2ZrHCl R ZrCp2
Cl
1-68, R = TMS
Me2Zn
R
MeZn
R ZnMe
1-44
1-69
1-70
N
P(O)Ph2
R1
MeZn
1-73, R1 = (p-MeO2C)Ph; R = TMS
R
1-44
N
P(O)Ph2
R1
MeZn
1-71
R
1-72
R1
NHP(O)Ph2
TMS
TMS

1-46
1-47MeO2C
NHP(O)Ph2
TMS
 
Figure 1-3. Proposed mechanism for homoallylic amine formation. 
 
After developing an efficient methodology for the synthesis of vinylic and allylic 
silyl homoallylic amines, we were interested in pursuing the further functionalization of 
several products.  Allylsilane 1-59 particularly drew our attention since we felt that its 
configuration could be transferred though the use of an allylation reaction with an 
aldehyde or ketone.  Attempting this reaction under standard Sakurai conditions (i.e. 
strong Lewis acids such as TiCl4 or BF3•OEt2) proved unsuccessful, yielding only the 
starting material, or in some cases large amounts of the desilated product 1-75 (Table 1-9).  
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This product arises under acidic conditions, and its formation could be prevented though 
the use of a hindered  base such as 2,6-di-tert-butyl-4-methylpyridine (entry 6, Table 1-9).  
Weaker Lewis acids such as Yb(OTf)3 also provided no conversion in this reaction even 
 
Table 1-9. Attempted allylation of benzaldehyde with allylsilane 1-59. 
Ph
NH
(Ph)2P
O
TMSH3C
Conditions
Ph
O
H
Ph
NH(Ph)2P
O
OH
Ph
1-59 1-74
 
entry conditions results 
1 TiCl4, CH2Cl2, -78 °C – rt, 18 h SM 
2 TiCl4, THF, rt - 80 °C, 18 h SM + 50% 1-75 
3 BF3•OEt2, CH2Cl2, -78 °C – rt, 18 h SM 
4 TiF4, CH2Cl2, -78 °C – rt, 18 h SM 
5 TMSOTf, CH2Cl2, -78 °C – rt, 14 h SM + 65% 1-75 
6 TMSOTf, CH2Cl2, -78 °C - rt, 14 h, 
1.5 eq 2,6-di-tert-butyl-4-methylpyridine 
 
SM 
7 Yb(OTf)3, Toluene, MWI 150 °C, 30 min SM 
8 10 mol% TBAF, CH2Cl2, -78 °C, 3 h 78% 1-76 
9 NaH, THF then 10 mol% TBAF, CH2Cl2 
- 78 °C, 60 min 
72% 1-76 
 
Ph
NH
(Ph)2P
O
1-75 1-76
Ph
 
when the reaction was heated to 150 °C in a microwave.  Finally, fluoride ion conditions 
rapidly eliminated the N-diphenylphosphinylamine moiety, generating diene 1-76.  This 
elimination was facile even after deprotonation of the amide with sodium hydride prior to 
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the reaction.  Although literature precedent for allylsilane chemistry is abundant, there are 
few examples of successful reactions with a leaving group β to the silicon and/or 
quaternary silanes undergoing Sakurai reactions.  The few existing examples involve 
intramolecular processes which greatly facilitate the allylation.   
Carbonylation reactions of homoallylic amines have proven to be an effective 
method for the synthesis of lactams.  Many of the literature examples for this 
transformation require harsh conditions (high pressure and temperature); however, mild 
copper-catalyzed conditions have also been developed.30  We subjected 1-59 to the latter 
carbonylation reaction conditions (Table 1-10), but desilylation by the HCl formed after 
treatment of the amide with CuCl2 was observed.30 Different conditions including higher 
temperatures, added base, various metal catalysts, and higher pressures could be explored 
to further investigate the potential of this transformation.   
 
Table 1-10. Carbonylation reactions of allylsilane 1-59. 
Ph
NH(Ph)2P
O
TMSH3C
Ph
N
TMSH3C
(Ph)2P
O O
Conditions
1-59 1-77
 
conditions results 
PdCl2(CH3CN)2, CuCl2, PhOH/THF 
CO/O2 (1:1, 1 atm) 
 
SM + desilylated material 
PdCl2(CH3CN)2, CuCl2, i-PrOH/THF 
CO/O2 (1:1, 1 atm) 
 
SM + desilylated material 
PdCl2, CuCl, i-PrOH/THF CO/O2 (1:1, 1 atm) SM + desilylated material 
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1.3 CONCLUSION 
We have developed a new synthesis of homoallylic amines with vinylic and allylic 
silane functions, employing both aromatic and aliphatic aldimines.  All reaction products 
were isolated as single diastereomers in high yield.  Although further extension of the 
functionalized products was not accomplished to date, these diverse building blocks hold 
promide for their application in complex molecule synthesis.   
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2.0  SILVER (I) - CATALYZED ADDITION OF ZIRCONOCENES TO 
ACTIVATED EPOXIDES 
2.1 INTRODUCTION  
2.1.1 Importance of C-Glycosides 
Oligosaccharides and glycoconjugates are involved in a vast array of biological 
processes including cell recognition, cell differentiation and cell adhesion.  Many 
glycosides also play key roles in cell signaling.31  While glycosides often play beneficial 
roles in the cell, others are thought to be key factors that allow binding between host and 
cancer cells.32  A number of carbohydrate based therapeutic agents have been developed to 
combat various diseases; however, most of these compounds suffer from the susceptibility 
of the glycosidic linkage to glycosidase enzymes in vivo.   
The replacement of the anomeric oxygen atom in glycosides with carbon provides 
carbohydrate mimetics with improved stability toward glycosidases. In principle, the 
greater chemical and enzymatic stability of these C-glycosides bodes well for their 
application as small molecule inhibitors of cell-surface recognition events and glycoside 
metabolism, but in practice the mimicry of conformational and electrostatic properties of 
the parent O-glycosides has been challenging to realize.  Not surprisingly, biological 
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activity is often critically dependent on solution conformation.33 While most synthetic C-
glycosides show diminished activity versus the corresponding O-glycoside lead structures, 
considerable enhancement of activity has also been observed.34   
2.1.2 Synthetic Methods for C-Glycoside Preparation 
Inspired by the desire to develop more potent carbohydrate analogues, the 
synthetic community has developed new methodologies for C-glycoside synthesis for 
application to important macromolecules such as spongistatin (Figure 2-1).35    In light of 
the amount of work in this field, a number of strategies have been developed for C-
glycoside synthesis for the creation of analogues as well as for complex natural product 
synthesis.36  While reductive lithiation to generate α-lithioethers was first demonstrated by 
Cohen,37 this methodology was extended to C-glycoside synthesis by Sinaÿ and later by 
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Figure 2-1.  Spongistatin. 
 
Kessler and co-workers.38  Kessler showed that the reaction of glycosyl chlorides 2-1 with 
n-BuLi generated a dianion that successfully reacted with various electrophiles with high  
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Scheme 2-1.  Synthesis of C-glycosides by reaction of electrophiles with glycosyl dianions. 
 
α-selectivity (Scheme 2-1).39  β- Glycosides could be generated though the use of an 
intermediate β-stannane 2-3, followed by dianion formation and addition of electrophile.   
Sinaÿ and Beau introduced the reduction of aryl sulfones with SmI2 to afford 
nucleophilic intermediate samarium (III) compounds that stereospecifically react with 
electrophiles such as aldehydes and ketones (Scheme 2-2).40  It was later discovered that  
 
OBnO
BnO
BnO OTMS
O2S
N
SmI2, THF
Bu4NF
OBnO
BnO
BnO OTMS
Sm(III)
OBnO
BnO
BnO OH
HO R
R
86% yield
2-5 2-6
R2CO
 
Scheme 2-2.  Stereoselective synthesis of α-C-glycosides via glycosyl samarium (III) compounds. 
 
treatment of β-aryl sulfones with SmI2 and NiI2 as a catalyst allowed for the selective 
formation of β-C-glycosides.41 
Another approach to C-glycosides involves the use of the anomeric carbon as an 
electrophile.  In 1982, Kishi and co-workers showed that treatment of benzylglucose 2-7 
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with allyltrimethylsilane and BF3•OEt2 yielded C-glycoside 2-8 in 50% yield and 10:1 α:β 
selectivity (Scheme 2-3).42  This approach was later modified to improve both yield and 
selectivity.43   
 
OBnO
BnO
OBn
BnO OH
allyltrimethylsilane
BF3•OEt2, MeCN
OBnO
BnO
OBn
BnO
50% yield;
10:1 selectivity
2-7 2-8
 
Scheme 2-3.  Allylation of 2,3:4,6-tetra-O-benzylglucose with allyltrimethylsilane. 
 
In 1989, Danishefsky and Halcomb demonstrated the use of dimethyldioxirane as 
an epoxidation reagent for glycals, allowing for the use of 1,2-anhydro sugars as potential 
glycosyl donors (Scheme 2-4).44  This development generated considerable research in 
       
O
O
OBn
BnO
BnO
O O
CH2Cl2
O
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BnO
BnO
quant.
2-9 2-10
 
Scheme 2-4.  Epoxidation of glycals with dimethyldioxirane. 
 
this field, with a number of groups developing methodology for nucleophilic additions to 
these activated epoxides.45  Table 2-1 shows a summary of addition reactions to 1,2-glycal 
epoxide 2-10 and the selectivity achieved in these additions.  Rainier and co-workers 
demonstrated that depending on the nature of the nucleophile employed in the reaction, 
exclusive α- and/or β-selectivity could be accomplished (Table 2-1).45e While alkylcuprate 
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Table 2-1.  Addition of nucleophiles to glycal epoxides. 
O
OBn
BnO
OBn
O O O
OBn
BnO
OBn
O
O
OBn
BnO
OBn
OH
R O
OBn
BnO
OBn
OH
R
+
β α
Nu
2-9 2-10  
entry           nucleophile             R  temperature β/α selectivity yield (%) 
  1             Me2CuLi            Me         0 °C 1:0    82 
  2          MgCl                  0 °C 1:0    82 
  3         MgCl                 0 °C 1:0    78 
  4        TMS Li     TMS          0 °C 0:1    80 
  5            MgBr                    0 °C 1:1    n.d. 
  6 
    BrMg
OMe
OMe    
OMe
OMe  
      -40 °C 1.7:1    29 
  7 
BrMgCu
OMe
OMe
2  
  
OMe
OMe  
      -30 °C 6:1    74 
  8 
        
O
Li, ZnCl2        
O
 
    -60 °C – rt 1:0    78 
  9             AlMe2                -65 °C - rt 0:1    40 
 
reagents, allylmagnesium reagents and propargylmagnesium reagents all provided 
exclusively β-addition products (entries 1-3, Table 2-1), lithium acetylide and vinylalanes 
provided the α-anomer as the exclusive product (entries 4,9, Table 2-1).  Unfortunately, 
other magnesium or copper based reagents yielded poorer ratios of products and often 
much lower yields when heteroatoms were incorporated into the nucleophile.  It is 
interesting to note that the furanyl zinc species (entry 8, Table 2-1) provided exclusively 
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the β-product even though addition of zinc and titanium reagents is believed to involve an 
alkoxy carbenium ion as depicted in Scheme 2-5.45j  Sinaÿ and co-workers proposed that 
the metallonucleophile, in this case the metalloalkyne, activates the 1,2-anhydrosugar 2-10 
by complexation of the Lewis acidic metal atom to the epoxide to generate the alkoxy 
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Scheme 2-5.  Proposed mechanism for exclusive α-selectivity with zinc nucleophiles. 
 
carbenium ion 2-12.  This process is then followed by intramolecular delivery of the 
nucleophile from the α-face to yield 2-13.  An analogous mechanism has been proposed to 
explain α-selectivity in organoaluminium additions to glycal epoxides.46  While there is 
evidence to support this mechanism, varying selectivities have been observed by several 
groups, and an explanation for these discrepancies has yet to be put forth. 
2.1.3 Cationic Zirconocenes in Organic Synthesis 
Cationic zirconocenes are reactive species that have seen significant attention from 
the synthetic community.  These reagents are usually formed in situ from a neutral 
complex, often via halide abstraction.  The use of Cp2ZrCl2/AgClO4 as a cationic 
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zirconocene system has been extensively investigated as an activator in glycoside 
synthesis.  These reactions have mainly been carried out with glycosyl fluorides,47 
however more recently glycosyl sulfoxides have also proven effective (Scheme 2-6).48   
 
O
OMe
OMe
MeO
MeO S
O
Ph
BnOH
Cp2ZrCl2/AgClO4 (1:2)
CH2Cl2, 4 Å sives
-20 °C - rt
O
OMe
OMe
MeO
MeO OBn
α or β 80% (α/β = 4.4 : 1) from β-sulfoxide79% (α/β = 1 : 1.15) from α-sulfoxide
2-14 2-15
 
Scheme 2-6.  Glycosylation reactions with glycosyl sulfoxides. 
 
While alkyl- and alkenylzirconocene chlorides are readily accessible through 
hydrozirconation chemistry,7 they are not sufficiently nucleophilic to add to aldehydes or 
epoxides.  Suzuki and co-workers discovered that a catalytic amount of silver salts 
strongly accelerated these reactions.49  AgClO4 was found to be the most effective 
promoter for the addition of alkenylzirconocenes to aldehydes and ketones, providing 
allylic alcohols in high yield (Scheme 2-7).  Alkylzirconocenes are much less reactive 
under these conditions and yields are often low in additions of these species to 
electrophiles. It was later found that AgAsF6 is a similarly effective catalyst for this 
process and allows for the addition of both alkenyl- and alkylzirconocenes in high 
yields.50   
R Cp2ZrHCl
CH2Cl2, rt, 10 min
R Zr
Cp
CpCl
Ph
O
H
1 mol% AgClO4 Ph
OH
R
R = Bu, 90% yield
2-16 2-17
 
Scheme 2-7.  Hydrozirconation followed by cationic zirconocene catalyzed aldehyde addition. 
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The addition of cationic alkenylzirconocenes to epoxides would be expected to 
provide homoallylic alcohols; however, research by the Wipf group has shown that allylic 
alcohols are the observed products from these intermolecular additions to epoxides under 
AgClO4 catalysis (Scheme 2-8).51  It was proposed that the strongly Lewis acidic cationic 
zirconocene caused epoxide opening, followed by a 1,2-hydride shift to generate an 
aldehyde that can undergo nucleophilic attack to provide allylic alcohols such as 2-20.  
Additionally, when an epoxy ester was subjected to the reaction conditions, either acetals 
or orthoesters were the observed products due to ester-assisted epoxide opening as the 
initial step.52   
 
TBSO ZrCp2Cl
O
5 mol% AgClO4
TBSO
OH
92% yield, 1:1 dr
2-18 2-20
2-19
 
Scheme 2-8.  Silver catalyzed reaction of alkenylzirconocenes with epoxides. 
2.2    RESULTS AND DISCUSSION 
2.2.1 Additions to Glycal Epoxides 
Previous work in our group focused on extending the use of cationic zirconocene 
species for glycal epoxide opening.53  In initial reactions performed with 
alkenylzirconocenes, it was found that 5 mol% AgClO4 promoted the expoxide opening, 
providing 80% yield of exclusively α-anomer 2-21 (Scheme 2-9).  In the course of this 
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early methodology development it was found that protecting groups on the pyran ring 
were of considerable importance, with the yield dropping to 54% when acetate protecting 
groups were employed.  The decrease in yield for more deactivating protecting groups 
such as acetates most likely is due to poor selectivity and low yield in the epoxide 
formation step.44 
 
O
OBn
O
BnO
OBn
Cp2ClZr C4H9
5 mol% AgClO4
    CH2Cl2, rt
O
OBn
BnO
OBn
OH
C4H9
80% yield
2-10 2-21
 
Scheme 2-9.  Initial C-glycoside formation developed in the Wipf group. 
 
It was our primary goal to extend this methodology to a variety of alkynes and 
alkenes to generate alkyl and alkenyl C-glycosides with functionality incorporated into the 
side chain.  While hydrozirconation methodology has shown great tolerance to silyl ether, 
carbamate and bulky ester groups, the addition of organometallic reagents to glycal 
epoxides has generally been focused on simple, commercially available reagents.45   
Attempts to repeat the reaction shown in Scheme 2-9 provided variable yields ranging 
from 10 – 70%.  Addition of triphenyl phosphite to the reaction mixture did not improve 
the reproducibility of this process, even though this method has proven useful for other 
cationic zirconocene methodologies (entry 1, Table 2-2).52  CH2Cl2 has generally proven 
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Table 2-2.  Optimization of cationic zirconocene additions to glucal epoxide 2-10. 
 
Cp2ZrHCl
O
OBn
BnO
OBnO
        AgClO4 O
OHBnO
OBn
BnO
2-22
2-10
conditions
2-21
 
entry conditions yield (%) 
1 5 mol% AgClO4, CH2Cl2, 1 equiv P(O)Ph3,         
0 °C – rt, 2 h 
 
58 
2 5 mol% AgClO4, THF, 0 °C – rt, 8 h 
 
20 
3 5 mol% AgClO4, toluene, 0 °C – rt, 8 h (solvent 
switch from CH2Cl2 after hydrozirconation) 
 
< 10 
4 10 mol% AgClO4, CH2Cl2, 0 °C – rt, 1.5 h (2x 
concentration); addition of epoxide to premixed 
silver/zirconocene 
77 
 
5 10 mol% AgClO4 on celite, CH2Cl2,  0 °C – rt, 1.5 
h (2x concentration); addition of epoxide to 
premixed silver/zirconocene 
 
78 
6 10 mol% AgClO4 on celite, CH2Cl2,  0 °C, 3 h (2x 
concentration); addition of epoxide to premixed 
silver/zirconocene 
76 
 
to be the most effective solvent for both hydrozirconation and cationic zirconocene 
reactions; however, THF and toluene were also screened to evaluate the solvent effect in 
this reaction.  CH2Cl2 proved to be the optimal solvent, with THF and toluene providing 
very slow conversions (entries 1-3, Table 2-2). 
 - 35 -  
Additional studies focused on the loading of silver perchlorate, the order of 
addition and the concentration of the reaction (entries 4-6, Table 2-2).  These experiments 
demonstrated that concentration, as well as order of addition were key factors for reaction 
success, with an increase of silver loading to 10 mol%, doubling of the final concentration 
and adding a solution of epoxide to the premixed silver/alkenylzirconocene solution 
yielding 77% of the desired product 2-21.  While silver perchlorate is potentially 
explosive, silver perchlorate on Celite® is thought to be safer and easier to handle,54 and 
proved equally effective in our reactions.  Additionally, lowering the reaction temperature 
to 0 °C was of no obvious advantage.   
The scope of this process is summarized in Table 2-3.  As it is typical with 
hydrozirconation methodology, a range of ether, ester, carbamate and sulfonamide 
functionalities were tolerated (entries 2-4, Table 2-3).  All products were obtained in high 
yield and in all cases only the α-C-glycoside was observed. The α-C-glycoside 
configuration was assigned based on the coupling constant 3J1,2 = 5.5 Hz, which is 
characteristic for the 1,2-gauche relationship of the neighboring hydrogen atoms and 
compares well with literature values (Figure 2-2).55 The stereochemistry of these reactions 
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Figure 2-2.  Coupling constant analysis of α-C-glycosides. 
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was also initially confirmed through NOE analysis showing very strong NOEs between 
hydrogens 2 and 4 and hydrogens 3 and 5, but weak NOEs between hydrogens 1 and 2.53 
 
Table 2-3.  Addition of a variety of  alkenylzirconocenes to benzyl protected glucal epoxide 2-10.a 
entry alkyne glycal epoxide product yield (%)b
1 
2-22  
O
OBn
BnO
OBnO
2-10  
O
OHBnO
OBn
BnO
2-21
 
78 
2 TBDPSO
2-23  
2-10 O
OHBnO
OBn
BnO OTBDPS
2-24
 
74 
3 TIPSO2C
2-25  
2-10 O
OHBnO
OBn
BnO CO2TIPS
2-26
 
67 
4 
N
2-27
MeO2C
Ts
 
2-10 
O
OHBnO
OBn
BnO N
2-28
Ts
CO2Me
 
70 
a All reactions were carried out by hydrozirconation of alkyne (1.5 eq) with Cp2ZrHCl (2 eq) in CH2Cl2 followed by 
addition of  silver perchlorate on Celite (10 mol%) and glycal epoxide (1 eq). b Yields based on glycal epoxides. 
 
 
In addition to varying the alkyne moiety, both benzyl protected galactose epoxide 
2-29 (entries 1 and 2, Table 2-4) and silyl protected glucal epoxide 2-32 (entries 3 and 4, 
Table 2-4) were used.  Both the benzyl ether and silyl ether moieties performed well, and 
the ability to employ easily removable protecting groups is an advantage.  Selective 
deprotection of the benzyl ethers has not been attempted.  Unfortunately, internal alkynes 
and alkenes did not produce any product under these conditions, most likely due to  
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Table 2-4.  Addition of cationic alkenylzirconocenes to glycal epoxides.a 
entry alkyne glycal epoxide product yield (%)b
1 
2-22  
O
OBn
BnO
OBnO
2-29  
O
OHBnO
OBn
BnO
2-30
 
73 
 
2 TBDPSO
2-23  
2-29 O
OHBnO
OBn
BnO OTBDPS
2-31
 
72 
3 2-22 O
TBSO
OTBS
TBSO O
2-32  
O
OHTBSO
OTBS
TBSO
2-33
 
74 
4 2-23 2-32 O
OHTBSO
OTBS
TBSO OTBDPS
2-34
 
71 
5 
2-35  
2-10 NR - 
a All reactions were carried out by hydrozirconation of alkyne (1.5 eq) with Cp2ZrHCl (2 eq) in CH2Cl2 followed by 
addition of  silver perchlorate on Celite (10 mol%) and glycal epoxide (1 eq). bYields based on glycal epoxides. 
 
 
increased steric hindrance and decreased reactivity, respectively.  The remainder of the 
material in all reactions appeared to be mainly decomposition products of the glycal 
epoxides. 
Treatment of 1-hexyne with Cp2ZrHCl provided a stoichiometric alkenyl 
zirconocene 2-36,7 which, upon addition of 10 mol% silver perchlorate on Celite® 
followed by glucal epoxide 2-10 yielded α-C-glycoside 2-21 in 78% yield (Figure 2-2).56 
Due to cationic zirconocene-assisted oxonium ion formation and chelation-directed 
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delivery of the alkenyl substituent, the reaction proceeded to give exclusively the α-
epimer.  After initial chloride ligand abstraction and initiation of the catalytic cycle by the 
silver(I) salt,49,50 subsequent formation of the cationic zirconium species was a chain 
transfer process, in which the more Lewis-acidic cationic alkoxy zirconium(IV) species 
accepted the chloride anion from the alkenyl(chloro)zirconocene 2-36.  A similar 
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Figure 2-3.  Proposed mechanism for cationic alkenylzirconocene addition and exclusive formation of the α-
anomer. 
 
mechanism was proposed for the addition of zinc reagents to glycal epoxides, accounting 
for the high α−selectivity observed in those reactions.45j 
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2.1.2 Application to Tetrahydropyridines 
 
In the course of Rutjes’ synthesis of (2S,5R)-5-hydroxypipecolic acid, an 
epoxidation/epoxide opening sequence of enamide 2-41 provided an alcohol intermediate 
in high yield and selectivity (Scheme 2-10).57  Inspired by this methodology, we 
envisioned an epoxidation of cyclic enamines followed by opening with an 
alkenylzirconocene species as a new method for stereoselective, functionalized piperidine 
synthesis. 
N
Cbz
MeO2C
Oxone, NaHCO3
MeOH
N
Cbz
MeO2C
OMe
OH
98% yield, 96:4 dr
2-41 2-42
 
Scheme 2-10.  Use of epoxidation/epoxide opening sequence in the synthesis of 5-hydroxypipecolic acid. 
 
 Tetrahydropyridine 2-45 was prepared in 4 steps from imine 2-43 as a test 
substrate for epoxidation (Scheme 2-11).  Allylation of imine 2-4358 with allyl-TMS and 
TiCl4 followed by a phase transfer alkylation reaction yielded allylamine 2-44 in 73% 
yield over 2 steps.  Ru-catalyzed ring closing metathesis59 followed by isomerization of the 
allylamine to the enamine 2-4560 were performed in 94% and 92% yield, respectively.   
N Ts
Ph
1. Allyl-TMS, TiCl4
2. AllylBr, 50% NaOH, 
    Bu4NI, Toluene
    (73%, 2 steps)
N
Ts
Ph
1.                         
2. Wilkinson's Catalyst
    DBU; (86%, 2 steps)
N
Ts
Ph
2-43 2-44 2-45
Ru
NMesMesN
Cl
Cl
PCy3 Ph
10 mol%
 
Scheme 2-11.  Synthesis of tetrahydropyridine 2-45. 
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With enamine 2-45 in hand, epoxidation of with DMDO, removal of solvent, 
redissolving the residue in CH2Cl2 and addition of the premixed alkenylzirconocene/silver 
perchlorate mixture provided no addition product by crude NMR and LCMS analysis 
(Scheme 2-12).  Although similar epoxides have been prepared in the literature,61 the 
stability of the epoxide to solvent removal seems to be problematic in this sequence.  
N
Ts
Ph
DMDO
CH2Cl2, 0 °C
N
Ts
Ph
O
ZrCp2Cl
C4H9
AgClO4, 0 °C
NTs
Ph
C4H9
OH
2-45 2-46 2-47  
Scheme 2-12.  Attemped opening of epoxide 2-46 with cationic alkenylzirconocene. 
 
 
2.2 Conclusion 
 
The ability to combine relatively sensitive functional groups with the nucleophilic 
zirconocene reagent under mild Ag(I)-catalysis allows for rapid conversion of 1,2-
anhydrosugars to complex α-C-glycosides that have previously not been readily available 
for synthetic or biological studies.  While there are numerous other methods for C-
glycoside synthesis from glycal epoxides,45 none of them are as mild and stereoselective 
as the aforementioned silver-catalyzed alkenylzirconocene addition.  
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3.0  EXPEDIENT SYNTHESIS OF α-C-GLYCOSIDE ANALOGUES OF THE 
IMMUNOSTIMULANT GALACTOSYLCERAMIDE (KRN7000) 
3.1 INTRODUCTION 
3.1.1 Biological Significance and Previous Synthetic Approaches 
In the mid 1990’s, the anticancer drug candidate KRN7000 (α-Gal-Cer, 3-1) was 
developed by researchers at Kirin Pharma.62  Extracts of the Okinawan sponge Agelas 
mauritianus were shown to contain members of the agelasphin family of glycolipids, the 
lead structures for the chemically simplified KRN7000.  3-1 is a galactose containing 
glycolipid, bearing a phytosphingosine side chain (Figure 3-1, left).  Over a decade of 
investigation has demonstrated that 3-1 serves as a ligand to CD1d protein with the greasy 
alkyl chains embedded in deep pockets and the sugar head group exposed for presentation 
to natural killer T (NKT) cells (Figure 3-1, right).63  The crystal structure of the bound 
KRN7000 (triple complex with CD1d and NKT receptor) further demonstrates the 
importance of the alkyl side chains but also the stereochemistry and presence of the 
galactose hydroxyl groups.64  Only the 6-position of galactose has been demonstrated to 
tolerate substitution to date.65  
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 Figure 3-1. Structures of KRN7000 and OCH (left); Mechanism of action for galactosylceramides (right). 
 
Upon formation of the CD1d-(3-1) complex, NKT cells are triggered to release 
both helper Th1 (interferon-γ (IFN-γ)) and Th2 (interleukin-4 (IL-4)) cytokines 
simultaneously.  Th1 and Th2 cytokines play key roles in immunology, with the former 
participating in protective immune function against external pathogens (ie, cancer) and the 
later involved in regulatory immune functions (ie, autoimmune disease).  KRN7000 
promotes significant increases in both types of cytokines, thereby causing adverse effects 
that have limited its progress as an effective therapy.66  This lack of success has inspired 
many research teams to explore the possibility of selectively activating a unique set of 
cytokines, a strategy that should provide a non-toxic therapy for a wide range of diseases 
ranging from cancer to malaria.67  Initial success was described by Miyamoto, who 
demonstrated that a truncated version of 3-1, OCH (3-2, Figure 3-1), caused selective 
production of IL-4 providing support for this immunotherapy strategy.68,69 A chain 
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shortened analog developed by Wong bearing a terminal phenyl moiety also proved to 
selectively activate IFN-γ production.70 
Determined to explore more deep-seated structural modifications, Franck and co-
workers proposed exchanging the glycosidic linkage present in 3-1 with an enzymatically 
stable C-glycoside bond (3-3, Scheme 3-1).34  3-3 not only lacks the additional hydrogen 
bond acceptor found in the parent molecule, but is also impacted by the loss of the 
anomeric effect in exchange for an unfavorable axial methylene group in the galactose 
chair conformation.  Additionally, all previous attempts to convert biologically active O-
glycosides to their C-glycoside analogs have been met with dramatically decreased 
activity.  The failure of these C-glycoside analogs is most likely due to the conformational 
change of the compounds that prevents binding in the O-glycoside binding site.33   
From the synthetic standpoint, the initial synthesis of 3-3 involved a late stage 
intramolecular hydride transfer to a glycosyl cation whose precursor was prepared via 
Ramberg-Backlund C-glycoside methodology (Scheme 3-1).34  Many difficulties were 
encountered both with the compatibility of protecting groups and installation of non-
glycosidic stereocenters, while the key reactions of the sequence were effective.  Although 
their route to this molecule proceeded in 26 steps and 1.4% overall yield, the Franck group 
generated enough glycoside to begin preliminary biological testing in collaboration with 
Tsuji.   
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Scheme 3-1. Key steps in Franck’s first approach to C-glycoside 3-3. 
 
In initial testing, mice were treated with either O-glycoside 3-1 or C-glycoside 3-3 
and then challenged with malaria (Figure 3-2, left).34  While both compounds were 
effective at reducing sporozoite levels at dosages of 1 µg, 3-3 was effective even at 1 ng 
levels proving to be 1000 times more protective than the parent O-glycoside.  A second 
assay was carried out with a melanoma challenge in mice, with the C-glycoside again 
proving 100 times more effective than 3-1 (Figure 3-2, right side).  The origins of this 
increased potency were not clear at this stage, as this was the first case of improved 
activity with C-glycoside analogues.   
 
Figure 3-2.  Assay for sporozoites in liver (left) and melanoma appearance (black spots) on mouse lung 
after two weeks (right). Taken from: Angew. Chem. Int. Ed. 2004, 43, 3818. 
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Subsequent to this initial report, Franck developed three additional approaches to 
3-3, consisting of cross-metathesis, Julia olefination and Sharpless asymmetric 
epoxidation (Scheme 3-2).71 The cross metathesis approach proved the most efficient and 
was accomplished in 11 steps while utilizing commercially available phytosphingosine as 
a coupling partner in the cross-metathesis.  Facile scale-up of this route (overall yield of 
the sequence is 30%) allowed for the synthesis of increased amounts of glycoside for 
biological testing and analog development.  Additionally, the epoxidation/epoxide opening 
approach provided access to all stereoisomers of 3-3 allowing for their biological 
evaluation.  Interestingly, of the four tested diastereomers, only the natural and unnatural 
enantiomer of 3-3 showed activity.   
Another approach to C-glycoside 3-3 was developed that allows for more facile 
analogue synthesis than either of Franck’s routes.  The key reaction in this sequence was 
the alkyne-aldehyde coupling to generate compound 3-15 that was then converted to the 
desired amide 3-14 through a Mitsunobu inversion (Scheme 3-3).72  While this route did 
allow for flexibility in the coupling partners employed, poor selectivity in the alkyne-
aldehyde coupling made scale up problematic  
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Scheme 3-2. Franck's synthetic approaches to 3-3. 
 
 as these diastereomers (1.6:1 ratio) must be separated before being subjected to the 
Mitsunobu conditions.  
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Scheme 3-3.  Mitsunobu approach to C-glycoside 3-14. 
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 With additional compound in hand, a great deal of effort was put toward 
evaluating the efficacy of 3-3 in vivo, particularly compared to its parent compound 3-1. 
Teng et al. explored the application of sequential tumor cell apoptosis and amplification of 
dendridic cell function utilizing either 3-1 or 3-3 provided by Franck.73  As observed 
previously, 3-3 provided remarkably increased activity, with complete eradication of 
established tumors in mice.  While the reasons for the greater therapeutic index for 3-3 are 
still uncertain, it appears that the C-glycoside provides a more sustained iNKT cell 
response than does 3-1.  This response could be due to either tighter binding or a slightly 
different binding pattern, although the authors have no evidence to support either of these 
hypotheses.   
To further explore the stereochemical properties of 3-3, Postema and co-workers 
targeted β-C-glycoside derivatives and developed an 18 step synthetic route.  Unlike other 
approaches that introduced the amino-diol stereotriad via a coupling reaction, directed 
achiral dihydroxylation of allylic amide 3-18 was employed (Scheme 3-4).74 
Disappointingly, this approach only gave a 1:1 mixture of diastereomers, therefore 
optimization of this step was necessary to improve the efficiency of this synthesis.   
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Scheme 3-4.  Retrosynthesis of a β-C-glycoside analogue of KRN7000. 
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More recently, Mori et. al. has synthesized a variety of analogs that include the 
carbocycle analog 3-21 and conformationally restricted analogs 3-22 and 3-23 (Figure 3-
3).75  The carbocyclic analog showed selective production of Th1 cytokines, very similar 
to 3-3; unfortunately, a direct comparison of 3-21 to 3-3 was not performed.  The 
conformationally restricted analogs were more of a disappointment, with only 3-22 
showing activity.  It could be of interest for future exploration into selective control over 
cytokine release that this compound appears to promote Th2 cytokine formation.   
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Figure 3-3. Analogs of 3-1 prepared by Mori et al. 
 
3.2 RESULTS AND DISCUSSION 
3.2.1 Development of an Asymmetric Synthesis of Allylic Amines.   
While investigating our cationic zirconocene addition to glycal epoxides, it became 
clear that the inclusion of nitrogen in the glycoside side chain would provide molecules 
with interesting biological properties.76 Accordingly, we envisioned N-tert-butanesulfinyl 
imine 3-25 as a key intermediate that could undergo a diastereoselective alkenylmetal 
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addition followed by epoxidation and carbamate ring opening of 3-24 to generate 
compounds such as 3-3 in a rapid fashion (Scheme 3-5).  From the outset, our 
requirements for this undertaking were to synthesize 3-3 in the shortest sequence to date 
while doing so in a modular and stereoselective fashion.    
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Scheme 3-5. Retrosynthetic analysis of 3-3. 
 
Although we believed that our glycoside methodology could prove useful for the 
incorporation of complex functionality into novel glycoside analogs, an existing approach 
to aldehyde 3-29 was considered to be superior for exploring our planned synthetic 
strategy.77 The synthesis of this aldehyde was accomplished in three steps from methoxy 
galactose 3-26 and could be performed on a multi-gram scale (Scheme 3-6).  Later, we 
found that conditions developed by Panek78 employing acetyloxy allyl silane as a 
homoenolate equivalent could be used to convert 3-26 via the resulting enol acetate79 in 
situ to the desired aldehyde 3-29 in 67% yield (Scheme 3-6).  All attempts to employ 
silyloxy allyl silanes in this transformation failed.  With the desired aldehyde in hand, we 
 - 50 -  
chose to form a sulfinylimine80 and explore subsequent organometallic additions to this 
substrate to form the desired stereocenter in our target molecule.  Treatment of aldehyde 
3-29 with tert-butanesulfinamide under dehydrating conditions in the presence of MgSO4 
yielded the desired imine 3-25 in 94% yield.   
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Scheme 3-6.  Synthesis of imine 3-25 from glycoside 3-26. 
 
Previous research in our group has shown that transmetalation of alkenyl-
zirconconocenes to dimethylzinc provides organometallic species that react readily with 
aldehydes and imines.81  Typically, N-diphenylphosphinoyl imines are employed in this 
methodology; however, to date, no catalytic asymmetric addition to these substrates has 
been realized.82  A screen of catalysts to achieve a diastereoselective addition to imine 3-
25 was performed (Table 3-1).  While dimethylzinc and boron Lewis acids were 
completely ineffective, either dimethylaluminum chloride or trimethylaluminum proved 
excellent in this transformation, providing high yield of homoallylic amide 3-31 as a 
single diastereomer by 1H NMR analysis of the crude reaction mixture.       
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Table 3-1.  Optimization of reaction conditions for alkenyl organometallic addition to N-tert-butanesulfinyl 
imine 3-25. 
C3H7
1. Cp2ZrHCl
2. Conditions
O
HN
S
O
C4H9BnO
OBn
OBn
OBn
3-30
O
BnO
OBn
OBn
OBn
N
H
S
O
3-25
3-31  
entry conditions yield (%) 
1 Me2Zn, toluene,  -78 - 100 °C trace 
2 BF3•OEt2, CH2Cl2, 0 °C - rt decomposition 
3 Me2AlCl, CH2Cl2 0 °C - rt 82 
4 Me3Al, CH2Cl2 0 °C - rt 76 
 
 Furthermore, we were able to demonstrate that silyl ether, carbamate, and 
sulfonamide functionalities were well tolerated and provided allylic amides in high yield 
and excellent diastereoselectivity (entries 1-3, Table 3-2).  We propose the 4-membered 
chelate model 3-32 to account for the observed selectivity, analogous to additions of 
alkenylalanes derived from alkyne carboalumination.83   The mild and efficient conditions 
for generating N-tert-butanesulfinyl imines coupled with the rapid, stereoselective and 
functional group tolerant method of alkenylalane addition described 
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Table 3-2. Exploration of functional group compatibility in organoalane addition to imine 3-25. 
R O
OBn
OBn
BnO
OBn HN S
O
3-25, 0 °C - rt, 3 h
R
Cp2ZrHCl, then
Me3Al
four-membered
chelate model
Me2Al
N
R
3-32
S
tBu
O
R
H
 
entry alkyne product yield [%] 
 
 
 
1 
 
 
OTBDPS
3-33  
O
HN
S
O
BnO
OBn
OBn
OBn
3-34 OTBDPS  
 
 
 
81a 
 
 
 
2 
 
N
3-35
Ts
CO2Me
 
O
HN
S
O
BnO
OBn
OBn
OBn
3-36 N CO2Me
Ts  
 
 
 
65b 
 
 
 
3 
 
 
3-37  
O
HN
S
O
BnO
OBn
OBn
OBn
3-38  
 
 
 
85a 
a Products were diastereomerically pure by 1H NMR analysis of the crude reaction mixture.  b93:7 mixture of 
diastereomers by HPLC analysis.  All yields are based on isolated, pure materials.   
 
herein provides an attractive method for allylic amine synthesis.84 After establishing a 
diastereoselective vinylalane addition to imine 3-25, we extended this process to the 
addition of the alkenyl zirconocene derived from 3-39 (Scheme 3-7).  Removal of the 
sulfinyl protecting group upon work-up yielded 72% of the allylic amine 3-40 in a one pot 
transformation.   
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Scheme 3-7. Hydrozirconation/transmetalation/imine addition of alkyne 3-39 to imine 3-25 followed by in 
situ deprotection. 
3.2.2 Synthesis of the C-Glycoside Analog of KRN7000 
Our original strategy involved epoxidation of the allylic amide bearing the tert-
butylsulfinyl protecting group; however, epoxidation of this species also oxidized the 
sulfur to generate the Bus protecting group85 that could not be removed even under forcing 
conditions.  To further explore the epoxidation chemistry, bis-Boc protection of 3-40 was 
accomplished via a 2-step procedure that proved higher yielding upon scale-up (Scheme 
3-8).   
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Scheme 3-8. Optimized formation of bis-Boc protected amine 3-24. 
 
At this stage, conditions had to be indentified to stereoselectively epoxidize the 
alkene 3-24 and effect the intramolecular addition of the tert-butylcarbamate to the 
epoxide to form oxazolidinone 3-43.86  Work by Roush87a and O’Brien86b has 
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demonstrated the feasibility of this sequence, although Roush employed 
trichloroacetamides and O’Brien focused on cyclic allylic amides.86c Initial trials focused 
on MCPBA as the epoxidizing agent, with varying temperatures and solvents.  The best 
result could be obtained at 0 °C in CH2Cl2 to yield 85% of 3-43 as a 1.6:1 mixture of 
diastereomers (entry 1, Table 3-3).  In situ generated dimethyldioxirane (DMDO) was 
ineffective, producing no conversion after 20 h at rt.  Increasing the electrophilicity of 
        
Table 3-3. Evaluation of oxidation conditions to generate epoxide intermediate 3-42 followed by carbamate 
opening of the epoxide to form 3-43. 
O
OBn
OBn
BnO
OBn BocNR
C14H29
Conditions O
OBn
OBn
BnO
OBn ORN
O
C14H29
OHO
OBn
OBn
BnO
OBn BocNR
C14H29
O
3-24; R = Boc
3-41; R = H 3-43; R = Boc3-44; R = H
3-42
9 10
 
entry substrate conditions yield [%], dra 
 
1 3-24 MCPBA, 0 °C 85, 1.6:1 
 
2 
 
3-24 
 
Oxone, NaHCO3, acetone, rt 
 
trace 
 
3 
 
3-24 
 
TFAA, UHP, -20 °C, Na2HPO4 
 
93, 9:1 
 
4 
 
3-41 
 
TFAA, UHP, -20 °C, Na2HPO4 
 
50, n.d. 
 
a Yields refer to isolated, pure products.  Diastereoselectivity was determined by HPLC analysis of the 
  crude reaction mixtures: HPLC separation was preformed using a Chiralcel AD-H column and elution   
  with 7% i-PrOH/Hexanes.  Retention times = 12.8 min (major), 19.1 min (minor). 
 
peracids has been shown to increase selectivity in directed epoxidations.88 
Trifluoroperacetic acid (TFAA), generated in situ from trifluoroacetic acid and urea-
hydrogen peroxide (UHP) inclusion complex,89 improved the selectivity of the 
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epoxidation to 9:1 and increased the yield to 93% (entry 3, Table 3-3).  Mono-Boc 
protected amide 3-41 did not perform well in this reaction, seemingly due to increased 
decomposition pathways.  The assignment of the relative configuration in 3-43 was in 
accordance with previous reports;86a moreover, it was confirmed by coupling constant 
analysis90 and by converting both diastereomers to the desired C-glycosides 3-3 and 3-
3’.91  The increased selectivity in the TFAA epoxidation was attributed to the increased 
acidity of the peracid proton, which is essential for the carbamate to direct the approach of 
the reagent (Figure 3-4).   
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Figure 3-4. Model for stereoselectivity in epoxidation reaction. 
 
Epoxidation of 3-24 under the TFAA conditions from entry 3 in Table 3-3, and 
subsequent ring opening of the crude material yielded 89% of Boc-amino diol 3-45 as a 
9:1 mixture of diastereomers that were separated by column chromatography on SiO2 
(Scheme 3-9).  
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Scheme 3-9. Completion of the synthesis of 3-3 and 3-3’. 
 
Removal of the Boc group with HCl, coupling of the amine salt with acid chloride 
3-46 and global deprotection of the galactosyl benzyl groups provided 3-3 in 71% yield 
over 3 steps.  This sequence was also carried out on the diastereomer (3-45’) to provide 3-
3’ in comparable yields.   
Confirmation of the target structure was obtained by comparison of the [α]D and 
13C NMR data of previously prepared 3-3 with newly synthesized 3-3 and 3-3’.  As shown 
in Table 3-4, the 13C NMR data for 3-3 and the literature data for this compound compare 
well, while there are considerable differences between 3-3’ and the previously reported 
data.  Further confirmation was achieved through comparison of [α]D values which were 
in agreement.34   
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Table 3-4. Comparison of 13C NMR chemical shift and [α]D values.a 
 
 
 
 
Carbon 
No.b 
Difference 
between 
literature  and 
experimental 
shifts 
δ 3-3' 
(experimental 
values) 
δ 3-3 
(from 
literature)
δ 3-3 
(experimental 
values) 
Difference  
between  
literature  
and 
 experimental 
shifts 
12 -2.0 175.9 173.9 173.8 0.1 
10 1.2 77.7 78.9 78.8 0.1 
1 0.5 76.9 77.4 77.3 0.1 
5 0.0 74.1 74.1 74.1 0.0 
11 0.6 72.5 73.1 73.0 0.1 
4 0.2 72.4 72.6 72.5 0.1 
3 0.1 70.7 70.8 70.8 0.0 
6 0.4 62.7 63.1 63.1 0.0 
9 1.2 51.9 53.1 53.1 0.0 
[α]Dc 31.2 +9.6 +40.8  +38.4 2.4 
 
     a 13C NMR data for 3 and 3-3’ were obtained in d5-Pyridine at 126 MHz. b Tentative 
          assignments. c [α]D values were obtained in pyridine (c = 0.13) and are 
        reported as average values of 3 measurements.   
3.2.3 Biological Evaluation and Analog Synthesis 
Malaria is a widespread parasitic disease that is present in tropical regions of the 
world and results in more than 300 million new infections annually.92  There are four main 
plasmodial species known to infect humans, with Plasmodium falciparum the most 
virulent.  Multi-drug resistance of the various strains of malaria has only complicated the 
problem.  While there are a number of approved drugs to treat malaria, various problems 
from toxicity to inefficacy plague many of these treatments (Figure 3-5).91  Additionally, 
while vaccine research has provided valuable data, the complex life cycle of malarial 
parasites has made the effectiveness of such a vaccine very limited. The development of 
novel drugs for current malarial targets is an important area of current research; however, 
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the discovery of novel malarial targets and treatment strategies is of pivotal importance in 
the on-going battle against this widespread disease.    
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Figure 3-5. Selected examples of currently used drugs for the treatment of malaria. 
 
Our synthesis was able to provide multi-gram quantities of 3-3 and its analogs, and 
therefore we sought to further explore the biological properties of these 
immunostimulants.  A collaboration with the Walter Reed Army Institute of Research 
(WRAIR) was established to explore the effects of 3-3 and selected analogs in in vivo 
malaria screens.   Initial studies were performed dissolving 3-3 in DMSO and 
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administering the compound at varying doses, one injection per day for 3 days prior to 
challenge with the parasite.  The sporozoite levels were measured each following day, 
with the results at day 6 being shown in Figure 3-5 (for daily sporozoite levels and 
experimental protocols, see Appendix C).  To our delight, 3-3 showed substantial activity 
against the malarial parasite, particularly at the 1 mg/kg/day dosage level and inspired us 
to begin synthesis of novel analogs for testing.   
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Figure 3-6. Efficacy and dose dependence of 3-3 in mouse model. 
 
Due to the very limited analog development of the of 3-3, we sought to first 
investigate replacement of the fatty acid chain with shortened derivatives bearing aromatic 
groups, ureas and sulfonamides.  Of particular interest to us were the intriguing results by 
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Wong, who demonstrated that shortening the alkyl chain and addition of a suitably 
positioned aromatic moiety could selectively trigger Th1 vs. Th2 cytokine release.69 
Additionally, we postulated that the urea and sulfonamide groups would retain a Lewis 
basic moiety shown to be essential for binding to CD1d in X-ray structures, while possibly 
improving the extremely poor solubility properties of these glycolipids.93  The solubility 
of 3-3 in DMSO was below 1-2 mg/mL and non-existent in water.   
The synthesis of the first set of analogs began with intermediate 3-45 from the 
synthesis of 3-3.  Deprotection of the Boc group with HCl followed by coupling to a 
carboxylic acid (entry 1 and 2, Table 3-5), isocyanate (entry 3 and 4, Table 3-5) or 
sulfonyl chloride (entry 5, Table 3-5) provided the desired products in high yield with the 
exception of sulfonamide analog 3-51.  Under a variety of conditions the only products 
isolated during attempts to synthesize 3-51 appeared to arise from epoxide formation from 
the diol unit of 3-45.  The solubility properties of these new analogs were greatly 
improved as compared to the parent compound, and we hoped this would help with 
various compound administration issues found previously.  
 With a new set of analogs in hand, additional biological evaluation was conducted 
at the WRAIR to compare the effectiveness to 3-3.  Administration of 1.85 mg/kg of 
analogs and 3-3 for three days prior to challenge with sporozoites was performed, 
followed by monitoring of sporozite levels for 10 days.  The reported data are the 
sporozoite levels at day 6 after sporozoite challenge.  While none of the analogs were as 
active as the parent compound, 3-47 and 3-50 were competent in the study providing 
encouragement that simple modifications in the molecular structure could be tolerated.   
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Table 3-5. Synthesis of novel amide and urea analogs of 3-3. 
OBnO
BnO
BnO
BnO
NHBoc
C14H29
HO OH
1. HCl/dioxane
2. Acid, isocyanate or sulfonyl chloride
3. H2, Pd(OH)2/C, MeOH/CH2Cl2
OHO
HO
HO
OH
NHR
C14H29
HO OH
3-45  
entry coupling reagent/ conditions product yield [%] 
 
1 O
HO
EDCI, DMAP 
O
HO
HO
HO
HO
HN
C14H29
HO
OH
O
3-47
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O
OH  
EDCI, DMAP 
OHO
HO
HO
OH
NH
C14H29
HO OH
O
3-48
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C17H35O
• N  
Et3N 
O
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HO
HO
HO
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O
HN
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O
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O
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HO
HO
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OH
O
HN
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S
O
O
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0 
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Figure 3-7. Biological evaluation of novel C-glycoside analogs. 
 
 Seeking to further explore novel analogs of galactoceramide immunostimulants, it 
was proposed that a thiazole moiety could mimic the Lewis basic amide moiety while 
providing an analog with improved stability and solubility properties.94  Initial attempts 
were focused on the coupling of thiazole bromide 3-53 with amine 3-52 under a variety of 
transition metal and thermal conditions (Scheme 3-10).95  Disappointingly, all efforts to 
achieve this transformation failed.   
N
S
BrOBnO
BnO
BnO
BnO
NH2
C14H29
HO OH
O
O
OBnO
BnO
BnO
BnO
NH
C14H29
HO OH
Cu, Pd or ∆
NS
O
O
3-52
3-53
3-54  
Scheme 3-10. Attempted synthesis of thiazole containing analog as amide mimic. 
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An alternative approach that would build the thiazole moiety in a modular fashion 
was investigated (Scheme 3-11).96  Treatment of carbamate 3-45 with HCl generated the 
HCl salt that was subsequently coupled with Fmoc-thioisocyanate followed by Fmoc 
deprotection to yield thiourea 3-55 in 78% yield over the three steps.   
 
OBnO
BnO
BnO
BnO
NHBoc
C14H29
HO OH
1. HCl/dioxane
2.
S • N
Fmoc
3. Et2NH
OBnO
BnO
BnO
BnO
NH
C14H29
HO OH
S NH2
78% 
(3 steps)
3-45 3-55
 
Scheme 3-11. Synthesis of thiourea 3-55. 
 
Conversion of thiourea 3-55 to the desired thiazole scaffold was accomplished via 
treatment with α-bromo ketones and triethylamine followed by global deprotection of the 
benzyl ethers (Table 3-6).  In this way, aryl ether analog 3-57 and aliphatic analog 3-59 
were prepared in high yield.  Initial attempts to perform the benzyl ether deprotection 
under palladium hydrogenation conditions failed under a variety of conditions, most likely 
due to catalyst poisoning by the thiazole moiety.97   
Biological evaluation of these novel thiazole glycolipids was performed; 
unfortunately, the assay suffered from irreproducibility.  Poor solubility of the parent 
compound and most analogs was the proposed cause for these assay complications.  To 
address these solubility issues a study to determine a more suitable delivery method was 
performed (Table 3-7).  While 3-3 was not soluble in a variety of aqueous solutions, it was 
discovered that cremophore EL allows dissolving of 3-3 in aqueous media.  With the 
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optimized conditions (10% cremophore EL, 10% DMSO, 80% water) employed, >10 
mg/mL of 3-3 could be dissolved in 1 mL of delivery media.  Although this new delivery 
cocktail allowed for higher dosing of 3-3, complete cures of treated mice were not 
obtained in mice studies.  Greatly reduced sporozoite counts were achieved showing the 
utility of this class of galactoceramides as immunostimulants; however, the lack of 
complete eradication of the malarial sporozoites may demonstrate the inability of such a 
therapeutic strategy from being employed as a stand alone malarial treatment.65-68   
 
Table 3-6. Conversion of thiourea to thiazole analogs of 3-3. 
OBnO
BnO
BnO
BnO
H
N
C14H29
HO OH
S
NH2
R
O
Br1.
2. BCl3, -78 ÞC
OHO
HO
HO
HO
NH
C14H29
HO OH
SN
R
EtOH
 
entry ketone product yield [%] 
 
 
1 
 
O
Br
3-56
O
C12H25
 
OHO
HO
HO
HO
NH
C14H29
HO OH
SN
O
C12H25
3-57  
 
 
83 
 
 
2 
 
O
Br C16H33
3-58  
O
HO
HO
HO
HO
NH
C14H29
HO OH
SN
C16H33
3-59  
 
 
88 
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Table 3-7. Solubility studies of 3-3. 
entry conditions solubility 
1 DMSO < 2 mg/mL 
2 50% EtOH, 50% DMSO < 1 mg/mL 
3 20% cremophore EL, 80% water < 5 mg/mL 
4 10% cremophore EL, 10% DMSO, 
80% water 
> 10 mg/mL 
 
3.3 CONCLUSION 
We have demonstrated that an organometallic addition to N-tert-butyl sulfinyl 
imines followed by an epoxidation-epoxide opening sequence can be used to construct the 
necessary stereocenters for target molecules such as 3-3.  Unlike other approaches, our 
current route is short and stereoselective while allowing for facile analogue synthesis. To 
this end we have synthesized a series of analogs that allowed for the biological evaluation 
of this class of immunostimulants.  Although complete cures of malaria were not obtained 
in mice studies, a greatly reduced sporozoite count was achieved.  These results provide 
proof of principle for the use of galactoceramides as immunostimulants, but also highlight 
the inability of these agents to act as stand alone therapies. 
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4.0  ADDITION OF IN-SITU GENERATED ORGANOALANES TO 
ACYLIMINIUM IONS AND IMINES: FROM ISOINDOLINONES TO 
RADIOPROTECTANTS 
4.1 ISOINDOLINONES 
4.1.1 Introduction 
Isoindolinones constitute the core structures of numerous naturally occurring 
biologically active compounds such as magallanesine 4-198 and lennoxamine 4-299 as well 
as many drug candidates such as pagoclone 4-3100 (Figure 4-1).  Isoindolinones  
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Figure 4-1.  Biologically active isoindolinones. 
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demonstrate a remarkably wide array of biological activity, including anti-
inflammatory,101 antihypertensive,102 antipsychotic,103 vasodilatory104 and antileukemic105 
effects, which makes the development of new synthetic routes to these heterocycles 
particularly attractive.  While multiple methods have been reported for the preparation of 
isoindolinones,106 some leading to the synthesis of natural products107 and libraries,108 
many suffer from a lack of generality or functional group compatibility. 
In view of the potent and diverse biological activity of isoindolinones, previous 
studies by Waller and Wipf were directed at their preparation as part of a program for the 
synthesis of nitrogen containing heterocycles.109 The combination of water-accelerated 
carboalumination110 with an intramolecular N-acyliminium ion addition in a cascade 
process that would generate medium-ring containing isoindolinones was envisioned 
(Scheme 4-1).  N-Acyliminium ions are versatile synthetic intermediates111 and have 
previously been employed in the formation of simple isoindolinones;112 however, with the 
exception of allylsilanes, the addition of functionalized organometallic reagents to  
 
N
OMe
n>4
N
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R
Al
N R
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N
R
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O  
Scheme 4-1. Proposed intramolecular addition of alkenylalanes to N-acyliminium ions.  A: Zirconium-
Catalyzed, Water-Accelerated Carboalumination or Hydrozirconation/Transmetallation; B: Elimination; C: 
Addition/Ring Closure. 
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these systems has not yet been exploited.  Moreover, the intramolecular addition would 
potentially provide an entry toward strained medium rings containing (E)-alkenes. 
Investigations began with the synthesis of methoxy-4-8 and phenoxy lactam 4-9 
(Scheme 4-2).  Alcohol 4-5 was obtained in 85% yield by the isomerization of the 
commercially available hept-3-yne-1-ol with the KAPA reagent in 85% yield.113  Imide 4-
6 could then be constructed by a Mitsunobu alkylation with alkynol 4-5, which proceeded 
in 82% yield. Reduction with sodium borohydride was followed by a methanol exchange 
to give methoxylactam 4-8 in 40% overall yield (Scheme 4-2).  With the key substrate in 
hand, submission of 4-8 to Wipf’s water accelerated carboalumination conditions (AlMe3 
(3 eq), H2O (1 eq), zirconocene dichloride (10 mol%)) only returned starting material with 
no evidence for elimination or carboalumination (Scheme 4-3).  
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MeOH, d,l-CSA
40%
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4-5
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4-7
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Scheme 4-2.  Synthesis of lactam precursors. 
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To explore the effect of the leaving group on the aminal, phenoxy lactam 4-9 was 
generated by treatment of 4-7 with SOCl2 and catalytic DMF.  The resulting unstable 
chloride intermediate was immediately treated with phenol in the presence of 
triethylamine to yield 4-9 in 34% yield.114 
 
N
O
OR
AlMe3 (3 eq)
H2O (1 eq)
CH2Cl2
Cp2ZrCl2 (10 mol%)
4-8, No Reaction
4-9, 10% 4-10 + SM
N
O
R = Me, 4-8
R = Ph, 4-9
4-10
 
Scheme 4-3.  Attempted cascade cyclization of 4-8 and 4-9. 
 
When 4-9 was subjected to the carboalumination conditions, only alkylated lactam 4-10 
(10%), starting material (52%), and decomposition products were observed by NMR 
analysis (Scheme 4-3). 
These experiments demonstrated that the functionality present in these lactam 
acetals was inhibiting the carboalumination step.  It was postulated that the lactam group 
was responsible for the observed inhibition, as highly Lewis basic functionality has been 
noted to decrease the reactivity of aluminoxanes.115  Therefore, a series of GC experiments 
to test this hypothesis with 1-heptyne, which is known to undergo rapid water-accelerated 
carboalumination, were performed.  A control experiment demonstrated that the 
carboalumination of heptyne with AlMe3 (3 eq), H2O (1 eq), and Cp2ZrCl2 (10 mol%) 
proceeded to completion in under 5 min at low temperatures (-78 °C to -25 °C) to furnish 
a 97:3 mixture of regioisomers by GC (Scheme 4-4).  Conducting the identical experiment 
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in the presence of 1 equivalent of methoxylactam 4-8 dramatically inhibited 
carboalumination, with only 4.4% of heptyne undergoing conversion after 1 h at ambient 
temperature.  Most likely, this inhibition is due to the coordination of Lewis basic 
functional groups to AlMe3 oligomers, thus preventing alkyne carboalumination.   
 
AlMe3, H2O
Cp2ZrCl2
-78 oC to rt
97:3
100% in <5 min
+
AlMe3, H2O
Cp2ZrCl2
-78 oC to rt
4.4% after 60 min
N
O
OMe
5
4-8
 
Scheme 4-4.  GC analysis of the water-accelerated carboalumination of heptyne in the presence of 4-8. 
 
4.1.2 Results and Discussion 
Due to the lack of reactivity in the previously investigated carboalumination 
approach, we turned to hydrozirconation, known to be quite tolerant of diverse 
functionality.14 When lactam 4-8 was treated with Cp2ZrHCl, only the corresponding 
alkene was recovered (Scheme 4-5). Treatment of the intermediate alkenylzirconocene 
with AgClO4 or trimethylaluminum also provided no desired cyclization products.  
Enhancing the leaving group ability by using the pivaloate 4-11 also failed to promote 
cyclization under any of the above conditions.  Highly concentrated reaction mixtures or 
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prolonged heating resulted only in slow methyl group addition.  Possibly, the ring strain 
incorporated in these systems is too high to allow the reaction to proceed under the current 
conditions.  
N
O
R
O
N
Cp2ZrHCl, then
Me3Al, rt, 0.01 M
4-8, R = OMe 
4-11, R = OPiv
4-12
 
Scheme 4-5.  Attempted hydrozirconation and medium ring formation. 
 
Because the cyclizations proved elusive, we turned our attention toward an 
alternative construction of these systems starting with an intermolecular addition process.  
Alkenylation of N-acyliminium ions can often require harsh reaction conditions116 or 
unusual anomeric leaving groups117 with the exception of the intermolecular addition of 
alkenyl boronates used by Batey et al.118 Accordingly, we first explored the 
hydrozirconation of terminal alkynes as a method to generate alkenyl nucleophiles (Table 
4-1).  Hydrozirconation of 1-hexyne, followed by treatment with silver perchlorate119 and 
lactam 4-13 yielded only a trace of addition product after 24 h at rt (entry 1, Table 4-1).  
Transmetallation to dimethylzinc also proved unsuccessful (entry 2, Table 4-1).  
Gratifyingly, hydrozirconation-transmetallation to trimethylaluminum120 generated an 
alkenylalane that reacted with lactam 4-13 in a moderate 43% yield (entry 3, Table 4-1).  
Again, we increased the leaving group ability by using acetate 4-14; however, product 4-
17 was only formed in 30% yield while the remaining starting material was consumed 
(entry 4, Table 4-1).  Attempts to perform this reaction in THF or toluene led to recovered 
starting material. In an effort to prevent decomposition pathways while retaining leaving 
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group ability, pivaloate 4-15 was synthesized and treated with the in situ generated alane 
to provide hexenyl isoindolinone 4-17 in 81% yield without any observed isomerization of 
the alkene moiety (entry 5, Table 4-1). Attempts to achieve this transformation under 
cationic conditions with silver perchlorate20 led to complex  
 
Table 4-1. Reaction optimization for the addition of hexenylzirconocene to lactams (4-13)-(4-15). 
NBn
O
R
C4H9
Conditions
NBn
O
C4H9
Cp2ZrHCl (2 eq)
CH2Cl2
(4-13)-(4-15)
4-17
(2 eq)
 
entry conditions R(lactam acetal) 4-17 [%] 
1 AgClO4 (10 mol%), 24 h, rt OMe (4-13) Tracea 
2 Me2Zn (2 eq), 12 h, rt OMe (4-13) - 
3 Me3Al (2 eq), 12 h, rt OMe (4-13) 43b 
4 Me3Al (2 eq), 4 h, rt OAc (4-14) 30 
5 Me3Al (2 eq), 4 h, rt OPiv (4-15) 81 
6 AgClO4 (10 mol%), 12 h, rt OPiv (4-15) Complex mixture 
a Product was formed as a mixture of alkene isomers.  b Starting material observed after 12 h.   
 
mixtures, seemingly arising from alkene isomerization.  The mild conditions under which 
the reaction proceeded and the ability to utilize readily available alkynes and pivaloate 
iminium ion precursors encouraged us to explore this addition further. 
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Among the numerous methods known for the synthesis of substituted 
isoindolinones, only a few examples of Heck-type cyclizations install an alkenyl moiety at 
the 3-position.121  The modularity of our approach warranted further investigation, and 
therefore we evaluated the substrate scope of this process.  As shown in Table 4-2, silyl 
ether, carbamate, and sulfonamide functionalities are well tolerated, generating 
functionalized isoindolinones in a high yielding, one-pot procedure. To further extend the 
scope of this addition we synthesized succinimide derived pivaloate 4-25 and subjected it  
 
Table 4-2.  Examination of substrate scope. 
NBn
O
OPiv
R
Me3Al, rt NBn
O
R
Cp2ZrHCl
CH2Cl2
4-15  
entry R (alkyne) product [%]a 
1 C4H9 (4-16) 4-17 [81] 
2 c-C6H11 (4-18) 4-19 [79] 
3 CH2CH2OTBDPS (4-20) 4-21 [71] 
4 CH2CH2N(CO2Me)Ts (4-22) 4-23 [62] 
  a  All reactions were carried out by hydrozirconation of alkyne (2 eq) in  
     CH2Cl2 with Cp2ZrHCl (2.2 eq), followed by cooling to 0 ˚C and addtion 
     of Me3Al (2.2 eq) and 4-15.   
 
to our optimized conditions to provide 4-26 in 83% yield (Scheme 4-6).  The success of 
this reaction bodes well for the extension of this alkenylation methodology to a broad 
class of heterocyclic electrophiles.  
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Scheme 4-6.  Addition to succinimide derived iminium ion precursor. 
  
Additionally, we explored the formation of trisubstituted alkenes in this 
transformation.  Although the lactam functionality had prevented the intramolecular 
addition, preforming the alkenylalane under our water-accelerated conditions followed by 
addition of 4-15 provided isoindolinones 4-27 and 4-29 in 77% yield after only 15 minutes 
(Table 4-3).  The flexibility and mild nature of these transformations are well  
 
Table 4-3.  Water-accelerated carboalumination – addition to lactam 4-15. 
NBn
O
OPiv
R
NBn
O
R
Me3Al, Cp2ZrCl2
H2O
4-15
 
entry R product [%] 
1 C4H9 (4-16) 4-27 [77] 
2 Ph (4-28) 4-29 [77]a 
                                     a Product contains ~5% of a carbometallation regioisomer.   
 
suited for their application in the synthesis of biologically interesting targets and libraries. 
With a methodology in hand to generate alkenyl-functionalized phthalimides, we 
sought to revisit our initial goal of generating medium rings, this time employing ring 
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closing metathesis.23 To begin exploring this approach, we synthesized alkyne 4-30 and 
allyl-pivaloate 4-31 and subjected them to our hydrozirconation-transmetallation 
conditions to generate 4-32 in 55% yield accompanied by considerable methyl addition 
side product (Scheme 4-7).  It should be noted that carbometallation of 4-30 failed and the 
rate of addition for the alkenyl alane generated via the transmetallation was retarded due to 
the presence of the ether functionality.  With 4-32 in hand we screened conditions to form 
the desired 12-membered macrocycle.  Although ring closing metathesis methodology has 
been demonstrated to perform well for the synthesis of a variety of macrocycles,122 rapid 
formation of the undesired 5-membered ring 4-33 was observed (Scheme 4-7).123  
Increased dilution, change of metathesis catalyst, addition of Ti(OiPr)4,124 or varying 
solvents did not influence the reaction pathway.   
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O
N
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61%
4-31
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Scheme 4-7.  Attempted medium ring formation via ring closing metathesis. 
  
Due to the ease of formation of 4-33, we explored the synthesis of this compound 
via addition of hexyne to 4-31 and subsequent ring closing metathesis to provide the 
tricycle 4-33 in 75% yield (Scheme 4-8).  Extension of this approach to the synthesis of 7-
membered rings was achieved though the synthesis of pivaloate 4-36 and subsequent 
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addition of hexyne in 72% yield.  Ring closing metathesis of 4-37 proved to be 
problematic in CH2Cl2 with either Grubbs 1st or 2nd generation catalyst yielding only 
starting material or decomposition products.  Addition of Ti(OiPr)4 in toluene at rt proved 
to be the most successful conditions yielding 4-38 in 67% yield.  Surprisingly, the alkene 
of the product azepene had isomerized, most likely due to a ruthenium hydride species 
generated during the extended reaction times.125  Possible deactivation of the metathesis 
intermediate by the neighboring amide carbonyl could explain the difficulty of this 
transformation.126  While not fully optimized, these reactions provide proof of concept for 
the extension of our phthalimide substrates to yield structurally diverse tricyclic products.   
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Scheme 4-8. Application of ring closing metathesis to generate 5- and 7-membered rings. 
Further derivatization of these scaffolds has been accomplished in the University 
of Pittsburgh Center for Chemical Methodology and Library Development (UPCMLD).  
To this end, 4-38 has been selectively epoxidized with MCPBA and subsequently opened 
via treatment with amines or anilines to provide a small library of isoindolinones that will 
be screened for biological activity (Figure 4-2).   
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Figure 4-2. Selected examples of a library of isoindolinones. 
4.1.3 Conclusions 
We have demonstrated that in situ generated alkenylalanes represent versatile 
nucleophiles for additions to N-acyliminium ions.  While carboalumination is inhibited by 
the phthalamide functionality, preforming alkenylalanes via hydrozirconation-
transmetalation or carboalumination and subsequent addition to the lactam acetal 
substrates yields functionalized isoindolinones.  This method uses easily prepared or 
commercially available starting materials that provide opportunities for diversification at 
numerous points and yields synthetically useful heterocyclic products in a one-pot 
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transformation.  Further elaboration of the alkenyl heterocycles through the use of ring 
closing metathesis provides tri-cyclic products that are common motifs in natural products 
and drug-like molecules.  An initial demonstration of the utility of these products was 
accomplished by a library synthesis in the UPCMLD.   
4.2 SYNTHESIS OF NOVEL RADIOPROTECTANTS 
4.2.1 Introduction 
The role of intracellular reactive oxygen species in mitochondria has been an area 
of increasing study.127  Cellular damage, including aging, and cardiovascular damage are 
two examples of areas that are thought to be directly affected by the build-up of reactive 
oxygen species (ROS) in the mitochondrial membrane.128  Nitroxide radicals have been 
shown to prevent the formation of ROS upon their reduction to hydroxylamine radical 
scavengers via the mitochondrial electron transport chain.129  Traditionally, the delivery of 
therapeutically useful amounts of nitroxides to the mitochondria has proven difficult, 
thereby limiting the application of this strategy.130   
To circumvent these delivery issues, Wipf et al. has developed hemigramicidin-
TEMPO conjugates (4-44, Scheme 4-9) that rely on the similarity of mitochondrial 
membranes to bacterial cell walls that gramicidin natively targets.131  The key intermediate 
in the synthesis of these peptide conjugates is acid 4-42.  The synthesis of this compound 
begins with alkyne 4-39, which is synthesized via a known route.132  Hydrozirconation of 
4-39, subsequent transmetalation to dimethylzinc and addition to N-  
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Scheme 4-9.  Synthesis of novel hemigramicidin conjugates by Xiao and Wipf. 
 
Boc-isovaleraldimine provided 4-40 as a mixture of diastereomers.  Acylation, separation 
of the diastereomers and deprotection provided the necessary alcohol to undergo a 2-step 
oxidation that yielded 4-42 in good overall yield.  4-42 was subsequently coupled with 4-
amino tempo (4-AT) to provide truncated analog 4-43 and with the tri-peptide H-Pro-Val-
Orn(Cbz)-OMe followed by 4-AT to provide hemigramicidin conjugate 4-44.  This 
compound proved to be an effective conjugate for the delivery of nitroxides into 
mitochondria where they accumulate, are reduced, and provide impressive protection 
against apoptosis.   
 Further exploration into the utility of these conjugates revealed their efficacy as 
radioprotectants.133  Ionizing radiation activates a variety of cytoplasmic transduction 
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pathways, some of which are likely mediated by ROS.134  It has been demonstrated that 
exposure to radiation activates nitric oxide synthase in the uroepithelial cells that line the 
bladder, causing increased nitric oxide production and decreased respiration resulting in 
superoxide production.135  Utilizing a potent NOS inhibitor, 2-amino-6-methylthiazine 
(AMT), conjugated to a hemigramicidin targeting sequence (4-45, Figure 4-3), Wipf and 
Kanai were able to demonstrate the localization of the inhibitor in the mitochondria and its 
ability to perform its protective duties.131   
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Figure 4-3. AMT conjugated to hemigramicidin prepared for radiation protection studies. 
 
4.2.2 Results and Discussion 
Having previously developed an efficient method for the asymmetric synthesis of 
allylic amines,119 we envisioned employing this method for the preparation of peptide 
conjugates such as 4-44. Approaches to this class of compounds were effective at 
providing small amounts of material for biological testing, but the 20-step routes proved 
daunting upon scale up.  Additionally, analog development was hindered by the synthetic 
effort involved.  To explore the N-tert-butyl sulfinyl imine chemistry, imine 4-46 was 
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prepared from isovaleraldehyde in 88% yield. Simple filtration through a plug of silica gel 
provided imine of high purity, and the imine proved stable on the order of months on the 
bench top – in stark contrast to the Boc-imine previously employed.   
O N S
O
88%
S
O
H2N
MgSO4, PPTS
CH2Cl2 4-46
 
Scheme 4-10.  Synthesis of imine 4-46. 
 
As a common intermediate for a number of our proposed endeavors, alcohol 4-49 
served as our initial target for synthetic studies (Scheme 4-11).  Hydrozirconation of 
alkyne 4-47, transmetalation to trimethylaluminum, and addition to 4-46 provided an 
allylic amine that was >95:5 dr by 1H NMR analysis of the crude reaction mixture.  
Treatment of this crude reaction mixture with HCl in diethyl ether yielded the amine 
hydrochloride 4-48 as a colorless solid in 74% yield over the 2 steps.  Boc-protection and 
TBAF mediated deprotection of the silyl ether provided the desired alcohol 4-49.   
NH3Cl
OTBDPS
NHBoc
OH
OTBDPS
1. a) Cp2Zr(H)Cl
    b) Me3Al
    c) 4-46
2. HCl/ether
74%, 2 steps; >95:5 dr
1. Boc2O, Et3N
     CH2Cl2
2. TBAF, THF
88%, 2 steps4-47
4-48
4-49  
Scheme 4-11.  Application of alkenyl alane methodology to the synthesis of 4-49. 
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 With alcohol 4-49 in hand, our focus turned to the synthesis of a number of novel 
tempo-peptide conjugates as well as the development of an improved approach to acid 4-
42.  Oxidation of alcohol 4-49 to the desired carboxylic acid was achieved by treatment 
with Jones’ reagent in acetone (Scheme 4-12).  This method proved quite tolerant of the 
Boc-protecting group and was significantly simplified from the previous 2-step oxidation 
procedures.  Subsequent coupling of the acid with 4-AT provided the desired amide 4-51 
(jp4_039) in 76% yield.  The purity of this compound was initially determined to be 85-
90% by LCMS analysis, and has subsequently been improved by SFC purification to 
>98%.136 
 
NHBoc O
N
H
N O
Jones Oxidation
    4-amino tempo
    EDCI, DMAP
    HOBt
4-51, jp4_039
76%, 2 steps
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OH
4-49  4-50
NHBoc O
OH
 
Scheme 4-12.  Oxidation and coupling of 4-49 to yield 4-51 (jp4_039). 
 
 With acid 4-50 readily available, attention was turned to a stereoselective 
alkylation to install the benzyl side chain of 4-43.  Conversion of acid 4-50 to methyl ester 
4-52 was accomplished in 84% yield via the action of TMSCHN2.  Alkylation of this ester 
proved challenging, usually providing mixtures of mono- and bis-alkylated products upon 
treatment of the enolates with benzyl bromide.  The potassium enolate exclusively 
provided the bis-alkylated product 4-54 (entry 1, Table 4-4).  Gratifyingly, after variation 
of solvent, additives, bases and temperatures, formation of the lithium enolate in THF 
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employing DMPU as an additive and treatment with benzyl bromide at -30 ˚C yielded 
78% of alkylated product as a 1.5:1 mixture of diastereomers that have not been assigned 
(entry 4, Table 4-4).  Interestingly, no δ-alkylation or N-alkylation was observed in any of 
the studied cases.   
 
Table 4-4.  Development of alkylation conditions for the preparation of 4-53. 
 
NHBoc O
OH
TMSCHN2
NHBoc O
O
conditions NHBoc O
O4-50 4-52
4-53
 
entry conditions alkylating agent (eq) yield [%] (product) 
1 KHMDS, -78 ˚C - -20 ˚C, 4 h BnBr (1.2 eq) 45 (4-54) 
2 NaHMDS, -78 ˚C - -20 ˚C, 6 h BnBr (1.2 eq) 4-53 + 4-54a 
3 LDA, THF, -78 ˚C - -30 ˚C, 14 h BnBr (5 eq) 23 (4-53) 
4 LiHMDS, DMPU, -78 ˚C - -30 ˚C, 14 h BnBr (5 eq) 78 (4-53, 1.5:1 dr)b 
a Yield not determined. b Yield of isolated and purified product.  dr determined by HPLC analysis: Chiracel®  
  AD-H column and elution with 3% i-PrOH/hexanes.  Major diastereomer not assigned.   
 
NHBoc O
O
PhPh
4-54  
 
 
 Unfortunately, attempts to hydrolize the methyl ester to generate the requisite acid 
for coupling to 4-amino tempo failed, yielding only conjugated alkene product (Scheme 4-
13).  This product was converted to the corresponding 4-AT adduct 4-55 for biological 
testing. 
 - 84 -  
NHBoc O
O
NHBoc O
N
H
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4-53
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NHBoc O
OH
 
Scheme 4-13. Hydrolysis and coupling of methyl ester 4-53. 
  
 To circumvent the problems associated with ester hydrolysis, acid 4-50 was 
converted to allyl ester 4-56 by treatment with allyl alcohol and DCC.  Alkylation of this 
ester went smoothly under the previously optimized conditions, providing an inseparable 
1.5:1 mixture of diastereomers of 4-57 that has not been assigned.  Allyl ester 4-56 was 
smoothly deprotected under palladium catalysis conditions and the acid subsequently 
converted to an inseparable mixture of 4-43 by coupling with 4-AT.   
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NHBoc O
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NHBoc O
O
OH
DCC
LiHMDS
NHBoc O
N
H
N
O
1. Pd(PPh3)4
    PhSiH3
2. 4-amino tempo
    EDCI, DMAP
    HOBt
4-50 4-56
4-57 4-43
87%
71%
1.5:1 dr
79%, 2 steps  
Scheme 4-14. Synthesis of allyl ester alkylaton substrate and synthesis of 4-43. 
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 With this streamlined approach to novel nitroxide compounds, a collaboration with 
the newly formed University of Pittsburgh Center for Medical Countermeasures Against 
Radiation was established.  Upon screening of a variety of nitroxide containing conjugates 
it was discovered that 4-51 (jp4_039) was the most effective radioprotectant screened in-
vitro.137  To our delight, positive results also extended to in-vivo studies. C57BL/6NHsd 
female mice injected with 1 mg/kg jp4-039 before irradiation had a significant increase in 
survival of 80% compared to 20% for control irradiated mice (p = 0.0005) (Figure 4-4).137  
These impressive results are under further examination; additionally, jp4-039 will be 
produced on a 200 gram scale to begin primate studies in the near future.   
 
 
Figure 4-4.  In-vivo studies of various nitroxide containing conjugates for radiation protection.138 
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Although detailed experiments to determine the mechanism of action of jp4_039 
are only beginning, the current hypothesis is that through targeting of jp4_039 to the 
mitochondria, reduction of damaging superoxide radical anion is achieved.  While 
jp4_039 is smaller than XJB-5-125, early experiments have demonstrated that the current 
compound is also preferentially located in the mitochondria.139 Further studies to 
determine the mechanism of action of jp4_039 are currently underway.   
4.2.3 Conclusion 
We have extended our alkenyl alane addition to imines to the synthesis of 
biologically relevant peptide mimetics.  These studies have led to an improved route to a 
key fragment of hemigramicidin tempo hybrid molecules as well as to a novel radiation 
protection agent.  Biological evaluation has shown the in-vivo ability of 4-51 (jp4_039) to 
prevent death from intense radiation exposure. Future studies aim at the large scale 
synthesis and primate studies of this readily accessible compound.   
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5.0  L-TYROSINE AS A SYNTHETIC BUILDING BLOCK: THE SYNTHESIS 
OF OCTAHYDROINDOLES AND PROGRESS TOWARD THE TOTAL 
SYNTHESIS OF TUBEROSTEMONONE 
5.1 INTRODUCTION 
5.1.1 Stemona Alkaloids: Tuberostemonone 
The Stemonaceae plant family, which comprises over 30 species, produces a large 
class of structurally diverse alkaloids featuring a conserved pyrrolo[1,2-a]azepine nucleus 
(Figure 5-1).140  The natural products isolated from these plants are classified into 6 
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Figure 5-1. Classification of the Stemona alkaloids. 
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groups, each bearing a unique molecular architecture around the azepine core.  Natural 
products from Stemona and Croomia plants have been isolated since before the 1930’s in 
the western literature and possess a broad array of complex functionality (Figure 5-2).141 
The plant extracts have been used for centuries in eastern cultures as remedies for 
respiratory conditions, such as bronchitis and tuberculosis.  To date, with the exception of 
insecticide activity, few human health benefits have been observed from the purified 
compounds of the Stemona family.142 
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Figure 5-2.  Representative structural diversity in the Stemona alkaloid family. 
 
Synthetic efforts to this family of natural products has spanned two decades, 
beginning with the first total synthesis of croomine in 1989 by Williams et al.143a Since 
this time, a number of novel synthetic strategies have been developed to synthesize 
Stemona alkaloids.143,138 Of particular interest are the elegant syntheses of stenine and 
tuberostemonine by Wipf et al. who rapidly construct the core of these natural products 
via functionalization of a hydroxyhydroindole derived from L-tyrosine (Scheme 5-1).144  
The synthesis of tuberostemonine was particularly interesting due to the development of a 
novel synthesis of the appended lactone by the addition of an anionic ortho ester to a 
Weinreb amide (5-6 – 5-8, Scheme 5-1).   
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Scheme 5-1. Overview of Wipf's total synthesis of tuberostemonine. 
 
Tuberostemonone (5-11, Scheme 5-2), a Stemona alkaloid isolated in 1991 and 
structurally assigned by X-ray and spectroscopic means, bears a unique 9-membered 
lactam core.145  The origin of this unusual structure sparked the interest of Wipf et al. and  
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Scheme 5-2.  Proposed biosynthetic origins of several Stemona alkaloids by Wipf. 
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studies toward the synthesis of this natural compound began.  A key element to the initial 
approach was the concept that 5-11 could arise via an oxidative cleavage of 
tuberostemonine.146  In this way, it was envisioned that a number of the members of the 
Stemona family had a common biological precursor and were linked through a series of 
oxidations and fragmentations (Scheme 5-2).   
5.1.2 Alkoxy Radical Fragmentations 
To transform the biosynthetic concept to a synthetic reality, Wipf and Li explored 
the alkoxy radical fragmentations of hydroxyhydroindole model systems.140 Utilizing the 
Suarez reagent147 (PhI(OAc)2, I2), hydroxyhydroindole 5-13 was readily converted to 
aminal 5-17 in 80% yield.  The reaction proceeded via an intermediate unstable iodine 
trapping product which was displaced by acetate under the reaction conditions.  Further 
conversion of the acetal to the required 9-membered keto-lactam 5-18 was achieved by 
treatment with MCPBA and pyridine.148 
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Scheme 5-3.  Radical fragmentation of hydroxyhydroindoles developed by Wipf and Li. 
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Although only demonstrated on a model substrate, this chemistry provided support for the 
hypothesis that tuberostemonone arises via oxidative fragmentation of tuberostemonine or 
a related alkaloid.   
5.1.3 Hydroindoles 
Aeruginosin 298-A (5-19, Figure 5-3) is a serine protease inhibitor that was 
isolated from a fresh water blue green algae in 1994.149 Approximately sixteen members 
of the aeruginosin family have been identified, and fourteen share the unusual bicyclic 
amino acid L-Choi  [(2S,3aS,6R,7aS)-2-carboxy-6-hydroxyoctahydroindole] or a close 
derivative as a common motif.150 L-Choi is an example of the growing class of sterically 
encumbered proline analogues that exert a profound influence on the secondary structure 
when embedded in oligopeptide sequences. Several synthetic approaches to Choi and 
aeruginosin natural products have been reported.151  Many other natural and synthetic 
compounds contain fused bicyclic scaffolds that closely resemble Choi.152  The naturally 
occurring di-, tri- and tetrahydroxylated indolizidine alkaloids, lentiginosine (an 
amyloglucosidase inhibitor), swainsonine (an α-mannosidase inhibitor), and 
castanospermine (5-20, an α-glucosidase inhibitor; analog 5-21145f) are particularly 
noteworthy (Figure 1).  Parkacine (5-22) is an alkaloid from Amaryllis belladonna var 
blanda Brunsvigia josephinae. The significance of these fused bicyclic scaffolds for 
biologically active natural products has inspired the development of novel chemical 
libraries.153 
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Figure 5-3. Representative biologically active hydroxyhydroindoles. 
5.2 RESULTS AND DISCUSSION 
5.2.1 Hydroxyhydroindole Synthesis  
At the outset of this project it was envisioned that the previously developed 
oxidative cyclization/methanolysis methodology would provide ample access to our 
requisite hydroxyhydroindole.  Unfortunately, at this time it was discovered that 
significant racemization of the hydroindole product was occurring during the basic 
methanolysis protocol.138,154 Since this was the starting material for our proposed 
synthesis, as well as for other current and previous natural product targets, a thorough 
         
N
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OH
H
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O
O
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O
Na2CO3PhI(OAc)2
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50-60% ee
5-4 5-23 5-5
 
Scheme 5-4. Previously developed oxidative spiro-cyclization / methanolysis. 
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evaluation and optimization of this reaction sequence needed to be performed. Initial 
efforts were focused on the large scale synthesis of spirocycle 5-23 via a protocol 
previously developed by Wipf.147 Although this oxidation was originally performed in 
methanol and subsequently nitromethane, a 3:1 mixture of acetonitrile:isopropanol has 
proven more successful upon scale-up (Scheme 5-6).  This optimized procedure led to 
spirocycle 5-23 in 42% yield and >99% ee as determined by chiral HPLC analysis. 
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O
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32%
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MeCN/i-PrOH (3:1)
42% [50 g]
O
O
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5-4 5-23
 
Scheme 5-5.  Improved protocol for oxidative cyclization. 
 
With spirocycle 5-23 in hand, methanolysis conditions were screened to explore 
the effects of bases, solvents, temperatures and additives on the desired transformation 
(Table 5-1). We measured product ratios and enantiomeric excess by chiral HPLC 
analysis. Stronger bases and/or extended reaction times gave products with further 
deteriorated enantiomeric purity, while weak bases (NaOAc, entry 5) or nucleophilic bases 
(DMAP, entry 9) promoted only spirocycle opening to generate hydroxydienone 5-24.  
Lowering the reaction temperature and using NaOMe had a beneficial effect, providing 5-
5 in 87% ee (Table 5-1, entry 11).  Addition of water and switching the base to KOH not 
only improved the ee further to 97%, but also decreased the reaction time to 10 min and 
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increased the yield to 80%.  Utilizing this optimized protocol, 5-5 could be prepared in 
overall 34% yield and 97% ee from L-tyrosine on a 50 gram scale. 
 
Table 5-1.  Optimization of methanolysis to avoid racemization. 
NO
CO2Me
OH
H CbzO
O
NHCbz
O
+
O
NHCbzOH
CO2Me
Conditions
MeoH
5-5
5-245-23
 
 
                     a Determined by HPLC analysis of crude reaction mixtures using a Chiracel AD-H  
entry conditions ratioa  ee (%)a 
 
1 
 
Na2CO3 (1 eq), rt, 3 h 
 
5-5 only 
 
53 
2 NaHCO3 (2 eq), rt, 14 h 5-5 only 67 
3 NaHCO3 (2 eq), MWI, 80 °C, 20 min 5-5:5-23, 6:1 12, 2 
4 Na2HPO4 (1 eq), rt, 27 h 5-24:5-23, 3.6:1 93, 86 
5 NaOAc (1 eq), rt, 12 h 5-24:5-23, 4.6:1 92, 89 
6 Li2CO3 (1 eq), rt, 16 h 5-5 only 50 
7 Cs2CO3 (1 eq), rt, 5 min 5-5 only 51 
8 i-Pr2NEt (1 eq), rt, 19 h 5-5 only 58 
9 DMAP (1 eq), rt, 20 min 5-24:5-23, 2.3:1 97, 93 
10 NaOMe (1 eq), -78 °C, 80 min 5-24:5-23, 9:1 99, 99 
11 NaOMe (1 eq), - 25 °C, 14 h 5-5 only 87 
12 3 M KOH/H2O, -20 °C, 10 min 5-5 only 97 
                              column; individual yields were not determined. 
 
After identifying a stereoselective protocol to desired hydroindole 5-5, our focus 
turned toward the synthesis of hydroxylated L-Choi derivatives.  Realizing the potential to 
generate a number of stereoisomers from the common intermediate 5-5, we first subjected 
the enone to NaBH4 at 0 °C to provide in 73% yield the axial alcohol 5-25, which upon 
dihydroxylation led to tetrol 5-26 in 1.4:1 facial selectivity and 78% yield (Scheme 5-7). 
The Cbz group was removed by hydrogenolysis to yield a mixture of amines (5-27), and 
separation of diastereomers was achieved by formation of their hydrochloride salts in 
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methanol, followed by selective precipitation to generate 5-28 as a single diastereomer in 
47% yield based on 5-26. 
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Scheme 5-6.  Synthesis of tetrahydroxy hydroindole 5-28. 
 
The configuration at the C4 and C5 positions of 5-28 was initially assigned based on 
1H NMR analysis; specifically, the hydrogen atoms were assigned by COSY and HMQC 
and the relative configuration was determined in 1H NMR double resonance experiments 
from the coupling constants J4,5 = 3.5 Hz  and J5,6 = 2.4 Hz for 5-28 (Figure 5-4).  Among 
the C6-α-hydroxy isomers 5-28 and 5-29, only 5-28 provided a good agreement between 
the dihedral angles of the minimized structure and these coupling constants.155 This 
assignment was further confirmed by an X-ray analysis of the N-alkylated derivative 5-30.  
In the solid state, this compound adopted a conformation closely analogous to the 
calculated structure of 5-28 shown in Figure 5-4, with dihedral angles τ HC6-C5H = -63.3° 
and τ HC5-C4H = 53.7°.  It is interesting to note that the osmate in the dihydroxylation step 
favors an approach from the concave α−face which is sterically only slightly shielded by 
the equatorial secondary alcohol.156  This result demonstrates the role of the tertiary 
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alcohol at the bridgehead position in controling the anti-approach of osmium tetraoxide to 
the allylic double bond. 
 
 
Figure 5-4. Conformational analysis of 5-28 and 5-29. 
 
The synthesis of the C6-epimer 5-33 began with a reduction of enone 5-5 with L-
Selectride at -78 °C to give the axial alcohol in 77% yield and in >95:5 selectivity when 
the reagent was added by syringe pump (Scheme 5-7). Subsequent dihydroxylation of the 
diol gave 5-32 as a single diastereomer by 1H NMR analysis. Tetrol 5-32 was 
subsequently deprotected to provide hydroindole 5-33.   
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Scheme 5-7. Synthesis of hydroxyhydroindole 5-33. 
 
In contrast to 5-28, the differentiation of the two possible diastereomers of 5-33 by 
coupling constant analysis was not possible, since the two energy minimized structures 
had very similar dihedral angles. Fortunately, sulfonylation of 5-33 provided the 
crystalline material 5-34 which enabled the unambiguous assignment of the relative 
configuration through X-ray analysis.  Based on our previous result, it was not surprising 
that the approach of the osmium reagent occurred opposite to the cis-1,4-diol 
functionality, exclusively from the α-face of alkene 5-31. 
After establishing a facile approach to hydroxylated L-Choi derivatives, we 
pursued a reductive amination as a way to install diverse functionality onto the secondary 
amine.  To this end, a number of conditions were screened to achieve high yields in the 
amination. MP-cyanoborohydride resin157 was found to be the most effective reducing 
agent, which we attributed to its greater stability in methanol.  Applying these optimized 
conditions to both intermediates 5-28 and 5-33, we produced tertiary amines bearing 
thiophene (5-35), cyclohexyl (5-30), cyclopropyl (5-36) and pyridine (5-37) hetero- and 
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carbocyclic ring functionality (Scheme 5-8).  These conversions illustrate the broad 
substituent diversity that can be introduced with this transformation. 
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Scheme 5-8. Functionalization of hydroindoles through reductive amination. 
5.2.2 Tuberostemonone 
The stereochemical difference between 5-11 and tuberostemonine (5-9) or stenine 
(5-2) provided substantially different chemical problems and therefore required a novel 
approach for its synthesis.  Retrosynthetically, it was envisioned that tuberostemonone 
would arise from late-stage epoxidation/epoxide opening of alkene 5-38, readily available 
from a Claisen rearrangement of allylic alcohol 5-39 (Scheme 5-9).  The 9-membered 
lactam would arise via fragmentation of an appropriately functionalized 
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hydroxyhydroindole, utilizing the Suarez reagent as previously investigated by Wipf and 
Li.140 Synthesis of alcohol 5-39 from hydroxyhydroindole 5-5 could be envisioned by a 
sequential bis-alkylation, ring-closing metathesis and reduction protocol.  
Hydroxyhydroindole 5-5 is a known compound158 that would arise from the oxidative 
cyclization and subsequent methanolysis of L-tyrosine.  
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Scheme 5-9.  Initial retrosynthetic analysis of tuberostemonone. 
 
Key to a successful synthesis of tuberostemonone is the ability to install the 
requisite stereocenters of the natural product from the functionalized hydroindole 5-5.  
While this scaffold has been transformed to stenine and tuberostemonine, early removal of 
the tertiary alcohol and opposite stereochemistry at several centers facilitated these 
efforts.138 Previous work by Wipf and Li focused on the alkylation of enone 5-5, and this 
work demonstrated the difficulties in this reaction.159  Although troublesome, this 
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transformation provided the most rapid access to the core of tuberostemonone and 
therefore warranted further investigation.  To this end, a variety of bases and protecting 
groups were screened to explore the alkylation of hydroindole 5-5 with a simple allyl 
electrophile (Table 5-2).  Treatment of 5-5 with lithium, sodium or potassium 
                      
Table 5-2.  Attempted alkylation of hydroindole 5-5. 
N
Cbz
OR
CO2Me
HO
N
Cbz
OR
CO2Me
HO
Conditions
5-40
N
Cbz
OR
CO2Me
HO
5-42
N
Cbz
OR
CO2Me
H
O
5-415-5
 
entry R conditions result 
1 TMS LiHMDS, allyl iodide, THF, - 40 ˚C, 12 h 25% (5-40 + 5-41, 3:1) + 5-42 
2 TMS NaHMDS, allyl iodide, THF, - 40 ˚C, 12 h 10% 5-40 + 50% 5-42 
3 TMS KHMDS, allyl iodide, THF, - 40 ˚C, 6 h 65% 5-42 
4 MOM LiHMDS, allyl iodide, THF, - 40 ˚C, 12 h 40% (5-40 + 5-41, 1.1:1) + 5-42 
5 THP LiHMDS, allyl iodide, THF, - 40 ˚C, 12 h 35% (5-40 + 5-41, 1.2:1) + 5-42 
6 H LiHMDS, allyl iodide, THF, -40 ˚C, 4 h 33% 5-40, 100 mg scale 
22% 5-40, 2 g scale 
7 H LiHMDS, allyl chloride, THF, -30 ˚C, 8 h 12% 5-40, 2 g scale 
 
bistrimethylsilyl amide followed by reaction with allyl iodide, led to low yields of the 
desired product 5-40 and often mixtures of diastereomers.  Rapid elimination of the 
carbamate moiety upon enolate formation can be blamed for the observed difficulties.  To 
further complicate matters, further deprotonation-elimination-alkylation of the desired 
product 5-40 to provide 5-42 is a rapid process, particularity when employing potassium 
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bases.  Difficulty in the alkylation of dieneolates has been well documented, and solutions 
have been developed (such as hydrazone formation).160 Unfortunately, none of these 
approaches were successful in our system.   
To further probe the reactivity of these systems, the alkylation of silyl enol ethers 
was explored (Table 5-3).  Formation of the required silyl enol ether was straightforward 
as this reaction could be performed at -78 ˚C and thereby avoid carbamate elimination.  
With 5-43 in hand, it quickly became apparent that this substrate did not perform well in 
typical reactions of silyl enol ethers, with low yields or no conversion observed in all 
explored cases.161   
 
Table 5-3.  Formation of silyl enol ether and attempted alkylation. 
N
Cbz
OR
CO2Me
H
TESON
Cbz
OR
CO2Me
H
O
LiHMDS
TESCl
78%
Conditions
N
Cbz
OR
CO2Me
H
O
R
5-5
5-43 5-44
 
entry R conditions result 
1 TMS AgBF4 or AgOC(O)CF3, allyl iodide, CH2Cl2, -20 ˚C, 4 h 12% 5-44 + 5-5 
2 TMS Pd (PPh3)4, butadiene monoxide, THF, rt, 10 h complex  
3 TMS MeLi, allyl iodide, THF, -78 ˚C - rt 5-5 + dec 
4 MOM MAD, CH2Cl2, MeOTf, rt, 24 h 5-43 
  
Previous work in the area of ketone allylation has shown the power of palladium 
catalyzed intramolecular allylations in both a diastereoselective and enantioselective 
sense.162,163 We envisioned that formation of the requisite enol carbonate 5-45 would be 
straightforward as in the case of the silyl enol ether 5-43 and proposed that the subsequent 
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allylation reaction would proceed rapidly, thereby circumventing many of the previously 
observed difficulties (Table 5-4).  Subjecting of 5-5 to KHMDS and allyl chloroformate 
provided enol carbonate 5-45; unfortunately, treatment of 5-45 under a variety of 
palladium catalysis conditions led to poor diastereoselectivities in the allylation reaction.  
Variation of the protecting group on the tertiary alcohol also did not improve the reaction 
selectivity. 
 
Table 5-4. Palladium catalyzed intramolecular allylation of 5-45. 
N
Cbz
OR
H
CO2Me
O
O O
N
Cbz
OR
CO2Me
HO
KHMDS, THF
then AllocCl
87% NCbz
OR
H
CO2Me
O
Conditions
5-5
5-45
5-40
 
entry R conditions result 
1 TMS Pd(PPh3)4, THF, -50 ˚C, 14 h  90%, 1.5:1 dr  
2 TMS Pd2(dba)3, DPPE, THF, -40 ˚C, 12 h complex 
3 Bz Pd(PPh3)4, THF, -50 ˚C, 14 h 70%, 1.2:1 dr 
4 MOM Pd(PPh3)4, THF, -50 ˚C, 14 h 81%, 1.1:1 dr 
 
 After obtaining these disappointing results, we sought to determine if the 
problematic step in the reaction was the palladium catalyzed allylation or the formation of 
the enol carbonate (Scheme 5-10).  Treatment of 5-46 with KHMDS at -78 ˚C followed by 
addition of allyl chloroformate and warming to -40 ˚C provided a 1.4:1 mixture of 
diastereomers (5-47 and 5-48) thereby demonstrating the troublesome step was the enol 
carbonate formation.  All attempts at improving this transformation were not successful. 
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N
Cbz
OBz
H
CO2Me
O
O O
N
Cbz
OBz
CO2Me
HO
KHMDS, THF
then AllocCl
+
N
Cbz
OBz
H
CO2Me
O
O O
~1.4 : 1 dr
5-46
5-47 5-48  
Scheme 5-10.  Observed deterioration of diastereoselectivity in enol carbonate formation. 
 
 The limited success that was previously obtained in the allylation of 5-5 occurred 
when no protecting group was employed on the tertiary alcohol. This observation inspired 
us to explore the effect of an alkoxide ion at this position on the palladium allylation 
chemistry.  With this goal in mind, 5-5 was treated with KHMDS and allyl chloroformate 
to provide a compound that was assumed to be enol carbonate 5-49 (Scheme 5-11).  To 
our delight, subjecting this compound to LiHMDS and Pd(PPh3)4 provided the desired 
allyated product 5-40 in 60% yield as a single diastereomer.  While this result was 
encouraging, the reasons for the success were unclear and prompted a closer inspection of 
the reaction intermediates.   
 
N
Cbz
OH
CO2Me
HO
N
Cbz
OH
CO2Me
HO
O O
KHMDS
Allylchloroformate
N
Cbz
OH
CO2Me
HO
60% yield + SM
1 diastereomer
crude
90%
LiHMDS, 0 ÞC
then Pd(PPh3)4
THF
5-5
5-49
5-40
 
Scheme 5-11. Successful intramolecular allylation of proposed enol carbonate 5-49. 
 
Purification and characterization of intermediate 5-49 quickly revealed that the 
product of the previous enol carbamate forming reaction was the tertiary carbonate and not 
the enol carbonate.  Accordingly, tertiary carbonate 5-50 was synthesized by treatment 
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with NaH and allyl chloroformate to provide the desired product in 82% yield (Table 5-5).  
This compound was identical to the intermediate in the previous reaction sequence.  A 
variety of conditions were screened to explore this intriguing reaction.  Interestingly, of all 
the bases and palladium sources explored, the lithium enolate and Pd(PPh )  were the only 
effective combination to promote this allylation reaction.  Although no mechanistic details 
have been explored to date, these observations could be rationalized by a soft-soft 
interaction between the π-allyl palladium complex and the lithium enolate.  The instability 
of the allylic carbonate upon prolonged exposure to palladium could also play a role in the 
observed limitations.   
3 4
 
Table 5-5.  Optimization of palladium catalyzed intramolecular allylation reaction. 
N
Cbz
OH
CO2Me
HO
N
Cbz
OH
CO2Me
HO
N
Cbz
O
CO2Me
HO
O
O
NaH,
allylchloroformate
THF, 0 ÞC
Conditions
5-5
5-50
5-4082%
 
entry conditions  a result 
1 LiHMDS, Pd(PPh3)4, THF, 0 ˚C, 15 min  60%  
2 NaHMDS, Pd(PPh3)4, THF, 0 ˚C, 30 min trace  
3 KHMDS, Pd(PPh3)4, THF, 0 ˚C, 30 min NR 
4 DBU, Pd(PPh3)4, -20 ˚C – rt, 6 h 5-5 
5 Cs2CO3, Pd(PPh3) -20 ˚C – rt, 6 h 5-5 
6 LiHMDS, ZnCl2, THF, 0 ˚C, 30 min trace 
7 LiHMDS, Pd(OAc)2, DPPE, THF, 0 ˚C, 2 h complex 
4, 
                                  a All reactions were performed on a 100 mg scale. 
 The extremely rapid nature of the allylation reaction (10 min at 0 ˚C) when 
compared to other palladium catalyzed reactions of allyl carbonates raises interesting 
 - 105 -  
mechanistic questions.  We propose, upon lithium enolate formation and addition of Pd0, 
an intramolecular transfer of the π-allyl palladium intermediate to the enolate and 
regeneration of Pd0 (Scheme 5-12).  Experiments to further probe the mechanistic details 
of this transformation have not been performed, but we observed that the reaction was not 
affected by 5x dilution.   
N
Cbz
O
CO2Me
HO
[Pd]
Li
5-51  
Scheme 5-12.  Proposed intermediate for allylation. 
 
While investigating the use of the allylation as the first step in the construction of 
5-11, we also became interested in investigating the conjugate addition of organometallic 
reagents to enone 5-5 (Scheme 5-13).  Disappointingly, a number of nucleophiles, 
including organocuprates and allyl silanes, provided poor diastereoselectivity.164  This is 
most likely due to the electronic repulsion by the hydroxy group, as this was also a 
problem in the previously discussed dihydroxylation chemistry.   
 
N
Cbz
OH
H
CO2Me
O N
Cbz
OH
H
CO2Me
O
R
5-5 5-51
organocuprates
+
N
Cbz
OH
H
CO2Me
O
R
5-52
1.5:1 - 1:1 mixtures  
Scheme 5-13.  Addition of organocuprates provided poor diastereoselection. 
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To circumvent these selectivity issues, we chose to investigate organometallic 
agents that would be directed by, as opposed to repelled by, the tertiary hydroxyl group.  
Gratifyingly, the use of triorganoaluminum reagents, prepared in-situ from the 
corresponding Grignard reagents and aluminum trichloride, proved effective for the 
desired conjugate addition (Scheme 5-14).165  In this manner, vinylated product 5-53 was 
obtained in 63% yield as a single diastereomer.  
 
N
Cbz
OH
H
CO2Me
O
Al
CH2Cl2, 0 °C
63% NCbz
OH
H
CO2Me
O N
Cbz
OH
H
CO2Me
O
1. Cy2BH, then
    NaBO4
2. TBDPSCl, Im.
     24%, 2 steps
OTBDPS
5-5 5-53
5-54  
Scheme 5-14.  Application of organoalane addition reaction to provide vinylated product. 
 
Conversion of the alkene to the terminal primary alcohol was explored via 
hydroboration chemistry.  Upon screening of a variety of hydroboration conditions, 
dicyclohexylborane was chosen as the most effective reagent in terms of both yield and 
chemoselectivity.  Although promising, the low 24% yield over the hydroboration-
oxidaton-silyl protection sequence and the inability to install the needed methyl group on 
this side chain in a selective manner led us to reconsider our overall synthetic strategy.   
 Having spent considerable effort exploring alkylation and conjugate addition, we 
became convinced that the tertiary alcohol moiety of the hydroindole was an essential 
directing element to install key stereocenters of tuberostemonone.  Although previous 
attempts at functionalization of hydroindole 5-5 had been hindered by this tertiary alcohol, 
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we envisioned employing it not only to direct the palladium allylation previously 
discussed, but to also utilize it to direct an intramolecular 1,4-addition (Scheme 5-15).  In  
 
Coupling/
Hydroboration
Fragmentation
Mitsunobu
N
OO
O OH
H
H O O
H
Tuberostemonone (5-11)
N
Cbz
OH
H
CO2Me
OSiR3
OBn
O
Intramolecular
1,4-addition
Alkylation
N
Cbz
O
H
CO2Me
O
O
OBn
Reduction
N
Cbz
O
H
CO2Me
O
O
X
Acylation
OBn
5-55
5-565-57
 
Scheme 5-15. Revised retrosynthesis: Tertiary alcohol as pivotal directing group. 
 
this fashion we would target the installation of the newly formed carbon-carbon bond 
while hopefully also achieving the introduction of the neighboring methyl group early in 
the synthesis.  This new retrosynthetic analysis provides, upon allylation and 1,4-addition, 
ketone 5-55 that serves as a versatile intermediate for addition of the remaining two 
stereocenters of the natural product’s core.   
 Initial attempts to explore the nature of intramolecular 1,4-additions of ester 
enolates focused on ester 5-59, readily available by coupling alcohol 5-58 with propionic 
acid (Scheme 5-16).  Upon treatment with KHMDS, 5-59 was converted to a new 
compound which unfortunately was found to be the elimination/carbamate addition 
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product 5-60.  This result is not surprising given the readiness of the potassium enolate to 
eliminate the carbamate moiety as was previously seen in the enolate alkylation studies.   
 
N
Cbz
OH
H
CO2Me
O N
Cbz
O
H
CO2Me
OO
HO
DCC, DMAP,
O
75%
N
Cbz
O
H
CO2Me
O
O
KHMDS
only product observed
5-40 5-59 5-60
2.
1. PtO2, H2, 98% (5-58)
 
Scheme 5-16.  Initial attempts at an intramolecular Michael addition of 5-59. 
 
Requiring chemoselective deprotonation of the ester moiety, we turned our 
attention to the Reformatsky reaction.166  The synthesis of α-bromo ester 5-61 was readily 
accomplished by coupling with 2-bromopropionic acid.  Disappointingly, treatment of this 
ester with activated zinc only led to de-bromination products and none  
 
N
Cbz
OH
H
CO2Me
O N
Cbz
O
H
CO2Me
O
O
HO
Br
DCC, DMAP
O
Br
84%
N
Cbz
O
H
CO2Me
O
O
Zn, I2
only product observed
N
Cbz
O
H
CO2Me
O
O
AIBN, Bu3SnH
Toluene
73%
5-5 5-61
5-62
5-63  
Scheme 5-17. Utilization of α-bromo esters to install two stereocenters of tuberostemonone. 
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of the desired 1,4-addition.  Already having access to 5-61, attempts at employing an 
intramolecular radical addition into the enone were also explored.  While radical additions 
of organohalide derived radicals to alkenes have a long history, the intramolecular 
addition of α-halo esters to enones by radical means has seen less study.167  To our 
delight, treatment of 5-61 with tributyltin hydride and AIBN in toluene at 100 ˚C provided 
lactone 5-63 in 73% yield and as a single diastereomer.  It is not clear at this time whether 
this exclusive product formation is due to selective decomposition of the undesired 
diastereomer or exclusive diastereoselectivity in the radical addition.   
The stereochemical outcome of this transformation was confirmed through 2D 
NMR analysis (ROESY, Figure 5-5).  Key correlations are between the α-methyl group, 
hydroindole methylene and α-methyl ester proton.   
 
Figure 5-5. Key ROESY interactions to confirm stereochemical assignment of 5-63.  Methyl carbamate 
used on 3-D structure (left) for clarity.   
 
With 5-63 in hand, we investigated the conversion of this compound to ketone 5-
66, which could serve as a useful intermediate in our synthesis after selective alkylation 
(Scheme 5-18).  Protection of ketone 5-63 as its ketal with ethylene glycol, reduction of 
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the lactone to the primary alcohol, protection of the newly formed alcohol as a silyl ether 
and deprotection of the ketal provided ketone 5-66. Previously studied alkylations of 
unsymmetrical ketones of this type by Wipf and Joo allowed us to postulate that the 
desired alkylation would occur.168  Surprisingly, subjecting 5-66 to LiHMDS followed by 
allyl iodide led to exclusive formation of the undesired regioisomer 5-67 in 59% yield.   
N
Cbz
O
H
CO2Me
O
O
5-63
ethylene glycol
PPTS, benzene
Dean-Stark
94%
N
Cbz
O
H
CO2Me
O
5-64
O
O NCbz
OH
H
CO2MeO
O
1. DIBAL-H
2. NaBH4, MeOH/
     H2O
OH
5-65
1. TBDPSCl, Im.
2. PPTS, acetone
N
Cbz
OH
H
CO2Me
OTBDPS
O
LiHMDS, then 
allyl iodide
N
Cbz
OH
H
CO2Me
OTBDPS
O
5-67
undesired regioisomer
79%, 2 steps
48%, 2 steps
59% + SM
5-66
 
Scheme 5-18. Synthesis of ketone 5-66 and subsequent alkylation. 
 
Confirmation of this selectivity was achieved by inspection of the 1H NMR, which 
clearly showed a doublet of doublet for the proton next to the carbamate (Figure 5-6).  
Additionally, initial 2-D NMR studies (NOESY) showed a correlation between the allylic 
methylene and the β-proton next to the carbonyl.  While the regioselectivity assignment is 
concrete, additional experiments are necessary to confidently assign the stereochemical 
outcome of this alkylation reaction.   
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N
Cbz
OH
H
CO2Me
OTBDPS
O
5-67 remains doublet of
doublet in 1H spectra
H H
NOESY
correlation
 
Figure 5-6. Tentative assignment of regio- and stereoselectivity in the alkylation reaction of 5-66. 
 
Having demonstrated the success of the radical chemistry on unsubstituted 
hydroindole 5-5, we sought to apply this reaction to the allylated substrate 5-40 (Scheme 
5-19).  Acylation of the tertiary alcohol was efficient as before, providing α-bromo ester 
5-68.  Subjection of 5-68 to the tributyltin / AIBN conditions led to formation of the 
desired lactone 5-69, albeit in a lower 59% yield.  This reaction provides, for the first 
time, access to the correct stereochemistry of several core stereocenters in 
tuberostemonone for application to the natural product.   
 
N
Cbz
OH
H
CO2Me
O N
Cbz
O
H
CO2Me
O
O
HO
Br
DCC, DMAP
O
Br
N
Cbz
O
H
CO2Me
O
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AIBN, Bu3SnH
Toluene
59%, 2 steps
5-69
5-685-40
 
Scheme 5-19.  Successful installation of 4 of the 6 stereocenters in the core of tuberostemonone. 
 
Upon further optimization of the radical reaction to produce 5-69, extension of this 
ketone to tuberostemonone should be straightforward.  Regioselective enol triflate 
formation, coupling and hydroboration169 will install all of the stereocenters in the core of 
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5-11, while cross metathesis and reduction elaborates the allyl side chain for subsequent 
azapane formation (Scheme 5-20).   
 
N
Cbz
O
H
CO2Me
O
O
5-69
1. Grubbs II, Allyl    
    benzyl ether
2. PtO2, EtOAc, H2 N
Cbz
O
H
CO2Me
O
O
5-70
OBn
N
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O
H
CO2Me
O
5-71
OBn
1. KHMDS, Tf2NPh
2. EtMgBr, Fe(acac)3
3. Hydroboration/
     oxidation
HO
 
Scheme 5-20.  Proposed installation of the remaining stereocenters of 5-11. 
5.3 CONCLUSION 
Initial exploration in the synthesis of the hydroindoles for the synthesis of the 
Stemona alkaloids provided an unforeseen obstacle: deterioration of the enantiomeric 
excess of these compounds.  During the optimization of this reaction we were able to not 
only achieve high enantiomeric excess for the desired products, but also improve the 
overall yield and technical ease of this reaction. Subsequently, we explored the synthesis 
of L-Choi derivatives and produced a small set of functionalized analogs.   
The hydroindole intermediate also served as a key starting material for our 
approach toward tuberostemonone.  Through the use of an intramolecular palladium 
allylation and stereoselective radical additions to enones we were able to construct the 
core of tuberostemonone that for the first time bears the correct stereochemistry of the 
natural product.  Key to this success was the realization that the tertiary alcohol moiety 
could serve as a handle to install the stereocenters around the core of tuberostemonone, 
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including serving as the radical fragmentation origin for late-stage formation of the 9-
membered lactam.   
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6.0  EXPERIMENTAL 
6.1 GENERAL  
All reactions were performed under an N2 atmosphere and all glassware was dried 
in an oven at 140 °C for 2 h prior to use.  Reactions carried out at –78 °C employed a CO2 
/ acetone bath.  THF was distilled over sodium / benzophenone ketyl, Et3N was distilled 
from CaH2, and CH2Cl2 and toluene were purified using an alumina filtration system.   
Reactions were monitored by TLC analysis (EM Science pre-coated silica gel 60 
F254 plates, 250 µm layer thickness) and visualization was accomplished with a 254 nm 
UV light and by staining with a PMA solution (5 g of phosphomolybdic acid in 100 mL of 
95% EtOH), p-anisaldehyde solution (2.5 mL of p-anisaldehyde, 2 mL of AcOH, and 3.5 
mL of conc. H2SO4 in 100 mL of 95% EtOH), Vaughn’s reagent (4.8 g of 
(NH4)6Mo7O24•4 H2O and 0.2 g of Ce(SO4)2 in 100 mL of a 3.5 N H2SO4 solution) or a 
KMnO4 solution (1.5 g of KMnO4 and 1.5 g of K2CO3 in 100 mL of a 0.1% NaOH 
solution).  Flash chromatography on SiO2 was used to purify the crude reaction mixtures. 
Melting points were determined using a Laboratory Devices Mel-Temp II.  
Infrared spectra were determined on a Nicolet Avatar 360 FT-IR spectrometer.  1H and 13C 
NMR spectra were obtained on a Bruker Avance 300 instrument in CDCl3 unless 
otherwise noted.  Chemical shifts were reported in parts per million with the residual 
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solvent peak used as an internal standard.  1H NMR spectra were run at 300 MHz (unless 
otherwise noted) and are tabulated as follows: chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, qn = quintet, sept = septet, m = multiplet), number of 
protons, and coupling constant(s).  13C NMR spectra were obtained at 76 MHz using a 
proton-decoupled pulse sequence with a d1 of 3 sec, and are tabulated by observed peak.  
Mass spectra were obtained on a Micromass Autospec double focusing instrument. 
 
6.2 EXPERIMENTAL PROCEDURES 
 
 
(S)-Buta-1,2-dienyltributylstannane (1-38).170  To a solution of diisopropylamine 
(4.0 mL, 28.0 mmol) in THF (100 mL) was added 11.2 mL (28.0 mmol) of n-BuLi (2.5 M 
in hexanes) at 0 °C. After 30 min, tributyltin hydride (8.15 g, 28.0 mmol) was added 
dropwise and the mixture was stirred for an additional 30 min. The yellow solution was 
cooled to –78 °C and CuBr·SMe2 (5.76 g, 28.0 mmol) was added over 10 min.  The dark 
solution was stirred for an additional 30 min and (R)-3-butyn-2-yl mesylate (4.47 g, 27.6 
mmol) was added.  The mixture was stirred for 15 min, and poured into a rapidly stirred 
solution of 9:1 sat. aq. NH4Cl/NH4OH (400 mL) solution and Et2O (300 mL). Once the 
Et2O layer clarified, it was separated, dried (MgSO4), filtered, and concentrated under 
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reduced pressure. The crude oil was purified by bulb-to-bulb distillation (120 °C/ 0.5 
mmHg) to yield 5.77 g (88%) of 1-38 as a yellow oil: 1H NMR δ 5.12-4.87 (m, 1 H), 
4.71–4.45 (m, 1 H), 1.70-0.80 (m, 30 H); 13C NMR δ 209.0, 75.2, 74.3, 28.9, 27.2, 13.7, 
10.3. 
 
 
Tert-butyldimethyl(propa-1,2-dienyl)silane (1-39).24a A solution of 
triphenylphosphine (15.7 g, 60.0 mmol) in THF (120 mL) was treated at –15 °C with 
DIAD (11.3 mL, 57.5 mmol) over 2 min, followed by addition of 3-(tert-
butyldimethylsilyl)-2-propyn-1-ol (8.52 g, 50.0 mmol) in THF (18 mL).  After 2 min, a 
solution of o-nitrobenzenesulfonyl hydrazide (13.0 g, 60.0 mmol) in THF (65 mL) was 
added over 5 min via cannula. The resulting orange-red solution was stirred at –15 °C for 
45 min and allowed to warm to rt for 5 h.  The reaction mixture was diluted with of 
pentane (400 mL) and washed with ice-cold water (4 x 500 mL).  The organic layer was 
dried (MgSO4) and concentrated in vacuo at 0 °C to avoid loss of product.  The residue 
was purified by chromatography on SiO2 (pentane) and the fractions containing the 
product were concentrated in vacuo at 0 °C to yield 5.39 g (70%) of 1-39 as a colorless 
oil: 1H NMR δ 4.87 (app t, 1 H, J = 7.2 Hz), 4.32 (app d, 2 H, J = 7.2 Hz), 0.91 (s, 9 H), 
0.07 (s, 6 H). 
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1-45MeO2C
NHP(O)Ph2
TBS
 
 
(E) - Methyl 4-[4-(tert-butyldimethylsilyl) – 1 - (diphenylphosphinamido) - 
but-3-enyl]benzoate (1-45). General Protocol A.  A solution of allene 1-39 (31.9 mg, 
0.207 mmol) in CH2Cl2 (1 mL) was treated at –78 °C with Cp2ZrHCl (53.4 mg, 0.207 
mmol) and allowed to warm to room temperature over 20 min.  After approximately 90% 
of the CH2Cl2 was removed under reduced pressure, toluene (1 mL) was added.  The 
resulting red solution was cooled to –78 °C, and treated with Me2Zn (104 µL, 0.207 
mmol, 2.0 M in toluene) and imine 1-44 (50.0 mg, 0.138 mmol).  The reaction mixture 
was warmed to room temperature and stirred for 3 h, quenched with saturated aqueous 
NaHCO3, extracted with EtOAc (3x), dried (MgSO4), and concentrated in vacuo.  
Analysis of the crude reaction mixture by 1H NMR showed one geometric isomer of the 
alkene.  The residue was purified by chromatography on SiO2 (7:3, EtOAc:hexanes) to 
yield 57.2 mg (80%) of 1-45 as a colorless solid: mp 114-115 °C (CH2Cl2); IR (KBr) 
3167, 2951, 2854, 1723, 1611, 1437, 1279, 1187, 1110, 828, 725, 698 cm-1; 1H NMR 
(CD2Cl2) δ 7.93 (d, 2 H, J = 8.3 Hz), 7.89-7.70 (m, 4 H), 7.58-7.40 (m, 4 H), 7.40-7.30 
(m, 2 H), 7.28 (d, 2 H, J = 8.3 Hz), 5.83 (dt, 1 H, J = 18.6, 6.4 Hz), 5.73 (d, 1 H, J = 18.6 
Hz), 4.38 (tt, 1 H, J = 9.8, 6.5 Hz), 3.88 (s, 3 H), 3.50 (dd, 1 H, J = 9.4, 6.3 Hz), 2.81-2.95 
(m, 2 H), 0.753 (s, 9 H), -0.046 (s, 3 H), -0.072 (s, 3 H); 13C NMR (CD2Cl2) δ 167.13, 
149.08, 143.02, 134.49, 134.18, 132.67, 132.55, 132.35, 129.95, 129.60, 129.08, 128.91, 
128.71, 127.14, 54.79, 52.28, 47.16, 47.11, 26.55, 16.60, -5.91, -6.08; ESIMS m/z 542 
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([M+Na]+, 100), 520 ([M+H]+, 45); HRMS (ESI) m/z calcd for C30H38NO3PSiNa 
542.2256 (M+Na), found 542.2283. 
 
 
Trimethyl(propa-1,2-dienyl)silane (1-46).24a  A solution of triphenylphosphine (15.7 g, 
60.0 mmol) in THF (120 mL) was treated at –15 °C with DIAD (11.3 mL, 57.5 mmol) 
over 2 min followed by addition of 3-(trimethylsilyl)-2-propyn-1-ol (6.41 g, 50.0 mmol) in 
THF 18 mL.  After 2 min, a solution of o-nitrobenzenesulfonyl hydrazide (13.0 g, 60.0 
mmol) in THF 65 mL was added over 5 min via cannula. The resulting orange-red 
solution was stirred at –15 °C for 45 min and allowed to warm to rt for 5 h.  The reaction 
mixture was diluted with pentane 400 mL and washed with ice-cold water (4 x 500 mL).  
The organic layer was dried (MgSO4) and concentrated in vacuo at 0 °C to avoid loss of 
product.  The residue was purified by chromatography on SiO2 (pentane) and the fractions 
containing the product were concentrated in vacuo at 0 °C to yield 2.97 g (53%) of 1-46 as 
a colorless oil: 1H NMR δ 4.87 (app t, 1 H, J = 7.1 Hz), 4.32 (app d, 2 H, J = 7.1 Hz), 0.07 
(s, 9 H). 
 
1-47MeO2C
NHP(O)Ph2
TMS
 
(E) - Methyl 4 - [1 - (diphenylphosphinamido) – 4 - (trimethylsilyl) but – 3 -
enyl] benzoate (1-47).  According to the General Protocol A, allene 1-46 (23.2 mg, 0.207 
mmol), Cp2ZrHCl (53.4 mg, 0.207 mmol), Me2Zn (104 µL, 0.207 mmol, 2.0 M in 
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toluene), and imine 1-44 (50.0 mg, 0.138 mmol) afforded 51.6 mg (78%) of 1-47 as a 
colorless solid: mp 147-148 °C (CH2Cl2); IR (KBr) 3169, 2952, 1721, 1611, 1437, 1280, 
1186, 1110, 838, 697 cm-1; 1H NMR (CD2Cl2) δ 7.93 (d, 2 H, J = 8.3 Hz), 7.88-7.70 (m, 4 
H), 7.58-7.41 (m, 4 H), 7.40-7.30 (m, 2 H), 7.28 (d, 2 H, J = 8.3 Hz), 5.87 (dt, 1 H, J = 
18.5, 6.3 Hz), 5.75 (d, 1 H, J = 18.6 Hz), 4.34 (tt, 1 H, J = 9.4, 6.5 Hz), 3.88 (s, 3 H), 4.46 
(dd, 1 H, J = 9.4, 6.8 Hz), 2.73-2.56 (m, 2 H), 0.00 (s, 9 H); 13C NMR (CD2Cl2) δ 166.59, 
148.70, 141.35, 135.66, 133.97, 133.67, 132.11, 131.99, 131.84, 131.72, 129.38, 129.02, 
128.52, 128.35, 128.18, 126.54, 54.34, 51.76, 46.55, 46.48, -1.80; ESIMS m/z 500 
([M+Na]+, 100), 478 ([M+H]+, 33); HRMS (ESI) m/z calcd for C27H32NO3PSiNa 
500.1787 (M+Na), found 500.1778. 
 
1-49MeO2C
NHP(O)Ph2
SnBu3
 
(E)-Methyl 4 - [1 - (diphenylphosphinamido) – 4 - (tributylstannyl) but – 3 -
enyl] benzoate (1-49).  According to the General Protocol A, allene 1-48 (68.1 mg, 0.207 
mmol), Cp2ZrHCl (53.4 mg, 0.207 mmol), Me2Zn (104 µL, 0.207 mmol, 2.0 M in 
toluene), and imine 1-44 (50.0 mg, 0.138 mmol) afforded 77.6 mg (81%) of 1-49 as a 
colorless solid: mp 63-64 °C (CH2Cl2); IR (KBr) 3168, 2955, 2925, 2871, 2852, 1723, 
1437, 1278, 1186, 1109, 696 cm-1; 1H NMR δ 7.98 (d, 2 H, J = 8.3 Hz), 7.95-7.73 (m, 4 
H), 7.58-7.41 (m, 4 H), 7.38-7.26 (m, 2 H), 7.28 (d, 2 H, J = 7.3 Hz), 6.04 (d, 1 H, 2JH-Sn = 
74.0, JH-H = 16.5 Hz), 5.64 (dt, 1 H, J = 18.8, 7.4 Hz), 4.53-4.41 (m, 1 H), 3.92 (s, 3 H), 
3.49 (dd, 1 H, J = 9.6, 5.8 Hz), 2.90-2.65 (m, 2 H), 1.56-1.17 (m, 12 H), 0.97-0.70 (m, 15 
H); 13C NMR δ 166.87, 148.46, 142.92, 134.80, 133.12, 132.42, 132.29, 131.83, 131.39, 
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129.64, 128.98, 128.62, 128.45, 128.24, 126.65, 54.13, 51.95, 47.55, 47.50, 29.03, 27.16, 
13.56, 9.49; ESIMS m/z 718 ([M+Na]+, 85), 696 ([M+H]+, 100); HRMS (ESI) m/z calcd 
for C36H50NO3PSnNa 718.2448 (M+Na), found 718.2469. 
 
 
Propa-1,2-dienylbenzene (1-50).24b To a solution of propargyl bromide (5.02 g, 
42.1 mmol) and copper(I) bromide (7.20 g, 50.0 mmol) in THF 100 mL at –40 °C was 
added  phenylmagnesium bromide (16.7 mL, 50.0 mmol, 3.0 M in Et2O) over 15 min.  
The reaction mixture was stirred at 0 °C for 1 h, and poured into an separatory funnel 
containing ice-cold 3 N HCl (1 L) and xylenes (250 mL).  The organic layer was washed 
with 3 N HCl (5 x 50 mL) and dried (MgSO4).  The volatile product was isolated by 
distillation (distillation at 80 °C, 30 mmHg; receiving flask at –78 °C) to yield 3.42 g 
(70%) of 1-50 as a colorless oil: 1H NMR δ 7.46 – 7.18 (m, 5 H), 6.18 (app t, 1 H, J = 6.8 
Hz), 5.16 (app d, 2 H, J = 6.8 Hz). 
 
1-51
MeO2C
NHP(O)Ph2
Ph
 
Methyl 4-[(1S*,2S*)-1-(diphenylphosphinamido)-2-phenylbut-3-enyl]benzoate 
(1-51).  According to the General Protocol A, allene 1-50 (24.0 mg, 0.207 mmol), 
Cp2ZrHCl (53.4 mg, 0.207 mmol), Me2Zn (104 µL, 0.207 mmol, 2.0 M in toluene), and 
imine 1-44 (50.0 mg, 0.138 mmol) (1.5 h reaction time) afforded 55.1 mg (83%) of 1-51 
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as a colorless solid: mp 192-193 °C (CH2Cl2); IR (KBr) 3176, 3059, 2924, 2854, 1721, 
1437, 1281, 1184, 1109, 698 cm-1; 1H NMR δ 7.88 (d, 2 H, J = 8.3 Hz), 7.70-7.56 (m, 4 
H), 7.55-7.47 (m, 1 H), 7.46-7.37 (m, 3 H), 7.34-7.23 (m, 5 H), 7.08-7.02 (m, 2 H), 6.98 
(d, 2 H, J = 8.4 Hz), 6.01 (dt, 1 H, J = 19.6, 10.2 Hz), 5.18 (d, 1 H, J = 10.2 Hz), 5.15 (d, 1 
H, J = 17.4 Hz), 4.56 (ddd, 1 H, J = 9.8, 6.3 Hz), 3.94 (s, 3 H), 3.85 (dd, 1 H, J = 9.1, 6.3 
Hz), 3.54 (dd, 1 H, J = 9.7, 6.2 Hz); 13C NMR δ 166.90, 146.23, 139.91, 136.15, 133.70, 
132.97, 132.39, 132.26, 131.73, 131.60, 129.11, 128.60, 128.37, 128.28, 128.11, 127.72, 
127.12, 118.83, 59.36, 57.95, 57.89, 51.95; ESIMS m/z 504 ([M+Na]+, 100), 482 
([M+H]+, 98); HRMS (ESI) m/z calcd for C30H28NO3PNa 504.1705 (M+Na), found 
504.1703. 
 
 
4,4-Dimethylpenta-1,2-diene (1-52).24b  To a solution of propargyl bromide (5.00 
g, 42.0 mmol) and copper(I) bromide (7.20 g, 50.0 mmol) in THF (100 mL) at –40 °C was 
added tert-butylmagnesium chloride (25.0 mL, 50.0 mmol, 2.0 M in Et2O) over 15 
minutes.  The reaction mixture was stirred at 0 °C for 1 h, and poured into a separatory 
funnel containing ice-cold 3 N HCl (1 L) and xylenes (250 mL).  The organic layer was 
washed with 3 N HCl (5 x 50 mL) and dried (MgSO4).  The volatile product was isolated 
by distillation (20 – 30 mmHg, receiving flask at –78 °C) to yield 2.62 g (65%) of 1-52 as 
a colorless oil: bp 79 °C (30 mmHg); 1H NMR δ 5.12 (app t, 1 H, J = 6.7 Hz), 4.72 (app d, 
2 H, J = 6.6 Hz), 1.06 (s, 9 H). 
 
+1-53aMeO2C
NHP(O)Ph2
t-Bu
1-53b
MeO2C
NHP(O)Ph2
t-Bu
 
 
(E)-Methyl 4 - [1-(diphenylphosphinamido) - 5,5-dimethylhex-3-enyl]benzoate 
(1-53a) and methyl 4-[(1S*,2S*)-2-tert-butyl-1-(diphenylphosphinamido)but-3-
enyl]benzoate (1-53b).  According to the General Protocol A, allene 1-52 (19.9 mg, 0.207 
mmol), Cp2ZrHCl (53.4 mg, 0.207 mmol), Me2Zn (104 µL, 0.207 mmol, 2.0 M in 
toluene), and imine 1-44 (50.0 mg, 0.138 mmol) (12 h reaction time) afforded 40.6 mg 
(64%) of a 1.5:1 mixture of 1-53a:1-53b (determined by analysis of the crude reaction 
mixture): IR (KBr) 3183, 3058, 2954, 1721, 1611, 1437, 1280, 1190, 1109, 1019, 972, 
914, 725, 698 cm-1; 1H NMR δ 7.96-7.71 (m, 6 H), 7.55-7.37 (m, 4 H), 7.34-7.25 (m, 3.2 
H), 7.12 (d, 0.8 H, J = 8.3 Hz), 5.87 (dt, 0.4 H, J = 16.9, 10.5 Hz), 5.53 (d, 0.6 H, J = 15.6 
Hz), 5.39 (dd, 0.4 H, J = 10.4, 2.2 Hz), 5.36 (dd, 0.4 H, J = 16.6, 2.2 Hz), 5.09 (dt, 0.6 H, 
J = 15.7, 7.0 Hz), 4.54 (dt, 0.4 H, J = 10.8, 3.6 Hz), 4.38 (tt, 0.6 H, J = 10.0, 6.4 Hz), 3.93 
(s, 1.2 H), 3.92 (s, 1.8 H), 3.75 (dd, 0.4 H, J = 10.4, 7.1 Hz), 3.47-3.37 (m, 0.6 H), 2.65-
2.53 (m, 1.2 H), 2.47 (dd, 0.4 H, J = 11.2, 4.0 Hz), 0.91 (s, 5.6 H), 0.70 (s, 3.4 H); 13C 
NMR δ 166.91, 166.84, 148.62, 148.55, 147.86, 147.74, 146.99, 134.85, 133.85, 133.58, 
132.80, 132.64, 132.55, 132.42, 132.37, 132.24, 132.16, 131.90, 131.86, 131.80, 131.74, 
131.62, 131.51, 131.07, 130.91, 130.15, 130.02, 129.54, 129.25, 128.78, 128.72, 128.57, 
128.40, 128.36, 128.22, 128.19, 128.06, 126.53, 120.96, 118.76, 62.85, 62.81, 54.41, 
53.93, 52.06, 52.03, 42.46, 42.39, 33.10, 32.65, 31.54, 30.89, 29.47, 29.25, 28.19, 25.22, 
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22.65, 22.61, 14.09; EIMS m/z 430 ([M-OCH3]+, 20), 364 (95), 201 (100); HRMS (EI) m/z 
calcd for C27H29NO2P 430.1936 (M-OCH3), found 430.1920. 
 
HN
S
P(O)Ph2
O
O
1-54a
 
P,P-Diphenyl-N-(3-phenyl-1-tosylpropyl)phosphinic amide (1-54a).25  To a 
solution of P,P-diphenylphosphinic amide (1.00 g, 4.60 mmol) and sulfinic acid (1.08 g, 
6.90 mmol) in Et2O was added hydrocinnamaldehyde (926 mg, 0.910 mmol) and the 
resulting suspension was stirred for 15 h at rt.  The white precipitate was filtered, washed 
with anhydrous Et2O, and dried under reduced pressure to yield 1.40 g (91%) of 1-54a as 
a colorless solid.  1H NMR δ 7.92–7.80 (m, 2 H), 7.74–7.62 (m, 2 H), 7.60–7.41 (m, 6 H), 
7.37–7.10 (m, 9 H), 4.51–4.20 (m, 1 H), 3.62–3.40 (m, 1 H), 3.12–2.97 (m, 1 H), 2.97–
2.80 (m, 1 H), 2.68 (s, 3 H), 2.21 – 2.08 (m, 1 H), 1.62–1.50 (m, 1 H); HRMS (ESI) m/z 
calcd for C28H28NO3PSNa 512.1425 (M+Na), found 512.1434. 
 
NHP(O)Ph2
TBS
1-55
 
(E) - N- [6-(tert-Butyldimethylsilyl)-1-phenylhex-5-en-3-yl]-P,P-diphenyl phos-
phinamide (1-55).  General Protocol B.  A solution of allene 1-39 (23.2 mg, 0.207 
mmol) in CH2Cl2 (1 mL) was treated at –78 °C with Cp2ZrHCl (53.4 mg, 0.207 mmol) 
and allowed to warm to room temperature over 20 min.  After approximately 90% of the 
CH2Cl2 was removed under reduced pressure, toluene (1 mL) was added.  The resulting 
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red solution was cooled to –78 °C, treated with Me2Zn (173 µL, 0.345 mmol, 2.0 M in 
toluene) and sulfinyl adduct 1-54a (67.6 mg, 0.138 mmol), and allowed to stir at –78 °C 
for 15 min.  The reaction mixture was then warmed to room temperature and stirred for an 
additional 3 h, quenched with saturated aqueous NaHCO3, extracted with EtOAc (3x), 
dried (MgSO4), and concentrated in vacuo. Analysis of the crude reaction mixture by 1H 
NMR showed one geometric isomer of the alkene.  The residue was purified by 
chromatography on SiO2 (6:4, EtOAc:hexanes) to yield 53.3 mg (79%) of 1-55 as a 
colorless solid: mp 109-110 °C (CH2Cl2); IR (KBr) 3180, 2926, 2854, 1438, 1186, 1122, 
828, 697 cm-1; 1H NMR δ 8.02-7.85 (m, 4 H), 7.60-7.41 (m, 6 H), 7.32-7.21 (m, 2 H), 
7.21-7.11 (m, 3 H), 6.05 (dt, 1 H, J = 18.5, 7.1 Hz), 5.83 (d, 1 H, J = 18.5 Hz), 3.38-3.20 
(m, 1 H), 2.87 (dd, 1 H, J = 10.3, 6.3 Hz), 2.81-2.61 (m, 2 H), 2.61-2.41 (m, 2 H), 1.96-
1.84 (m, 2 H), 0.81 (s, 9 H), 0.46 (s, 6 H); 13C NMR δ 143.46, 141.82, 134.32, 134.10, 
132.40, 132.26, 132.21, 132.17, 132.12, 132.04, 131.67, 131.64, 128.53, 128.36, 125.79, 
50.83, 44.27, 44.21, 38.23, 38.17, 32.03, 26.44, 16.37, -5.98, -6.08; EIMS m/z 490 
([M+H]+, 3), 432 (100), 335 (75), 201 (52); HRMS (EI) m/z calcd for C30H40NOPSi 
489.2617, found 489.2626. 
 
NHP(O)Ph2
SnBu3
1-56
 
(E) - P,P – Diphenyl – N - [1 – phenyl – 6 - (tributylstannyl) hex – 5 – en – 3 -
yl]phosphinamide (1-56).  According to the General Protocol B, allene 1-48 (68.1 mg, 
0.207 mmol), Cp2ZrHCl (53.4 mg, 0.207 mmol), Me2Zn (173 µL, 0.345 mmol, 2.0 M in 
toluene), and sulfinyl adduct 1-54a (67.6 mg, 0.138 mmol) afforded 72.1 mg (79%) of 1-
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56 as a colorless solid: mp 57.9-58.4 °C (CH2Cl2); IR (KBr) 3183, 3059, 2925, 1438, 
1376, 1190, 1122, 991, 723, 698 cm-1; 1H NMR δ 8.00-7.82 (m, 4 H), 7.58-7.40 (m, 6 H), 
7.29-7.20 (m, 2 H), 7.20-7.09 (m, 3 H), 6.09 (d, 1 H, JH-H = 18.8, 2JH-Sn = 75.0 Hz), 5.92 
(dt, 1 H, J = 18.6, 6.6 Hz), 3.35-3.19 (m, 1 H), 2.88 (dd, 1 H, J = 10.6, 6.3 Hz), 2.82-2.61 
(m, 2 H), 2.60-2.39 (m, 2 H), 1.95-1.82 (m, 2 H), 1.71-1.22 (m, 12 H), 1.10-0.75 (m, 15 
H); 13C NMR δ 144.15, 141.85, 134.11, 133.94, 133.24, 132.20, 132.12, 132.00, 131.67, 
128.49, 128.32, 125.73, 50.65, 45.02, 44.97, 38.05, 37.99, 32.04, 29.10, 27.20, 13.61, 
9.46; ESI m/z 672 ([M+Li]+, 45), 666 ([M+H]+, 100); HRMS (ESI) m/z calcd for 
C36H52NOPSnLi 672.2969 (M+Li), found 672.2968. 
 
NHP(O)Ph2
1-57 t-Bu
 
N - [(3R*,4S*) - 4-tert – Butyl – 1 – phenylhex – 5 – en – 3 - yl] - P,P - diphenyl 
phosphinamide (1-57).  According to the General Protocol B, allene 1-52 (19.1 mg, 0.207 
mmol), Cp2ZrHCl (53.4 mg, 0.207 mmol), Me2Zn (173 µL, 0.345 mmol, 2.0 M in 
toluene), and sulfinyl adduct 1-54a (67.6 mg, 0.138 mmol) afforded 47.5 mg (80%) of 1-
57 as a colorless solid: mp 109-110 °C (CH2Cl2); IR (KBr) 3216, 3060, 2960, 1438, 1365, 
1198, 1122, 1057, 918, 725, 699 cm-1; 1H NMR δ 8.04-7.92 (m, 4 H), 7.55-7.41 (m, 6 H), 
7.30-7.21 (m, 2 H), 7.21-7.13 (m, 3 H), 5.74 (dt, 1 H, J = 16.9, 10.4 Hz), 5.23 (dd, 1 H, J 
= 16.9, 2.5 Hz), 5.21 (dd, 1 H, 10.1, 2.5 Hz), 3.32 (q, 1 H, J = 10.8 Hz), 3.10-2.95 (m, 2 
H), 2.63-2.51 (m, 1 H), 2.23 (dd, 1 H, J = 10.7, 1.7 Hz), 2.0-1.8 (m, 1 H), 1.56-1.40 (m, 1 
H), 0.70 (s, 9 H); 13C NMR δ 142.51, 135.48, 132.47, 132.36, 131.85, 128.74, 128.60, 
128.41, 125.84, 119.48, 62.15, 51.62, 36.83, 36.62, 33.29, 32.49, 28.73; EIMS m/z 374 
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([M-C3H9]+, 4), 335 (80), 201 (65); HRMS (EI) m/z calcd for C24H25NOP 374.1674 (M-
C3H9), found 374.1665. 
 
NHP(O)Ph2
1-59
TMSMe
 
N - [(3R*,4S*) – 4 – Methyl – 1 – phenyl – 4 - (trimethylsilyl) hex – 5 – en – 3 -
yl] - P,P-diphenylphosphinamide (1-59).  According to the General Protocol B, allene 1-
58 (26.1 mg, 0.207 mmol), Cp2ZrHCl (53.4 mg, 0.207 mmol), Me2Zn (173 µL, 0.345 
mmol, 2.0 M in toluene), and  of sulfinyl adduct 1-54a (67.6 mg, 0.138 mmol) afforded 
51.8 mg (81%) of 1-59 as a colorless solid: mp 155-156 °C (CH2Cl2); IR (KBr) 3230, 
3058, 2954, 1619, 1437, 1248, 1190, 1122, 1108, 838, 697 cm-1; 1H NMR δ 8.10-7.82 (m, 
4 H), 7.60-7.42 (m, 6 H), 7.31-7.22 (m, 2 H), 7.21-7.10 (m, 3 H), 6.04 (dd, 1 H, J = 17.2, 
10.7 Hz), 5.19 (dd, 1 H, J = 10.7, 1.2 Hz), 4.99 (dd, 1 H, J = 17.2, 1.4 Hz), 3.24 (q, 1 H, J 
= 8.6 Hz), 2.99 (ddd, 1 H, J = 11.8, 4.8, 1.8 Hz), 2.80 (t, 1 H, J = 9.5 Hz), 2.50 (ddd, 1 H, 
J = 11.4, 5.8, 2.1 Hz), 2.15-1.98 (m, 1 H), 1.9-1.7 (m, 1 H), 1.10 (s, 3 H), -0.02 (s, 9 H); 
13C NMR δ 142.33, 139.38, 131.94, 131.49, 128.30, 128.13, 125.50, 114.58, 57.64, 38.72, 
38.10, 33.67, 17.57, -2.50; EIMS m/z 461 ([M]+, 10), 356 (75), 201 (95); HRMS (EI) m/z 
calcd for C28H36NOPSi 461.2304, found 461.2284. 
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1-61
NHP(O)Ph2
 
N - (4,4-Dimethyl-1-phenylhex-5-en-3-yl) - P,P - diphenylphosphinamide (1-
61).  According to the General Protocol B, allene 1-60 (14.1 mg, 0.207 mmol), Cp2ZrHCl 
(53.4 mg, 0.207 mmol), Me2Zn (173 µL, 0.345 mmol, 2.0 M in toluene), and sulfinyl 
adduct 1-54a (67.6 mg, 0.138 mmol) afforded 42.0 mg (76%) of 1-61 as a colorless solid: 
mp 173-174 °C (CH2Cl2); IR (KBr) 3207, 3058, 2962, 1437, 1185, 1122, 985, 910, 721, 
697 cm-1; 1H NMR δ 8.00-7.82 (m, 4 H), 7.58-7.40 (m, 6 H), 7.29-7.21 (m, 2 H), 7.20-
7.07 (m, 3 H), 5.77 (dd, 1 H, J = 17.3, 10.9 Hz), 5.05 (d, 1 H, 10.8 Hz), 5.02 (d, 1 H, J = 
17.7 Hz), 3.00-2.82 (m, 2 H), 2.79-2.68 (m, 1 H), 2.55-2.42 (m, 1 H), 2.10-1.92 (m, 1 H), 
1.65-1.42 (m, 1 H), 1.04 (s, 3 H), 1.01 (s, 3 H); 13C NMR δ 145.00, 142.37, 132.31, 
132.26, 132.18, 132.14, 131.78, 131.74, 131.66, 131.62, 130.85, 128.53, 128.44, 128.38, 
128.21, 125.63, 113.38, 59.73, 41.98, 41.91, 36.09, 33.64, 25.44, 23.27; EIMS m/z 403 
(M+, 20), 334 (100), 201 (100); HRMS (EI) m/z calcd for C26H30NOP 403.2065, found 
403.2050. 
 
TMS

1-62
 
Trimethyl (3-methylbuta - 1,2-dienyl) silane (1-62).171  A solution of 
methyllithium (4.00 mL, 1.84 M), 1,1-dimethylallene (1.00 g, 14.7 mmol), and 
diisopropylamine (20.0 µL, 0.143 µmol) in Et2O (10 mL) was cooled to -78 °C and 
trimethylchlorosilane (0.88 g, 8.10 mmol) in 1 mL of ether was added dropwise. The 
mixture was warmed to rt and stirred for 30 min, and quenched with H2O. The organic 
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layer was separated and solvents were removed by distillation using a Vigreux column.  
The residue was purified by distillation (bp 63-65 °C, 82 mmHg) to yield 0.86 g (66%) of 
1-62 as a yellow oil:  1H NMR δ 4.77 (sept, 1 H, J = 3.7 Hz), 1.66 (d, 6 H, J = 3.7 Hz), 
0.07 (s, 9 H). 
HN
S
1-63a
Ts
O
O
 
4-methyl-N-(3-phenyl-1-tosylpropyl)benzenesulfonamide (1-63a).57  A solution 
of hydrocinnamaldehyde (2.68 g, 2.63 mmol), p-tolunesulfonamide (3.42 g, 20.0 mmol), 
p-toluenesulfinate (3.57 g, 20.0 mmol) and formic acid (30 mL) in water (30 mL) was 
stirred at rt for 24 h, filtered, washed with water (30 mL) and pentane (10 mL) and dried 
under reduced pressure to yield 7.36 g (83%) of 1-63a as a colorless solid.  1H NMR 
δ 7.70 (d, 2 H, J = 8.2 Hz), 7.55 (d, 2 H, J = 8.3 Hz), 7.35–7.15 (m, 7 H), 7.06–7.00 (m, 2 
H), 5.74 (d, 1 H, J = 10.3 Hz), 4.60 (dt, 1 H, J = 9.4, 4.2 Hz), 2.69–2.47 (m, 3 H), 2.44 (s, 
3 H), 2.41 (s, 3 H), 2.04–1.89 (m, 1 H). 
 
NHSO2Tol
TMSMe
1-64  
4 - Methyl – N - [(3R*,4R*) – 4 – methyl – 1 – phenyl – 4 - (trimethylsilyl) hex-
5-en-3-yl] benzenesulfonamide (1-64).  A solution of allene 1-58 (210 mg, 1.65 mmol) in 
CH2Cl2 (5 mL) was treated at –78 °C with Cp2ZrHCl (425 mg, 1.65 mmol) and allowed to 
warm to room temperature over 20 min.  After approximately 90% of the CH2Cl2 was 
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removed under reduced pressure, toluene (5 mL) was added.  The resulting red solution 
was cooled to –78 °C, treated with Et2Zn (2.47 mL, 2.47 mmol, 1.0 M in hexane) and 
sulfinyl adduct 1-63a (500 mg, 1.10 mmol), and allowed to stir at –78 °C for 15 min.  The 
reaction mixture was then warmed to room temperature and stirred for an additional 3 h, 
quenched with saturated aqueous NaHCO3, extracted with EtOAc (3x), dried (MgSO4), 
and concentrated in vacuo.  Analysis of the crude reaction mixture by 1H NMR showed 
one diastereomer.  The residue was purified by chromatography on SiO2 (6:4, 
EtOAc:hexanes) to yield 401 mg (85%) of 1-64 as a colorless solid: mp 131.2-132.4 °C 
(CH2Cl2); IR (KBr) 3286, 3027, 2953, 1496, 1323, 1157, 840 cm-1; 1H NMR δ 7.84-7.75 
(m, 2 H), 7.35-7.21 (m, 4 H), 7.21-7.13 (m, 1 H), 7.03-6.96 (m, 2 H), 5.89 (dd, 1 H, J = 
17.2, 10.7 Hz), 5.14 (dd, 1 H, J = 10.7, 1.3 Hz), 4.89 (dd, 1 H, J = 17.2, 1.4 Hz), 4.31 (d, 1 
H, J = 9.3 Hz), 3.56 (dt, 1 H, J = 9.5, 2.7 Hz), 2.58-2.43 (m, 2 H), 2.43 (s, 3 H), 1.95-1.84 
(m, 1 H), 1.73-1.58 (m, 1 H), 0.88 (s, 3 H), 0.01 (s, 9 H); 13C NMR δ 142.83, 141.78, 
139.44, 138.81, 129.40, 128.20, 128.16, 128.12, 126.74, 125.68, 114.76, 60.51, 37.28, 
36.65, 33.57, 21.36, 16.56, -2.67; ESIMS m/z 438 ([M+Na]+, 100); HRMS (ESI) m/z calcd 
for C23H33NO2SSiNa (M+Na) 438.1899, found 438.1891. 
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1-65
 
(R,E)-2-Methyl-N-(3-phenylpropylidene)propane-2-sulfinamide (1-65).172  To 
a solution of hydrocinnamaldehyde (255 mg, 1.90 mmol) in CH2Cl2 (10 mL) was added 
tert-butanesulfinamide (200 mg, 1.65 mmol), MgSO4 (993 mg, 8.25 mmol) and PPTS 
(41.5 mg, 0.165 mmol).  The suspension was stirred at rt for 12 h, filtered through a pad of 
Celite®, concentrated and purified by chromatography on SiO2 (7:3, EtOAc:hexanes) to 
yield 3.13 g (80%) of 1-65 as a yellow oil. 1H NMR δ 8.12 (t, 1 H, J = 4.3 Hz), 7.38–7.10 
(m, 5 H), 3.03–2.94 (m, 2 H), 2.92–2.83 (m, 2 H), 1.39 (s, 9 H). 
 
NHS(O)t-Bu
TMSMe+
NHS(O)t-Bu
TMS
CH3
1-66b1-66a
 
(E) – 2 – Methyl – N - (1-phenyl – 6 - (trimethylsilyl) hept – 5 – en – 3 - yl) 
propane – 2 - sulfinamide (1-66a) and 2-methyl-N-((3R*,4R*)-4-methyl-1-phenyl-4-
(trimethylsilyl)-hex-5-en-3-yl)propane-2-sulfinamide (1-66b).  A solution of allene 1-
58 (222 mg, 1.75 mmol) in CH2Cl2 (6 mL) was treated at –78 °C with Cp2ZrHCl (450 mg, 
1.75 mmol) and allowed to warm to room temperature over 20 min.  After approximately 
90% of the CH2Cl2 was removed under reduced pressure, toluene (6 mL) was added.  The 
resulting red solution was cooled to –78 °C, treated with Et2Zn (1.75 mL, 1.75 mmol, 1.0 
M in hexane) and imine 1-65 (312 mg, 1.31 mmol) in toluene (6 mL), and allowed to stir 
at –78 °C for 15 min.  The reaction mixture was then warmed to room temperature and 
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stirred for an additional 3 h, quenched with saturated aqueous NaHCO3, extracted with 
EtOAc (3x), dried (MgSO4), and concentrated in vacuo.  The residue was purified by 
chromatography on SiO2 (1:4, EtOAc:hexanes to 1:2 EtOAc:hexanes) to yield 167 mg 
(36%) of 1-66a and 221 mg (45%) of 1-66b as colorless oils. 1-66a: IR (neat) 3213, 3026, 
2953, 1618, 1496, 1247, 1055, 836 cm-1; 1H NMR δ 7.35-7.25 (m, 2 H), 7.24-7.15 (m, 3 
H), 5.72 (dt, 1 H, J = 7.0, 1.6 Hz), 3.45-3.31 (m, 1 H), 3.24 (d, 1 H, J = 5.85 Hz), 2.82-
2.60 (m, 2 H), 2.54-2.41 (m, 2 H), 1.92-1.81 (m, 2 H), 1.73 (d, 3 H, J = 1.0 Hz), 1.23 (s, 9 
H), 0.06 (s, 9 H); 13C NMR δ 141.73, 140.57, 133.68, 128.34, 128.24, 125.80, 55.56, 
54.75, 36.86, 34.73, 31.70, 22.56, 14.73, -2.23; ESIMS m/z 388 ([M+Na]+, 100), 332 (10), 
260 (30); HRMS (ESI) m/z calcd for C20H35NOSSiNa (M+Na) 388.2106, found 388.2087.  
1-66b: IR (neat) 3312, 3084, 3026, 2955, 1618, 1454, 1250, 1077, 889 cm-1; 1H NMR δ 
7.31-7.22 (m, 2 H), 7.20-7.13 (m, 3 H), 5.96 (dd, 1 H, J = 17.2, 10.7 Hz), 5.15 (dd, 1 H, J 
= 10.7, 1.4), 4.94 (dd, 1 H, J = 17.2, 1.5 Hz), 3.48 (d, 1 H, J = 6.3 Hz), 3.18 (ddd, 1 H, J = 
10.4, 6.3, 1.6 Hz), 2.86 (ddd, 1 H, J = 14.2, 10.0, 4.8 Hz), 2.54 (ddd, 1 H, J = 16.5, 9.8, 6.8 
Hz), 2.05-1.92 (m, 1 H), 1.86-1.71 (m, 1 H), 1.27 (s, 9 H), 1.12 (s, 3 H), -0.02 (s, 9 H); 13C 
NMR δ 141.79, 139.37, 128.32, 125.78, 114.59, 61.13, 56.64, 37.69, 37.07, 33.44, 23.09, 
17.15, -2.59; ESIMS m/z 388 ([M+Na]+, 100), 366 (20), 332 (25); HRMS (ESI) m/z calcd 
for C20H35NOSSiNa (M+Na) 388.2106, found 388.2090.   
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0.70%  
Figure 6-1. NOE Data for 1-66a. 
 
Silver perchlorate on Celite®.  To a 100 mL round bottom flask charged with 
silver perchlorate (1.00 g, 4.80 mmol) in H2O (30 mL) was added Celite® (5.02 g).  The 
resulting suspension was stirred for 30 min, filtered though a Buchner funnel, and dried in 
a vacuum oven (60 °C, 24 h) to yield 6.01 g of silver perchlorate on Celite® (20 wt %) as 
an off-white powder. 
 
O
OHBnO
OBn
BnO
2-21  
(2R,3S,4R,5R,6R,E) - 4,5 - Bis(benzyloxy) – 6 - (benzyloxymethyl) – 2 - (hex – 
1 - enyl) – tetrahydro - 2H – pyran – 3 - ol (2-21).  General Protocol C. To a 
suspension of zirconocene hydrochloride (38 mg, 0.15 mmol) in CH2Cl2 (1 mL) was 
added alkyne 2-22 (17 µL, 0.15 mmol).  The yellow reaction mixture was stirred at room 
temperature for 10 min, treated with AgClO4 on Celite® (15.5 mg, 15.0 µmol), stirred for 
5 min, and treated dropwise with a solution of glycal epoxide 2-10 (44 mg, 0.10 mmol) in 
CH2Cl2 (1 mL).  The reaction mixture was stirred for 1 h, quenched with saturated 
aqueous NaHCO3, extracted with EtOAc, dried (MgSO4), and concentrated in vacuo.  
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Analysis of the crude reaction mixture by 1H NMR showed one diastereomer.  The residue 
was purified by chromatography on SiO2 (3:7, EtOAc:hexanes) to yield 39 mg (76%) of 2-
21 as a colorless oil: [α]D + 49.2 (c 1.7, CHCl3); IR (neat) 3455, 3030, 2924, 2870, 1496, 
1454, 1361, 1208, 1084, 1028, 734, 697 cm-1; 1H NMR (600 MHz) δ 7.40-7.25 (m, 12 H), 
7.25-7.15 (m, 3 H), 5.87 (dt, 3 H, J = 15.5, 6.7 Hz), 5.70 (dd, 1 H, J = 15.6, 6.7 Hz), 4.79 
(d, 1 H, J = 11.5 Hz), 4.70 (t, 2 H, J = 10.9 Hz), 4.62 (d, 1 H, J = 12.1 Hz), 4.56 (d, 1 H, J 
= 11.1 Hz), 4.53 (d, 1 H, J = 12.1 Hz), 4.43 (t, 1H, J = 5.5 Hz), 4.00-3.94 (m, 1 H), 3.78 
(dd, 1 H, J = 10.5, 10.4 Hz), 3.77 (dd, 1 H, J = 9.0, 8.5 Hz), 3.70 (dd, 1 H, J = 10.5, 10.2 
Hz), 3.70 (t, 1 H, J = 7.1 Hz), 3.66 (t, 1 H, J = 6.7 Hz), 2.50 (bs, 1 H), 2.10 (q, 2 H, J = 6.9 
Hz), 1.42-1.37 (m, 2 H), 1.37-1.27 (m, 2 H), 0.90 (t, 3 H, J = 7.2 Hz); 13C NMR (126 
MHz) δ 138.3, 138.2, 137.8, 137.2, 128.6, 128.6, 128.5, 128.1, 128.0, 127.8, 124.0, 80.5, 
76.6, 74.3, 74.1, 73.9, 73.5, 73.1, 71.0, 68.6, 32.5, 31.2, 22.4, 14.0; ESIMS m/z 539 
([M+Na]+, 100); HRMS (ESI) m/z calcd for C33H40O5Na (M+Na) 539.2773, found 
539.2762. 
 
O
OHBnO
OBn
BnO OTBDPS
2-24  
(2R,3S,4R,5R,6R,E) - 4,5 - Bis(benzyloxy) - 6 - (benzyloxymethyl) - 2 - (4-(tert - 
butyl diphenylsilyloxy)but-1-enyl)-tetrahydro-2H-pyran-3-ol (2-24).  According to the 
General Protocol C, zirconocene hydrochloride (38 mg, 0.15 mmol), alkyne 2-23 (93 mg, 
0.30 mmol), AgClO4 on Celite® (15.5 mg, 15.0 µmol) and glycal epoxide 2-10 (44 mg, 
0.10 mmol) afforded 55 mg (74%) of 2-24 as a colorless oil after purification on SiO2 
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(1:9, EtOAc:hexanes): [α]D + 34.2 (c 1.2, CHCl3); IR (neat) 3454, 3067, 3030, 2930, 
2858, 1454, 1428, 1110, 736, 700 cm-1; 1H NMR δ 7.67 (d, 4 H, J = 6.6 Hz), 7.44-7.35 
(m, 6 H), 7.35-7.28 (m, 13 H), 7.20 (d, 2 H, J = 7.0 Hz), 5.87 (dt, 1 H, J = 15.6, 6.5 Hz), 
5.76 (dd, 1 H, J = 15.7, 6.2 Hz), 4.77 (d, 1 H, J = 11.5 Hz), 4.71 (d, 1 H, J = 11.1 Hz), 
4.67 (d, 1 H, J = 11.5 Hz), 4.60 (d, 1 H, J = 12.1 Hz), 4.55 (d, 1 H, J = 11.1 Hz), 4.51 (d, 1 
H, J = 12.2 Hz), 4.43 (t, 1 H, J = 4.8 Hz), 3.98-3.93 (m, 1 H), 3.80-3.70 (m, 4 H), 3.70-
3.64 (m, 3 H), 2.50 (d, 1 H, 6.4 Hz), 2.36 (q, 2 H, J = 6.5 Hz), 1.05 (s, 9 H); 13C NMR δ 
138.2, 138.0, 137.7, 135.5, 133.8, 133.0, 129.5, 128.5, 128.4, 128.3, 127.9, 127.8, 127.6, 
127.6, 126.1, 80.4, 76.4, 74.7, 73.9, 73.7, 73.4, 73.0, 70.9, 68.4, 63.3, 36.1, 26.8, 19.2; 
ESIMS m/z 565 ([M+Na]+, 100); HRMS (ESI) m/z calcd for C47H54O6SiNa (M+Na) 
765.3587, found 765.3550. 
 
O
OHBnO
OBn
BnO CO2TIPS
2-26  
(E) - Triisopropylsilyl 5 - ((2R,3S,4R,5R,6R) - 4,5 - bis(benzyloxy) – 6 - 
(benzyloxymethyl) – 3 – hydroxy – tetrahydro - 2H – pyran – 2 - yl)pent – 4 - enoate 
(2-26).  According to the General Protocol C, zirconocene hydrochloride (38 mg, 0.15 
mmol), alkyne 2-25 (76 mg, 0.30 mmol), AgClO4 on Celite® (15.5 mg, 15.0 µmol) and 
glycal epoxide 2-10 (44 mg, 0.10 mmol) afforded 46 mg (67%) of 2-26 as a colorless oil 
after purification on SiO2 (6:4, CH2Cl2:hexanes): IR (neat) 3479, 3030, 2944, 2867, 1716, 
1454, 1365, 1073, 884, 735, 697 cm-1; 1H NMR δ 7.38-7.28 (m, 13 H), 7.21 (d, 2 H, J = 
6.1 Hz), 5.88 (dt, 1 H, J = 15.6, 6.0 Hz), 5.76 (dd, 1 H, J = 15.6, 6.1 Hz), 4.77 (d, 1 H, J = 
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11.5 Hz), 4.70 (t, 2 H, J = 10.9 Hz), 4.61 (d, 1 H, J = 12.1 Hz), 4.56 (d, 1 H, J = 11.2 Hz), 
4.52 (d, 1 H, J = 12.2 Hz), 4.43 (t, 1 H, J = 4.5 Hz), 4.00-3.93 (m, 1 H), 3.80-3.73 (m, 2 
H), 3.73-3.64 (m, 3 H), 2.62 (d, 1 H, J = 6.7 Hz), 2.51-2.45 (m, 2 H), 2.45-2.38 (m, 2 H), 
1.34-1.25 (m, 3 H), 1.08 (d, 18 H, J = 7.4 Hz); 13C NMR δ 173.0, 138.2, 138.0, 137.7, 
134.3, 128.5, 128.4, 128.4, 127.9, 127.8, 127.7, 125.3, 80.1, 77.2, 76.2, 74.1, 73.6, 73.4, 
73.2, 70.8, 68.4, 35.1, 28.2, 17.8, 11.9; ESIMS m/z 711 ([M+Na]+, 100), 515 (57); HRMS 
(ESI) m/z calcd for C41H56O7SiNa (M+Na) 711.3693, found 711.3687. 
 
O
OHBnO
OBn
BnO N
Ts
CO2Me
2-28  
Methyl (E) – 4 - ((2R,3S,4R,5R,6R)-4,5-bis(benzyloxy)-6-(benzyloxymethyl)-3-
hydroxy-tetrahydro-2H-pyran-2-yl)but-3-enyl(tosyl)carbamate (2-28).  According to 
the General Protocol C, zirconocene hydrochloride (38 mg, 0.15 mmol), alkyne 2-27 (84 
mg, 0.30 mmol), AgClO4 on Celite® (15.5 mg, 15.0 µmol) and glycal epoxide 2-10 (44 
mg, 0.10 mmol) afforded 50 mg (70%) of 2-28 as a colorless oil after purification on SiO2 
(4:6, EtOAc:hexanes): IR (neat) 3521, 3030, 2921, 1736, 1453, 1359, 1168, 910, 734, 699 
cm-1; 1H NMR δ 7.84 (d, 2 H, J = 8.1 Hz), 7.39-7.23 (m, 15 H), 7.21 (d, 2 H, J = 6.0 Hz), 
5.89-5.77 (m, 2 H), 4.79 (d, 1 H, J = 11.5 Hz), 4.72 (d, 1 H, J = 11.3 Hz), 4.62 (d, 1 H, J = 
12.1 Hz), 4.54 (t, 2 H, 11.4 Hz), 4.45 (t, 1 H, J = 4.4 Hz), 3.97-3.88 (m, 3 H), 3.82-3.74 
(m, 2 H), 3.73-3.64 (m, 6 H), 2.63 (d, 1 H, J = 6.7 Hz), 2.58-2.51 (m, 2 H), 2.42 (s, 3 H); 
13C NMR δ 152.8, 144.5, 138.3, 138.2, 137.9, 136.8, 131.3, 129.3, 128.5, 128.4, 127.9, 
127.8, 127.7, 127.6, 80.4, 74.1, 73.7, 73.4, 73.3, 71.0, 68.6, 53.7, 46.6, 33.4, 21.6; ESIMS 
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m/z 738 ([M+Na]+, 100); HRMS (ESI) m/z calcd for C40H45O9SNa (M+Na) 738.2713, 
found 738.2692. 
 
O
OHBnO
OBn
BnO
2-30  
(2R,3S,4R,5S,6R,E)-4,5-Bis(benzyloxy)-6-(benzyloxymethyl)-2-(hex-1-enyl)-
tetrahydro-2H-pyran-3-ol (2-30).  According to the General Protocol C, zirconocene 
hydrochloride (38 mg, 0.15 mmol), alkyne 2-22 (17 µL, 0.30 mmol), AgClO4 on Celite® 
(15.5 mg, 15.0 µmol) and glycal epoxide 2-29 (44 mg, 0.10 mmol) afforded 38 mg (73%) 
of 2-30 as a colorless oil after purification on SiO2 (1:9, EtOAc:hexanes): IR (neat) 3453, 
3030, 2925, 2871, 1454, 1094, 735, 698 cm-1; 1H NMR δ 7.33-7.23 (m, 15 H), 5.84 (dt, 1 
H, J = 15.6, 6.7 Hz), 5.56 (dd, 1 H, J = 15.9, 5.5 Hz), 4.74 (d, 1 H, J = 11.6 Hz), 4.71 (d, 1 
H, J = 11.6 Hz), 4.55 (d, 1 H, J = 11.7 Hz), 4.52 (d, 1 H, J = 5.7 Hz), 4.50 (d, 1 H, J = 6.1 
Hz), 4.45 (d, 1 H, J = 11.9 Hz), 4.16-4.09 (m, 1 H), 4.04-3.97 (m, 2 H), 3.75-3.68 (m, 1 
H), 3.65-3.57 (m, 2 H), 2.10-2.02 (m, 3 H), 1.38-1.22 (m, 4 H), 0.86 (t, 3 H, J = 7.3 Hz); 
13C NMR δ 138.5, 138.3, 138.1, 136.4, 128.6, 128.5, 128.4, 128.0, 130.0, 127.8, 123.1, 
79.3, 73.8, 73.6, 73.5, 72.4, 68.8, 68.1, 32.5, 31.3, 22.4, 14.1; ESIMS m/z 539 ([M+Na]+, 
100), 536 (20); HRMS (ESI) m/z calcd for C33H40O5Na (M+Na) 539.2773, found 
539.2800. 
 
 
 - 137 -  
OOHBnO
OBn
BnO OTBDPS
2-31  
(2R,3S,4R,5S,6R,E)-4,5-Bis(benzyloxy)-6-(benzyloxymethyl)-2-(4-(tert-butyl 
diphenylsilyloxy)but-1-enyl)-tetrahydro-2H-pyran-3-ol (2-31).  According to the 
General Protocol C, zirconocene hydrochloride (38 mg, 0.15 mmol), alkyne 2-23 (93 mg, 
0.30 mmol), AgClO4 on Celite® (15.5 mg, 15.0 µmol) and glycal epoxide 2-29 (44 mg, 
0.10 mmol) afforded 53 mg (72%) of 2-31 as a colorless oil after purification on SiO2 
(hexanes to EtOAc:hexanes, 0.5:9.5): IR (neat) 3459, 3066, 3030, 2929, 2857, 1454, 1428, 
1110, 736, 700 cm-1; 1H NMR δ 7.69 (d, 4 H, J = 6.8 Hz), 7.45-7.35 (m, 6 H), 7.35-7.28 
(m, 15 H), 5.89 (dt, 1 H, J = 15.6, 6.6 Hz), 5.68 (dd, 1 H, J = 15.7, 4.5 Hz), 4.78 (d, 1 H, J 
= 11.5 Hz), 4.72 (d, 1 H, J = 11.6 Hz), 4.62-4.55 (m, 2 H), 4.53 (d, 1 H, J = 6.7 Hz), 4.51 
(d, 1 H, J = 6.3 Hz), 4.49-4.45 (m, 1 H), 4.19-4.13 (m, 1 H), 4.09-4.04 (m, 1 H), 4.04-4.01 
(m, 1 H), 3.73 (t, 3 H, J = 6.4 Hz), 3.69-3.63 (m, 1 H), 3.61 (d, 1 H, J = 6.9 Hz), 2.37 (q, 2 
H, J = 6.5 Hz), 2.11 (d, 1 H, J = 2.5 Hz), 1.06 (s, 9 H); 13C NMR δ 138.4, 138.1, 138.0, 
135.6, 133.8, 132.1, 129.6, 128.5, 128.3, 128.3, 128.1, 127.9, 127.8, 127.6, 127.6, 125.3, 
79.2, 77.2, 73.7, 73.5, 73.3, 72.5, 72.2, 68.6, 67.8, 63.3, 36.1, 26.8, 19.2; ESIMS m/z 765 
([M+Na]+, 100), 391 (10); HRMS (ESI) m/z calcd for C47H54O6SiNa (M+Na) 765.3587, 
found 765.3582. 
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2-33  
(2R,3S,4R,5R,6R,E)- 4,5 – Bis (tert - butyldimethylsilyloxy) - 6 - ((tert-butyl 
dimethylsilyloxy) methyl) – 2 - (hex – 1 - enyl) – tetrahydro - 2H – pyran - 3- ol (2 -
33).  According to the General Protocol C, zirconocene hydrochloride (38 mg, 0.15 
mmol), alkyne 2-22 (17 µL, 0.30 mmol), AgClO4 on Celite® (15.5 mg, 15.0 µmol) and 
glycal epoxide 2-32 (50 mg, 0.10 mmol) afforded 44 mg (74%) of 2-33 as a colorless oil 
after purification on SiO2 (1:9, EtOAc:hexanes): IR (neat) 3532, 2930, 2858, 1472, 1254, 
1093, 836, 778 cm-1; 1H NMR (300 MHz) δ 5.81-5.66 (m, 2 H), 4.25-4.17 (m, 1 H), 4.10-
3.93 (m, 2 H), 3.92-3.81 (m, 3 H), 3.82-3.78 (m, 1 H), 3.71 (d, 1 H, J = 11.5 Hz), 3.34-
3.26 (m, 1 H), 2.15-2.00 (m, 2 H), 1.43-1.30 (m, 4 H), 0.96-0.84 (m, 30 H), 0.17-0.02 (m, 
18 H); 13C NMR δ 134.1, 127.9, 80.3, 72.3, 70.6, 69.8, 68.9, 61.3, 32.1, 31.2, 25.9, 25.8, 
22.3, 17.9, 13.9, -4.9, -5.0, -5.1, -5.3; ESIMS m/z 611 ([M+Na]+, 100), 439 (20); HRMS 
(ESI) m/z calcd for C30H64O5Si3Na (M+Na) 611.3959, found 611.3936. 
 
O
OHTBSO
OTBS
TBSO OTBDPS
2-34  
(2R,3S,4R,5R,6R,E) - 4,5 – Bis (tert - butyldimethylsilyloxy) – 6 - ((tert – butyl 
dimethylsilyloxy) methyl) – 2 - (4 - (tert - butyldiphenylsilyloxy) but – 1 - enyl) – tetra 
hydro - 2H – pyran – 3 - ol (2-34). According to the General Protocol C, zirconocene 
hydrochloride (38 mg, 0.15 mmol), alkyne 2-23 (93 mg, 0.30 mmol), AgClO4 on Celite® 
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(15.5 mg, 15.0 µmol) and glycal epoxide 2-32 (50 mg, 0.10 mmol) afforded 58 mg (71%) 
of 2-34 as a colorless oil after purification on SiO2 (hexanes to EtOAc:hexanes, 0.5:9.5): 
IR (neat) 3528, 2930, 2858, 1472, 1255, 1095, 836, 778, 702 cm-1; 1H NMR (300 MHz) 
δ 7.70-7.64 (m, 4 H), 7.45-7.33 (m, 6 H), 5.84-5.70 (m, 2 H), 4.25-4.18 (m, 1 H), 3.91 (t, 1 
H, J = 2.5 Hz), 3.89-3.79 (m, 3 H), 3.76-3.73 (m, 1 H), 3.71 (d, 2 H, J = 6.7 Hz), 3.35-3.27 
(m, 1 H), 2.43-2.33 (m, 2 H), 1.04 (s, 9 H), 1.00-0.86 (m, 27 H), 0.13-0.05 (m, 18 H); 13C 
NMR δ 135.7, 134.1, 130.5, 129.9, 129.6, 127.7, 80.3, 72.2, 70.4, 69.9, 68.8, 63.7, 61.3, 
35.9, 31.7, 26.9, 26.0, 25.9, 22.8, 19.3, 18.3, 18.0, 14.2, -4.5, -4.9, -5.1, -5.2; ESIMS m/z 
765 ([M+Na]+, 100), 391 (10); HRMS (ESI) m/z calcd for C47H54O6SiNa (M+Na) 
765.3587, found 765.3582. 
 
N Ts
Ph
2-44  
N-Allyl-4-methyl-N-(1-phenylhex-5-en-3-yl)benzenesulfonamide (2-44).    To a 
solution of (E)-4-methyl-N-(4-phenylbutan-2-ylidene)benzenesulfonamide (4.30 g, 15.0 
mmol) and allyl-TMS (7.15 mL, 45.0 mmol) in CH2Cl2 (150 mL) was added at -78 °C 
TiCl4 (1.75 mL, 16.0 mmol). The resulting solution was allowed to warm to rt and stirred 
at this temperature for 1 h, quenched with sat. aq. NH4Cl, extracted with EtOAc, dried 
(MgSO4) and concentrated in vacuo.  The crude allyl amine was carried on without further 
purification.   To a solution of allyl amine in toluene (150 mL) was added allyl bromide 
(6.50 mL, 75.0 mmol), 50% NaOH in H2O (150 mL) and Bu4NI (5.50 g, 15.0 mmol) and 
the biphasic reaction mixture was rapidly stirred at rt for 6 h.  After dilution with H2O, the 
solution was extracted with EtOAc, and the organic layer was separated, dried (MgSO4) 
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and concentrated in vacuo.  The crude residue was purified by chromatography on SiO2 
(3:7, EtOAc:hexanes) to yield 4.04 g (73%) of 2-44 as a yellow oil: IR (neat) 3063, 3023, 
2926, 1641, 1599, 1339, 1159, 1091 cm-1; 1H NMR δ 7.74 (d, 2 H, J = 8.1 Hz), 7.36-7.25 
(m, 4 H), 7.25-7.18 (m, 1 H), 7.13 (d, 2 H, J = 7.2 Hz), 6.05-5.88 (m, 1 H), 5.70-5.53 (m, 
1 H), 5.24 (dd, 1 H, J = 17.2, 0.9 Hz), 5.15 (dd, 1 H, J = 10.1, 0.8 Hz), 5.05-4.94 (m, 2 H), 
4.00-3.85 (m, 2 H), 3.85-3.68 (m, 1 H), 2.75-2.60 (m, 1 H), 2.60-2.49 (m, 1 H), 2.45 (s, 3 
H), 2.27-2.10 (m, 2 H), 1.88-1.57 (m, 2 H); 13C NMR δ 143.2, 141.8, 138.4, 136.4, 135.0, 
129.6, 128.5, 128.4, 127.4, 126.0, 117.5, 117.4, 58.6, 46.6, 38.3, 34.9, 33.1, 21.6; ESIMS 
m/z 392 ([M+Na]+, 100); HRMS (ESI) m/z calcd for C22H27O2SNa (M+Na) 392.1660, 
found 392.1667. 
 
N
Ts
Ph
2-45  
2-Phenethyl-1-tosyl-1,2,3,4-tetrahydropyridine (2-45).  To a solution of amine 
2-44 (890 mg, 2.4 mmol) in CH2Cl2 (32 mL) was added 1,3-bis-(2,4,6-trimethylphenyl)-2-
imidazolidinylidene)dichloro-(phenylmethylene)tricyclohexylphosphine)ruthenium (200 
mg, 0.236 mmol). The resulting solution was stirred at rt for 2 h, filtered through a pad of 
SiO2 and concentrated in vacuo.  To a solution of cyclic amine in EtOH (16 mL) was 
added tris(triphenylphosphine)rhodium(I) chloride (333 mg, 0.360 mmol) and DBU (183 
mg, 1.20 mmol).  The reaction mixture was heated at 60 °C for 2 h, concentrated in vacuo 
and the crude residue was purified by chromatography on SiO2 (1.5:8.5, EtOAc:hexanes) 
to yield 705 mg (86%) of 2-45 as a colorless solid: mp 105.1-107.3 °C (CH2Cl2); IR (KBr) 
3026, 2925, 2848, 1644, 1340, 1168, 1098 cm-1; 1H NMR δ 7.68 (d, 2 H, J = 8.0 Hz), 
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7.38-7.15 (m, 7 H), 6.65 (d, 1 H, J = 8.1 Hz), 5.10-5.00 (m, 1 H), 4.07-3.97 (m, 1 H), 
2.91-2.68 (m, 2 H), 2.40 (s, 3 H), 2.05-1.85 (m, 2 H), 1.85-1.72 (m, 1 H), 1.72-1.57 (m, 1 
H), 1.51 (dd, 1 H, J = 13.5, 5.2 Hz), 0.98-0.82 (m, 1 H); 13C NMR δ 143.1, 141.7, 129.4, 
128.2, 128.1, 126.8, 125.6, 123.4, 109.2, 52.6, 33.2, 32.1, 23.0, 21.2, 17.1; ESIMS m/z 364 
([M+Na]+, 100); HRMS (ESI) m/z calcd for C20H23NO2SNa (M+Na) 364.1347, found 
364.1360. 
 
O
BnO
OBn
OBn
OBn
OH
3-27  
3 - ((2R,3S,4R,5S,6R) - 3,4,5 - Tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-
2H-pyran-2-yl)propan-1-ol (3-27).112  To a solution of 2,3,4,6-tetra-O-benzyl methyl-α-
D-glucopyranoside (3-26) (6.54 g, 11.8 mmol) and allylsilane (5.8 mL, 36.0 mmol) in 
acetonitrile (60 mL) at - 50 °C was added dropwise trimethylsilyl 
trifluoromethanesulfonate (2.49 mL, 12.8 mmol).  The reaction mixture was stirred at rt 
for 16 h, quenched with sat. aq. NaHCO3, extracted with EtOAc, dried (MgSO4), and 
concentrated in vacuo.  The residue was purified by chromatography on SiO2 (2:8, 
EtOAc:hexanes) to yield 5.72 g (86%) of allylgalactose as a colorless oil with traces of β-
C-glycoside present: 1H NMR δ 7.52-6.80 (m, 20 H), 5.90-5.73 (m, 1 H), 5.14 (d, 1 H, J = 
18.2 Hz), 5.09 (d, 1 H, J = 10.2 Hz), 4.80-4.35 (m, 3 H), 4.18-3.98 (m, 3 H), 3.92 (dd, 1 H, 
J = 10.3, 7.2 Hz), 3.85-3.60 (m, 3 H), 2.55-2.30 (m, 2 H); ESIMS m/z 587 ([M+Na]+, 
100); HRMS (ESI) m/z calcd for C37H40O5Na (M+Na) 587.2773, found 587.2725. 
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A 0.5 M solution of 9-BBN in THF (11.4 mL, 5.70 mmol) was added dropwise to 
a solution of allylgalactose (2.91 g, 5.20 mmol) in THF (12 mL) at 0 °C.  The resulting 
solution was stirred at 65 °C for 16 h, then cooled to 0 °C.  To this solution was 
successively added EtOH (1.75 mL, 55.0 mmol), 3 N NaOH (1.75 mL, 0.33 eq,), and 30% 
H2O2 solution in water (1.3 eq, 1.75 mmol) and the resulting cloudy solution was heated at 
55 °C for 2 h.  The reaction mixture was allowed to cool to rt and poured into a mixture of 
Et2O (120 mL) and H2O (60 mL).  The aqueous layer was saturated with K2CO3, and the 
organic phase was separated, dried (MgSO4), and and concentrated in vacuo. The residue 
was purified by chromatography on SiO2 (1:1, EtOAc:hexanes) to yield 2.52 g (83%) of 3-
27 as a colorless oil: 1H NMR δ 7.45 – 7.05 (m, 20 H), 4.80-4.41 (m, 8 H), 4.08-3.93 (m, 
3 H), 3.87-3.77 (m, 2 H), 3.72 (dd, 1 H, J = 7.3, 2.7 Hz), 3.69-3.61 (m, 2 H), 3.58 (dd, 1 
H, J = 10.3, 4.2 Hz), 2.11 (bs, 1 H), 1.82-1.53 (m, 4 H); ESIMS m/z 605 ([M+Na]+, 100); 
HRMS (ESI) m/z calcd for C37H42O6Na 605.2879 (M+Na), found 605.2848. 
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3-29  
3-((2R,3S,4R,5S,6R)-3,4,5-Tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-
2H-pyran-2-yl)propanal (3-29).  Prepared according to literature procedure (on a 5+ 
gram scale),173 or by the following procedure:  To a solution of 3-26 (1.00 g, 1.80 mmol) 
and 3-28 (930 mg, 5.40 mmol) in MeCN (5 mL) was added TMSOTf174 (489 µL, 2.70 
mmol) at 0 °C.  The resulting solution was stirred at this temp for 18 h, allowed to warm 
to rt and stirred an additional 5 h followed by addition of EtOH (10 mL) and NaOMe 
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(1.00 g, 18.5 mmol).  The reaction was allowed to stir until the enol acetate was consumed 
by TLC analysis (3:7, EtOAc:hexanes).  After completion, the reaction was diluted with 
H2O (10 mL), extracted with Et2O (3 x 25 mL), the organic layer was separated, dried 
(MgSO4), concentrated175 and purified by chromatography on SiO2 (3:7, EtOAc:hexanes) 
to yield 700 mg (67%) of 3-29 as a light yellow syrup which slowly decomposed upon 
storage: 1H NMR δ 9.76 (s, 1 H), 7.45-7.15 (m, 20 H), 4.81-4.41 (m, 8 H), 4.02-3.86 (m, 3 
H), 3.85-3.78 (m, 2 H), 3.75 (dd, 1 H, J = 7.1, 2.0 Hz), 3.63 (dd, 1 H, J = 10.5, 4.6 Hz), 
2.55-2.40 (m, 2 H), 2.10-1.85 (m, 2 H); ESIMS m/z 603 ([M+Na]+, 100); HRMS (ESI) m/z 
calcd for C37H40O6Na (M+Na) 603.2723, found 603.2664. 
 
O
BnO
OBn
OBn
OBn
N
H
S
O
3-25  
(R,E) – 2 – Methyl – N - (3 - ((2R,3S,4R,5S,6R) - 3,4,5 – tris (benzyloxy) – 6 -
(benzyloxymethyl)tetrahydro- 2H-pyran-2-yl)propylidene)propane-2-sulfinamide (3-
25).  To a solution of 3-29 (2.18 g, 3.75 mmol) in CH2Cl2 (30 mL) was added MgSO4 
(2.53 g, 21.0 mmol), (R)-2-methylpropane-2-sulfinamide (500 mg, 4.13 mmol), and PPTS 
(104 mg, 0.410 mmol).  The resulting suspension was stirred at rt for 24 h, filtered through 
Celite®, and concentrated in vacuo.  The residue was purified by chromatography on SiO2 
(4:6, EtOAc:hexanes) to yield 2.40 g (94%) of 3-25 as a colorless oil: [α]D -32.3 (c 1.1, 
CH2Cl2); IR (neat) 3063, 3030, 2921, 1622, 1454, 1185 cm-1; 1H NMR δ 8.08 (t, 1 H, J = 
4.1 Hz), 7.40-7.15 (m, 20 H), 4.79-4.41 (m, 8 H), 4.05-3.95 (m, 3 H), 3.89-3.79 (m, 1 H), 
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3.79-3.70 (m, 2 H), 3.70-3.61 (m, 1 H), 2.70-2.52 (m, 1 H), 2.50-2.36 (m, 1 H), 2.04-1.80 
(m, 2 H); 13C NMR δ 168.7, 138.1, 138.0, 137.9, 137.8, 128.0, 128.0, 127.9, 127.6, 127.5, 
127.4, 127.2, 127.2, 127.1, 76.2, 73.8, 72.8, 72.8, 72.6, 72.1, 69.9, 67.1, 56.0, 32.1, 22.9, 
21.9; ESIMS m/z 706 ([M+Na]+, 100), 684 ([M+H]+, 20); HRMS (ESI) m/z calcd for 
C41H49NO6SNa (M+Na) 706.3178, found 706.3201. 
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3-31  
(R) – 2 – Methyl – N - ((E) – 1 - ((3S,4R,5S,6R) - 3,4,5 - tris(benzyloxy) – 6 -
(benzyloxymethyl)tetrahydro - 2H - pyran-2 - yl) non – 4 – en – 3 - yl) propane – 2 -
sulfinamide (3-31).  General Protocol D.  To a solution of 1-hexyne (3-30) (18.9 mg, 
0.230 mmol) in CH2Cl2 (1 mL) was added zirconocene hydrochloride (72.2 mg, 0.280 
mmol) and the resulting suspension was stirred for 5 min.  The yellow solution was cooled 
to 0 °C and Me3Al (115 µL, 0.230 mmol, 2.0 M in CH2Cl2)176 and imine 3-25 (100 mg, 
0.150 mmol) in CH2Cl2 (1 mL) were added. The mixture was stirred at rt for 3 h, 
quenched with sat. aq. NH4Cl, extracted with CH2Cl2, dried (MgSO4) and concentrated in 
vacuo.  The residue was purified by chromatography on SiO2 (1:1, EtOAc:hexanes) to 
yield 94.4 mg (82%) of 3-31 as a colorless oil: [α]D +5.1 (c 0.8, CH2Cl2); 1H NMR δ 7.50-
7.15 (m, 20 H), 5.70 (dt, 1 H, J = 15.3, 6.7 Hz), 5.19 (dd, 1 H, J = 15.3, 8.3 Hz), 4.82-4.43 
(m, 8 H), 4.05-3.90 (m, 3 H), 3.90-3.69 (m, 4 H), 3.64 (dd, 1 H, J = 10.5, 4.5 Hz), 3.13 (d, 
1 H, J = 2.4 Hz), 2.15-1.92 (m, 2 H), 1.80-1.25 (m, 8 H), 1.20 (s, 9 H), 0.91 (t, 3 H, J = 7.1 
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Hz); 13C NMR δ 138.3, 138.2, 138.1, 137.9, 134.1, 130.1, 128.1, 127.7, 127.6, 127.4, 
127.3, 127.2, 76.3, 74.1, 73.0, 72.9, 72.8, 71.8, 70.9, 67.5, 57.2, 54.8, 32.7, 31.6, 30.9, 
23.1, 22.3, 21.9, 13.6; ESIMS m/z 790 ([M+Na]+, 100), 768 ([M+H]+, 80); HRMS (ESI) 
m/z calcd for C47H61NO6SNa (M+Na) 790.4117, found 790.4153. 
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(R) – N - ((S,E) – 7 - (tert-Butyldiphenylsilyloxy) – 1 - ((2R,3S,4R,5S,6R) - 3,4,5 
– tris (benzyloxy) – 6 - (benzyloxymethyl)tetrahydro-2H-pyran-2-yl)hept-4-en-3-yl) -
2-methylpropane-2-sulfinamide (3-34).  According to General Protocol D, alkyne 3-33 
(51.5 mg, 0.167 mmol), zirconocene hydrochloride (43.1 mg, 0.167 mmol), Me3Al (167 
µL, 0.167 mmol, 1.0 M in CH2Cl2) and imine 3-25 (57.0 mg, 0.0833 mmol) in CH2Cl2 (1 
mL) afforded 67.1 mg (81%) of 3-34 as a colorless oil after purification on SiO2 (1:1, 
EtOAc:hexanes): [α]D + 3.6 (c 0.4, CH2Cl2);  IR (neat) 3030, 2929, 2859, 1496, 1454, 
1428, 1110, 736, 700 cm-1;  1H NMR δ 7.71-7.65 (m, 4 H), 7.46-7.21 (m, 26 H), 5.64 (dt, 
1 H, J = 15.1, 6.9 Hz), 5.25 (dd, 1 H, J = 15.5, 8.0 Hz), 4.80-4.41 (m, 8 H), 4.00-3.88 (m, 
3 H), 3.87-3.68 (m, 6 H), 3.63 (dd, 1 H, J = 10.5, 4.5 Hz), 3.10 (d, 1 H, J = 2.9 Hz), 2.31 
(app q, 2 H, J = 6.6 Hz), 1.78-1.35 (m, 4 H), 1.16 (s, 9 H), 1.05 (s, 9 H);  13C NMR 
δ 138.6, 138.5, 138.4, 138.3, 135.5, 133.9, 132.6, 130.1, 129.6, 128.3, 128.0, 127.9, 127.7, 
127.6, 127.5, 127.4, 74.5, 73.3, 73.2, 73.1, 73.0, 72.1, 71.4, 67.8, 57.4, 55.2, 35.8, 33.1, 
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26.9, 23.4, 22.6, 19.2;  ESIMS m/z 1016 ([M+Na]+, 100), 995 (20); HRMS (ESI) m/z 
calcd for C61H75NO7SiSNa (M+Na) 1016.4931, found 1016.4927. 
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O
O
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Methyl (S,E)-5-((R)-1,1-dimethylethylsulfinamido)-7-((2R,3S,4R,5S,6R)-3,4,5-
tris (benzyloxy) - 6 - (benzyloxymethyl)tetrahydro-2H-pyran-2-yl) hept - 3 - enyl 
(tosyl) carbamate (3-36).  According to General Protocol D, alkyne 3-35 (90.6 mg, 0.322 
mmol), zirconocene hydrochloride (91.3 mg, 0.354 mmol), Me3Al (322 µL, 0.322 mmol, 
1.0 M in CH2Cl2) and imine 3-25 (110 mg, 0.161 mmol) in CH2Cl2 (2 mL) afforded 101 
mg (65%) of 3-36 (93:7 mixture of diastereomers by chiral HPLC analysis)177 as a 
colorless oil after purification on SiO2 (7:3, EtOAc:hexanes) (data for major diastereomer 
reported): [α]D + 13.7 (c 1.0, CH2Cl2); IR (neat) 3436, 3030, 2922, 2243, 1735, 1495, 
1453, 1360, 1168, 1090, 910, 734, 698 cm-1; 1H NMR δ 7.86-7.78 (m, 2 H), 7.39-7.20 (m, 
22 H), 5.62 (dt, 1 H, J = 15.4, 6.9 Hz), 5.35 (dd, 1 H, J = 15.4, 7.9 Hz), 4.80-4.40 (m, 8 
H), 4.03-3.90 (m, 3 H), 3.90-3.70 (m, 6 H), 3.67 (s, 3 H), 3.70-3.56 (m, 1 H), 3.18 (d, 1 H, 
J = 2.6 Hz), 2.58-2.45 (m, 2 H), 2.43 (s, 3 H), 1.78-1.60 (m, 2 H), 1.60-1.33 (m, 2 H), 1.19 
(s, 9 H); 13C NMR δ 152.7, 144.4, 138.7, 138.6, 138.5, 138.4, 136.8, 134.0, 129.3, 128.9, 
128.3, 128.3, 128.2, 128.0, 127.9, 127.8, 127.7, 127.4, 76.8, 74.6, 73.4, 73.2, 73.0, 72.1, 
71.5, 68.0, 57.4, 55.3, 46.8, 33.1, 33.0, 23.4, 22.6, 21.5; ESIMS m/z 990 ([M+Na]+, 100), 
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968 ([M]+, 8); HRMS (ESI) m/z calcd for C54H66N2O10S2Na (M+Na) 989.4057, found 
989.4066. 
O
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3-38  
(R) – N - ((S,E) – 1 – Cyclohexyl – 5 - ((2R,3S,4R,5S,6R) -3,4,5-tris(benzyloxy)-
6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl) pent-1-en-3-yl)-2- methylpropane - 2-
sulfinamide (3-38). According to General Protocol D, alkyne 3-37 (18.1 mg, 0.167 
mmol), zirconocene hydrochloride (43.1 mg, 0.167 mmol), Me3Al (167 µL, 0.167 mmol, 
1.0 M in CH2Cl2) and imine 3-25 (57.0 mg, 0.0833 mmol) in CH2Cl2 (1 mL) afforded 56.2 
mg (85%) of 3-38 as a colorless oil after purification on SiO2 (1:1, EtOAc:hexanes): [α]D 
+ 13.7 (c 0.7, CH2Cl2); IR (neat) 3434, 3063, 3030, 2922, 2852, 1665, 1496, 1453, 971, 
1363, 1207, 734, 697 cm-1; 1H NMR δ 7.45-7.20 (m, 20 H), 5.59 (dd, 1 H, J = 15.5, 6.7 
Hz), 5.12 (dd, 1 H, J = 15.5, 8.2 Hz), 4.79-4.40 (m, 8 H), 4.00-3.87 (m, 3 H), 3.86-3.67 
(m, 4 H), 3.62 (dd, 1 H, J = 10.8, 4.5 Hz), 3.09 (d, 1 H, J = 2.2 Hz), 2.20-1.85 (m, 1 H), 
1.78-1.57 (m, 7 H), 1.57-1.33 (m, 2 H), 1.33-0.95 (m, 5 H), 1.18 (s, 9 H); 13C NMR 
δ 140.2, 138.6, 138.5, 138.3, 138.2, 128.3, 128.3, 128.3, 128.0, 127.9, 127.9, 127.8, 127.7, 
127.6, 127.5, 127.5, 74.3, 73.3, 73.2, 73.0, 73.0, 72.1, 67.7, 57.5, 55.1, 40.3, 33.1, 32.8, 
32.8, 26.1, 25.9, 23.4, 22.6; ESIMS m/z 816 ([M+Na]+, 100), 794 ([M]+, 40); HRMS (ESI) 
m/z calcd for C49H63NO6SNa (M+Na) 816.4274, found 816.4245. 
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(S,E)-1-((2R,3S,4R,5S,6R)-3,4,5- Tris (benzyloxy) - 6 - (benzyloxymethyl) tetra 
hydro-2H-pyran-2-yl)nonadec-4-en-3-amine (3-40).  To a solution of 1-hexadecyne (3-
39) (979 mg, 4.40 mmol) in CH2Cl2 (20 mL) was added zirconocene hydrochloride (1.13 
g, 4.40 mmol) and the resulting suspension was stirred at rt for 5 min.  The yellow 
solution was cooled to 0 °C and treated with AlMe3 (2.20 mL, 4.40 mmol, 2.0 M in 
CH2Cl2) and a solution of imine 3-25 (2.01 g, 2.92 mmol) in CH2Cl2 (10 mL).  The 
reaction mixture was stirred at rt for 5 h, quenched with 25 mL of MeOH and 10 mL of 3 
M HCl were added and stirred at rt for 1 h.  The solution was diluted with EtOAc, washed 
with NaHCO3, dried (MgSO4) and concentrated in vacuo.  The residue was purified by 
chromatography on SiO2 (3:7, MeOH:CH2Cl2) to yield 1.69 g (72%) of 3-40 as a colorless 
oil: [α]D +28.5 (c 0.9, CH2Cl2); IR (neat) 3063, 3030, 2927, 2853, 1454, 1097 cm-1; 1H 
NMR δ 7.50-7.10 (m, 20 H), 5.51 (dt, 1 H, J = 15.1, 6.5 Hz), 5.32 (dd, 1 H, J = 15.3, 7.2 
Hz), 4.80-4.41 (m, 8 H), 4.02-3.90 (m, 3 H), 3.85-3.75 (m, 2 H), 3.75-3.70 (m, 1 H), 3.64 
(dd, 1 H, J = 10.2, 4.5 Hz), 3.24 (app q, 1 H, J = 6.6 Hz), 2.05-1.90 (m, 2 H), 1.75-1.42 
(m, 6 H), 1.42-1.10 (m, 24 H), 0.89 (t, 3 H, J = 6.3 Hz); 13C NMR δ 138.6, 138.4, 138.2, 
134.2, 130.7, 128.3, 128.2, 127.9, 127.8, 127.7, 127.6, 127.5, 127.4, 127.4, 76.7, 74.3, 
73.2, 73.2, 73.0, 72.9, 71.9, 67.6, 53.6, 33.9, 32.3, 31.9, 29.6, 29.6, 29.5, 29.3, 29.3, 29.2, 
22.6, 14.1; ESIMS m/z 805 ([M+H]+, 100); HRMS (ESI) m/z calcd for C53H74NO5 (M+H) 
804.5567, found 804.5587. 
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[(S,E)-1-((2R,3S,4R,5S,6R)-3,4,5-Tris (benzyloxy) - 6 - (benzyloxymethyl) tetra 
hydro-2H-pyran-2-yl)nonadec-4-en-3-yl]-bis carbamic acid tert-butyl ester (3-24). To 
a solution of allylic amine 3-40 (1.50 g, 2.25 mmol) and Et3N (627 µL, 4.50 mmol) in 
CH2Cl2 (25 mL) was added a solution of Boc2O (515 mg, 2.36 mmol) and DMAP (27.5 
mg, 0.225 mmol) and the mixture was stirred at rt for 1 h.  The reaction was filtered 
through a pad of SiO2 and concentrated to yield 1.95 g (96%) of mono-boc amide 3-41 as 
a colorless solid which was carried on without further purification.  To a solution of 3-41 
(1.95 g, 2.16 mmol) in THF (25 mL) at -78 °C was added n-BuLi (1.66 mL, 2.16 mmol, 
1.3M in hexanes) and the yellow solution was stirred at -78 °C for 30 min.  To this 
solution was then added Boc2O (565 mg, 2.59 mmol) and the resulting solution was 
warmed to rt and stirred for 1 h.  The reaction was quenched with sat. aq. NH4Cl, 
extracted with EtOAc, organic layer separated, dried (MgSO4), concentrated and purified 
by chromatography on SiO2 (1.5:8.5, EtOAc:hexanes) to yield 1.95 g (90%, 86% over 2 
steps) of 3-24 as a yellow oil: [α]D +24.7 (c 1.1, CHCl3); IR (neat) 3063, 3030, 2924, 
2854, 1740, 1701, 1454, 1343, 1112 cm-1; 1H NMR δ 7.45-7.10 (m, 20 H), 5.80-5.65 (m, 2 
H), 4.90-4.40 (m, 9 H), 4.10-3.95 (m, 3 H), 3.90-3.80 (m, 2 H), 3.80-3.65 (m, 2 H), 2.10-
2.05 (m, 2 H), 2.00-1.63 (m, 4 H), 1.60-1.45 (m, 18 H), 1.40-1.25 (m, 24 H), 0.94 (t, 3 H, 
J = 6.4 Hz); 13C NMR δ 153.0, 138.6, 138.3, 133.6, 129.0, 128.2, 127.7, 127.6, 127.5, 
127.3, 81.6, 74.5, 73.2, 73.0, 72.9, 71.9, 71.7, 67.7, 59.0, 32.2, 31.8, 29.6, 29.2, 29.1, 27.9, 
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27.7, 24.0, 22.6, 14.0; ESIMS m/z 1026 ([M+Na]+, 100), 905 ([M-Boc]+, 30), 805 ([M-
2Boc]+, 100); HRMS (ESI) m/z calcd for C63H89NO9Na (M+Na) 1026.6435, found 
1026.6396. 
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 tert - Butyl (3S,4S,5R) - 4,5 – dihydroxy – 1 - ((2R,3S,4R,5S,6R) - 3,4,5 - tris 
(benzyloxy) – 6 - (benzyloxymethyl) tetrahydro - 2H – pyran – 2 - yl) nonadecan - 3-
ylcarbamate (3-45).  To a solution of carbamate 3-24 (400 mg, 0.398 mmol) in CH2Cl2 
(25 mL) at -40 °C was added urea hydrogen peroxide (169 mg, 1.79 mmol), dibasic 
sodium phosphate (283 mg, 1.99 mmol) and trifluoroacetic anhydride (167 mg, 0.796 
mmol).  The mixture was stirred at -40 °C for 8 h and at rt for 4 h, quenched with sat. aq. 
NaHCO3, extracted with CH2Cl2, dried (MgSO4) and concentrated in vacuo. HPLC 
analysis of the crude mixture showed a 9:1 mixture of diastereomers).178  To the crude 
residue was added EtOH (10 mL) and KOH (100 mg, 1.78 mmol) and the reaction mixture 
was heated at 40 °C for 2 h,179 extracted with EtOAc, dried (MgSO4) and concentrated in 
vacuo.  The residue was purified by chromatography on SiO2 (1:1, EtOAc:hexanes) to 
yield 298 mg (80%) of 3-45 and 33.7 mg (9%) of 3-45’ as greasy colorless waxes: 3-45: 
[α]D +27.1  (c 1.0, CH2Cl2); IR (neat) 3436, 3357, 2921, 2852, 1682, 1526, 1108 cm-1; 1H 
NMR (500 MHz) δ 7.40-7.25 (m, 20 H), 5.12 (d, 1 H, J = 8.3 Hz), 4.78-4.71 (m, 1 H), 
4.71-4.61 (m, 3 H), 4.60-4.45 (m, 4 H), 4.08-3.97 (m, 2 H), 3.96-3.92 (m, 1 H), 3.92-3.79 
(m, 2 H), 3.78-3.68 (m, 2 H), 3.52 (app d, 2 H, J = 7.1 Hz), 3.43 (app t, 1 H, J = 4.5 Hz), 
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2.80-2.30 (bs, 2 H), 1.95-1.63 (m, 4 H), 1.61-1.47 (m, 2 H), 1.45 (s, 9 H), 1.39-1.22 (m, 24 
H), 0.92 (t, 3 H, J = 6.7 Hz); 13C NMR δ 156.6, 138.6, 138.4, 138.2, 128.3, 128.2, 127.9, 
127.8, 127.6, 127.6, 127.5, 79.4, 74.7, 73.2, 73.1, 72.9, 72.0, 68.2, 53.3, 33.2, 31.8, 29.6, 
29.3, 28.4, 26.3, 25.9, 23.6, 22.6, 14.0; ESIMS m/z 960 ([M+Na]+, 50), 839 ([M-Boc]+, 
100); HRMS (ESI) m/z calcd for C58H84NO9 938.6146, found 938.6176. 
 
O
HO
OH
OH
OH
HN
C14H29HO
OH
O
C25H51
3-3  
N - ((3S,4S,5R) - 4,5 – Dihydroxy – 1 - ((2R,3R,4R,5R,6R) - 3,4,5 -trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-yl)nonadecan-3-yl)hexacosanamide (3-3). To 
a solution of 3-45 (89.5 mg, 0.0954 mmol) in Et2O (5 mL) at rt was added HCl (0.25 mL, 
1.00 mmol, 4.0 M in dioxane) and the reaction was stirred at rt for 30 min, concentrated, 
and the crude amine salt carried on without further purification.   
To a solution of the crude amine salt in THF (2 mL) was added Et3N (22.6 µL, 
0.191 mmol) and 3-46 (39.6 mg, 0.0954 mmol, in 1 mL THF).180  The reaction was stirred 
at rt for 20 min, quenched with sat. aq. NH4Cl, extracted with CH2Cl2 (3x), organic layer 
separated, dried (MgSO4), concentrated and purified by chromatography on SiO2 (3:7, 
EtOAc:hexanes) to yield 86.0 mg (74%, 2 steps) as a colorless wax.   
To a solution the amide (41.0 mg, 0.0337 mmol) in CH2Cl2 (2 mL) and MeOH (2 
mL) was added Pd(OH)2/C (~ 20 mol% Pd, 10 mg) and the atmosphere was exchanged 
with hydrogen gas (3x).  The reaction was allowed to stir under an atmosphere of 
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hydrogen at rt for 12 h and the reaction was filtered though a pad of Celite and 
concentrated.  The crude reside was purified by chromatography on SiO2 (2.5:7.5, 
MeOH:CHCl3) to yield 27.7 mg (96%) of 3-3 as a colorless waxy solid: [α]D +38.4  (c 
0.13, pyridine); IR (neat) 3583, 3350, 2916, 2848, 1729, 1681, 1613, 1529, 1453, 1063 
cm-1; 1H NMR (500 MHz, d5-Pyridine) δ 8.37 (d, 1 H, J = 8.9 Hz), 5.59 (bs, 4 H), 5.09 
(dd, 1 H, J = 9.4, 9.4 Hz), 4.70 (dd, 1 H, J = 8.7, 5.5 Hz), 4.55-4.43 (m, 3 H), 4.35 (dd, 1 
H, J = 11.2, 4.5 Hz), 4.26-4.15 (m, 4 H), 2.75-2.62 (m, 1 H), 2.61-2.51 (m, 1 H), 2.51-2.37 
(m, 2 H), 2.37-2.25 (m, 2 H), 2.25-2.13 (m, 1 H), 2.00-1.78 (m, 4 H), 1.78-1.61 (m, 1 H), 
1.50-1.21 (m, 68 H), 0.89 (t, 6 H, J = 6.4 Hz); 13C NMR (126 MHz, d5-Pyridine) δ 173.8, 
78.8, 77.3, 74.1, 73.0, 72.5, 70.9, 70.8, 63.1, 53.1, 37.3, 34.8, 32.4, 30.7, 30.5, 30.3, 30.1, 
29.9, 26.9, 23.0, 14.6; ESIMS m/z 857 ([M]+, 15), 839 ([M-H2O]+, 100); HRMS (ESI) m/z 
calcd for C51H102NO8 856.7605, found 856.7690. 
 
O
HO
OH
OH
OH
HN
C14H29HO
OH
O
C25H51
3-3'  
N-((2R,3S)-2-Hydroxy-1-(tridecyloxy)-5-((2R,3R,4R,5R,6R)-3,4,5-trihydroxy-
6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)pentan-3-yl)hexacosanamide (3-3’). To 
a solution of 3-45’ (26.9 mg, 0.0287 mmol) in Et2O (2 mL) at rt was added HCl (0.10 mL, 
0.400 mmol, 4.0 M in dioxane) and the reaction was stirred at rt for 30 min, concentrated, 
and the crude amine salt carried on without further purification.   
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To a solution of the crude amine salt in THF (0.5 mL) was added Et3N (6.78 µL, 
0.0486 mmol) and 3-46 (11.9 mg, 0.0287 mmol, in 0.1 mL THF).119 The reaction was 
stirred at rt for 20 min, quenched with sat. aq. NH4Cl, extracted with CH2Cl2 (3x), organic 
layer separated, dried (MgSO4), concentrated and purified by chromatography on SiO2 
(3:7, EtOAc:hexanes) to yield 25.3 mg (73%, 2 steps) as a colorless wax.   
To a solution the amide (25.3 mg, 0.0208 mmol) in CH2Cl2 (1 mL) and MeOH (1 
mL) was added Pd(OH)2/C (~ 20 mol% Pd, 5 mg) and the atmosphere was exchanged 
with hydrogen gas (3x).  The reaction was allowed to stir under an atmosphere of 
hydrogen at rt for 12 h and the reaction was filtered though a pad of Celite and 
concentrated.  The crude residue was purified by chromatography on SiO2 (2.5:7.5, 
MeOH:CHCl3) to yield 17.3 mg (97%) of 3-3’ as a colorless waxy solid: [α]D +9.6  (c 
0.13, pyridine);  1H NMR (d5-Pyridine) δ 8.88 (d, 1 H, J = 8.8 Hz), 5.50-5.00 (bs, 4 H + 
H2O), 5.00-4.88 (m, 1 H), 4.72 (dd, 1 H, J = 9.0, 5.5 Hz), 4.65-4.58 (m, 1 H), 4.47-4.36 
(m, 3 H), 4.28 (dd, 1 H, J = 9.2, 3.3 Hz), 4.19 (app t, 1 H, J = 4.7 Hz), 3.98-3.81 (m, 2 H), 
2.60-2.41 (m, 3 H), 2.41-2.20 (m, 4 H), 2.00-1.61 (m, 5 H), 1.60-1.20 (m, 68 H), 0.97-0.77 
(m, 6 H); 13C NMR (126 MHz, d5-Pyridine) δ 175.9, 77.7, 76.9, 74.1, 72.5, 72.4, 70.7, 
62.7, 51.9, 36.9, 34.6, 32.4, 30.7, 30.5, 30.3, 30.1, 30.1, 29.9, 27.1, 26.9, 23.4, 23.3, 14.6; 
ESIMS m/z 878 ([M+Na]+, 100); HRMS (ESI) m/z calcd for C51H101NO8Na (M+Na) 
878.7425, found 878.7659. 
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HO
HO
HO
OH
HN
C14H29
HO
OH
O
3-47
 
N - ((3S,4S,5R) - 4,5 - Dihydroxy – 1 - ((2R,3R,4R,5R,6R) - 3,4,5 - trihydroxy – 
6 - (hydroxymethyl)tetrahydro-2H-pyran-2-yl) nonadecan-3-yl)-8-phenyloctanamide 
(3-47). To a solution of 3-45 (150 mg, 0.160 mmol) in CH2Cl2 (2 mL) at rt was added HCl 
(1.00 mL, 4.00 mmol, 4.0 M in dioxane) and the reaction mixture was stirred at rt for 2 h, 
concentrated, and the crude amine salt carried on without further purification.  
To the crude amine salt in CHCl3 (1.5 mL) was added Et3N (5.0 eq, 116 µL, 0.800 
mmol), 8-phenyloxtanoic acid (1.1 eq, 38.8 mg, 0.176 mmol), DMAP (1.1 eq, 21.5 mg, 
0.176 mmol) and EDCI (1.1 eq, 33.7 mg, 0.176 mmol) and the reaction mixture was 
stirred at rt for 5 h.  The reaction was quenched with sat. aq. NH4Cl, extracted with 
CH2Cl2 (2x), washed with brine, dried (MgSO4), filtered and concentrated.  The crude 
residue was purified by chromatography on SiO2 (40% EtOAc/hexanes) to yield 142 mg 
(85% over 2 steps) as a colorless waxy solid.  
To a solution of coupled product (142 mg, 0.136 mmol) in CHCl3/MeOH (3:1, 5 
mL) was added Pd(OH)2/C (10 mg) and the reaction mixture was stirred under and 
atmosphere of H2 for 2 h.  The reaction mixture was filtered though a pad of Celite, 
concentrated and the crude residue purified by chromatography on SiO2 (20% 
MeOH/CHCl3) to yield 70.3 mg, (76%) of 3-47 as a colorless waxy solid: [α]D +13.2  (c 
0.11, pyridine); IR (neat) 3446, 3398, 2922, 2852, 2256, 1636, 1586, 1549, 1372, 1144, 
1075 cm-1;1H NMR (600 MHz, d5-Pyridine) δ 8.39 (d, 1 H, J = 9.0 Hz), 7.61-7.56 (m, 2 
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H), 7.54-7.49 (m, 2 H), 7.36-7.31 (m, 2 H), 7.26-7.21 (m, 1 H), 7.20-7.15 (m, 2 H), 5.25 
(bs, 6 H), 5.09-5.02 (m, 1 H), 4.64 (dd, 1 H, J = 9.0, 6.0 Hz), 4.46-4.36 (m, 3 H), 4.26 (dd, 
1 H, J = 11.4, 4.8 Hz), 4.17-4.06 (m, 4 H), 2.67-2.57 (m, 1 H), 2.54-2.43 (m, 3 H), 2.43-
2.29 (m, 2 H), 2.27-2.16 (m, 2 H), 2.16-2.05 (m, 1 H), 1.88-1.73 (m, 4 H), 1.67-1.53 (m, 3 
H), 1.37-1.22 (m, 2 H), 1.22-1.03 (m, 20 H), 0.75 (t, 3 H, J = 6.6 Hz); 13C NMR (150 
MHz, d5-Pyridine) δ 173.1, 142.2, 141.4, 138.7, 129.4, 129.3, 127.5, 127.3, 127.3, 78.5, 
77.1, 73.8, 72.6, 72.2, 70.6, 70.4, 62.8, 52.7, 36.7, 35.6, 34.6, 32.1, 31.5, 30.4, 30.2, 30.0, 
30.0, 30.0, 29.9, 29.6, 26.6, 26.3, 23.0, 22.7, 14.3; ESIMS m/z 738 (5), 737 (10), 736 
([M+Na]+, 100); HRMS (ESI) m/z calcd for C42H67NO8Na (M+Na) 736.4764, found 
736.4821.  
 
OHO
HO
HO
OH
NH
C14H29
HO OH
O
3-48
 
 5 - (Biphenyl - 4 - yl) – N - ((3S,4S,5S) - 4,5 – dihydroxy - 1-((2R,3R,4R,5R,6R)-
3,4,5- trihydroxy - 6 - (hydroxymethyl) tetrahydro-2H-pyran-2-yl) nonadecan - 3 - yl) 
pentanamide (3-48). To a solution of 3-45 (114 mg, 0.122 mmol) in CH2Cl2 (2 mL) at rt 
was added HCl (1.00 mL, 4.00 mmol, 4.0 M in dioxane) and the reaction mixture was 
stirred at rt for 2 h, concentrated, and the crude amine salt carried on without further 
purification.  
To the crude amine salt in CHCl3 (2 mL) was added Et3N (3.0 eq, 51.0 µL, 0.366 
mmol), biphenyl propionic acid (1.2 eq, 37.1 mg, 0.146 mmol), DMAP (.05 eq, 0.745 mg, 
 - 156 -  
0.00610 mmol) and EDCI (1.1 eq, 25.7 mg, 0.134 mmol) and the reaction mixture was 
stirred at rt for 5 h.  The reaction was quenched with sat. aq. NH4Cl, extracted with 
CH2Cl2 (2x), washed with brine, dried (MgSO4), filtered and concentrated.  The crude 
residue was purified by chromatography on SiO2 (40% EtOAc/hexanes) to yield 97.4 mg 
(79% over 2 steps) as a colorless waxy solid.  
 To a solution of coupled product (97.4 mg, 0.0906 mmol) in CHCl3/MeOH (3:1, 4 
mL) was added Pd(OH)2/C (10 mg) and the reaction mixture was stirred under and 
atmosphere of H2 for 2 h.  The reaction mixture was filtered though a pad of Celite, 
concentrated and the crude residue purified by chromatography on SiO2 (20% 
MeOH/CHCl3) to yield 62.1 mg, (96%) of 3-48 as a colorless waxy solid: [α]D +18.2  (c 
0.10, pyridine); IR (neat) 3444, 3397, 2921, 2852, 2256, 1739, 1624, 1587, 1548, 1455, 
1372, 1143, 1079 cm-1;1H NMR (300 MHz, d5-Pyridine) δ 8.47 (d, 1 H, J = 9.0 Hz), 7.36-
7.27 (m, 2 H), 7.25-7.17 (m, 3 H), 6.80-5.80 (m, 6 H), 5.13 (dd, 1 H, J = 9.6, 9.6 Hz), 4.72 
(dd, 1 H, J = 8.7, 5.4 Hz), 4.56-4.43 (m, 3 H), 4.34 (dd, 1 H, J = 11.1, 4.2 Hz), 4.27-4.09 
(m, 4 H), 2.80-2.63 (m, 1 H), 2.63-2.54 (m, 1 H), 2.54-2.45 (m, 2 H), 2.45-2.36 (m, 2 H), 
2.36-2.08 (m, 3 H), 2.01-1.83 (m, 2 H), 1.83-1.72 (m, 2 H), 1.72-1.59 (m, 1 H), 1.54-1.11 
(m, 30 H), 0.85 (t, 3 H, J = 5.4 Hz); 13C 
NMR (150 MHz, d5 pyridine) δ 173.4, 143.3, 128.9, 128.7, 126.1, 78.5, 77.1, 73.8, 72.6, 7
2.2, 70.6, 70.4, 62.8, 52.7, 37.0, 36.1, 34.5, 32.2, 31.9, 30.4, 30.2, 30.1, 30.0, 30.0, 29.7, 2
9.7, 29.6, 29.5, 26.6, 26.5, 26.4, 23.0, 22.6, 14.3; ESIMS m/z 675 (5), 702 ([M+Na]+, 100), 
707 (10), 708 (3); HRMS (ESI) m/z calcd for C39H69NO8Na (M+Na) 702.4921, found 
702.4881. 
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C14H29
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C17H35
3-49  
1 - ((3S,4S,5R) - 4,5 – Dihydroxy – 1 - ((2R,3R,4R,5R,6R) - 3,4,5 – trihydroxy-
6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)nonadecan-3-yl) - 3 - octadecylurea (3-
49). To a solution of 3-45 (150 mg, 0.160 mmol) in CH2Cl2 (2 mL) at rt was added HCl 
(1.00 mL, 4.00 mmol, 4.0 M in dioxane) and the reaction mixture was stirred at rt for 2 h, 
concentrated, and the crude amine salt carried on without further purification.  
To the crude amine salt in acetonitrile (3 mL) and diethyl ether (2 mL) was added 
Et3N (3.0 eq, 67.0 µL, 0.480 mmol) and octadecyl isocyanate (1.0 eq, 55.8 µL, 0.160 
mmol), and the reaction mixture was stirred at rt for 6 h.  The reaction was quenched with 
H2O, extracted with CH2Cl2 (2x), washed with brine, dried (MgSO4), filtered and 
concentrated.  The crude residue was carried on without further purification. 
To a solution of crude urea in CHCl3/MeOH (3:1, 6 mL) was added Pd(OH)2/C (10 
mg) and the reaction mixture was stirred under and atmosphere of H2 for 2 h.  The 
reaction mixture was filtered though a pad of Celite, concentrated and the crude residue 
purified by chromatography on SiO2 (20% MeOH/CHCl3) to yield 99.0 mg, (80%, 3 
steps) of 3-49 as a colorless waxy solid: [α]D +9.4  (c 0.09, pyridine); IR (neat) 3327, 
2918, 2850, 1630, 1561, 1467, 1305, 1068 cm-1;1H NMR (300 MHz, d5-Pyridine) δ 6.81-
6.57 (m, 5 H), 6.47 (bs, 1 H), 6.24 (bs, 1 H), 6.00 (bd, 1 H, J = 4.8 Hz), 4.99-4.83 (m, 1 
H), 4.74-4.63 (m, 1 H), 4.63-4.46 (m, 3 H), 4.41-4.29 (m, 1 H), 4.29-4.10 (m, 4 H), 3.59-
3.33 (m, 2 H), 2.58 (bd, 2 H, J = 8.4 Hz), 2.44-2.18 (m, 3 H), 2.00-1.77 (m, 2 H), 1.77-
1.48 (m, 3 H), 1.45-1.12 (m, 52 H), 0.85 (t, 3 H, J = 6.9 Hz), 0.85 (t, 3 H, J = 6.9 Hz); 13C 
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NMR (150 MHz, d5-Pyridine) δ 160.3, 79.0, 76.9, 74.0, 73.0, 72.2, 70.6, 70.5, 64.9, 62.7, 
57.4, 53.5, 49.7, 40.8, 35.0, 32.2, 31.1, 30.5, 30.3, 30.1, 30.0, 29.8, 29.7, 27.5, 26.8, 26.6, 
23.0, 22.6, 19.3, 14.4. 
 
O
HO
HO
HO
HO
HN
C14H29
HO
OH
O
HN
3-50  
1 - ((3S,4S,5R) - 4,5 – Dihydroxy – 1 - ((2R,3R,4R,5R,6R) - 3,4,5 – trihydroxy-
6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)nonadecan-3-yl)-3-(4-phenylbutyl) urea 
(3-50). To a solution of 3-45 (100 mg, 0.107 mmol) in CH2Cl2 (1.5 mL) at rt was added 
HCl (0.75 mL, 3.00 mmol, 4.0 M in dioxane) and the reaction mixture was stirred at rt for 
2 h, concentrated, and the crude amine salt carried on without further purification.  
To the crude amine salt in acetonitrile (2.5 mL) and diethyl ether (1.5 mL) was 
added Et3N (3.0 eq, 44.7 µL, 0.321 mmol) and 4-phenylbutyl isocyanate (1.0 eq, 18.3 µL, 
0.109 mmol), and the reaction mixture was stirred at rt for 6 h.  The reaction was 
quenched with H2O, extracted with CH2Cl2 (2x), washed with brine, dried (MgSO4), 
filtered and concentrated.  The crude residue was carried on without further purification. 
To a solution of crude urea in CHCl3/MeOH (3:1, 4 mL) was added Pd(OH)2/C (10 
mg) and the reaction mixture was stirred under and atmosphere of H2 for 2 h.  The 
reaction mixture was filtered though a pad of Celite, concentrated and the crude residue 
purified by chromatography on SiO2 (20% MeOH/CHCl3) to yield 51.7 mg, (74%) of 3-50 
as a colorless waxy solid: [α]D +15.2  (c 0.17, pyridine); IR (neat) 3329, 2922, 2853, 1627, 
1561, 1454, 1248, 1071 cm-1;1H NMR (300 MHz, d5-Pyridine) δ 7.33-7.23 (m, 2 H), 7.22-
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7.11 (m, 3 H), 6.74 (d, 1 H, J = 8.7 Hz), 6.65 (dd, 1 H, J = 5.4, 5.4 Hz), 6.50-5.10 (bs, 6 
H), 4.92 (dd, 1 H, J = 7.5, 7.5 Hz), 4.70 (dd, 1 H, 8.7, 5.4 Hz), 4.62-4.51 (m, 2 H), 4.51-
4.45 (m, 1 H), 4.33 (dd, 1 H, J = 11.4, 4.2 Hz), 4.28-4.09 (m, 4 H), 3.53-3.22 (m, 2 H), 
2.65-2.54 (m, 2 H), 2.54-2.45 (m, 2 H), 2.41-2.20 (m, 3 H), 1.98-1.77 (m, 2 H), 1.72-1.48 
(m, 3 H), 1.45-1.09 (m, 24 H), 0.85 (t, 3 H, J = 6.9 Hz); 13C NMR (76 MHz, d5-Pyridine) 
δ 160.2, 142.9, 128.9, 128.7, 126.1, 79.0, 76.9, 74.1, 72.8, 72.2, 70.6, 70.5, 62.7, 53.5, 
40.4, 35.8, 35.1, 32.2, 30.7, 30.4, 30.2, 30.1, 30.0, 30.0, 29.6, 29.2, 26.7, 26.6, 23.0, 22.6, 
14.3; ESIMS m/z 675 ([M+Na]+, 100), 676 (8); HRMS (ESI) m/z calcd for C36H64N2O8Na 
(M+Na) 675.4560, found 675.4512. 
 
OBnO
BnO
BnO
BnO
NH
C14H29
HO OH
S NH2
3-55  
1 - ((3S,4S,5S) - 4,5 – Dihydroxy – 1 - ((2R,3S,4R,5S,6R) -3,4,5-tris(benzyloxy)-
6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)nonadecan-3-yl)thiourea (3-55). To a 
solution of 3-45 (100 mg, 0.107 mmol) in CH2Cl2 (1.5 mL) at rt was added HCl (0.75 mL, 
3.00 mmol, 4.0 M in dioxane) and the reaction mixture was stirred at rt for 2 h, 
concentrated, and the crude amine salt carried on without further purification.  
To the crude amine salt in THF (4 mL) was added Et3N (3.0 eq, 44.7 µL, 0.321 
mmol) and Fmoc isothiocyanate (1.0 eq, 30.1 mg, 0.107 mmol), and the reaction mixture 
was stirred at rt for 6 h.  The reaction mixture was treated with Et2NH (10 eq, 111 µL, 
1.07 mmol) and stirred at rt for 2 h.  The reaction was quenched with sat. aq. NH4Cl, 
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extracted with CH2Cl2 (2x), washed with brine, dried (MgSO4), filtered and concentrated.  
The crude residue was purified by chromatography on SiO2 (40% EtOAc/hexanes) to 
yield 74.9 mg (78%) of thiourea 3-55 as a yellow solid. 
 
OHO
HO
HO
HO
NH
C14H29
HO OH
SN
O
C12H25
3-57  
 
(2R,3R,4R,5R,6R) – 2 - ((3S,4S,5S) – 3 - (4 - (4 - (Dodecyloxy) phenyl) thiazol-
2-ylamino) -4,5-dihydroxynonadecyl)-6-(hydroxymethyl) tetrahydro-2H-pyran-3,4,5-
triol (3-57). To a solution of crude thiourea (75.7 mg, 0.0844 mmol) in EtOH (1 mL) was 
added bromo ketone 3-56 (32.4 mg, 0.0844 mmol) and the reaction mixture was heated at 
60 ˚C for 4 h.  The reaction mixture was concentrated and the crude solid carried on 
without further purification.   
 To a solution of crude thiazole in CH2Cl2 (2 mL) at -78 ˚C was added BCl3 (1.0 M 
in hexanes, 10 eq, 0.844 mmol, 0.844 mL) and the reaction mixture stirred at -78 ˚C for 30 
min.  The reaction mixture was quenched at this temperature with sat. aq. NH4Cl, 
extracted with CHCl3 (2x), washed with brine, dried (MgSO4), filtered and concentrated.  
The crude residue was purified by chromatography on SiO2 (20% MeOH/CHCl3) to 
provide 57.5 mg (83%, 2 steps) of aryl thiazole 3-57 as a light yellow waxy solid: [α]D 
+20.2  (c 0.10, pyridine); IR (neat) 3348, 2922, 2853, 1688, 1606, 1467, 1251, 1076 cm-
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1;1H NMR (600 MHz, CDCl3/MeOD) δ 7.61-7.57 (m, 2 H), 6.89-6.84 (m, 2 H), 6.48 (s, 1 
H), 3.98-3.92 (m, 3 H), 3.91-3.82 (m, 3 H), 3.79 (dd, 1 H, J = 12.6, 8.4 Hz), 3.70-3.65 (m, 
2 H), 3.61 (dd, 1 H, J = 9.6, 3.6 Hz), 3.57 (dd, 1 H, J = 7.8, 3.6 Hz), 3.50 (ddd, 1 H, J = 
9.0, 2.4, 2.4 Hz), 1.93-1.86 (m, 1 H), 1.86-1.72 (m, 4 H), 1.71-1.62 (m, 2 H), 1.56-1.47 
(m, 1 H), 1.47-1.41 (m, 2 H), 1.40-1.17 (m, 40 H), 0.85 (t, 3 H, J = 7.2 Hz), 0.85 (t, 3 H, J 
= 7.2 Hz); 13C NMR (150 MHz, CDCl3/MeOD) δ 169.1, 158.1, 149.6, 127.0, 126.3, 
113.6, 97.7, 77.4, 77.0, 76.6, 76.5, 74.8, 71.7, 71.4, 69.9, 68.5, 67.2, 60.8, 57.3, 28.9, 28.9, 
28.8, 28.8, 28.8, 28.6, 28.5, 28.5, 28.5, 25.2, 25.0, 24.6, 21.8, 21.0, 12.8.  
 
OHO
HO
HO
HO
NH
C14H29
HO OH
SN
C16H33
3-59  
(2R,3R,4R,5R,6R) – 2 - ((3S,4S,5S) – 3 - (4 - Heptadecylthiazol-2-ylamino) -4,5-
dihydroxynonadecyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (3-59). To a 
solution of crude thiourea (75.7 mg, 0.0844 mmol) in EtOH (1 mL) was added bromo 
ketone 3-58 (30.5 mg, 0.0844 mmol) and the reaction mixture was heated at 60 ˚C for 4 h.  
The reaction mixture was concentrated and the crude solid carried on without further 
purification.   
 To a solution of crude thiazole in CH2Cl2 (2 mL) at -78 ˚C was added BCl3 (1.0 M 
in hexanes, 10 eq, 0.844 mmol, 0.844 mL) and the reaction mixture stirred at -78 ˚C for 30 
min.  The reaction mixture was quenched at this temperature with sat. aq. NH4Cl, 
extracted with CHCl3 (2x), washed with brine, dried (MgSO4), filtered and concentrated.  
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The crude residue was purified by chromatography on SiO2 (20% MeOH/CHCl3) to 
provide 59.4 mg (88%) of aryl thiazole 3-59 as a light yellow waxy solid: [α]D +17.7  (c 
0.12, pyridine); IR (neat) 3330, 2918, 2850, 1557, 1519, 1467, 1075 cm-1;1H NMR (600 
MHz, d5-Pyridine) δ 8.59 (dd, 1 H, J = 8.4, 3.0 Hz), 6.23 (s, 1 H), 6.20-5.60 (bs, 6 H), 
4.95-4.86 (m, 1 H), 4.74-4.68 (m, 1 H), 4.57-4.47 (m, 3 H), 4.42-4.32 (m, 2 H), 4.29-4.18 
(m, 3 H), 2.79-2.71 (m, 1 H), 2.71-2.62 (m, 3 H), 2.50-2.40 (m, 1 H), 2.40-2.30 (m, 2 H), 
1.98-1.86 (m, 2 H), 1.85-1.76 (m, 2 H), 1.73-1.61 (m, 1 H), 1.52-1.17 (m, 50 H), 0.89 (t, 3 
H, J = 7.2 Hz), 0.88 (t, 3 H, J = 7.2 Hz); 13C NMR (150 MHz, d5-Pyridine) δ 170.5, 154.2, 
99.8, 78.2, 77.7, 74.3, 73.2, 72.7, 71.2, 70.9, 63.3, 59.5, 35.6, 32.9, 32.7, 30.9, 30.7, 30.6, 
30.5, 30.4, 30.3, 30.2, 29.8, 27.0, 26.6, 23.5, 23.3, 14.8; EIMS m/z 781 (30), 782 (30), 800 
([M+H]+, 100); HRMS (EI) m/z calcd for C45H86N2O7S 799.6234, found 799.6198. 
 
N
O
OMe
4-8  
2-(Hept-6-ynyl)-3-methoxyisoindolin-1-one (4-8).  To a 0 °C solution of imide 4-
6 (40.0 mg, 0.166 mmol) in MeOH (4 mL) was added NaBH4 (5.00 mg, 0.125 mmol).  
The reaction mixture was stirred at rt for 2.5 h, quenched with H2O (1 mL) and the MeOH 
was removed in vacuo.  The residue was extracted with CH2Cl2 (5 x 3 mL) and the 
combined organic layers were washed with brine, dried (Na2SO4), and concentrated to 
provide crude hydroxylactam which was immediately dissolved in MeOH (4 mL), treated 
with d,l-camphorsulfonic acid (3.85 mg, 0.0166 mmol) and stirred for 16 h.  The solvent 
was removed in vacuo and the residue was partitioned between H2O (5 mL) and CH2Cl2 (5 
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mL). The aqueous layer was extracted with CH2Cl2 (3 x 5 mL).  The combined organic 
layers were washed with brine, dried (Na2SO4), concentrated and chromatographed on 
SiO2 (EtOAc:hex, 1:4) to yield methoxy lactam 4-8 (17.0 mg, 0.0661 mmol, 40% over 
two steps) as a colorless oil:  IR (neat) 3298, 2925, 2854, 2115, 1702, 1466, 1412, 1059, 
746 cm-1; 1H NMR δ 7.84-7.80 (m, 1 H), 7.61-7.49 (m, 3 H), 5.88 (s, 1 H), 3.79 (ddd, 1 H, 
J = 13.7, 8.1, 7.3 Hz), 3.24 (ddd, 1 H, J = 14.0, 8.0, 6.3 Hz), 2.87 (s, 3 H), 2.19 (td, 2 H, J 
= 6.7, 2.6 Hz), 1.92 (t, 1 H, J = 2.6 Hz), 1.75-1.63 (m, 2 H), 1.62-1.43 (m, 4 H); 13C NMR 
δ 167.6, 140.3, 133.2, 131.9, 129.9, 123.4, 86.2, 84.3, 68.4, 49.1, 39.3, 28.0, 27.6, 26.0, 
18.3; MS (EI) m/z (rel intensity) 257 ([M]+, 18), 242 (17), 226 (20), 176 (66), 146 (100), 
132 (39), 117 (21); HRMS (EI) m/z calcd for C16H19NO2 257.1416, found 257.1419. 
 
NBn
O
OPiv
4-15  
2-Benzyl-3-oxoisoindolin-1-yl pivaloate (4-15).  To a solution of benzyl 
phtalimide (8.89 g, 37.5 mmol) in MeOH (130 mL) was added sodium borohydride (1.42 
g, 37.5 mmol) at 0 °C.  The resulting reaction mixture was stirred at 0 °C for 2 h and 
carefully quenched with H2O.  The aqueous layer was extracted with EtOAc (2x) and the 
organic layer was separated, dried (MgSO4) and concentrated.  The residue was dried to 
yield a white solid which was carried on to the next step without further purification.  To a 
solution of the crude reduced phthalamide (1.00 g, 4.20 mmol) in THF (30 mL) was added 
Et3N (1.17 mL, 8.40 mmol) and pivaloyl chloride (621 µL, 5.04 mmol) at 0 °C and the 
reaction mixture was allowed to warm to rt and stirred at this temperature for 4 h.  The 
 - 164 -  
mixture was quenched with sat. aq. NaHCO3, extracted with EtOAc (2x), dried (MgSO4) 
and concentrated. The residue was purified by chromatography on SiO2 (EtOAc:Hex, 3:7) 
to yield 1.09 g (80% over 2 steps) of 4-15 as a colorless solid: mp 88.1 - 89.0 °C 
(CH2Cl2); IR (neat) 3419, 3062, 3031, 2973, 2934, 2872, 1717, 1408, 1276, 1122, 959, 
751 cm-1; 1H NMR δ 7.92-7.84 (m, 1 H), 7.61-7.53 (m, 2 H), 7.50-7.43 (m, 1 H), 7.38-
7.22 (m, 5 H), 6.89 (s, 1 H), 5.01 (d, 1 H, J = 15 Hz), 4.44 (d, 1 H, J = 15 Hz), 1.13 (s, 9 
H); 13C NMR δ 178.4, 167.9, 141.3, 136.8, 132.5, 131.9, 130.2, 128.7, 128.1, 127.7, 
123.7, 123.7, 81.0, 44.2, 39.0, 26.8; MS (EI) m/z (rel intensity) 323 ([M]+, 35), 221 (100), 
133 (65), 91 (100); HRMS (EI) m/z calcd for C21H23NO 323.1521, found 323.1515. 
 
NBn
O
4-17
 
(E)-2-Benzyl-3-(hex-1-enyl)isoindolin-1-one (4-17).  General Protocol E.  To a 
solution of 1-hexyne (4-16) (60.5 µL, 0.526 mmol) in CH2Cl2 (1.5 mL) was added 
zirconocene hydrochloride (156 mg, 0.605 mmol) and the resulting suspension was stirred 
at rt for 10 min.  The resulting yellow solution was cooled to 0 °C and Me3Al (1.0 M in 
CH2Cl2, 0.605 mL, 0.605 mmol) and 4-15 (85.0 mg, 0.263 mmol) were added.  The 
mixture was warmed to rt and stirred at this temperature for 1 h, quenched with sat. aq. 
NH4Cl, and extracted with CH2Cl2.  The organic layers were separated, dried (MgSO4) 
and concentrated.  The residue was purified by chromatography on SiO2 (EtOAc:Hex, 3:7) 
to yield 65.1 mg (81%) of 4-17 as a colorless oil: IR (neat) 3479, 3031, 2927, 2857, 1694, 
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1615, 1400, 972 cm-1; 1H NMR δ 7.91-7.86 (m, 1 H), 7.56-7.42 (m, 2 H), 7.36-7.21 (m, 6 
H), 5.90 (dt, 1 H, J = 15.0, 6.8 Hz), 5.30 (d, 1 H, J = 14.8 Hz), 5.09 (dd, 1 H, J = 15.2, 9.2 
Hz), 4.70 (d, 1 H, J = 9.2 Hz), 4.17 (d, 1 H, J = 14.9 Hz), 2.13 (app q, 2 H, J = 6.7 Hz), 
1.50-1.30 (m, 4 H), 0.94 (t, 3 H, J = 7.2 Hz); 13C NMR δ 167.9, 145.1, 138.3, 137.5, 
131.8, 131.5, 128.6, 128.3, 127.3, 126.1, 123.6, 123.0, 62.7, 43.8, 31.8, 31.1, 22.1, 13.8; 
MS (EI) m/z (rel intensity) 305 ([M]+, 100), 248 (40), 237 (70), 214 (40); HRMS (EI) m/z 
calcd for C21H23NO 305.1780, found 305.1785. 
 
NBn
O
4-19
 
(E)-2-Benzyl-3-(2-cyclohexylvinyl)isoindolin-1-one (4-19).  According to 
general protocol E, alkyne 4-18 (66.9 mg, 0.618 mmol), CH2Cl2 (1.5 mL), zirconocene 
hydrochloride (183 mg, 0.711 mmol), Me3Al (1.0 M in CH2Cl2, 0.711 mL, 0.711 mmol) 
and 4-15 (100 mg, 0.309 mmol) afforded 80.8 mg (79%) of 4-19 as a colorless oil after 
purification on SiO2 (EtOAc:Hex, 3:7): IR (neat) 3375, 3030, 2921, 2851, 2243, 1220, 
1200, 1097, 844 cm-1; 1H NMR δ 7.92-7.86 (m, 1 H), 7.54-7.41 (m, 2 H), 7.35-7.20 (m, 6 
H), 5.85 (dd, 1 H, J = 15.3, 6.6 Hz), 5.28 (d, 1 H, J = 14.8 Hz), 5.02 (ddd, 1 H, J = 15.3, 
9.2, 1.2 Hz), 4.67 (d, 1 H, J = 9.2 Hz), 4.18 (d, 1H, J = 14.8 Hz), 2.14-1.96 (m, 1 H), 1.85-
1.60 (m, 4 H), 1.42-1.00 (m, 6 H); 13C NMR δ 167.9, 145.1, 144.1, 137.4, 131.8, 131.4, 
128.5, 128.3, 128.2, 127.3, 123.6, 122.9, 62.8, 43.8, 40.3, 32.6, 26.0, 25.8; MS (EI) m/z 
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(rel intensity) 331 ([M]+, 86), 248 (40), 237 (100); HRMS (EI) m/z calcd for C23H25NO 
331.1936, found 331.1951. 
 
NBn
O
4-21
OTBDPS  
(E)-2-Benzyl-3-(4-(tert-butyldiphenylsilyloxy)but-1-enyl)isoindolin-1-one (4-
21). According to general protocol E, alkyne 4-20 (94.4 mg, 0.306 mmol), CH2Cl2 (1 mL), 
zirconocene hydrochloride (78.9 mg, 0.306 mmol), Me3Al (1.0 M in CH2Cl2, 0.306 mL, 
0.306 mmol) and 4-15 (50.0 mg, 0.153) afforded 57.6 mg (71%) of 4-21 as a colorless oil 
after purification on SiO2 (EtOAc:Hex, 2:8): IR (neat) 3450, 2930, 2857, 1692, 1428, 
1111, 735, 701 cm-1; 1H NMR δ 7.92-7.86 (m, 1 H), 7.72-7.65 (m, 4 H), 7.53-7.35 (m, 9 
H), 7.32-7.21 (m, 5 H), 5.96 (dt, 1 H, J = 15.3, 6.8 Hz), 5.27 (d, 1 H, J = 14.9 Hz), 5.16 
(dddd, 1 H, J = 15.3, 9.1, 1.2, 1.2 Hz), 4.71 (d, 1 H, J = 9.1 Hz), 4.16 (d, 1 H, J = 14.9 
Hz), 3.77 (dt, 2 H, J = 6.3, 1.2 Hz), 2.37 (app q, 2 H, J = 6.6 Hz), 1.08 (s, 9 H); 13C NMR 
δ 168.0, 144.9, 137.5, 135.6, 134.8, 133.8, 131.9, 131.5, 129.7, 128.6, 128.4, 128.2, 127.7, 
127.4, 123.6, 123.1, 63.2, 62.6, 43.9, 35.6, 26.9, 19.2; MS (EI) m/z (rel intensity) 532 
([M]+, 35), 488 (100), 474 (45), 306 (65), 252 (75); HRMS (EI) m/z calcd for 
C35H37NO2Si 532.2664, found 532.2664. 
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O
4-23
N CO2MeTs  
(E)-Methyl 4-(2-benzyl-3-oxoisoindolin-1-yl)but-3-enyl(tosyl)carbamate (4-
23).  According to general protocol E, alkyne 4-22 (174 mg, 0.618 mmol), CH2Cl2 (1.5 
mL), zirconocene hydrochloride (183 mg, 0.711 mmol), Me3Al (1.0 M in CH2Cl2, 0.711 
mL, 0.711 mmol) and 15 (100 mg, 0.309) afforded 95.1 mg (62%) of 4-23 as a colorless 
oil after purification on SiO2 (acetone:CH2Cl2, 0.3:9.7): IR (neat) 3467, 3032, 2957, 2245, 
1735, 1686, 1359, 1168, 733 cm-1; 1H NMR δ 7.92-7.78 (m, 3 H), 7.56-7.41 (m, 2 H), 
7.39-7.18 (m, 9 H), 5.93 (dt, 1 H, J = 15.2, 7.0 Hz), 5.26 (d, 1 H, J = 14.9 Hz), 5.21 (dd, 1 
H, J = 15.1, 9.1 Hz), 4.73 (d, 1 H, J = 9.0), 4.18 (d, 1 H, J = 14.9 Hz), 3.95 (t, 2 H, J = 7.0 
Hz), 3.69 (s, 3 H), 2.58 (app q, 2 H, J = 7.0 Hz), 2.43 (s, 3 H); 13C NMR δ 168.0, 152.8, 
144.8, 144.6, 137.4, 136.5, 133.0, 131.7, 131.6, 129.7, 129.4, 128.6, 128.3, 128.3, 127.4, 
123.6, 123.2, 62.3, 53.8, 46.5, 43.8, 32.9, 21.6; MS (EI) m/z (rel intensity) 504 ([M]+, 50), 
262 (40), 155 (100); HRMS (EI) m/z calcd for C28H28N2O5S 504.1719, found 504.1724. 
 
NBn
O
O
4-24  
1-Benzyl-3,3-dimethylpyrrolidine-2,5-dione (4-24).  A mixture of 2,2-
dimethylsuccinic anhydride (710 mg, 5.55 mmol) and benzyl amine (712 mg, 6.66 mmol, 
1.2 eq) was heated over a bunsen burner for ~ 1 min.  The cooled mixture was purified by 
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chromatography on SiO2 (EtOAc:hex, 1:1) to furnish 1.14 g (95%) of 4-24 as a colorless 
oil:  IR (neat) 2969, 2933, 1777, 1702, 1344, 1142, 709 cm-1; 1H NMR δ 7.29-7.21 (m, 5 
H), 4.57 (s, 2 H), 2.47 (s, 2 H), 1.22 (s, 6 H); 13C NMR δ 182.5, 175.1, 135.8, 128.3, 
128.1, 127.5, 43.2, 42.0, 39.7, 25.1; MS (EI) m/z (rel intensity) 217 ([M]+, 100), 174 (33), 
133 (22); HRMS (EI) m/z calcd for C13H15NO2 217.1103, found 217.1104.  
 
NBn
O
OPiv
4-25  
1-Benzyl-4,4-dimethyl-5-oxopyrrolidin-2-yl pivalate (4-25).  A solution of imide 
4-24 (1.14 g, 5.25 mmol) in MeOH (53 mL) was treated with NaBH4 (200 mg, 2.62 
mmol) at ambient temperature.  After 6 h, the reaction mixture was concentrated, the 
residue dissolved in CH2Cl2 (50 mL) and treated with sat. aq. NH4Cl.  The aqueous layer 
was separated and washed with CH2Cl2 (2x) and the combined organic layers were dried 
(MgSO4), filtered, concentrated and the resulting oil used without further purification.  
The crude oil was dissolved in CH2Cl2 (50 mL) and treated sequentially with Et3N (2.19 
mL, 15.7 mmol, 3 eq), DMAP (128 mg, 1.05 mmol, 20 mol %) and pivaloyl chloride 
(1.29 mL, 10.5 mmol, 2 eq) at ambient temperature.  After 6 h, the reaction mixture was 
quenched with 3 M HCl and the aqueous layer washed with CH2Cl2 (3x).  The combined 
organic layers were washed with H2O, dried (MgSO4), filtered, concentrated and the 
residue purified by chromatography on SiO2 (EtOAc:hex, 1:2) to yield 398 mg (25%) of 
4-25 as a colorless oil:  IR (neat) 2971, 1710, 1419, 1125, 707 cm-1; 1H NMR δ 7.33-
7.21(m, 5 H), 5.99 (d, 1 H, J = 6.3 Hz), 4.74 (d, 1 H, J = 14.7 Hz), 4.15 (d, 1 H, J = 14.7 
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Hz), 2.14 (dd, 1 H, J = 14.1, 6.3 Hz), 1.87 (d, 1 H, J = 14.4 Hz), 1.32 (s, 3 H), 1.22 (s, 3 
H), 1.10 (s, 9 H); 13C NMR δ 180.6, 177.9, 136.6, 128.7, 128.2, 127.6, 82.1, 44.8, 41.5, 
39.3, 38.7, 26.8, 26.5, 25.6; MS (EI) m/z (rel intensity) 303 ([M]+, 36), 275 (15), 202 (85), 
158 (46); HRMS (EI) m/z calcd for C18H25NO3 303.1834, found 303.1827. 
 
NBn
O
4-26
 
(E)-1-Benzyl-5-(hex-1-enyl)-3,3-dimethylpyrrolidin-2-one (4-26).  According to 
general protocol E, hexyne (4-16) (9.77 mg, 0.119 mmol), CH2Cl2 (1 mL), zirconocene 
hydrochloride (30.7 mg, 0.119 mmol), Me3Al (1.0 M in CH2Cl2, 0.119 mL, 0.119 mmol) 
and 4-25 (18.0 mg, 0.0593 mmol) afforded 14.0 mg (83%) of 4-26 as a colorless oil after 
purification on SiO2 (EtOAc:hex, 2.5:7.5): IR (neat) 2958, 2928, 2868, 1692, 1411, 1262, 
972, 752 cm-1; 1H NMR δ 7.35-7.23 (m, 3 H), 7.21-7.13 (m, 2 H), 5.53 (dt, 1 H, J = 15.0, 
6.6 Hz), 5.16 (dd, 1 H, J = 15.3, 9.0 Hz), 4.94 (d, 1 H, J = 14.4 Hz), 3.88 (d, 1 H, J = 14.4 
Hz), 3.73 (app q, 1 H, J = 7.8 Hz), 2.10-1.98 (m, 2 H), 1.99 (dd, 1 H, J = 12.9, 7.2 Hz), 
1.58 (dd, 1 H, J = 12.9, 8.1 Hz), 1.42-1.28 (m, 4 H), 1.24 (s, 3 H), 1.11 (s, 3 H), 0.92 (t, 3 
H, J = 6.9 Hz); 13C NMR δ 179.6, 137.2, 135.8, 129.8, 128.4, 128.3, 127.2, 56.9, 44.2, 
42.0, 40.3, 31.8, 31.2, 25.5, 24.7, 22.2, 13.9; MS (EI) m/z (rel intensity) 285 ([M]+, 20), 
228 (20), 175 (30), 91 (100); HRMS (EI) m/z calcd for C19H27NO 285.2093, found 
285.2090. 
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O
4-27
 
 (E)-2-Benzyl-3-(2-methylhex-1-enyl)isoindolin-1-one (4-27).  General Protocol 
F.  To a -30 °C solution of AlMe3 (89.0 mg, 1.24 mmol) and Cp2ZrCl2 (9.00 mg, 0.0309 
mmol) in CH2Cl2 (1.5 mL) was added H2O (11.1 mg, 0.619 mmol) dropwise.  The 
reaction mixture was warmed to ambient temperature, cooled to 0 °C, treated with 1-
hexyne (4-16) (71.0 µL, 0.619 mmol), stirred for 30 min and treated with 4-15 (100 mg, 
0.309 mmol).  The reaction mixture was warmed to rt and stirred at this temperature for 1 
h, quenched with sat. aq. NH4Cl, and extracted with CH2Cl2.  The organic layers were 
separated, dried (MgSO4) and concentrated.  The residue was purified by chromatography 
on SiO2 (EtOAc:Hex, 3:7) to yield 76.0 mg (77%) of 4-27 as a colorless oil: IR (neat) 
2956, 2929, 2858, 1694, 1468, 1401, 749, 703 cm-1; 1H NMR δ 7.89-7.50 (m, 1 H), 7.53-
7.40 (m, 2 H), 7.35-7.20 (m, 6 H), 5.31 (d, 1 H, J = 14.9 Hz), 5.06 (d, 1 H, J = 9.8), 4.81 
(dq, 1 H, J = 9.8, 1.2 Hz), 4.09 (d, 1 H, J = 14.9 Hz), 2.07 (t, 2 H, J = 7.1 Hz), 1.67 (d, 3 
H, J = 1.3 Hz), 1.50-1.22 (m, 4 H), 0.91 (t, 3 H, J = 7.2 Hz); 13C NMR δ 168.1, 145.7, 
143.4, 137.5, 132.0, 131.4, 128.5, 128.2, 128.0, 127.3, 123.6, 122.8, 120.6, 57.9, 43.9, 
39.3, 29.8, 22.2, 16.5, 13.8; MS (EI) m/z (rel intensity) 319 ([M]+, 100), 221 (40); HRMS 
(EI) m/z calcd for C22H25NO 319.1936, found 319.1921. 
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O
4-29
 
(E)-2-Benzyl-3-(2-phenylprop-1-enyl)isoindolin-1-one (4-29).  According to 
general protocol F, alkyne 4-28 (68.0 µL, 0.619 mmol), AlMe3 (89.0 mg, 1.24 mmol), 
Cp2ZrCl2 (9.00 mg, 0.0309 mmol), CH2Cl2 (1.5 mL), H2O (11.1 mg, 0.619 mmol) and 4-
15 (100 mg, 0.309 mmol) afforded 81.0 mg (77%) of 4-29 as a colorless oil and a 95:5 
mixture of regioisomers after purification on SiO2 (EtOAc:Hex, 1:3): Major isomer: IR 
(neat) 3030, 2918, 1693, 1602, 1432, 1400, 1250, 749 cm-1; 1H NMR δ 7.93 (dd, 1 H, J = 
6.3, 2.1 Hz), 7.54-7.46 (m, 2 H), 7.35-7.26 (m, 11 H), 5.41 (dd, 1 H, J = 9.6, 0.9 Hz), 5.35 
(d, 1 H, J = 15.0 Hz), 5.27 (d, 1 H, J = 9.9 Hz), 4.21 (d, 1 H, J = 15.0 Hz), 2.12 (d, 3 H, J 
= 0.9 Hz); 13C NMR δ 168.1, 145.0, 142.0, 141.3, 137.4, 132.0, 131.6, 128.6, 128.3, 
127.8, 127.5, 125.8, 123.8, 123.7, 122.9, 58.2, 44.3, 16.3; MS (EI) m/z (rel intensity) 339 
([M]+, 41), 248 (47), 234 (77), 91 (100); HRMS (EI) m/z calcd for C24H21NO 339.1623, 
found 339.1631. Minor isomer (characteristic peaks): 1H NMR δ 1.44 (d, 3 H, J = 6.9 Hz); 
13C NMR δ 128.0, 121.9, 18.0. 
 
OPh
4-30  
(E)-(3-(Pent-4-ynyloxy)prop-1-enyl)benzene (4-30).  To a solution of 4-pentyn-
1-ol (4.03 mL, 43.3 mmol) in hexanes (75 mL) was added 50% NaOH (75 mL), TBAI 
(801 mg, 2.17 mmol) and cinnamyl bromide (8.97 g, 45.5 mmol).  The reaction mixture 
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was rapidly stirred for 10 h, the organic layer was separated, dried (MgSO4) and 
concentrated.  The residue was purified by chromatography on SiO2 (EtOAc:Hex, 1:9) to 
yield 9.00 g (69%) of 4-30 as a colorless oil: IR (neat) 3298, 3027, 2951, 2854, 2117, 
1478, 1365, 1111, 967 cm-1; 1H NMR δ 7.44-7.37 (m, 2 H), 7.37-7.27 (m, 2 H), 7.27-7.21 
(m, 1 H), 6.62 (d, 1 H, J = 15.9 Hz), 6.30 (dt, 1 H, J = 15.9, 6.0), 4.15 (dd, 2 H, J = 6.0, 
0.9 Hz), 3.60 (t, 2 H, J = 6.3 Hz), 2.34 (dt, 2 H, J = 7.2, 2.7 Hz), 1.96 (t, 1 H, J = 2.7 Hz), 
1.85 (app p, 2 H, J = 6.6 Hz); 13C NMR δ 136.5, 131.8, 128.3, 127.4, 126.2, 126.0, 83.7, 
71.2, 68.5, 68.3, 28.5, 15.1; MS (EI) m/z (rel intensity) 199 ([M]+, 100), 186 (35), 173 
(35), 131 (100); HRMS (EI) m/z calcd for C14H16O 199.1123, found 199.1126. 
 
N
O
OPiv4-31  
2-Allyl-3-oxoisoindolin-1-yl pivalate (4-31).  To a solution of 2-allylisoindoline-
1,3-dione (3.64 g, 19.4 mmol) in MeOH (100 mL) was added sodium borohydride (734 
mg, 19.4 mmol) at 0 °C.  The resulting reaction mixture was stirred at 0 °C for 2 h and 
carefully quenched with H2O.  The aqueous layer was extracted with EtOAc (2x) and the 
organic layer was separated, dried (MgSO4) and concentrated.  The residue was dried to 
yield a white solid which was carried on to the next step without further purification.  To a 
solution of the crude reduced phthalamide (3.60 g, 19.0 mmol) in THF (100 mL) was 
added Et3N (7.90 mL, 57.0 mmol) and pivaloyl chloride (2.81 mL, 22.8 mmol) at 0 °C and 
the reaction mixture was allowed to warm to rt and stirred at this temperature for 4 h.  The 
mixture was quenched with sat. aq. NaHCO3, extracted with EtOAc (2x), dried (MgSO4) 
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and concentrated. The residue was purified by chromatography on SiO2 (EtOAc:Hex, 
2.5:7.5) to yield 4.40 g (83% over 2 steps) of 4-31 as a colorless oil: IR (neat) 2976, 1716, 
1405, 1135, 753; 1H NMR δ 7.88-7.80 (m, 1 H), 7.62-7.46 (m, 3 H), 6.99 (s, 1 H), 5.94-
5.77 (m, 1 H), 5.29-5.15 (m, 2 H), 4.44 (dd, 1 H, J = 15.9, 5.1 Hz), 3.88 (dd, 1 H, J = 15.3, 
6.6 Hz), 1.23 (s, 9 H) cm-1; 13C NMR δ 178.3, 167.5, 141.2, 132.4, 132.4, 131.8, 130.0, 
123.6, 123.5, 118.0, 80.9, 42.8, 39.0, 26.9; MS (EI) m/z (rel intensity) 273 ([M]+, 60), 172 
(100; HRMS (EI) m/z calcd for C16H19NO3 273.1365, found 273.1358. 
 
N
O
O
Ph
4-32
 
2-Allyl-3-((E)-5-(cinnamyloxy)pent-1-enyl)isoindolin-1-one (4-32).  According 
to general protocol E, alkyne 4-30 (733 mg, 3.66 mmol), CH2Cl2 (10 mL), zirconocene 
hydrochloride (944 mg, 3.66 mmol), Me3Al (1.0 M in CH2Cl2, 3.66 mL, 3.66 mmol) and 
4-31 (500 mg, 1.83 mmol) (reaction time increased to 12 h) afforded 376 mg (55%) of 4-
32 as a colorless oil after purification on SiO2 (Acetone:CH2Cl2, 0.7:9.3): IR (neat) 2924, 
2853, 1694, 1468, 1289, 1098, 968, 746 cm-1; 1H NMR δ 7.85 (d, 1 H, J = 6.6 Hz), 7.57-
7.20 (m, 8 H), 6.61 (d, 1 H, J = 15.9 Hz), 6.29 (dt, 1 H, J = 15.9, 6.0 Hz), 6.02 (dt, 1 H, J 
= 13.8, 6.9 Hz), 5.90-5.73 (m, 1 H), 5.25-5.07 (m, 3 H), 4.87 (d, 1 H, J = 9.0 Hz), 4.60 
(ddd, 1 H, J = 15.6, 4.5, 2.7 Hz), 4.15 (dd, 2 H, J = 6.0, 1.2 Hz), 3.70 (dd, 1 H, J = 15.3, 
7.2 Hz), 3.53 (t, 2 H, J = 6.3 Hz), 2.25 (app q, 2 H, J = 6.9 Hz), 1.77 (app p, 2 H, J = 7.8 
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Hz); 13C NMR δ 167.7, 144.9, 137.2, 136.6, 133.2, 132.3, 131.8, 131.4, 128.5, 128.3, 
127.6, 126.7, 126.4, 126.1, 123.5, 122.9, 117.5, 71.5, 69.4, 62.9, 42.5, 29.2, 28.9; MS 
(ESI) m/z (rel intensity) 396 ([M+Na]+, 100), 307 (20), 297 (20); HRMS (ESI) m/z calcd 
for C25H27NO2Na 396.1939, found 396.1928. 
 
O
N
4-33  
3H-Pyrrolo[2,1-a]isoindol-5(9bH)-one (4-33).  To a solution of 4-32 (41.7 mg, 
0.112 mmol) in CH2Cl2 (6 mL) was added Grubbs 2nd generation catalyst (4.75 mg, 5.60 
µmol) and the red solution was heated at 50 °C for 1 h, cooled to rt and concentrated.  The 
residue was purified by chromatography on SiO2 (Acetone:CH2Cl2, 0.4:9.6) to yield 11.7 
mg (61%) of 4-33 as a colorless oil: IR (neat) 2872, 1614, 1468, 1395, 1366, 1080, 746 
cm-1; 1H NMR δ 7.74-7.66 (m, 2 H), 7.66-7.58 (m, 1 H), 7.54-7.45 (m, 1 H), 6.28-6.20 (m, 
1 H), 6.08-5.99 (m, 1 H), 5.53 (app d, 1 H, J = 1.8 Hz), 4.57-4.43 (m, 1 H), 3.98-3.83 (m, 
1 H); 13C NMR δ 175.4, 148.4, 133.6, 133.1, 131.9, 129.4, 129.2, 124.6, 124.0, 71.1, 52.0; 
MS (EI) m/z (rel intensity) 171 ([M]+, 60), 160 (70), 130 (55), 105 (60), 83 (100); HRMS 
(EI) m/z calcd for C11H9NO 171.0684, found 171.0676. 
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NO
C4H9
4-34
 
(E)-2-Allyl-3-(hex-1-enyl)isoindolin-1-one (4-34).  According to general protocol 
E, hexyne (4-16) (420 µL, 3.66 mmol), CH2Cl2 (10 mL), zirconocene hydrochloride (944 
mg, 3.66 mmol), Me3Al (1.0 M in CH2Cl2, 3.66 mL, 3.66 mmol) and 4-31 (500 mg, 1.83 
mmol) afforded  341 mg (73%) of 4-34 as a colorless oil after purification on SiO2 
(EtOAc:Hex, 3:7): IR (neat) 2957, 2926, 1697, 1468, 1396, 971, 748 cm-1; 1H NMR δ 
7.83 (d, 1 H, J = 7.2 Hz), 7.57-7.38 (m, 2 H), 7.33 (d, 1 H, J = 7.5 Hz), 5.97 (dt, 1 H, J = 
15.0, 6.9 Hz), 5.88-5.71 (m, 1 H), 5.22-4.97 (m, 3 H), 4.85 (d, 1 H, J = 9.3 Hz), 4.59 (dd, 
1 H, J = 15.6, 4.5 Hz), 3.69 (dd, 1 H, J = 15.3, 7.2 Hz), 2.12 (app q, 2 H, J = 6.6 Hz), 
1.48-1.28 (m, 4 H), 0.91 (t, 3 H, J = 6.9 Hz); 13C NMR δ 167.7, 145.0, 138.2, 133.1, 
131.7, 131.4, 128.2, 126.0, 123.4, 122.9, 117.4, 62.9, 42.5, 31.8, 31.1, 27.0, 22.0, 13.8; 
MS (EI) m/z (rel intensity) 255 ([M]+, 30), 198 (100), 172 (55); HRMS (EI) m/z calcd for 
C17H21NO 255.1623, found 255.1627. 
 
N
O
O4-35  
2-(Pent-4-enyl)isoindoline-1,3-dione (4-35).  A solution of 4-penten-1-ol (3.51 
mL, 34.0 mmol), phthalimide 4-4  (5.00 g, 34.0 mmol), and PPh3 (8.92 g, 34.0 mmol) in 
THF (220 mL) was cooled to 0 °C and treated with DIAD (6.69 mL, 34.0 mmol) over 5 
min.  The reaction mixture was warmed to rt and stirred for 6 h.  The solvent was 
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evaporated, the residue was dissolved in EtOAc/hex (1:1, 100 mL) and the solids were 
filtered off.  The filtrate was concentrated and chromatographed on SiO2 (EtOAc:hex, 1:5) 
to yield 6.44 g (88%) of imide 4-35 as a colorless oil:  IR (neat) 3466, 3077, 2939, 1773, 
1641, 1397, 995, 720 cm-1; 1H NMR δ 7.88-7.81 (m, 2 H), 7.76-7.67 (m, 2 H), 5.90-5.73 
(m, 1 H), 5.12-4.94 (m, 2 H), 3.70 (dt, 2 H, J = 7.5, 4.5 Hz), 2.20-2.07 (m, 2 H), 1.87-1.73 
(m, 2 H); 13C NMR δ 168.1, 137.1, 133.7, 131.9, 122.9, 115.1, 37.3, 30.8, 27.4; MS (EI) 
m/z (rel intensity) 215 ([M]+, 45), 173 (70), 160 (100), 148 (80), 130 (80), 104 (90); 
HRMS (EI) m/z calcd for C13H13NO2 215.0946, found 215.0946. 
 
N
O
OPiv4-36  
3-Oxo-2-(pent-4-enyl)isoindolin-1-yl pivalate (4-36).  To a solution of imide 4-
35 (4.42 g, 20.5 mmol) in MeOH (100 mL) was added sodium borohydride (776 mg, 20.5 
mmol) at 0 °C.  The resulting reaction mixture was stirred at 0 °C for 2 h and carefully 
quenched with H2O.  The aqueous layer was extracted with EtOAc (2x) and the organic 
layer was separated, dried (MgSO4) and concentrated.  The residue was dried to yield a 
white solid which was carried on to the next step without further purification.  To a 
solution of the crude reduced phthalamide (4.23 g, 19.5 mmol) in THF (100 mL) was 
added Et3N (8.15 mL, 58.5 mmol), pivaloyl chloride (3.61 mL, 29.3 mmol) and DMAP 
(119 mg, 0.975 mmol) at 0 °C and the reaction mixture was allowed to warm to rt and 
stirred at this temperature for 8 h.  The mixture was quenched with sat. aq. NaHCO3, 
extracted with EtOAc (2x), dried (MgSO4) and concentrated. The residue was purified by 
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chromatography on SiO2 (EtOAc:Hex, 1:5) to yield 4.70 g (76% over 2 steps) of 4-36 as a 
colorless oil: IR (neat) 3077, 2974, 2873, 1739, 1641, 1618, 1369, 1208, 1141, 959, 751 
cm-1; 1H NMR δ  7.67 (d, 1 H, J = 6.0 Hz), 7.49-7.32 (m, 3 H), 6.89 (s, 1 H), 5.79-5.58 
(m, 1 H), 4.91 (d, 1 H, J = 17.1 Hz), 4.84 (d, 1 H, J = 10.5 Hz), 3.73-3.55 (m, 1 H), 3.27-
3.09 (m, 1 H), 2.07-1.93 (m, 2 H), 1.77-1.50 (m, 2 H), 1.11 (s, 9 H); 13C NMR δ 178.2, 
167.4, 140.9, 137.1, 132.0, 131.8, 129.8, 123.2, 123.1, 114.9, 80.8, 39.5, 38.7, 30.7, 27.1, 
26.6; MS (EI) m/z (rel intensity) 301 ([M]+, 15), 246 (45), 216 (65), 200 (85), 146 (85), 
133 (65); HRMS (EI) m/z calcd for C18H23NO3 301.1678, found 301.1681. 
 
N
O
4-37
 
(E)-3-(Hex-1-enyl)-2-(pent-4-enyl)isoindolin-1-one (4-37).  According to general 
protocol E, hexyne (4-16) (420 µL, 3.66 mmol), CH2Cl2 (10 mL), zirconocene 
hydrochloride (944 mg, 3.66 mmol), Me3Al (1.0 M in CH2Cl2, 3.66 mL, 3.66 mmol) and 
4-36 (552 mg, 1.83 mmol) afforded 368 mg (72%) of 4-37 as a colorless oil after 
purification on SiO2 (EtOAc:Hex, 3:7): IR (neat) 3076, 2967, 2928, 2860, 1693, 1468, 
1404, 972, 749 cm-1; 1H NMR δ 7.72 (d, 1 H, J = 7.5 Hz), 7.44-7.28 (m, 2 H), 7.23 (d, 1 
H, J = 7.2 Hz), 5.94 (dt, 1 H, J = 14.4, 6.6 Hz), 5.80-5.63 (m, 1 H), 5.03-4.82 (m, 3 H), 
4.75 (d, 1 H, J = 9.0 Hz), 3.83-3.65 (m, 1 H), 3.23-3.07 (m, 1 H), 2.13-1.93 (m, 4 H), 
1.75-1.51 (m, 2 H), 1.42-1.19 (m, 4 H), 0.83 (t, 3 H, J = 6.9 Hz); 13C NMR δ 167.6, 144.6, 
137.5, 137.3, 131.7, 131.0, 127.9, 126.2, 122.9, 122.6, 114.7, 39.4, 31.5, 30.8, 30.7, 27.3, 
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26.9, 21.8, 13.5; MS (EI) m/z (rel intensity) 283 ([M]+, 20), 228 (70), 160 (100), 146 (50), 
76 (50); HRMS (EI) m/z calcd for C19H25NO 283.1936, found 283.1934. 
 
O
N
4-38  
(Z)-7,8,9,11a-Tetrahydro-5H-azepino[2,1-a]isoindol-5-one (4-38).  To a 
solution of 4-37 (150 mg, 0.529 mmol) in toluene (100 mL) was added Ti(OiPr)4 (157 µL, 
0.529 mmol) and Grubbs 2nd generation catalyst (22.5 mg, 0.0265 mmol) and the red 
solution was stirred at rt for 12 h and concentrated.  The residue was purified by 
chromatography on SiO2 (acetone:CH2Cl2, 0.4:9.6) to yield 70.7 mg (67%) of 4-38 as a 
colorless oil: IR (neat) 3024, 2926, 1680, 1469, 1419, 1298, 938, 709 cm-1; 1H NMR δ 
7.76 (dd, 1 H, J = 6.9, 1.2 Hz), 7.58-7.51 (m, 1 H), 7.46 (app t, 2 H, 7.2 Hz), 6.13-6.02 (m, 
1 H), 6.02-5.91 (m, 1 H), 4.49 (dd, 1 H, J = 11.4, 2.1 Hz), 4.26 (ddd, 1 H, J = 13.5, 6.6, 
3.0 Hz), 3.22 (ddd, 1 H, J = 12.6, 9.6, 2.7 Hz), 2.81 (app ddd, 1 H, J = 15.9, 7.8, 2.4 Hz), 
2.53-2.26 (m, 2 H), 2.25-2.09 (m, 1 H); 13C NMR δ 167.5, 145.9, 133.0, 132.7, 131.6, 
128.8, 128.5, 123.5, 122.4, 60.6, 41.6, 35.2, 28.2; MS (EI) m/z (rel intensity) 199 ([M]+, 
45), 145 (100), 117 (40), 90 (35); HRMS (EI) m/z calcd for C13H13NO 199.0997, found 
199.0991. 
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O
4-46  
(R,E)-2-Methyl-N-(3-methylbutylidene)propane-2-sulfinamide (4-46).181   To a 
solution of isovaleraldehyde (5.41 mL, 48.5 mmol) in CH2Cl2 (250 mL) was added (R)-2-
methylpropane-2-sulfinamide (5.00 g, 40.4 mmol), MgSO4 (5.0 eq, 24.3 g, 202 mmol) and 
PPTS (10 mol%, 1.05 g, 4.04 mmol) and the resulting suspension was stirred at rt for 24 h.  
The reaction was filtered through a pad of Celite and the crude residue was purified by 
chromatography on SiO2 (3:7, EtOAc:hexanes) to yield 6.75 g (88%) of 4-46 as a 
colorless oil:  1H NMR δ 8.07 (t, 1 H, J = 5.2 Hz), 2.47-2.38 (m, 2 H), 2.18-1.90 (m, 1 H), 
1.21 (s, 9 H), 1.00 (d, 6 H, J = 6.7 Hz).  As an alternative, filtration through a pad of SiO2 
provides crude imine that functions equally well in subsequent reactions.   
 
NH3Cl
OTBDPS
4-48  
(S,E)-8-(tert-Butyldiphenylsilyloxy)-2-methyloct-5-en-4-amine hydrochloride 
(4-48).    To a solution of 4-47 (15.9 g, 51.5 mmol) in CH2Cl2 (300 mL) was added 
zirconocene hydrochloride (15.1 g, 58.4 mmol) in 3 portions and the resulting suspension 
was stirred at rt for 10 min.  The resulting yellow solution was cooled to 0 °C and Me3Al 
(2.0 M in hexanes, 27.5 mL, 54.9 mmol) was added and stirred for 5 minutes followed by 
addition of a solution of imine 4-46 (6.50 g, 34.3 mmol) in CH2Cl2 (50 mL).  The orange 
solution was stirred for an additional 4 h while being allowed to warm to rt.  The reaction 
was quenched with MeOH, diluted with H2O and CH2Cl2 and HCl (1 M) was added to 
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break up the emulsion (prolonged stirring with Rochelle’s salt can also be utilized).  The 
organic layer was separated and the aqueous layer was washed with CH2Cl2 (2x).  The 
organic layers were combined, washed with brine, dried (MgSO4), filtered though a pad of 
Celite and concentrated.  Since the crude oil was contaminated with metal salts, the oil 
was dissolved in Et2O, allowed to sit for 2 h, and then filtered though a pad of Celite and 
concentrated.   Analysis of the crude residue by 1H NMR showed only 1 diastereomer (> 
95:5 dr).   
To the crude residue in Et2O (800 mL) was added HCl (4.0 M in dioxane, 17.2 
mL, 68.7 mmol) and the reaction mixture was stirred for 30 minutes, during which time a 
white precipitate formed.  The precipitate was filtered, washed with dry Et2O, and dried to 
afford 11.0 g (74% over 2 steps) of 4-48 as a colorless solid: [α]D -2.9 (c 1.0, CH2Cl2); 1H 
NMR δ 8.42 (bs, 3 H), 7.70-7.55 (m, 4 H), 7.48-7.30 (m, 6 H), 5.90 (dt, 1 H, J = 14.9, 7.5 
Hz), 5.52 (dd, 1 H, J = 15.4, 8.4 Hz), 3.69 (app t, 3 H, J = 6.5 Hz), 2.45-2.20 (m, 2 H), 
1.80-1.50 (m, 3 H), 1.03 (s, 9 H), 0.95-0.84 (m, 6 H); 13C NMR δ 135.5, 134.5, 133.7, 
129.5, 127.6, 127.3, 63.0, 52.9, 42.1, 35.6, 26.7, 24.4, 22.9, 21.5, 19.1; EIMS m/z 395 
([M-HCl]+, 40), 338 (86), 198 (100); HRMS (EI) m/z calcd for C25H37NOSi (M-HCl) 
395.2644, found 395.2640. 
 
NHBoc OH
4-49
 
(S,E)-tert-Butyl 8-hydroxy-2-methyloct-5-en-4-ylcarbamate (4-49).   To a 
solution of 4-48 (10.5 g, 24.3 mmol) in CH2Cl2 (400 mL) was added Et3N (3.0 eq, 10.3 
mL, 72.9 mmol) and Boc2O (1.05 eq, 5.74 g, 25.5 mmol) and the resulting suspension was 
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stirred at rt for 14 h.  The reaction was quenched with sat. aq. NH4Cl.  The organic layers 
were separated, dried (MgSO4), filtered and concentrated.  The crude residue was carried 
onto the next step without further purification.   
To a solution of crude TBDPS ether (12.0 g, 24.3 mmol) in THF (200 mL) at 0 °C 
was added TBAF (1.0 M in THF, 1.25 eq, 30.4 mL, 30.4 mmol) and the reaction mixture 
was warmed to rt, stirred for 2 h, and quenched with sat. aq. NH4Cl.  The organic layer 
was washed with brine, dried (MgSO4), filtered and concentrated. The crude residue was 
purified by chromatography on SiO2 (3:7, EtOAc:hexanes) to yield 5.51 g (88%, 2 steps) 
of 4-49 as a colorless oil: [α]D -12.7 (c 1.0, CH2Cl2); IR 3335, 2956, 2870, 1689, 1525, 
1366, 1173, 1046, 1022 cm-1; 1H NMR δ 5.53 (dt, 1 H, J = 15.4, 6.9 Hz), 5.37 (dd, 1 H, J 
= 15.4, 6.5 Hz), 4.50 (bs, 1 H), 4.11-3.95 (m, 1 H), 3.60 (t, 2 H, J = 6.2 Hz), 2.42 (bs, 1 
H), 2.25 (app q, 2 H, J = 6.4 Hz), 1.70-1.51 (m, 1 H), 1.41 (s, 9 H), 1.37-1.20 (m, 2 H), 
0.89 (d, 3 H, J = 6.6 Hz), 0.88 (d, 3 H, J = 6.6 Hz); 13C NMR δ 155.4, 134.3, 126.9, 79.2, 
61.5, 50.9, 44.5, 35.6, 28.3, 24.6, 22.5; EIMS m/z 257 ([M]+, 10), 227 (55), 171 (65); 
HRMS (EI) m/z calcd for C14H27NO3 257.1991, found 257.1994. 
 
NHBoc O
OH
4-50
    
(S,E)-5-(tert-Butoxycarbonylamino)-7-methyloct-3-enoic acid (4-50).  To a 
solution of 4-49 (1.00 g, 3.89 mmol) in acetone (40 mL) at 0 °C was added a freshly 
prepared solution of Jones Reagent (2.5 M, 3.89 mL, 9.71 mmol) and the reaction mixture 
was stirred at 0 °C for 1 h.  The dark solution was extracted with Et2O (3 x 50 mL).  The 
organic layers were washed with water (2 x 75 mL), brine (1 x 50 mL), dried (Na2SO4), 
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filtered and concentrated to yield 990 mg (94% crude) of acid 4-50 as a yellow oil that 
was used without further purification.   
NHBoc O
N
H
N
O
4-51 (jp4_039)
 
(S,E)-5-(tert-Butoxycarbonylamino)-7-methyloct-3-enoic acid-TEMPO (4-51).  
To a solution of 4-50 (678 mg, 2.50 mmol, crude) in CH2Cl2 (35 mL) at 0 °C was added 4-
amino tempo (1.5 eq, 662 mg, 3.75 mmol), EDCI (1.2 eq, 575 mg, 3.00 mmol), DMAP 
(1.1 eq, 339 mg, 2.75 mmol) and HOBt-hydrate (1.1 eq, 377 mg, 2.75 mmol) and the 
resulting orange solution was stirred at rt for 14 h.  The reaction mixture was diluted with 
CH2Cl2 and washed with sat. aq. NH4Cl.  The organic layer was dried (Na2SO4), filtered 
and concentrated.  The crude residue was purified by chromatography on SiO2 (1:1 to 2:1, 
EtOAc/hexanes) to yield 857 mg (76%, 2 steps) of 4-51 as a peach colored solid: ESIMS 
m/z 365 (40), 391 (50), 447 ([M+Na]+, 100), 527 (20); HRMS (ESI) m/z calcd for 
C23H42N3O4Na (M + Na) 447.3073, found 447.3109. 
 
NHBoc O
O
4-52
 
(S,E)-Methyl 5-(tert-butoxycarbonylamino)-7-methyloct-3-enoate (4-52). To a 
solution of 4-50 (116 mg, 0.427 mmol) in benzene/MeOH (4:1, 2.5 mL) was added 
TMSCHN2 (2.0 M in Et2O, 5 eq., 1.07 mL, 2.13 mmol) and the reaction was stirred at rt 
for 20 min.  The yellow solution was concentrated and the crude residue purified by 
chromatography on SiO2 (30% EtOAc/hexanes) to yield 103 mg (84%) of 4-52 as a 
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colorless oil: [α]D -11.3 (c 1.0, CH2Cl2); IR 3374, 2957, 2927, 2855, 1697, 1515, 1366, 
1253, 1170 cm-1; 1H NMR δ 5.70 (ddt, 1 H, J = 15.4, 6.9, 1.0 Hz), 5.49 (dd, 1 H, 15.5, 5.0 
Hz), 4.39 (bs, 1 H), 4.24-4.02 (m, 1 H), 3.69 (s, 3 H), 3.07 (d, 2 H, J = 6.9 Hz), 1.74-1.56 
(m, 1 H), 1.45 (s, 9 H), 1.40-1.20 (m, 2 H), 0.93 (d, 3 H, J = 6.5 Hz), 0.92 (d, 3 H, J = 6.6 
Hz); 13C NMR δ 172.0, 155.2, 135.4, 121.8, 79.2, 51.7, 50.2, 44.6, 37.5, 28.4, 24.7, 22.5, 
22.4; EIMS m/z 228 ([M-tBu]+, 60), 172 (85), 128 (85), 117 (65), 96 (70); HRMS (EI) m/z 
calcd for C11H18NO4 (M-tBu) 228.1236, found 228.1239. 
 
NHBoc O
O
4-54
 
(S,E)-Methyl 2,2-dibenzyl-5-(tert-butoxycarbonylamino)-7-methyloct-3-enoate 
(4-54).  To a solution of 4-52 (47.8 mg, 0.167 mmol) in THF (2.5 mL) at -78 ˚C was 
added DMPU (0.5 mL) and KHMDS (2.1 eq, 73.7 mg, 0.351 mmol) and the reaction was 
stirred at this temperature for 45 min.  To the resulting yellow solution at -78 ˚C was 
added BnCl (1.1 eq, 21.2 µL, 0.184 mmol) in one portion and the reaction warmed to -40 
˚C and stirred at this temperature for 2 h.  The reaction was quenched with sat. aq. NH4Cl, 
extracted with EtOAc, washed with brine, dried (MgSO4), filtered and concentrated.  The 
crude residue was purified by chromatography on SiO2 (20% EtOAc/hexanes) to yield 
35.0 mg (45%) of 4-54 as a light yellow oil: 1H NMR δ 7.50-7.05 (m, 10 H), 5.80 (d, 1 H, 
J = 16.1 Hz), 5.39 (dd, 1 H, J = 16.2, 6.4 Hz), 4.42-4.23 (m, 1 H), 4.23-4.05 (m, 1 H), 3.63 
(s, 3 H), 3.23 (d, 1 H, J = 13.8 Hz), 3.22 (d, 1 H, J = 13.7 Hz), 3.03 (d, 1 H, J = 13.7 Hz), 
 - 184 -  
3.00 (d, 1 H, J = 13.8 Hz), 1.75-1.60 (m, 1 H), 1.47 (s, 9 H), 1.35-1.15 (m, 2 H), 0.87 (d, 6 
H, J = 6.6 Hz).   
 
NHBoc O
O
NHBoc O
O
+
 
(2S,5S,E)-Methyl 2 – benzyl – 5 - (tert - butoxycarbonylamino) - 7-methyloct-
3-enoate (4-53). To a solution of 4-52 (549 mg, 1.92 mmol) in THF (30 mL) and DMPU 
(2.0 mL) at -78 ˚C was added LiHMDS (1.0 eq, 321 mg, 1.92 mmol) in one portion.  The 
reaction was stirred at this temperature for 1 h, followed by addition of BnBr (5 eq, 1.14 
mL, 9.60 mmol) and the resulting yellow solution allowed to warm to -40 ˚C and stirred at 
this temperature for 5 h. The reaction was quenched with sat. aq. NH4Cl, extracted with 
EtOAc, washed with brine, dried (MgSO4), filtered and concentrated.  The crude residue 
was purified by chromatography on SiO2 (20% EtOAc/hexanes) to yield 561 mg (78%) of 
4-53 as an inseperable 1.5:1 mixture of diastereomers: 1H NMR δ 7.35-7.08 (m, 5 H), 5.62 
(dt, 1 H, J = 15.3, 7.8 Hz), 5.32 (dd, 1 H, J = 15.5, 6.1 Hz), 4.28 (bs, 1 H), 4.10 (bs, 1 H), 
3.63 (s, 1.2 H), 3.63 (s, 1.8 H), 3.38-3.22 (m, 1 H), 3.08 (dd, 1 H, J = 13.4, 7.4 Hz), 2.80 
(ddd, 1 H, J = 11.5, 7.5, 2.0 Hz), 1.60-1.48 (m, 1 H), 1.45 (s, 5.4 H), 1.44 (s, 3.6 H), 1.35-
1.13 (m, 2 H), 0.92-0.83 (m, 6 H); ESIMS m/z 423 (10), 398 ([M+Na]+, 60), 362 (40), 342 
(100); HRMS (ESI) m/z calcd for C22H33NO4Na (M+Na) 398.2307, found 398.2313. 
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4-55
 
(S,E) – 2 – Benzyl – 5 - (tert-butoxycarbonylamino) - 7-methyloct -2-enoic acid 
- TEMPO (4-55).  To a soluton of 4-53 (250 mg, 0.666 mmol) in THF (10 mL) at 0 ˚C 
was added LiOH (2.0 M in H2O, 5.0 eq, 1.67 mL, 3.33 mmol) and the reaction was 
allowed to stir for 2 h.  The reaction mixture was acidified with 1 N HCl, extracted with 
EtOAc, washed with brine, dried (MgSO4), filtered and concentrated.  The crude acid was 
carried on without further purification.  Key 1H NMR data: 7.09 (dd, 1 H, J = 7.3, 7.3 Hz).  
To a solution of crude acid (242 mg, 0.669 mmol, crude) in CH2Cl2 (14 mL) at 0 
°C was added 4-amino tempo (1.5 eq, 171 mg, 1.00 mmol), EDCI (1.2 eq, 154 mg, 0.803 
mmol), DMAP (1.1 eq, 89.9 mg, 0.736 mmol) and HOBt-hydrate (1.1 eq, 99.4 mg, 0.736 
mmol) and the resulting orange solution was stirred at rt for 14 h.  The reaction was 
diluted with CH2Cl2, washed with sat. aq. NH4Cl and the organic layer dried (Na2SO4), 
filtered and concentrated.  The crude residue was purified by chromatography on SiO2 
(1:1 to 2:1, EtOAc/hexanes) to yield 215 mg (63%, 2 steps) of 4-55 as a peach colored 
solid: ESIMS m/z 537 ([M+Na]+, 100), 481 (95), 415 (60); HRMS (ESI) m/z calcd for 
C30H48N3O4Na (M + Na) 537.3543, found 537.3580. 
 
 
 
 - 186 -  
NHBoc O
O
4-56
 
(S,E)-Allyl 5-(tert-butoxycarbonylamino)-7-methyloct-3-enoate (4-56).  To a 
solution of 4-52 (250 mg, 0.921 mmol, crude) in CH2Cl2 (10 mL) at rt was added allyl 
alcohol (2.0 eq, 125 µL, 1.84 mmol), EDCI (1.1 eq, 157 mg, 1.01 mmol) and DMAP (0.1 
eq, 11.3 mg, 0.0921 mmol) and the reaction was stirred at rt for 12 h.  The reaction was 
diluted with CH2Cl2, washed with 10% HCl, washed with brine, dried (MgSO4), filtered 
and concentrated.  The crude residue was purified by chromatography on SiO2 (15% 
EtOAc/hexanes) to yield 249 mg (87%) of 4-56 as a colorless oil: [α]D -8.6 (c 1.1, 
CH2Cl2); IR 3361, 2757, 2930, 2871, 1737, 1696, 1513, 1366, 1246, 1161 cm-1; 1H NMR 
δ 6.01-5.83 (m, 1 H), 5.71 (ddt, 1 H, J = 15.4, 8.3, 1.0 Hz), 5.50 (dd, 1 H, J = 14.6, 5.2 
Hz), 5.32 (app ddd, 1 H, J = 17.1, 1.5, 1.5 Hz), 5.24 (app ddd, 1 H, J = 10.4, 1.3, 1.2 Hz), 
4.60 (dd, 1 H, J = 1.3, 1.3 Hz), 4.58 (dd, 1 H, J = 1.3, 1.3 Hz), 4.39 (bs, 1 H), 4.16 (bs, 1 
H), 3.10 (d, 2 H, J = 6.9 Hz), 1.76-1.50 (m, 1 H), 1.45 (s, 9 H), 1.40-1.25 (m, 2 H), 0.92 
(d, 3 H, J = 6.5 Hz), 0.92 (d, 3 H, J = 6.6 Hz); 13C NMR δ 171.2, 155.3, 135.5, 132.1, 
121.9, 118.3, 79.3, 65.3, 44.7, 37.7, 28.4, 24.7, 22.7, 22.5; ESIMS m/z 536 (10), 334 
([M+Na]+, 70), 278 (100), 219 (60); HRMS (ESI) m/z calcd for C17H29NO4Na(M+Na) 
334.1994, found 334.1983. 
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(2S,5S,E) - Allyl 2 -benzyl-5-(tert-butoxycarbonylamino)-7-methyloct-3-enoate 
(4-57). To a solution of 4-56 (196 mg, 0.629 mmol) in THF (8 mL) and DMPU (0.5 mL) 
at -78 ˚C was added LiHMDS (1.05 eq, 114 mg, 0.660 mmol) and resulting solution was 
stirred at this temperature for 1 h.  To the yellow solution was added BnBr (1.05 eq, 78.9 
µL, 0.660 mmol) and the reaction was warmed to -40 ˚C and stirred at this temperature for 
6 h. The reaction was quenched with sat. aq. NH4Cl, extracted with EtOAc, washed with 
brine, dried (MgSO4), filtered and concentrated.  The crude residue was purified by 
chromatography on SiO2 (15% EtOAc/hexanes) to yield 179 mg (71%) of 4-57 as an 
inseperable 1.5:1 mixture of diastereomers: [α]D -4.5 (c 1.0, CH2Cl2); IR 3375, 2956, 
2932, 1734, 1701, 1497, 1365, 1247, 1160 cm-1; 1H NMR δ 7.44-7.18 (m, 5 H), 6.20-5.87 
(m, 1 H), 5.83-5.68 (m, 1 H), 5.46 (dd, 1 H, J = 15.4, 6.2 Hz), 5.40-5.25 (m, 2 H), 4.65 (d, 
2 H, J = 5.6 Hz), 4.42 (bs, 1 H), 4.22 (bs, 1 H), 3.49-3.34 (m, 1 H), 3.21 (dd, 1 H, J = 13.5, 
7.6 Hz), 2.97-2.75 (m, 1 H), 1.75-1.60 (m, 1 H), 1.57 (s, 5.4 H), 1.56 (s, 3.4 H), 1.45-1.25 
(m, 2 H), 1.08-0.91 (m, 6 H); 13C NMR δ 173.0, 173.0, 155.1, 138.6, 138.5, 134.7, 132.0, 
129.1, 129.1, 128.3, 127.2, 126.4, 118.1, 79.2, 65.2, 50.8, 44.6, 44.5, 38.7, 28.4, 24.6, 
24.6, 22.5; ESIMS m/z 424 ([M+Na]+, 100), 368 (20); HRMS (ESI) m/z calcd for 
C24H35NO4Na (M+Na) 424.2464, found 424.2464. 
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(2S,5S,E) -2-Benzyl-5-(tert-butoxycarbonylamino)-7-methyloct - 3 - enoic acid-
TEMPO (4-43). To a solution of 4-57 (67.0 mg, 0.167 mmol) in CH2Cl2 (1 mL) was 
added phenyl silane (2.0 eq, 41.2 µL, 0.334 mmol) and Pd(PPh3)4 (0.02 eq, 3.86 mg, 3.34 
µmol) and the reaction was stirred at rt for 8 h.  The reaction was filtered through a pad of 
Celite and concentrated.  To a solution of crude acid (60.4 mg, 0.167 mmol, crude) in 
CH2Cl2 (5 mL) at 0 °C was added 4-amino tempo (1.5 eq, 42.9 mg, 0.251 mmol), EDCI 
(1.0 eq, 25.9 mg, 0.167 mmol) and DMAP (1.0 eq, 20.4 mg, 0.167 mmol) and the 
resulting orange solution was stirred at rt for 13 h.  The reaction was diluted with CH2Cl2, 
washed with sat. aq. NH4Cl and the organic layer dried (Na2SO4), filtered and 
concentrated.  The crude residue was purified by chromatography on SiO2 (1:1 to 2:1, 
EtOAc/hexanes) to yield 67.7 mg (79%, 2 steps) of 4-43 as a peach colored solid: ESIMS 
m/z 537 ([M+Na]+, 100), 481 (60); HRMS (ESI) m/z calcd for C30H48N3O4Na (M + Na) 
537.3543, found 537.3528. 
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5-23  
(S)-Benzyl 2,8-dioxo-1-oxaspiro[4.5]deca-6,9-dien-3-ylcarbamate (5-23). To a 
solution of iodobenzene diacetate (39.1 g, 119 mmol) in MeCN/i-PrOH (4:1, 130 mL) was 
added a solution of Cbz-tyrosine (25.0 g, 79.3 mmol) in MeCN/i-PrOH (4:1, 150 mL) 
dropwise over 1 h. The reaction mixture was stirred for an additional 2 h, quenched with 
sat. aq. NaHCO3 (500 mL), and extracted with EtOAc (2x). The combined organic layers 
were washed with NaHCO3 (3 x 500 mL) and brine, dried (MgSO4) and concentrated. The 
crude residue was dissolved in 80% EtOAc/hexanes (400 mL) and the heterogeneous 
mixture was filtered though a pad of SiO2. The resulting solution was concentrated and 
purified by chromatography on SiO2 (45% EtOAc/hexanes to 60% EtOAc/hexanes). The 
orange solid was recrystallized from hot EtOAc/hexanes (placed in -20 °C freezer 
overnight after being dissolved in boiling solvent) to yield 9.57 g (39%) of spirocycle 5-23 
as a colorless solid (white fuzzy needles): [α]D -26.0 (c 1.08, CH2Cl2); IR (CH2Cl2) 3060, 
2956, 1789, 1710, 1674, 1635, 1523, 1198 cm-1; 1H NMR δ 7.53-7.20 (m, 5 H), 6.86 (bd, 
2 H, J = 7.5 Hz), 6.43-6.20 (m, 2 H), 5.59 (bs, 1 H), 5.14 (bs, 2 H), 4.70-4.54 (m, 1 H), 
2.74 (dd, 1 H, J = 11.1, 10.2 Hz), 2.49 (app t, 1 H, J = 12.3 Hz); 13C NMR δ 184.2, 173.8, 
156.1, 146.3, 144.4, 135.8, 129.8, 129.2, 128.8, 128.6, 128.3, 67.7, 50.5, 38.0; EIMS m/z 
313 (M+, 15), 269 (15), 226 (15), 107 (95), 91 (100); HRMS (EI) m/z calcd for C17H15NO5 
313.0950, found 313.0940. 
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5-5  
(2S,3aR,7aR) - 1-Benzyl 2-methyl 3a-hydroxy-6-oxo-3,3a,7,7a-tetrahydro-1H-
indole-1,2(2H,6H)-dicarboxylate (5-5). To a solution of KOH (3.0 M in H2O, 200 mL) 
and MeOH (200 mL) at -20 °C was added a solution of 5-23 (6.48 g, 20.7 mmol) in 150 
mL of MeOH in one portion. The reaction mixture was allowed to stir at -20 °C for 20 min 
during which time the solution became brown in color. The mixture was quenched by 
addition of 10% HCl (100 mL), extracted with EtOAc (3 x 150 mL), washed with brine, 
dried (MgSO4), filtered and concentrated. The crude residue was purified by 
chromatography on SiO2 (60% EtOAc/hexames to 80% EtOAc/hexanes) to yield 5.68 g 
(80%) of methyl ester 5-5 as a colorless waxy solid: [α]D -130 (c 1.0, CH2Cl2); IR 
(CH2Cl2) 3034, 2953, 1756, 1686, 1415, 1351, 1124 cm-1; 1H NMR (DMSO, 380 K) 
δ 7.43-7.26 (m, 5 H), 6.76 (d, 1 H, J = 10.2 Hz), 5.90 (d, 1 H, J = 10.5 Hz), 5.40 (bs, 1 H), 
5.18-5.03 (m, 2 H), 4.50 (dd, 1 H, J = 9.3, 3.0 Hz), 4.24 (dd, 1 H, J = 9.3, 5.7 Hz), 3.61 (s, 
3 H), 2.93 (dd, 1 H, J = 15.9, 5.4 Hz), 2.62 (dd, 1 H, J = 16.2, 9.6 Hz), 2.58 (dd, 1 H, J = 
13.2, 9.3 Hz), 2.29 (ddd, 1 H, J = 13.2, 3.0, 0.6 Hz); 13C NMR (DMSO, 380 K) δ 195.4, 
170.9, 153.0, 148.8, 136.1, 127.7, 127.6, 127.2, 126.9, 126.9, 73.9, 65.8, 63.7, 58.0, 51.0; 
ESI-MS m/z 368 ([M+Na]+, 50), 302 (10); HRMS (ESI) m/z calcd for C18H19NO6Na 
(M+Na) 368.1110, found 368.1121. 
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5-25  
(2S,3aR,6S,7aR)-1-Benzyl 2-methyl 3a,6-dihydroxy-3,3a,7,7a-tetrahydro-1H-
indole-1,2(2H,6H)-dicarboxylate (5-25).  To a solution of 5-5 (1.80 g, 5.21 mmol) in 
MeOH (35 mL) and THF (35 mL) was added cerium (III) chloride heptahydrate (1.94 g, 
5.16 mmol) followed by cooling to 0 °C and addition of sodium borohydride (217 mg, 
5.73 mmol) in one portion. The reaction mixture was stirred at 0 °C for 2 h, diluted with 
EtOAc (200 mL), quenched with water (100 mL) and the layers were separated. The 
organic layer was washed with brine, dried (MgSO4), filtered, and concentrated. The crude 
residue was purified by chromatography on SiO2 (EtOAc) to yield 1.32 g (73%) of 5-25 as 
a colorless waxy solid: [α]D -12.4 (c 1.16, CH2Cl2); IR (CH2Cl2) 3417, 3031, 2953, 1754, 
1687, 1417, 1355, 1122 cm-1; 1H NMR (DMSO, 380 K) δ 7.55-7.20 (m, 5 H), 5.67 (d, 1 
H, J = 9.9 Hz), 5.53 (dd, 1 H, J = 10.2, 2.4 Hz), 5.10 (bs, 2 H), 4.61-4.43 (m, 3 H), 4.16 
(bd, 1 H, J = 6.0 Hz), 3.90 (dd, 1 H, J = 12.3, 4.8 Hz), 3.58 (s, 3 H), 2.60-2.40 (m, 1 H), 
2.32 (dd, 1 H, J = 13.2, 9.6 Hz), 2.14 (app d, 1 H, J = 13.5 Hz), 1.37-1.17 (m, 1 H); 13C 
NMR (DMSO, 380 K) δ 171.2, 153.2, 136.4, 133.1, 128.7, 127.6, 127.0, 126.8, 74.7, 65.6, 
64.0, 63.6, 58.1, 50.8, 40.4, 37.1; EIMS m/z 347 (M+, 10), 329 (40), 244 (100); HRMS 
(EI) m/z calcd for C18H21NO6 347.1369, found 347.1368. 
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5-26  
(2S,3aS,4S,5S,6S,7aR) - 1 - Benzyl 2-methyl 3a,4,5,6 – tetrahydroxyhexahydro 
-1H-indole-1,2(2H,3H)-dicarboxylate (5-26). To a solution of 5-25 (500 mg, 1.44 mmol) 
in H2O/THF (1:10, 15 mL) was added OsO4 (480 µL, 0.144 mmol), NMO (596 mg, 4.32 
mmol) and methanesulfonamide (154 mg, 1.58 mmol). The reaction mixture was stirred at 
rt for 72 h, quenched with NaSO3, diluted with H2O and EtOAc, extracted with EtOAc 
(4x), washed with brine, dried (MgSO4) and concentrated. The crude residue was purified 
by chromatography on SiO2 (EtOAc to 5% MeOH/EtOAc) to yield 426 mg (78%) of 5-26 
as a colorless waxy solid and a 1.4:1 mixture of diastereomers: [α]D -45.8 (c 0.67, 
MeOH); IR (CH2Cl2) 3419, 3033, 2952, 1700, 1417, 1353, 1213, 1069 cm-1; 1H NMR 
(MeOD, 600 MHz, rotamers) δ 7.41-7.26 (m, 5 H), 5.20-5.10 (m, 1.60 H), 5.02 (app dd, 
0.40 H, J = 12.6, 2.4 Hz), 4.48 (app dd, 0.40 H, J = 15.0, 9.6 Hz), 4.40 (app dd, 0.60 H, J 
= 15.0, 9.6 Hz), 4.15-3.94 (m, 0.40 H), 3.94-3.89 (m, 0.60 H), 3.85-3.73 (m, 1.60 H), 3.72 
(app d, 1.70 H, J = 7.2 Hz), 3.67-3.61 (m, 0.60 H), 3.61-3.58 (m, 0.40 H), 3.58-3.54 (m, 
1.70 H), 3.46-3.39 (m, 0.40 H), 3.03-2.93 (m, 0.60 H), 2.60-2.50 (m, 0.60 H), 2.45-2.37 
(m, 0.14 H), 2.34-2.27 (m, 0.36 H), 2.17 (app dd, 1 H, J = 14.4, 7.8 Hz), 2.05 (app dd, 
0.40 H, J = 13.2, 7.8 Hz); 13C NMR (MeOD, 600 MHz, rotamers) δ 175.1, 174.4, 174.3, 
173.9, 156.6, 156.5, 156.2, 156.1, 137.8, 137.8, 129.6, 129.4, 129.2, 129.1, 128.9, 82.2, 
81.3, 80.9, 80.1, 75.3, 75.2, 75.1, 75.1, 74.4, 74.3, 73.8, 73.7, 68.4, 68.3, 68.2, 68.1, 68.0, 
67.7, 67.6, 64.4, 64.1, 63.4, 63.1, 58.6, 58.5, 52.8, 52.8, 52.7, 38.7, 38.5, 37.7, 37.5, 36.8, 
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35.9, 33.1, 32.1; ESI-MS m/z 404 ([M+Na]+, 100), 365 (25); HRMS (ESI) m/z calcd for 
C18H23NO8Na (M+Na) 404.1321, found 404.1338. 
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5-28  
(2S,3aS,4S,5S,6S,7aR) - Methyl 3a,4,5,6-tetrahydroxyoctahydro - 1H-indole-2-
carboxylate hydrochloride salt (5-28). To a solution of 5-26 (264 mg, 0.692 mmol) in 
MeOH (10 mL) was added 10% Pd/C (50 mg). The reaction mixture was stirred under an 
atmosphere of H2 for 6 h, filtered though a pad of Celite®, concentrated, and redissolved in 
MeOH (10 mL). After addition of HCl (5.0 mL, 4.0 M in dioxane), the solution was 
heated at reflux for 30 min, allowed to cool to rt, and filtered. The solid was dried in vacuo 
to yield 93 mg (47%) of amine hydrochloride 5-28 as a colorless powder with a dr of 
>95:5 as determined by 1H NMR analysis of the crude reaction mixture: 1H NMR (MeOD, 
600 MHz, crude) δ 4.61 (dd, 1 H, J = 11.4, 3.6 Hz), 3.96-3.89 (m, 1 H), 3.85 (s, 3 H), 
3.79-3.71 (m, 1 H), 3.71-3.65 (m, 1 H), 3.63-3.53 (m, 1 H), 3.18 (dd, 1 H, J = 14.4, 11.4 
Hz), 2.34 (dd, 1 H, J = 13.8, 2.4 Hz), 1.99-1.89 (m, 2 H).   
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5-30
 
(2S,3aS,4S,5S,6S,7aR) - Methyl 1 - (cyclohexylmethyl) - 3a,4,5,6-tetrahydroxy 
- octahydro-1H-indole-2-carboxylate (5-30). To a suspension of amine hydrochloride 5-
28 (40.0 mg, 0.141 mmol) in MeOH (2 mL) was added acetic acid (40.7 µL, 0.705 mmol, 
5 eq), cyclopropanecarboxaldehyde (26.1 µL, 0.211 mmol, 1.5 eq) and MP-
cyanoborohydride resin (2.34 mmol/g, 2.5 eq, 151 mg, 0.352 mmol). The reaction mixture 
was stirred at rt for 48 h and filtered. The filtrate was neutralized with 2 M NH3 in MeOH, 
concentrated and purified by chromatography on SiO2 (5% MeOH/EtOAc) to provide 40.0 
mg (83%) of 5-30 as a colorless oil that solidified upon standing: [α]D -53.1 (c 0.91, 
CH2Cl2); IR (CH2Cl2) 3334, 2919, 2847, 1732, 1196, 1176, 1134, 1114, 1063 cm-1; 1H 
NMR (MeOD) δ 3.85 (app t, 1 H, J = 2.7 Hz), 3.63 (s, 3 H), 3.58 (app d, 1 H, J = 3.9 Hz), 
3.52 (dt, 1 H, J = 11.4, 3.9 Hz), 3.31 (dd, 1 H, J = 11.1, 3.3 Hz), 2.98 (dd, 1 H, J = 14.1, 
10.8 Hz), 2.92 (dd, 1 H, J = 11.1, 5.1 Hz), 2.47 (dd, 1 H, J = 12.3, 6.0 Hz), 2.25 (dd, 1 H, J 
= 12.3, 8.7 Hz), 1.86-1.74 (m, 1 H), 1.74-1.53 (m, 6 H), 1.53-1.36 (m, 1 H), 1.35-1.18 (m, 
1 H), 1.18-1.00 (m, 3 H), 0.86-0.65 (m, 2 H); 13C NMR (MeOD) δ 178.7, 82.9, 74.4, 73.8, 
69.5, 66.9, 63.6, 57.1, 52.9, 38.7, 37.6, 32.9, 32.8, 28.1, 27.4, 27.2, 26.8; ESIMS m/z 344 
([M+H]+, 50), 326 (100), 308 (30); HRMS (ESI) m/z calcd for C17H30NO6 (M+H) 
344.2073, found 344.2090.  
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5-31  
(2S,3aR,6R,7aR)-1-Benzyl 2-methyl 3a,6-dihydroxy-3,3a,7,7a-tetrahydro-1H-
indole-1,2(2H,6H)-dicarboxylate (5-31). To a solution of 5-5 (4.42 g, 12.8 mmol) in 
freshly distilled THF (100 mL) at -78 °C was added L-selectride (19.2 mL, 19.2 mmol, 1.5 
eq) dropwise (syringe pump) over 1.5 h. The reaction mixture was stirred for an additional 
hour at -78 °C, quenched with 10% HCl (10 mL) and warmed to rt. The solution was 
extracted with EtOAc (2x), washed with brine, dried (MgSO4), filtered and concentrated 
to provide 3.41 g (77%) of 5-31 that was carried on without further purification: [α]D -
15.7 (c 1.09, CH2Cl2); IR (CH2Cl2) 3422, 3031, 2952, 1701, 1416, 1353, 1210 cm-1; 1H 
NMR (DMSO, 380 K) δ 7.45-7.25 (m, 5 H), 5.79 (dd, 1 H, J = 9.9, 3.9 Hz), 5.60 (d, 1 H, J 
= 10.2 Hz), 4.38 (bs, 2 H), 4.24 (dd, 1 H, J = 8.7, 4.5 Hz), 4.05-3.93 (m, 2 H), 3.58 (s, 3 
H), 2.22 (dd, 1 H, J = 12.9, 8.7 Hz), 2.17-2.04 (m, 2 H), 2.01-1.83 (m, 1 H); 13C NMR 
(DMSO, 380 K) δ 171.5, 153.2, 136.3, 130.5, 130.3, 127.6, 127.0, 126.8, 73.9, 65.5, 61.1, 
60.6, 57.6, 50.8, 40.4, 32.9; ESI-MS m/z 370 ([M+Na]+, 25), 286 (10); HRMS (ESI) m/z 
calcd for C18H21NO6Na (M+Na) 370.1267, found 370.1287. 
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5-32  
(2S,3aS,4S,5S,6R,7aR) - 1 - Benzyl 2 -methyl 3a,4,5,6-tetrahydroxyhexahydro 
-1H-indole-1,2(2H,3H)-dicarboxylate (5-32). To a solution of 5-31 (1.00 g, 2.88 mmol 
in THF (25 mL) and water (2.5 mL) was added methanesulfonamide (307 mg, 3.17 mmol, 
1.1 eq), NMO-H2O (1.19 g, 8.64 mmol, 3.0 eq) and osmium tetroxide (0.3 M in toluene, 
747 mg, 0.288 mmol, 0.960 mL) and the reaction mixture was stirred at rt for 48 h. After 
this time additional osmium tetroxide (0.3 M in toluene, 747 mg, 0.288 mmol, 0.960 mL) 
was added and the mixture was stirred for an additional 72 h. The solution was quenched 
with NaSO3, diluted with H2O and EtOAc, extracted with EtOAc (4x), washed with brine, 
dried (MgSO4) and concentrated. The crude residue was purified by chromatography on 
SiO2 (EtOAc to 5% MeOH/EtOAc) to yield 810 mg (74%) of tetraol 5-32 as a colorless 
waxy solid: [α]D -33.4 (c 0.44, MeOH); IR (CH2Cl2) 3410, 3063, 2952, 2901, 1686, 1419, 
1216, 1056 cm-1; 1H NMR (MeOD, 600 MHz, rotamers) δ 7.42-7.26 (m, 5 H), 5.18 (d, 0.5 
H, J = 12.6 Hz), 5.15 (d, 0.5 H, J = 12.6 Hz), 5.14 (d, 0.5 H, J = 12.6 Hz), 4.99 (d, 0.5 H, J 
= 12.6 Hz), 4.41 (app ddd, 1 H, J = 19.8, 10.2, 1.2 Hz), 4.12-4.04 (m, 1 H), 3.96 (app dd, 1 
H, J = 16.8, 3.6 Hz), 3.92-3.87 (m, 0.5 H), 3.87-3.82 (m, 1.5 H), 3.71 (s, 1.5 H), 3.56 (s, 
1.5 H), 2.92 (app ddd, 1 H, J = 13.8, 10.8, 1.2 Hz), 2.37-2.29 (m, 0.5 H), 2.25-2.18 (m, 0.5 
H), 2.15 (app dd, 1 H, J = 14.4, 0.6 Hz), 1.63 (ddd, 0.5 H, J = 13.8, 10.8, 2.4 Hz), 1.59 
(ddd, 0.5 H, J = 13.8, 10.8, 2.4 Hz); 13C NMR (MeOD, 150 MHz, rotamers) δ 175.3, 
174.9, 156.6, 156.0, 138.0, 137.8, 129.5, 129.4, 129.1, 129.0, 129.0, 128.9, 82.3, 81.3, 
73.6, 706., 70.5, 68.2, 68.1, 63.6, 63.4, 58.8, 58.7, 52.8, 52.7, 38.5, 37.4, 32.1, 31.3; 
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ESIMS m/z 404 ([M+Na]+, 100), 365 (15); HRMS (ESI) m/z calcd for C18H23NO8Na 
(M+Na) 404.1321, found 404.1305. 
 
N
H
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H
O
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HO
5-33  
(2S,3aS,4S,5S,6R,7aR) - Methyl 3a,4,5,6 -tetrahydroxyoctahydro-1H-indole-2-
carboxylate (5-33). To a solution of 5-32 (456 mg, 1.20 mmol) in MeOH (10 mL) was 
added 10% Pd/C (63.4 mg). The reaction mixture was stirred under an atmosphere of H2 
for 10 h, filtered through a pad of Celite and concentrated to provide 251 mg (85%) of 
amine 5-33 as an off-white solid that was carried on without further purification: 1H NMR 
(MeOD, 600 MHz, crude) δ 3.95-3.87 (m, 1 H), 3.87 (app d, 1 H, J = 3.6 Hz), 3.81 (dd, 1 
H, J = 10.2, 4.2 Hz), 3.77 (dd, 1 H, J = 5.4, 3.6 Hz), 3.73 (s, 3 H), 3.37-3.27 (m, 1 H), 2.83 
(dd, 1 H, J = 13.8, 10.2 Hz), 1.99 (dd, 1 H, J = 13.8, 4.2 Hz), 1.86-1.76 (m, 1 H), 1.76-
1.67 (m, 1 H).   
 
N
OH
H
O
OHO
OH
HO
SO25-34
Br
 
(2S,3aS,4S,5S,6R,7aR) - Methyl 1 - (2 - bromophenylsulfonyl) - 3a,4,5,6 – tetra 
hydroxy-octahydro-1H-indole-2-carboxylate (5-34).  To a solution of 5-33 (24.7 mg, 
0.100 mmol) in THF (2 mL) at rt was added Et3N (15.3 µL, 0.110 mmol), 2-
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bromobenzenesulfonylchloride (25.6 mg, 0.100 mmol) and DMAP (2.44 mg, 0.0200 
mmol). The reaction mixture was stirred at this temperature for 17 h, quenched with 1 M 
HCl, extracted with EtOAc (4x), washed with brine, dried (MgSO4) and concentrated. The 
crude residue was purified by chromatography on SiO2 (EtOAc to 5% MeOH/EtOAc) to 
yield 26.3 mg (56%) of 5-34 as a colorless solid: Mp 182 ˚C (MeOH); [α]D +7.6 (c 1.8, 
MeOH; obtained for an 58% ee sample); IR (CH2Cl2) 3650-2800 (br), 1725, 1434, 1323, 
1158, 1102, 1054 cm-1; 1H NMR (MeOD) δ 8.24 (dd, 1 H, J = 7.5, 1.8 Hz), 7.81 (dd, 1 H, 
J = 7.5, 1.8 Hz), 7.57-7.43 (m, 2 H), 4.74 (dd, 1 H, J = 10.2, 1.5 Hz), 4.22 (dd, 1 H, J = 
10.8, 5.7 Hz), 3.96 (d, 1 H, J = 3.9 Hz), 3.82 (appt, 1 H, J = 3.9 Hz), 3.75-3.67 (m, 1 H), 
3.54 (s, 3 H), 3.09 (dd, 1 H, J = 14.1, 10.2 Hz), 2.15 (d, 1 H, J = 13.8 Hz), 1.90-1.63 (m, 2 
H); 13C NMR (MeOD) δ 175.6, 142.4, 136.8, 135.2, 133.3, 129.0, 122.1, 82.9, 73.4, 73.3, 
70.7, 67.0, 61.6, 53.1, 38.9, 32.4; HRMS (ESI) m/z calcd for C16H20NO8NaSBr (M+Na) 
487.9991, found 487.9994. 
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5-35
 
(2S,3aS,4S,5S,6S,7aR) - Methyl 3a,4,5,6-tetrahydroxy-1-(thiophen-2-ylmethyl) 
octahydro-1H-indole-2-carboxylate (5-35). A suspension of amine hydrochloride 5-28  
(40.0 mg, 0.141 mmol) in MeOH (2 mL), acetic acid (40.7 µL, 0.705 mmol, 5 eq), 
thiophene-2-carboxaldehyde (20.0 µL, 0.211 mmol, 1.5 eq) and MP-cyanoborohydride 
resin (2.34 mmol/g, 2.5 eq, 151 mg, 0.211 mmol) was stirred at rt for 48 h. The reaction 
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mixture was filtered, neutralized with 2 M NH3 in MeOH, concentrated and purified by 
chromatography on SiO2 (5% MeOH/EtOAc) to provide 38.2 mg (79%) of 5-35 as a 
colorless oil: [α]D -64.8 (c 1.06, CH2Cl2); IR (CH2Cl2) 3357, 2949, 1731, 1438, 1213, 
1068 cm-1; 1H NMR (MeOD) δ 7.34 (dd, 1 H, J = 5.1, 1.2 Hz), 7.06-6.99 (m, 1 H), 6.96 
(dd, 1 H, J = 5.1, 3.6 Hz), 4.13, 4.07 (AB, 2 H, J = 13.8 Hz), 3.98 (app t, 1 H, J = 2.7 Hz), 
3.73-3.57 (m, 3 H), 3.66 (s, 3 H), 3.24-3.07 (m, 2 H), 1.95-1.67 (m, 3 H); 13C NMR 
(MeOD) δ 177.9, 143.3, 127.3, 127.3, 126.4, 82.4, 74.8, 73.6, 69.4, 66.5, 62.4, 52.7, 39.1, 
27.2; ESI-MS m/z 366 ([M+Na]+, 30), 344 ([M+H]+, 10); HRMS (ESI) m/z calcd for 
C15H22NO6S (M+H) 344.1168, found 344.1184. 
 
N
OH
H
O
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HO
5-36  
(2S,3aS,4S,5S,6R,7aR) - Methyl 1 - (cyclopropylmethyl) -3a,4,5,6-tetrahydroxy 
octahydro-1H-indole-2-carboxylate (5-36). To a solution of 5-33 (50.0 mg, 0.202 mmol) 
in MeOH (2 mL) was added acetic acid (57.9 µL, 1.01 mmol, 5 eq), 
cyclopropanecarboxaldehyde (23.1 µL, 0.303 mmol, 1.5 eq) and MP-cyanoborohydride 
resin (2.34 mmol/g, 2.5 eq, 216 mg, 0.506 mmol). The reaction mixture was stirred at rt 
for 48 h, filtered, neutralized with 2 M NH3 in MeOH, concentrated and purified by 
chromatography on SiO2 (5% MeOH/EtOAc) to provide 49.0 mg (80%) of 5-36 as a 
colorless oil: [α]D -69.1 (c 1.05, CH2Cl2); IR (CH2Cl2) 3334, 3001, 2950, 1733, 1438, 
1213, 1062 cm-1; 1H NMR (MeOD) δ 3.97-3.75 (m, 4 H), 3.77 (s, 3 H), 3.51 (app t, 1 H, J 
= 6.0 Hz), 2.99 (dd, 1 H, J = 13.8, 10.5 Hz), 2.80 (dd, 1 H, J = 12.6, 5.7 Hz), 2.35 (dd, 1 
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H, J = 12.6, 7.8 Hz), 1.99-1.71 (m, 3 H), 1.00-0.81 (m, 1 H), 0.63-0.40 (m, 2 H), 0.24-0.06 
(m, 2 H); 13C NMR (MeOD) δ 177.1, 80.9, 75.8, 74.4, 69.1, 66.6, 62.2, 54.6, 52.8, 39.9, 
27.8, 10.7, 4.6; EIMS m/z 302 ([M+H]+, 5), 284 (100), 230 (50), 224 (70); HRMS (EI) m/z 
calcd for C14H23NO6 302.1604, found 302.1615. 
 
N
OH
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5-37
 
(2S,3aS,4S,5S,6R,7aR) - Methyl 3a,4,5,6 - tetrahydroxy-1-(pyridin-3-ylmethyl) 
octahydro-1H-indole-2-carboxylate (5-37). To a solution of 5-33 (50.0 mg, 0.202 mmol) 
in MeOH (2 mL) was added acetic acid (57.9 µL, 1.01 mmol, 5 eq), pyridine-3-
carboxaldehyde (29.1 µL, 0.303 mmol, 1.5 eq) and MP-cyanoborohydride resin (2.34 
mmol/g, 2.5 eq, 216 mg, 0.506 mmol). The reaction mixture was stirred at rt for 48 h, 
filtered, neutralized with 2 M NH3 in MeOH, concentrated in vacuo and purified by 
chromatography on SiO2 (short plug, 5% MeOH/EtOAc to 10% MeOH/EtOAc) to yield 
51.0 mg (75%) of 5-37 as a colorless oil: [α]D -32.6 (c 0.95, CH2Cl2); IR (CH2Cl2) 3319, 
2949, 1730, 1432, 1365, 1211, 1063 cm-1; 1H NMR (MeOD) δ 8.40 (bs, 1 H), 8.30 (d, 1 
H, J = 3.9 Hz), 7.78 (d, 1 H, J = 7.5 Hz), 7.27 (dd, 1 H, J = 7.5, 4.8 Hz), 3.92-3.64 (m, 5 
H), 3.52-3.40 (m, 1 H), 3.44 (s, 3 H), 3.30-3.21 (m, 1 H), 2.87 (dd, 1 H, J = 13.8, 10.5 
Hz), 1.80-1.61 (m, 3 H); 13C NMR (MeOD) δ 177.4, 150.5, 149.0, 139.1, 136.7, 125.3, 
81.8, 74.6, 74.2, 69.7, 66.0, 62.6, 52.5, 51.1, 39.6, 27.5; ESI-MS m/z 339 ([M+H]+, 10), 
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321 (100), 261 (30), 246 (40); HRMS (ESI) m/z calcd for C16H22N2O6 (M+H) 339.1556, 
found 339.1544. 
N
Cbz
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H
CO2Me
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O
5-50  
 (2S,3aR,7aR) - 1 - Benzyl 2 - methyl 3a -(allyloxycarbonyloxy)-6-oxo-3,3a,7,7a 
- tetrahydro-1H-indole-1,2(2H,6H)-dicarboxylate (5-50). To a solution of 5-5 (7.00 g, 
20.3 mmol) in THF (190 mL) was added NaH (60% in mineral oil, 1.2 eq, 973 mg, 24.3 
mmol) and the reaction mixture stirred at rt for 30 min followed by addition of  
allylchloroformate (2.0 eq, 4.44 mL, 40.5 mmol).  The reaction mixture was stirred at rt 
for 4.5 h, quenched with sat. aq. NH4Cl, extracted with EtOAc (2x), washed with brine, 
dried (MgSO4), filtered and concentrated. The crude residue was purified by 
chromatography on SiO2 (40% EtOAc/hexanes) to yield 7.11 g (82%) of 5-50 as a 
colorless oil: [α]D -30.7 (c 0.9, CHCl3); IR (CH2Cl2) 2953, 2919, 2851, 1743, 1705, 1680, 
1410, 1244, 1229, 1034 cm-1; 1H NMR (CDCl3, 600 MHz, rotamers) δ 7.39-7.26 (m, 5 H), 
6.93 (d, 0.5 H, J = 8.4 Hz), 6.91 (d, 0.5 H, J = 8.4 Hz), 6.11 (d, 0.5 H, J = 10.2 Hz), 6.10 
(d, 0.5 H, J = 10.8 Hz), 5.93-5.84 (m, 1 H), 5.36 (dd, 0.5 H, J = 2.4, 1.2 Hz), 5.33 (dd, 0.5 
H, J = 3.0, 0.6 Hz), 5.28 (d, 0.5 H, J = 1.8 Hz), 5.26 (d, 0.5 H, J = 1.8 Hz), 5.22 (d, 0.5 H, 
J = 12.0 Hz), 5.20 (d, 0.5 H, J = 12.0 Hz), 5.12 (d, 0.5 H, J = 12.0 Hz), 5.03 (d, 0.5 H, J = 
12.0 Hz), 4.89 (dd, 0.5 H, J = 9.6, 6.6 Hz), 4.84 (dd, 0.5 H, J = 10.2, 6.6 Hz), 4.67 (d, 0.5 
H, J = 9.0 Hz), 4.61-4.55 (m, 2.5 H), 3.74 (s, 1.5 H), 3.56 (s, 1.5 H), 3.37 (dd, 0.5 H, J = 
16.8, 6.6 Hz), 3.20 (dd, 0.5 H, J = 16.8, 6.6 Hz), 2.93 (d, 0.5 H, J = 14.4 Hz), 2.88 (d, 0.5 
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H, J = 14.4 Hz), 2.61 (dd, 0.5 H, J = 13.8, 9.0 Hz), 2.56 (dd, 0.5 H, J = 14.4, 9.6 Hz), 2.43 
(dd. 0.5 H, J = 16.8, 10.2 Hz), 2.33 (dd, 0.5 H, J = 16.8, 10.8 Hz); 13C NMR (CDCl3, 150 
MHz, rotamers) δ 194.6, 194.5, 171.1, 170.5, 153.9, 153.6, 152.6, 152.5, 143.6, 143.2, 
135.9, 135.7, 130.9, 130.6, 130.3, 128.5, 128.4, 128.3, 128.2, 128.1, 128.1, 119.3, 119.2, 
84.8, 83.5, 68.6, 67.7, 67.3, 61.3, 60.8, 58.3, 58.1, 52.5, 52.3, 42.6, 41.4, 39.5, 38.3. 
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5-40  
 (2S,3aR,7R,7aR) - 1 - Benzyl 2 - methyl 7 – allyl - 3a -hydroxy-6-oxo-3,3a,7,7a-
tetrahydro-1H-indole-1,2(2H,6H)-dicarboxylate (5-40).  To a solution of 5-50 (99.1 
mg, 0.231 mmol) in THF (5 mL) at 0 °C was added LiHMDS (41.8 mg, 0.243 mmol) and 
the resulting yellow solution stirred for 20 min. To this reaction mixture was added 
Pd(PPh3)4 (20 mol %, 53.3 mg, 0.0462 mmol) and the reaction stirred at 0 °C for an 
additional 30 min. The reaction mixture was quenched with sat. aq. NH4Cl, washed with 
brine, dried (MgSO4), filtered and concentrated. The crude residue was purified by 
chromatography on SiO2 (50% EtOAc/hexanes) to yield 59.0 mg (66%) of 5-40 as a light 
yellow oil: [α]D -21.2 (c 1.2, CHCl3); IR (CH2Cl2) 3419, 2955, 1682, 1408, 1341, 1213, 
1121, 916 cm-1; 1H NMR (CDCl3, 600 MHz, rotamers) δ 7.41-7.29 (m, 5 H), 6.81 (d, 0.5 
H, J = 10.2 Hz), 6.80 (d, 0.5 H, J = 10.2 Hz), 6.03 (d, 0.5 H, J = 12.0 Hz), 6.01 (d, 0.5 H, J 
= 12.0 Hz), 5.93-5.83 (m, 0.5 H), 5.72-5.60 (m, 0.5 H), 5.23-5.16 (m, 2 H), 5.12 (d, 0.5 H, 
J = 12.0 Hz), 5.05 (d, 0.5 H, J = 10.8 Hz), 5.01 (d, 0.5 H, J = 12.0 Hz), 4.94-4.85 (m, 1 
H), 4.79 (s, 0.5 H), 4.57 (d, 0.5 H, J = 10.8 Hz), 4.51 (d, 0.5 H, J = 10.2 Hz), 4.47 (d, 0.5 
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H, J = 9.6 Hz), 4.41 (d, 0.5 H, J = 10.8 Hz), 3.88 (s, 1.5 H), 3.44 (s, 1.5 H), 2.70-2.61 (m, 
1 H), 2.59 (d, 0.5 H, J = 10.2 Hz), 2.57 (d, 0.5 H, J = 10.2 Hz), 2.50-2.43 (m, 0.5 H), 2.43-
2.35 (m, 1 H), 2.33-2.23 (m, 1.5 H); 13C NMR (CDCl3, 150 MHz, rotamers) δ 197.1, 
197.0, 175.5, 175.2, 154.9, 154.3, 147.2, 147.2, 135.4, 135.2, 135.1, 129.1, 129.0, 128.6, 
128.5, 128.4, 117.4, 117.0, 77.1, 76.1, 69.9, 69.5, 68.2, 67.9, 59.0, 58.6, 53.4, 52.9, 52.7, 
52.6, 41.3, 40.1, 30.5, 30.0; EIMS m/z 385 ([M]+, 65), 344 (45), 282 (100), 250 (45); 
HRMS (EI) m/z calcd for C21H23NO6 385.1525, found 385.1533. 
 
N
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5-53  
(2S,3aR,4S,7aR) - 1-Benzyl 2-methyl 3a-hydroxy-6-oxo-4-vinylhexahydro-1H-
indole-1,2(2H,3H)-dicarboxylate (5-53).  To a suspension of AlCl3 (11.7 g, 86.9 mmol) 
in CH2Cl2 (50 mL) at 0 °C was added vinylmagnesium chloride (1.6 M in THF, 163 mL, 
261 mmol) dropwise. The reaction mixture was stirred at 0 ˚C for 4 h followed by addition 
of 5-5 (10.0 g, 29.0 mmol) in CH2Cl2 (25 mL) in one portion and the mixture was allowed 
to stir for an additional 4 h at this temperature. The reaction mixture was carefully 
quenched with 10% aq. HCl, extracted with EtOAc (3x), washed with brine, dried 
(MgSO4) and concentrated. The crude residue was purified by chromatography on SiO2 
(40% EtOAc/hexanes to 50% EtOAc/hexanes) to yield 6.79 g (63%) of 5-53 as a light 
yellow oil that was > 95:5 dr by 1H NMR analysis of the crude reaction mixture: [α]D -
25.9 (c 1.1, CHCl3); IR (CH2Cl2) 3452, 2953, 1749, 1702, 1406, 1349, 1206, 1115 cm-1; 
1H NMR (CD2Cl2, 600 MHz, rotamers) δ 7.41-7.27 (m, 5 H), 5.98-5.90 (m, 1 H), 5.25-
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5.11 (m, 3.4 H), 5.01 (d, 0.6 H, J = 12 Hz), 4.54 (s, 0.4 H), 4.53 (s, 0.6 H), 4.13-4.03 (m, 1 
H), 3.76 (s, 1.4 H), 3.59 (s, 1.6 H), 3.37 (bs, 0.4 H), 3.12 (dd, 0.6 H, J = 16.2, 5.4 Hz), 
3.07 (bs, 0.6 H), 2.95 (dd, 0.4 H, J = 16.2, 4.8 H), 2.67-2.59 (m, 1 H), 2.57-2.45 (m, 1 H), 
2.40 (d, 0.4 H, J = 9.0 Hz), 2.38 (d, 0.6 H, J = 9.0 Hz), 2.32-2.18 (m, 3 H); 13C NMR 
(CD2Cl2, 150 MHz, rotamers) δ 208.2, 208.1, 174.8, 174.5, 154.9, 154.3, 136.4, 135.3, 
135.2, 128.6, 128.5, 128.2, 128.2, 128.0, 128.0, 117.7, 117.5, 80.6, 79.4, 67.5, 67.2, 65.3, 
64.7, 59.4, 59.2, 52.8, 52.6, 46.0, 43.4, 42.3, 41.7, 40.6, 40.6, 40.5; EIMS m/z 373 ([M]+, 
20), 355 (40), 314 (60), 270 (100), 92 (90); HRMS (EI) m/z calcd for C20H23NO6 
373.1525, found 373.1522. 
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5-63  
(3aS,6aR,8S,91R) - 7 - Benzyl 8 - methyl 3-methyl-2,5-dioxooctahydrofuro[2,3-
d]indole-7,8(2H)-dicarboxylate (5-63).  To a solution of 5-5 (1.00 g, 2.90 mmol) in 
toluene (30 mL) at 0 °C was added 2-bromopropionic acid (1.05 eq, 275 µL, 3.04 mmol) 
and DMAP (10 mol%, 35.4 mg, 0.290 mmol). To this reaction mixture was added a 
solution of DCC (1.05 eq, 683 mg, 304 mmol) in toluene (10 mL) over the course of 1 h. 
After addition was complete the reaction mixture was stirred for an additional 3 h, 
quenched with sat. aq. NH4Cl, washed with NaHCO3, washed with brine, dried (MgSO4), 
filtered and concentrated. The crude residue was purified by chromatography on SiO2 
(40% EtOAc/hexanes) to yield 1.17 g (84%) of α-bromo ester 5-61 as a colorless oil. 
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To a solution of 5-61 (1.05 g, 2.19 mmol) in toluene (300 mL) at 100 °C was 
added Bu3SnH (1.03 mL, 3.72 mmol, 1.7 eq.) and AIBN (10 mol%, 35.9 mg, 0.219 mmol) 
in toluene (20 mL) via syringe pump over 15 h. The reaction mixture was cooled to rt, 
concentrated in vacuo and the crude residue purified by chromatography on SiO2 (70% 
EtOAc/hexanes) to yield 640 mg (73%) of 5-63 as a colorless solid: [α]D -42.4 (c 1.0, 
CHCl3); IR (CH2Cl2) 2953, 1775, 1699, 1408, 1346, 1202, 1166, 1113, 1035 cm-1; 1H 
NMR (CDCl3, 600 MHz, rotamers) δ 7.32-7.21 (m, 5 H), 5.16-5.08 (m, 1.45 H), 4.96 (d, 
0.55 H, J = 12.0 Hz), 4.59 (d, 0.45 H, J = 9.0 Hz), 4.54 (d, 0.55 H, J = 9.0 Hz), 4.31 (dd, 
0.55 H, J = 11.4, 6.0 Hz), 4.24 (dd, 0.45 H, J = 12.0, 6.0 Hz), 3.69 (s, 1.35 H), 3.54 (s, 
1.65 H), 3.18 (dd, 0.55 H, J = 16.2, 5.4 Hz), 2.96 (dd, 0.45 H, J = 15.6, 5.4 Hz), 2.65 (d, 
0.45 H, J = 9.6 Hz), 2.62 (d, 0.55 H, J = 9.6 Hz), 2.56-2.46 (m, 2 H), 2.43-2.36 (m, 1 H), 
2.36-2.25 (m, 2 H), 2.17-2.09 (m, 1 H), 1.25 (d, 1.65 H, J = 7.2 Hz), 1.24 (d, 1.35 H, 6.6 
Hz); 13C NMR (CDCl3, 150 MHz, rotamers) δ 205.1, 205.1, 175.8, 175.6, 170.9, 170.3, 
153.8, 153.7, 135.8, 135.7, 128.6, 128.4, 128.3, 128.2, 128.2, 128.1, 88.4, 87.5, 67.7, 67.4, 
61.7, 61.3, 58.2, 58.2, 52.7, 52.6, 44.4, 44.3, 43.6, 42.4, 40.9, 40.8, 40.5, 40.2, 40.1, 38.7, 
15.2, 15.0; EIMS m/z 401 ([M]+, 25), 342 (50), 298 (90), 266 (35), 208 (25); HRMS (EI) 
m/z calcd for C21H23NO7 401.1475, found 401.1461. 
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5-64  
(3a'S,6a'R,8'S,91'R) - 7' - Benzyl 8' - methyl 3' – methyl - 2' – oxohexahydro -
2'H-spiro [[1,3] dioxolane-2,5'-furo[2,3-d]indole]-7',8'(3'H)-dicarboxylate (5-64).  To 
a solution of 5-63 (4.65 g. 11.6 mmol) in benzene (150 mL) was added ethylene glycol (5 
eq, 3.23 mL, 57.9 mmol) and PPTS (728 mg, 2.90 mmol) and the resulting solution was 
heated at reflux for 2 h (azeotropically removing water via a Dean-Stark apparatus). The 
reaction mixture was cooled to rt and the benzene removed in vacuo to provide a colorless 
solid. The solid was dissolved in EtOAc (required heating), washed with NaHCO3, 
washed with brine, dried (MgSO4), filtered and concentrated to yield 4.89 g (94%) of 5-64 
as a colorless solid: [α]D -31.2 (c 1.1, CHCl3); IR (CH2Cl2) 2976, 2934, 2883, 1761, 1713, 
1411, 1342, 1196, 1130, 1047, 990 cm-1; 1H NMR (d6-DMSO, 600 MHz, 1:1 ratio of 
rotamers) δ 7.46-7.31 (m, 5 H), 5.22 (d, 0.5 H, J = 12.6 Hz), 5.13 (d, 0.5 H, J = 12.6 Hz), 
5.09 (d, 0.5 H, J = 12.6 Hz), 5.03 (d, 0.5 H, J = 12.6 Hz), 4.56 (d, 0.5 H, J = 10.2 Hz), 
4.49 (d, 0.5 H, J = 10.2 Hz), 4.03-3.74 (m, 5 H), 3.68 (s, 1.5 H), 3.60 (s, 1.5 H), 3.08-2.95 
(m, 2 H), 2.52-2.44 (m, 1 H), 2.34 (ddd, 0.5 H, J = 13.2, 6.0, 2.4 Hz), 2.25 (d, 0.5 H, J = 
14.4 Hz), 2.21 (d, 0.5 H, J = 15.0 Hz), 2.19 (ddd, 0.5 H, 13.2, 5.4, 2.4 Hz), 1.94-1.78 (m, 2 
H), 1.56 (d, 0.5 H, J = 12.6 Hz), 1.54 (d, 0.5 H, J = 12.6 Hz), 1.13 (d, 1.5 H, J = 6.6 Hz), 
1.11 (d, 1.5 H, J = 7.2 Hz); 13C NMR (d6-DMSO, 150 MHz, rotamers) δ 177.8, 177.8, 
172.1, 171.5, 154.2, 154.1, 137.5, 129.4, 129.3, 129.0, 128.8, 128.7, 128.3, 107.8, 107.7, 
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88.8, 87.7, 67.3, 67.2, 65.3, 65.2, 64.2, 64.0, 62.4, 62.0, 57.7, 57.6, 52.9, 52.9, 43.8, 43.8, 
39.2, 39.2, 38.3, 37.8, 37.2, 37.1, 30.8, 30.8, 13.8, 13.8.  
 
N
Cbz
OH
H
CO2Me
OTBDPS
O
5-66  
(2S,3aR,4S,7aR)-1-Benzyl 2-methyl 4-(1-(tert-butyldiphenylsilyloxy) propan-2-
yl)-3a-hydroxy-6-oxohexahydro-1H-indole-1,2(2H,3H)-dicarboxylate (5-66).  To a 
solution of 5-64 (4.89 g, 10.9 mmol) in THF (120 mL) at -78 ˚C was added DIBAL-H (1.0 
M in hexanes, 12.0 mL, 12.0 mmol) in one portion. The reaction mixture was allowed to 
warm to rt and stirred at this temp for 18 h. The reaction mixture was carefully quenched 
with 10% aq. HCl, extracted with EtOAc (3x), washed with brine, dried (MgSO4), filtered 
and concentrated. The crude residue was dissolved in MeOH/H20 (80 mL, 10:1) and 
NaBH4 (4.0 eq, 1.65 g, 43.7 mmol) was added in 4 portions. The reaction mixture was 
heated to 70 ˚C and stirred at this temperature for 8 h, diluted with EtOAc (200 mL), 
washed with sat. aq. NaHCO3, washed with brine, dried (MgSO4), filtered and 
concentrated to provide 2.37 g (48%) of crude 5-65 as an off-white solid. 
To a solution of 5-65 (1.75 g, 3.88 mmol) in dichloromethane/DMF (5:1, 30 mL) 
was added imidazole (267 mg, 3.88 mmol) and TBDPSCl (1.03 mL, 3.88 mL) and the 
resulting reaction mixture was stirred at rt for 6 h. The reaction mixture was filtered 
through a pad of silica gel (washed with EtOAc) and concentrated to provide 2.25 g (84%) 
of crude ketal as a light yellow oil.  
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To a solution of crude ketal (2.12 g, 3.07 mmol) in acetone (40 mL) was added 
PPTS (77.0 mg, 0.306 mmol) and water (0.1 mL) and the reaction mixture was heated to 
reflux and stirred at this temperature for 14 h. The reaction mixture was concentrated, 
dissolved in EtOAc, washed with sat. aq. NaHCO3, washed with brine, dried (MgSO4), 
filtered and concentrated. The crude residue was purified by chromatography on SiO2 
(30% EtOAc/hexanes) to provide 1.87 g (94%) of 5-66 as a colorless oil: 1H NMR 
(CDCl3, 600 MHz, 1:1 ratio of rotamers) δ 7.65-7.58 (m, 4 H), 7.47-7.28 (m, 11 H), 5.22 
(d, 0.5 H, J = 12.6 Hz), 5.21 (d, 0.5 H, J = 12.0 Hz), 5.13 (d, 0.5 H, J = 12.6 Hz), 5.02 (d, 
0.5 H, 12.0 Hz), 4.54 (d, 0.5 H, J = 9.6 Hz), 4.51 (d, 0.5 H, J = 9.0 Hz), 4.16 (dd, 0.5 H, J 
= 13.2, 4.8 Hz), 4.09 (dd, 0.5 H, J = 13.2, 4.8 Hz), 4.01 (s, 0.5 H), 3.82 (s, 1.5 H), 3.76 (s, 
0.5 H), 3.58 (s, 1.5 H), 3.55 (app dd, 1 H, J = 10.8, 4.2 Hz), 3.39 (app dd, 1 H, J = 9.6, 9.6 
Hz), 3.18 (dd, 0.5 H, J = 16.8, 5.4 Hz), 2.93 (dd, 0.5 H, J = 16.8, 4.2 Hz), 2.43-2.19 (m, 3 
H), 2.18-2.03 (m, 4 H), 1.05 (s, 4.5 H), 1.05 (s, 4.5 H), 0.90 (d, 1.5 H, J = 7.2 Hz), 0.89 (d, 
1.5 H, J = 6.6 Hz); 13C NMR (CDCl3, 150 MHz, rotamers) δ 210.0, 209.7, 175.4, 175.1, 
154.9, 154.1, 135.9, 135.9, 135.5, 133.2, 133.1, 133.1, 133.0, 129.9, 129.8, 128.6, 128.5, 
128.3, 128.2, 128.1, 128.1, 127.8, 127.8, 82.4, 81.3, 67.7, 67.4, 67.1, 67.0, 66.1, 65.4, 
59.5, 59.2, 53.0, 52.7, 43.1, 42.1, 42.1, 41.3, 41.1, 41.0, 37.5, 37.3, 35.4, 35.3, 26.9, 19.1, 
13.9, 13.8. 
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5-67  
(2S,3aR,4R,5S,7aR)-1-Benzyl 2-methyl 5-allyl-4-(1-(tert-butyldiphenylsilyloxy) 
propan-2-yl)-3a-hydroxy-6-oxohexahydro-1H- indole - 1,2(2H,3H) - dicarboxylate (5-
67).  To a solution of 5-66 (725 mg, 1.12 mmol) in THF (15 mL) at -78 ˚C was added 
LiHMDS (2.5 eq, 474 mg, 2.81 mmol) and the resulting yellow solution stirred at this 
temperature for 1 h. Allyl iodide (5.0 eq, 531 µL, 5.61 mmol) was then added in one 
portion and the reaction mixture allowed to warm to -40 ˚C and stirred at this temperature 
for 5 h. The reaction mixture was quenched at this temperature with sat. aq. NH4Cl, 
extracted with EtOAc (3x), washed with brine, dried (MgSO4), filtered and concentrated. 
The crude residue was purified by chromatography on SiO2 (15% EtOAc/hexanes) to 
yield 457 mg (59%) of 5-67 as a light yellow oil: 1H NMR (CDCl3, 600 MHz, 1:1 ratio of 
rotamers) δ 7.70-7.61 (m, 4 H), 7.49-7.28 (m, 11 H), 5.69-5.57 (m, 1 H), 5.22 (d, 0.5 H, J 
= 12.0 Hz), 5.21 (d, 0.5 H,  J = 12.6 Hz), 5.13 (d, 0.5 H, J = 12.6 Hz), 5.01 (d, 0.5 H, J = 
12.6 Hz), 4.99-4.92 (m, 2 H), 4.56 (s, 0.5 H), 4.49 (d, 0.5 H, J = 9.0 Hz), 4.46 (s, 0.5 H), 
4.45 (d, 0.5 H, J = 8.4 Hz), 4.22 (dd, 0.5 H, J = 9.6, 6.6 Hz), 4.16-4.09 (m, 0.5 H), 3.79 (s, 
1.5 H), 3.75-3.69 (m, 1 H), 3.60-3.54 (m,  1 H), 3.56 (s, 1.5 H), 3.15 (dd, 0.5 H, J = 15.6, 
6.6 Hz), 2.95 (dd, 0.5 H, J = 15.6, 6.0 Hz), 2.54-2.41 (m, 2 H), 2.40-2.26 (m, 3 H), 2.26-
2.11 (m, 3 H), 1.11-1.03 (m, 3 H), 1.07 (s, 9 H); 13C NMR (CDCl3, 150 MHz, rotamers) δ 
211.1, 174.5, 174.3, 154.8, 154.1, 136.1, 136.0, 135.8, 135.6, 134.9, 134.7, 132.9, 132.8, 
132.8, 130.0, 129.9, 129.9, 128.6, 128.5, 128.3, 128.2, 128.1, 127.8, 127.8, 117.7, 117.6, 
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81.2, 79.8, 67.6, 67.3, 66.0, 65.9, 65.4, 64.7, 52.9, 52.5, 46.8, 46.7, 46.2, 45.9, 43.6, 42.8, 
42.4, 35.2, 35.0, 33.0, 32.8, 26.9, 19.2, 15.7, 15.6, 14.2.  
 
N
Cbz
O
H
CO2Me
O
O
5-69
 
(3aS,6R,6aR,8S,91R) – 7 - Benzyl 8 - methyl 6 – allyl – 3 – methyl - 2,5 – dioxo 
octahydrofuro [2,3-d]indole-7,8(2H)-dicarboxylate (5-69).  To a solution of 5-40 (127 
mg, 0.330 mmol) in toluene (12 mL) at 0 °C was added 2-bromopropionic acid (1.05 eq, 
32.4 µL, 0.346 mmol) and DMAP (10 mol%, 4.03 mg, 0.0330 mmol). To the resulting 
reaction mixture was added a solution of DCC (1.0 eq, 68.0 mg, 0.330 mmol) in toluene (3 
mL) over the course of 1 h and the reaction mixture was stirred for an additional 2 h. The 
reaction mixture was washed with sat. aq. NH4Cl, washed with NaHCO3, washed with 
brine, dried (MgSO4), filtered and the toluene solution was carried on to the next step 
without concentration or further purification. 
To a solution of 5-68 (171 mg, 0.329 mmol) in toluene (20 mL) at 90 °C was 
added a solution of Bu3SnH (2.0 eq, 182 µL, 0.657 mmol) and AIBN (10 mol%, 5.4 mg, 
0.0329 mmol) in toluene (1 mL) via syringe pump over 5 h. The reaction mixture was 
cooled to rt, concentrated in vacuo and the crude residue purified by chromatography on 
SiO2 (60% EtOAc/hexanes) to yield 85.0 mg (59%, 2 steps) of 5-69 as a colorless solid: 
IR (CH2Cl2) 2951, 1760, 1708, 1406, 1340, 1216, 1166, 1121, 1010 cm-1; 1H NMR 
(CDCl3, 600 MHz, 6:4 mixture of rotamers – contains EtOAc and tin by-product) δ 7.40-
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7.28 (m, 5 H), 5.84-5.74 (m, 0.6 H), 5.64-5.56 (m, 0.4 H), 5.25-4.82 (m, 4 H), 4.63-4.57 
(m, 1 H), 4.35 (d, 0.6 H, J = 10.8 Hz), 4.15 (d, 0.4 H, J = 10.8 Hz), 3.79 (s, 1.2 H), 3.54 (s, 
1.8 H), 2.95-2.86 (m, 1 H), 2.75-2.58 (m, 2 H), 2.58-2.25 (m, 7 H), 1.33-1.24 (m, 3 H). 
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Table 6-1. Crystal data and structure refinement for 1-51. 
Identification code  1-51 
Empirical formula  C30 H28 N O3 P 
Formula weight  481.50 
Temperature  295(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 10.4622(16) Å α= 90°. 
b = 24.020(4) Å β= 99.629(4)°. 
c = 10.5456(17) Å γ = 90°. 
Volume 2612.8(7) Å3 
Z 4 
Density (calculated) 1.224 Mg/m3 
Absorption coefficient 0.136 mm-1 
F(000) 1016 
Crystal size 0.37 x 0.03 x 0.03 mm3 
Theta range for data collection 1.70 to 22.50°. 
Index ranges -11<=h<=11, -25<=k<=25, -11<=l<=11 
Reflections collected 16213 
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Independent reflections 3414 [R(int) = 0.3255] 
Completeness to theta = 22.50° 100.0 % 
Absorption correction sadabs 
Max. and min. transmission 0.9959 and 0.9513 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3414 / 0 / 161 
Goodness-of-fit on F2 1.156 
Final R indices [I>2sigma(I)] R1 = 0.2114, wR2 = 0.3576 
R indices (all data) R1 = 0.2941, wR2 = 0.3990 
Largest diff. peak and hole 0.537 and -0.545 e.Å-3 
 
 
Table 6-2.  Atomic coordinates and equivalent isotropic displacement parameters for 1-51. 
Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for 1-51.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
                                                        x                         y                     z                       U(eq) 
________________________________________________________________________________ 
P 4252(4) 2444(2) 2(3) 15(1) 
N 5334(10) 2294(4) 1261(10) 13(3) 
O(1) 4832(10) 2431(5) -1173(9) 41(3) 
C(1) 3486(16) 3496(7) -765(16) 37(5) 
O(2) 9718(13) 4709(5) 1589(15) 67(5) 
C(2) 2950(20) 4030(10) -650(20) 79(7) 
C(3) 2560(20) 4154(11) 430(20) 76(7) 
O(3) 8385(17) 4885(6) 2962(19) 103(7) 
C(4) 2550(20) 3789(9) 1430(20) 65(6) 
C(5) 3044(19) 3260(9) 1320(20) 58(6) 
C(6) 3510(14) 3133(6) 211(14) 23(4) 
C(7) 1726(16) 2035(8) -513(16) 40(5) 
C(8) 804(19) 1660(8) -586(17) 46(5) 
C(9) 1110(20) 1136(9) -120(18) 57(6) 
C(10) 2290(20) 1008(9) 432(19) 60(6) 
C(11) 3290(18) 1400(7) 480(16) 41(5) 
C(12) 2977(16) 1961(7) -6(15) 30(4) 
C(13) 6738(16) 2363(7) 1314(16) 38(5) 
C(14) 7427(15) 1935(6) 2284(15) 26(4) 
C(15) 8860(30) 1946(14) 2370(30) 122(11) 
C(16) 9840(20) 1751(10) 2650(20) 72(7) 
C(17) 6930(20) 1060(9) 1000(20) 61(6) 
C(18) 6480(20) 516(10) 830(20) 73(7) 
C(19) 6010(20) 270(10) 1780(20) 75(7) 
C(20) 5970(20) 558(9) 2920(20) 64(6) 
C(21) 6434(18) 1097(8) 3080(19) 52(6) 
C(22) 6912(17) 1351(7) 2060(16) 37(5) 
C(23) 6667(17) 3306(7) 2227(16) 36(4) 
C(24) 7190(17) 3835(8) 2462(17) 42(5) 
C(25) 8235(16) 4009(7) 1896(15) 29(4) 
C(26) 8793(17) 3640(7) 1148(16) 37(5) 
C(27) 8287(14) 3121(6) 936(14) 25(4) 
C(28) 7241(14) 2943(6) 1494(14) 22(4) 
C(29) 8750(19) 4569(9) 2263(19) 47(5) 
C(30) 10300(20) 5233(10) 1940(20) 78(7) 
_______________________________________________________________________________ 
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Table 6-3. Bond lengths [Å] and angles [°] for 1-
51. 
 
 
 
 
______________________________________________  
P-O(1)  1.468(10) C(3)-C(2)-C(1) 118(2) 
P-N  1.635(11) C(2)-C(3)-C(4) 124(3) 
P-C(12)  1.767(16) C(3)-C(4)-C(5) 118(2) 
P-C(6)  1.858(15) C(6)-C(5)-C(4) 118(2) 
N-C(13)  1.470(19) C(1)-C(6)-C(5) 123.0(17) 
C(1)-C(6)  1.35(2) C(1)-C(6)-P 116.2(12) 
C(1)-C(2)  1.41(3) C(5)-C(6)-P 120.8(14) 
O(2)-C(29)  1.37(2) C(8)-C(7)-C(12) 126.2(19) 
O(2)-C(30)  1.42(2) C(7)-C(8)-C(9) 119(2) 
C(2)-C(3)  1.30(3) C(10)-C(9)-C(8) 121(2) 
C(3)-C(4)  1.37(3) C(9)-C(10)-C(11) 120(2) 
O(3)-C(29)  1.16(2) C(10)-C(11)-C(12) 119.1(17) 
C(4)-C(5)  1.38(3) C(7)-C(12)-C(11) 114.2(16) 
C(5)-C(6)  1.37(2) C(7)-C(12)-P 126.9(14) 
C(7)-C(8)  1.31(2) C(11)-C(12)-P 118.7(13) 
C(7)-C(12)  1.34(2) N-C(13)-C(28) 116.1(13) 
C(8)-C(9)  1.37(2) N-C(13)-C(14) 107.7(13) 
C(9)-C(10)  1.32(3) C(28)-C(13)-C(14) 115.0(13) 
C(10)-C(11)  1.40(2) C(15)-C(14)-C(22) 110.8(18) 
C(11)-C(12)  1.46(2) C(15)-C(14)-C(13) 112.6(18) 
C(13)-C(28)  1.49(2) C(22)-C(14)-C(13) 113.7(13) 
C(13)-C(14)  1.54(2) C(16)-C(15)-C(14) 151(3) 
C(14)-C(15)  1.48(3) C(22)-C(17)-C(18) 123(2) 
C(14)-C(22)  1.51(2) C(19)-C(18)-C(17) 119(2) 
C(15)-C(16)  1.12(3) C(18)-C(19)-C(20) 120(2) 
C(17)-C(22)  1.32(2) C(21)-C(20)-C(19) 121(2) 
C(17)-C(18)  1.39(3) C(20)-C(21)-C(22) 118.4(19) 
C(18)-C(19)  1.32(3) C(17)-C(22)-C(21) 118.6(18) 
C(19)-C(20)  1.40(3) C(17)-C(22)-C(14) 124.7(17) 
C(20)-C(21)  1.38(3) C(21)-C(22)-C(14) 116.7(16) 
C(21)-C(22)  1.40(2) C(28)-C(23)-C(24) 119.1(17) 
C(23)-C(28)  1.37(2) C(23)-C(24)-C(25) 120.7(17) 
C(23)-C(24)  1.39(2) C(26)-C(25)-C(24) 119.4(16) 
C(24)-C(25)  1.39(2) C(26)-C(25)-C(29) 124.4(16) 
C(25)-C(26)  1.38(2) C(24)-C(25)-C(29) 115.9(16) 
C(25)-C(29)  1.48(2) C(27)-C(26)-C(25) 119.5(16) 
C(26)-C(27)  1.36(2) C(26)-C(27)-C(28) 121.7(15) 
C(27)-C(28)  1.39(2) C(23)-C(28)-C(27) 119.4(15) 
O(1)-P-N                  110.7(6) 
O(1)-P-C(12) 113.6(7) 
C(23)-C(28)-C(13) 119.3(14) 
N-P-C(12) 106.2(7) 
C(27)-C(28)-C(13) 121.3(14) 
O(1)-P-C(6) 111.0(7) 
O(3)-C(29)-O(2) 121.2(19) 
N-P-C(6) 110.3(6) 
O(3)-C(29)-C(25) 128.0(19) 
C(12)-P-C(6) 104.8(7) 
O(2)-C(29)-C(25) 110.8(16) 
C(13)-N-P 123.9(10) 
______________________________________________ 
C(6)-C(1)-C(2) 118.5(18) 
C(29)-O(2)-C(30) 113.8(16) 
Symmetry transformations used to generate equivalent 
atoms: 
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Table 6-4. Anisotropic displacement parameters for 1-51. 
Units: (Å2x 103).  The anisotropic displacement factor exponent takes the form:  
 -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
P 26(2)  11(2) 7(2)  2(2) 3(1)  5(2) 
O(1) 44(7)  57(8) 25(6)  9(6) 19(5)  9(7) 
O(2) 65(10)  30(8) 115(13)  -29(8) 42(9)  -32(7) 
O(3) 110(15)  42(10) 175(19)  -32(12) 78(14)  -27(10) 
______________________________________________________________________________  
  
Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 1-51. 
________________________________________________________________________________ 
                                                       x                       y                        z               U(eq) 
________________________________________________________________________________ 
  
H(0A) 5066 2167 1933 16 
H(1B) 3813 3397 -1501 44 
H(2A) 2884 4286 -1315 95 
H(3A) 2259 4514 525 92 
H(4A) 2230 3895 2162 78 
H(5A) 3058 2999 1975 70 
H(7A) 1488 2386 -844 48 
H(8A) -44 1749 -949 55 
H(9A) 463 866 -195 68 
H(10A) 2469 657 790 72 
H(11A) 4140 1304 818 50 
H(13A) 6914 2244 471 45 
H(14A) 7249 2048 3130 31 
H(15) 9024 2285 2006 146 
H(16A) 9912 1402 3046 87 
H(16B) 10573 1937 2498 87 
H(17A) 7255 1229 325 73 
H(18A) 6515 328 68 88 
H(19A) 5708 -94 1681 90 
H(20A) 5628 386 3577 76 
H(21A) 6427 1287 3848 63 
H(23A) 5937 3200 2563 43 
H(24A) 6839 4076 3002 50 
H(26A) 9510 3747 791 45 
H(27A) 8647 2879 405 29 
H(30A) 10965 5304 1434 117 
H(30B) 10675 5228 2835 117 
H(30C) 9654 5520 1787 117 
________________________________________________________________________________ 
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Table 6-5. Crystal data and structure refinement for unit cell of 1-59. 
Identification code  1-59 (unit cell) 
Empirical formula  C28 H36 N O P Si (for single component of unit cell) 
Formula weight  461.64 
Temperature  295(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.9313(5) Å α= 90.8080(10)°. 
 b = 13.4272(7) Å β= 90.8930(10)°. 
 c = 19.5603(10) Å γ = 105.9390(10)°. 
Volume 2759.8(2) Å3 
Z 4 
Density (calculated) 1.111 Mg/m3 
Absorption coefficient 0.162 mm-1 
F(000) 992 
Crystal size 0.35 x 0.04 x 0.04 mm3 
Theta range for data collection 1.58 to 25.00°. 
Index ranges -12<=h<=12, -15<=k<=15, -23<=l<=23 
Reflections collected 22360 
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Independent reflections 9704 [R(int) = 0.0408] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction Sadabs 
Max. and min. transmission 0.9936 and 0.9455 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9704 / 0 / 565 
Goodness-of-fit on F2 1.275 
Final R indices [I>2sigma(I)] R1 = 0.0813, wR2 = 0.1862 
R indices (all data) R1 = 0.1219, wR2 = 0.1998 
Largest diff. peak and hole 0.521 and -0.405 e.Å-3 
  
Table 6-6. Atomic coordinates  (x 104) and equivalent isotropic displacement parameters (Å2x 103) for 1-
59. 
 
U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Si(1) 9192(1) 7401(1) 5595(1) 62(1) 
Si(2) 6738(1) 5634(1) 3248(1) 66(1) 
P(1) 8485(1) 7854(1) 8352(1) 54(1) 
P(2) 6458(1) 2094(1) 1686(1) 48(1) 
O(1) 7149(2) 7654(2) 8117(1) 71(1) 
O(2) 7823(2) 2347(2) 1865(1) 64(1) 
N(1) 9427(3) 7660(2) 7755(1) 53(1) 
N(2) 5751(2) 2890(2) 2042(1) 49(1) 
C(1) 11643(5) 9329(4) 6467(3) 108(2) 
C(2) 10950(4) 8416(3) 6574(2) 67(1) 
C(3) 9530(3) 7992(3) 6499(2) 52(1) 
C(4) 9011(3) 7204(3) 7075(2) 48(1) 
C(5) 9315(3) 6158(3) 7017(2) 53(1) 
C(6) 8432(4) 5334(3) 7439(2) 76(1) 
C(7) 8855(4) 8854(3) 6557(2) 76(1) 
C(8) 9401(5) 8439(4) 4956(2) 99(2) 
C(9) 10305(4) 6630(4) 5337(2) 85(1) 
C(10) 7515(4) 6597(4) 5542(2) 95(2) 
C(11) 8381(5) 3741(4) 6755(3) 100(2) 
C(12) 8612(8) 2757(6) 6716(5) 160(4) 
C(13) 9034(11) 2354(9) 7283(8) 205(9) 
C(14) 9235(10) 2855(8) 7851(8) 195(7) 
C(15) 9042(5) 3821(5) 7911(3) 115(2) 
C(16) 8634(4) 4276(3) 7374(3) 69(1) 
C(17) 10276(6) 9786(4) 8418(3) 106(2) 
C(18) 10793(8) 10777(5) 8681(4) 137(2) 
C(19) 10234(9) 11137(5) 9179(4) 126(2) 
C(20) 9131(8) 10564(6) 9435(3) 123(2) 
C(21) 8575(5) 9538(5) 9177(3) 108(2) 
C(22) 9181(4) 9167(3) 8666(2) 66(1) 
C(23) 7557(5) 6564(4) 9431(3) 96(2) 
C(24) 7683(6) 5995(5) 10009(3) 113(2) 
C(25) 8837(7) 5901(4) 10203(3) 105(2) 
C(26) 9876(6) 6383(4) 9862(2) 94(2) 
C(27) 9786(5) 6955(3) 9296(2) 76(1) 
C(28) 8628(4) 7062(3) 9071(2) 60(1) 
C(29) 4839(5) 5399(4) 1707(3) 101(2) 
C(30) 5065(4) 4795(3) 2188(2) 63(1) 
 - 218 -  
C(31) 6307(3) 4703(3) 2469(2) 50(1) 
C(32) 6217(3) 3573(3) 2637(2) 44(1) 
C(33) 5445(3) 3131(3) 3265(2) 50(1) 
C(34) 5748(5) 2173(4) 3528(2) 85(1) 
C(35) 7390(4) 5067(3) 1956(2) 77(1) 
C(36) 7284(5) 6982(3) 2946(3) 113(2) 
C(37) 5351(4) 5589(4) 3806(3) 100(2) 
C(38) 8055(4) 5322(4) 3742(3) 89(2) 
C(39) 5674(5) 2325(4) 4799(3) 90(2) 
C(40) 5218(8) 1985(6) 5431(3) 122(2) 
C(41) 4253(8) 1146(7) 5450(5) 132(3) 
C(42) 3699(6) 556(6) 4913(5) 126(3) 
C(43) 4204(5) 908(4) 4250(3) 100(2) 
C(44) 5187(4) 1789(4) 4200(2) 67(1) 
C(45) 4333(4) 464(4) 1951(3) 88(1) 
C(46) 3707(6) -499(4) 2146(3) 116(2) 
C(47) 4341(7) -1156(4) 2331(3) 109(2) 
C(48) 5615(8) -887(5) 2316(3) 126(2) 
C(49) 6277(5) 102(4) 2101(3) 103(2) 
C(50) 5631(4) 791(3) 1922(2) 54(1) 
C(51) 5919(5) 3035(3) 515(2) 179(4) 
C(52) 5761(6) 3101(4) -188(2) 215(5) 
C(53) 5831(6) 2285(5) -616(1) 157(3) 
C(54) 6060(6) 1402(4) -342(2) 216(5) 
C(55) 6218(5) 1335(3) 361(2) 189(4) 
C(56) 6147(3) 2152(3) 789(1) 62(1) 
________________________________________________________________________________  
  
Table 6-7. Bond lengths [Å] and angles [°] for 1-59. 
_____________________________________________________  
Si(1)-C(10)  1.854(4) C(3)-C(7)  1.539(5) 
Si(1)-C(8)  1.855(5) C(3)-C(4)  1.560(5) 
Si(1)-C(9)  1.871(4) C(4)-C(5)  1.532(5) 
Si(1)-C(3)  1.917(4) C(4)-H(4A)  0.9800 
Si(2)-C(36)  1.852(5) C(5)-C(6)  1.516(5) 
Si(2)-C(38)  1.866(4) C(5)-H(5A)  0.9700 
Si(2)-C(37)  1.870(5) C(5)-H(5B)  0.9700 
Si(2)-C(31)  1.925(4) C(6)-C(16)  1.500(6) 
P(1)-O(1)  1.475(2) C(6)-H(6A)  0.9700 
P(1)-N(1)  1.633(3) C(6)-H(6B)  0.9700 
P(1)-C(28)  1.805(4) C(7)-H(7A)  0.9600 
P(1)-C(22)  1.813(4) C(7)-H(7B)  0.9600 
P(2)-O(2)  1.473(2) C(7)-H(7C)  0.9600 
P(2)-N(2)  1.635(3) C(8)-H(8A)  0.9600 
P(2)-C(56)  1.788(3) C(8)-H(8B)  0.9600 
P(2)-C(50)  1.805(4) C(8)-H(8C)  0.9600 
N(1)-C(4)  1.468(4) C(9)-H(9A)  0.9600 
N(1)-H(1B)  0.8600 C(9)-H(9B)  0.9600 
N(2)-C(32)  1.467(4) C(9)-H(9C)  0.9600 
N(2)-H(2B)  0.8600 C(10)-H(10A)  0.9600 
C(1)-C(2)  1.274(5) C(10)-H(10B)  0.9600 
C(1)-H(1C)  0.9300 C(10)-H(10C)  0.9600 
C(1)-H(1D)  0.9300 C(11)-C(16)  1.384(7) 
C(2)-C(3)  1.503(5) C(11)-C(12)  1.414(8) 
C(2)-H(2C)  0.9300 C(11)-H(11A)  0.9300 
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C(12)-C(13)  1.368(15) C(38)-H(38C)  0.9600 
C(12)-H(12A)  0.9300 C(39)-C(40)  1.375(7) 
C(13)-C(14)  1.275(18) C(39)-C(44)  1.386(6) 
C(13)-H(13A)  0.9300 C(39)-H(39A)  0.9300 
C(14)-C(15)  1.374(11) C(40)-C(41)  1.316(9) 
C(14)-H(14A)  0.9300 C(40)-H(40A)  0.9300 
C(15)-C(16)  1.353(7) C(41)-C(42)  1.339(9) 
C(15)-H(15A)  0.9300 C(41)-H(41A)  0.9300 
C(17)-C(22)  1.357(6) C(42)-C(43)  1.453(9) 
C(17)-C(18)  1.383(7) C(42)-H(42A)  0.9300 
C(17)-H(17A)  0.9300 C(43)-C(44)  1.369(6) 
C(18)-C(19)  1.312(9) C(43)-H(43A)  0.9300 
C(18)-H(18A)  0.9300 C(45)-C(46)  1.350(6) 
C(19)-C(20)  1.348(9) C(45)-C(50)  1.367(5) 
C(19)-H(19A)  0.9300 C(45)-H(45A)  0.9300 
C(20)-C(21)  1.425(8) C(46)-C(47)  1.314(7) 
C(20)-H(20A)  0.9300 C(46)-H(46A)  0.9300 
C(21)-C(22)  1.368(6) C(47)-C(48)  1.341(8) 
C(21)-H(21A)  0.9300 C(47)-H(47A)  0.9300 
C(23)-C(24)  1.399(7) C(48)-C(49)  1.400(7) 
C(23)-C(28)  1.387(6) C(48)-H(48A)  0.9300 
C(23)-H(23A)  0.9300 C(49)-C(50)  1.355(5) 
C(24)-C(25)  1.351(7) C(49)-H(49A)  0.9300 
C(24)-H(24A)  0.9300 C(51)-C(52)  1.3900 
C(25)-C(26)  1.335(7) C(51)-C(56)  1.3900 
C(25)-H(25A)  0.9300 C(51)-H(51A)  0.9300 
C(26)-C(27)  1.374(6) C(52)-C(53)  1.3900 
C(26)-H(26A)  0.9300 C(52)-H(52A)  0.9300 
C(27)-C(28)  1.379(5) C(53)-C(54)  1.3900 
C(27)-H(27A)  0.9300 C(53)-H(53A)  0.9300 
C(29)-C(30)  1.315(5) C(54)-C(55)  1.3900 
C(29)-H(29A)  0.9300 C(54)-H(54A)  0.9300 
C(29)-H(29B)  0.9300 C(55)-C(56)  1.3900 
C(30)-C(31)  1.494(5) C(55)-H(55A)  0.9300 
C(30)-H(30A)  0.9300 C(10)-Si(1)-C(8) 108.3(2) 
C(31)-C(32)  1.533(5) C(10)-Si(1)-C(9) 111.0(2) 
C(31)-C(35)  1.544(5) C(8)-Si(1)-C(9) 105.3(2) 
C(32)-C(33)  1.533(5) C(10)-Si(1)-C(3) 108.50(18) 
C(32)-H(32A)  0.9800 C(8)-Si(1)-C(3) 110.3(2) 
C(33)-C(34)  1.508(5) C(9)-Si(1)-C(3) 113.34(17) 
C(33)-H(33A)  0.9700 C(36)-Si(2)-C(38) 109.3(2) 
C(33)-H(33B)  0.9700 C(36)-Si(2)-C(37) 105.9(3) 
C(34)-C(44)  1.496(6) C(38)-Si(2)-C(37) 111.0(2) 
C(34)-H(34A)  0.9700 C(36)-Si(2)-C(31) 109.1(2) 
C(34)-H(34B)  0.9700 C(38)-Si(2)-C(31) 108.41(18) 
C(35)-H(35A)  0.9600 C(37)-Si(2)-C(31) 113.07(19) 
C(35)-H(35B)  0.9600 O(1)-P(1)-N(1) 113.32(15) 
C(35)-H(35C)  0.9600 O(1)-P(1)-C(28) 111.43(18) 
C(36)-H(36A)  0.9600 N(1)-P(1)-C(28) 108.24(16) 
C(36)-H(36B)  0.9600 O(1)-P(1)-C(22) 113.57(17) 
C(36)-H(36C)  0.9600 N(1)-P(1)-C(22) 105.71(19) 
C(37)-H(37A)  0.9600 C(28)-P(1)-C(22) 103.94(18) 
C(37)-H(37B)  0.9600 O(2)-P(2)-N(2) 112.78(14) 
C(37)-H(37C)  0.9600 O(2)-P(2)-C(56) 113.35(16) 
C(38)-H(38A)  0.9600 N(2)-P(2)-C(56) 104.89(15) 
C(38)-H(38B)  0.9600 O(2)-P(2)-C(50) 111.65(16) 
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N(2)-P(2)-C(50) 108.39(16) Si(1)-C(10)-H(10A) 109.5 
C(56)-P(2)-C(50) 105.26(17) Si(1)-C(10)-H(10B) 109.5 
C(4)-N(1)-P(1) 125.2(2) H(10A)-C(10)-H(10B) 109.5 
C(4)-N(1)-H(1B) 117.4 Si(1)-C(10)-H(10C) 109.5 
P(1)-N(1)-H(1B) 117.4 H(10A)-C(10)-H(10C) 109.5 
C(32)-N(2)-P(2) 126.4(2) H(10B)-C(10)-H(10C) 109.5 
C(32)-N(2)-H(2B) 116.8 C(16)-C(11)-C(12) 117.5(7) 
P(2)-N(2)-H(2B) 116.8 C(16)-C(11)-H(11A) 121.3 
C(2)-C(1)-H(1C) 120.0 C(12)-C(11)-H(11A) 121.3 
C(2)-C(1)-H(1D) 120.0 C(13)-C(12)-C(11) 120.0(9) 
H(1C)-C(1)-H(1D) 120.0 C(13)-C(12)-H(12A) 120.0 
C(1)-C(2)-C(3) 129.0(4) C(11)-C(12)-H(12A) 120.0 
C(1)-C(2)-H(2C) 115.5 C(14)-C(13)-C(12) 121.2(14) 
C(3)-C(2)-H(2C) 115.5 C(14)-C(13)-H(13A) 119.4 
C(2)-C(3)-C(7) 111.6(3) C(12)-C(13)-H(13A) 119.4 
C(2)-C(3)-C(4) 110.2(3) C(13)-C(14)-C(15) 120.9(14) 
C(7)-C(3)-C(4) 107.3(3) C(13)-C(14)-H(14A) 119.5 
C(2)-C(3)-Si(1) 106.7(2) C(15)-C(14)-H(14A) 119.5 
C(7)-C(3)-Si(1) 107.4(2) C(16)-C(15)-C(14) 121.5(8) 
C(4)-C(3)-Si(1) 113.6(2) C(16)-C(15)-H(15A) 119.2 
N(1)-C(4)-C(5) 108.7(3) C(14)-C(15)-H(15A) 119.2 
N(1)-C(4)-C(3) 111.4(3) C(15)-C(16)-C(11) 118.8(5) 
C(5)-C(4)-C(3) 116.3(3) C(15)-C(16)-C(6) 121.5(5) 
N(1)-C(4)-H(4A) 106.6 C(11)-C(16)-C(6) 119.7(4) 
C(5)-C(4)-H(4A) 106.6 C(22)-C(17)-C(18) 120.9(6) 
C(3)-C(4)-H(4A) 106.6 C(22)-C(17)-H(17A) 119.5 
C(6)-C(5)-C(4) 112.2(3) C(18)-C(17)-H(17A) 119.5 
C(6)-C(5)-H(5A) 109.2 C(19)-C(18)-C(17) 120.5(7) 
C(4)-C(5)-H(5A) 109.2 C(19)-C(18)-H(18A) 119.8 
C(6)-C(5)-H(5B) 109.2 C(17)-C(18)-H(18A) 119.8 
C(4)-C(5)-H(5B) 109.2 C(18)-C(19)-C(20) 121.1(7) 
H(5A)-C(5)-H(5B) 107.9 C(18)-C(19)-H(19A) 119.4 
C(16)-C(6)-C(5) 114.8(3) C(20)-C(19)-H(19A) 119.4 
C(16)-C(6)-H(6A) 108.6 C(19)-C(20)-C(21) 119.8(6) 
C(5)-C(6)-H(6A) 108.6 C(19)-C(20)-H(20A) 120.1 
C(16)-C(6)-H(6B) 108.6 C(21)-C(20)-H(20A) 120.1 
C(5)-C(6)-H(6B) 108.6 C(22)-C(21)-C(20) 118.4(6) 
H(6A)-C(6)-H(6B) 107.5 C(22)-C(21)-H(21A) 120.8 
C(3)-C(7)-H(7A) 109.5 C(20)-C(21)-H(21A) 120.8 
C(3)-C(7)-H(7B) 109.5 C(17)-C(22)-C(21) 119.3(5) 
H(7A)-C(7)-H(7B) 109.5 C(17)-C(22)-P(1) 122.5(4) 
C(3)-C(7)-H(7C) 109.5 C(21)-C(22)-P(1) 118.2(4) 
H(7A)-C(7)-H(7C) 109.5 C(24)-C(23)-C(28) 119.8(5) 
H(7B)-C(7)-H(7C) 109.5 C(24)-C(23)-H(23A) 120.1 
Si(1)-C(8)-H(8A) 109.5 C(28)-C(23)-H(23A) 120.1 
Si(1)-C(8)-H(8B) 109.5 C(25)-C(24)-C(23) 120.2(5) 
H(8A)-C(8)-H(8B) 109.5 C(25)-C(24)-H(24A) 119.9 
Si(1)-C(8)-H(8C) 109.5 C(23)-C(24)-H(24A) 119.9 
H(8A)-C(8)-H(8C) 109.5 C(26)-C(25)-C(24) 120.4(5) 
H(8B)-C(8)-H(8C) 109.5 C(26)-C(25)-H(25A) 119.8 
Si(1)-C(9)-H(9A) 109.5 C(24)-C(25)-H(25A) 119.8 
Si(1)-C(9)-H(9B) 109.5 C(25)-C(26)-C(27) 120.8(5) 
H(9A)-C(9)-H(9B) 109.5 C(25)-C(26)-H(26A) 119.6 
Si(1)-C(9)-H(9C) 109.5 C(27)-C(26)-H(26A) 119.6 
H(9A)-C(9)-H(9C) 109.5 C(26)-C(27)-C(28) 121.1(5) 
H(9B)-C(9)-H(9C) 109.5 C(26)-C(27)-H(27A) 119.5 
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C(28)-C(27)-H(27A) 119.5 H(38A)-C(38)-H(38C) 109.5 
C(27)-C(28)-C(23) 117.7(4) H(38B)-C(38)-H(38C) 109.5 
C(27)-C(28)-P(1) 122.3(3) C(40)-C(39)-C(44) 122.1(6) 
C(23)-C(28)-P(1) 120.0(4) C(40)-C(39)-H(39A) 118.9 
C(30)-C(29)-H(29A) 120.0 C(44)-C(39)-H(39A) 118.9 
C(30)-C(29)-H(29B) 120.0 C(41)-C(40)-C(39) 117.7(7) 
H(29A)-C(29)-H(29B) 120.0 C(41)-C(40)-H(40A) 121.1 
C(29)-C(30)-C(31) 129.6(4) C(39)-C(40)-H(40A) 121.1 
C(29)-C(30)-H(30A) 115.2 C(40)-C(41)-C(42) 126.2(8) 
C(31)-C(30)-H(30A) 115.2 C(40)-C(41)-H(41A) 116.9 
C(30)-C(31)-C(32) 110.5(3) C(42)-C(41)-H(41A) 116.9 
C(30)-C(31)-C(35) 111.8(3) C(41)-C(42)-C(43) 115.7(7) 
C(32)-C(31)-C(35) 107.6(3) C(41)-C(42)-H(42A) 122.2 
C(30)-C(31)-Si(2) 106.7(2) C(43)-C(42)-H(42A) 122.2 
C(32)-C(31)-Si(2) 113.7(2) C(44)-C(43)-C(42) 120.4(6) 
C(35)-C(31)-Si(2) 106.5(3) C(44)-C(43)-H(43A) 119.8 
N(2)-C(32)-C(33) 109.5(3) C(42)-C(43)-H(43A) 119.8 
N(2)-C(32)-C(31) 110.9(3) C(43)-C(44)-C(39) 117.8(5) 
C(33)-C(32)-C(31) 116.7(3) C(43)-C(44)-C(34) 122.2(5) 
N(2)-C(32)-H(32A) 106.4 C(39)-C(44)-C(34) 120.0(5) 
C(33)-C(32)-H(32A) 106.4 C(46)-C(45)-C(50) 122.3(5) 
C(31)-C(32)-H(32A) 106.4 C(46)-C(45)-H(45A) 118.8 
C(34)-C(33)-C(32) 112.9(3) C(50)-C(45)-H(45A) 118.8 
C(34)-C(33)-H(33A) 109.0 C(47)-C(46)-C(45) 120.3(6) 
C(32)-C(33)-H(33A) 109.0 C(47)-C(46)-H(46A) 119.8 
C(34)-C(33)-H(33B) 109.0 C(45)-C(46)-H(46A) 119.8 
C(32)-C(33)-H(33B) 109.0 C(46)-C(47)-C(48) 120.5(6) 
H(33A)-C(33)-H(33B) 107.8 C(46)-C(47)-H(47A) 119.7 
C(44)-C(34)-C(33) 116.1(3) C(48)-C(47)-H(47A) 119.7 
C(44)-C(34)-H(34A) 108.3 C(47)-C(48)-C(49) 119.8(5) 
C(33)-C(34)-H(34A) 108.3 C(47)-C(48)-H(48A) 120.1 
C(44)-C(34)-H(34B) 108.3 C(49)-C(48)-H(48A) 120.1 
C(33)-C(34)-H(34B) 108.3 C(50)-C(49)-C(48) 120.0(5) 
H(34A)-C(34)-H(34B) 107.4 C(50)-C(49)-H(49A) 120.0 
C(31)-C(35)-H(35A) 109.5 C(48)-C(49)-H(49A) 120.0 
C(31)-C(35)-H(35B) 109.5 C(49)-C(50)-C(45) 117.0(4) 
H(35A)-C(35)-H(35B) 109.5 C(49)-C(50)-P(2) 121.2(4) 
C(31)-C(35)-H(35C) 109.5 C(45)-C(50)-P(2) 121.8(3) 
H(35A)-C(35)-H(35C) 109.5 C(52)-C(51)-C(56) 120.0 
H(35B)-C(35)-H(35C) 109.5 C(52)-C(51)-H(51A) 120.0 
Si(2)-C(36)-H(36A) 109.5 C(56)-C(51)-H(51A) 120.0 
Si(2)-C(36)-H(36B) 109.5 C(53)-C(52)-C(51) 120.0 
H(36A)-C(36)-H(36B) 109.5 C(53)-C(52)-H(52A) 120.0 
Si(2)-C(36)-H(36C) 109.5 C(51)-C(52)-H(52A) 120.0 
H(36A)-C(36)-H(36C) 109.5 C(54)-C(53)-C(52) 120.0 
H(36B)-C(36)-H(36C) 109.5 C(54)-C(53)-H(53A) 120.0 
Si(2)-C(37)-H(37A) 109.5 C(52)-C(53)-H(53A) 120.0 
Si(2)-C(37)-H(37B) 109.5 C(53)-C(54)-C(55) 120.0 
H(37A)-C(37)-H(37B) 109.5 C(53)-C(54)-H(54A) 120.0 
Si(2)-C(37)-H(37C) 109.5 C(55)-C(54)-H(54A) 120.0 
H(37A)-C(37)-H(37C) 109.5 C(56)-C(55)-C(54) 120.0 
H(37B)-C(37)-H(37C) 109.5 C(56)-C(55)-H(55A) 120.0 
Si(2)-C(38)-H(38A) 109.5 C(54)-C(55)-H(55A) 120.0 
Si(2)-C(38)-H(38B) 109.5 C(55)-C(56)-C(51) 120.0 
H(38A)-C(38)-H(38B) 109.5 C(55)-C(56)-P(2) 119.6(2) 
Si(2)-C(38)-H(38C) 109.5 C(51)-C(56)-P(2) 120.3(2
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Table 6-8.   Anisotropic displacement parameters  (Å2x 103) for 1-59. 
The anisotropic displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Si(1) 57(1)  89(1) 47(1)  7(1) 2(1)  29(1) 
Si(2) 53(1)  58(1) 87(1)  -11(1) -6(1)  19(1) 
P(1) 47(1)  68(1) 50(1)  -7(1) -1(1)  22(1) 
P(2) 41(1)  55(1) 50(1)  0(1) 2(1)  16(1) 
O(1) 47(2)  103(2) 66(2)  -14(2) -1(1)  29(2) 
O(2) 44(1)  77(2) 75(2)  -7(1) 0(1)  23(1) 
N(1) 38(2)  73(2) 48(2)  -4(2) -2(1)  15(2) 
N(2) 39(2)  58(2) 53(2)  0(1) -5(1)  18(1) 
C(1) 82(3)  106(4) 118(4)  52(3) -7(3)  -8(3) 
C(2) 62(3)  72(3) 62(3)  27(2) -1(2)  9(2) 
C(3) 52(2)  62(2) 48(2)  11(2) 2(2)  25(2) 
C(4) 36(2)  61(2) 50(2)  -2(2) -1(2)  20(2) 
C(5) 48(2)  61(2) 53(2)  7(2) 9(2)  18(2) 
C(6) 78(3)  73(3) 75(3)  11(2) 29(2)  15(2) 
C(7) 89(3)  80(3) 72(3)  7(2) -7(2)  44(3) 
C(8) 126(4)  124(4) 60(3)  21(3) 4(3)  55(4) 
C(9) 77(3)  127(4) 65(3)  3(3) 10(2)  52(3) 
C(10) 69(3)  149(5) 64(3)  -18(3) -8(2)  25(3) 
C(11) 113(4)  72(4) 113(5)  9(3) 43(3)  17(3) 
C(12) 153(7)  75(5) 231(10)  -30(5) 115(7)  -12(4) 
C(13) 111(8)  101(8) 410(30)  116(11) 109(12)  32(6) 
C(14) 93(5)  141(11) 350(20)  146(10) -6(9)  24(7) 
C(15) 83(4)  96(4) 153(6)  60(4) -13(3)  0(3) 
C(16) 50(2)  64(3) 91(3)  23(3) 19(2)  9(2) 
C(17) 126(5)  63(3) 114(4)  -17(3) 14(4)  -1(3) 
C(18) 188(7)  77(4) 125(6)  -11(4) 5(5)  4(4) 
C(19) 195(8)  75(4) 116(6)  -6(4) -22(5)  55(5) 
C(20) 169(7)  126(6) 99(5)  -41(4) -21(5)  89(5) 
C(21) 114(4)  119(5) 106(4)  -47(4) -21(3)  63(4) 
C(22) 83(3)  73(3) 55(3)  -7(2) -20(2)  45(3) 
C(23) 84(3)  114(4) 76(3)  15(3) 9(3)  4(3) 
C(24) 125(5)  120(5) 76(4)  28(3) 27(4)  -2(4) 
C(25) 157(6)  91(4) 75(4)  21(3) 14(4)  48(4) 
C(26) 135(5)  98(4) 70(3)  20(3) 14(3)  65(4) 
C(27) 90(3)  84(3) 67(3)  13(2) 16(2)  47(3) 
C(28) 70(3)  63(3) 44(2)  -7(2) 13(2)  17(2) 
C(29) 89(4)  105(4) 112(4)  42(3) -9(3)  30(3) 
C(30) 55(2)  59(3) 73(3)  15(2) 1(2)  15(2) 
C(31) 41(2)  49(2) 59(2)  13(2) 8(2)  10(2) 
C(32) 33(2)  55(2) 45(2)  0(2) 1(2)  13(2) 
C(33) 49(2)  53(2) 52(2)  4(2) 5(2)  20(2) 
C(34) 121(4)  90(3) 65(3)  21(2) 33(3)  60(3) 
C(35) 74(3)  68(3) 82(3)  17(2) 21(2)  7(2) 
C(36) 108(4)  56(3) 173(6)  -10(3) -14(4)  19(3) 
C(37) 83(3)  110(4) 117(4)  -42(3) 6(3)  47(3) 
C(38) 71(3)  96(4) 104(4)  -31(3) -25(3)  30(3) 
C(39) 116(4)  102(4) 69(3)  16(3) 20(3)  55(3) 
C(40) 186(7)  149(6) 62(4)  19(4) 18(4)  97(6) 
C(41) 134(7)  121(7) 159(8)  59(5) 69(6)  60(5) 
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C(42) 88(4)  89(5) 210(9)  65(5) 35(5)  33(4) 
C(43) 84(4)  92(4) 135(5)  38(4) -6(3)  41(3) 
C(44) 77(3)  73(3) 66(3)  21(2) 17(2)  47(3) 
C(45) 75(3)  60(3) 124(4)  14(3) 19(3)  8(2) 
C(46) 103(4)  64(4) 168(6)  12(4) 38(4)  -2(3) 
C(47) 155(6)  66(4) 90(4)  9(3) -6(4)  6(4) 
C(48) 157(6)  79(4) 148(6)  19(4) -58(5)  45(4) 
C(49) 87(3)  71(3) 155(5)  8(3) -31(3)  30(3) 
C(50) 60(2)  55(2) 51(2)  -3(2) -6(2)  21(2) 
C(51) 346(12)  137(6) 67(4)  -3(4) -49(5)  94(7) 
C(52) 428(15)  175(8) 62(4)  11(5) -42(6)  121(9) 
C(53) 285(9)  152(7) 45(3)  -4(4) 1(4)  79(6) 
C(54) 403(15)  183(9) 65(5)  -20(5) -11(6)  89(9) 
C(55) 361(12)  160(7) 63(4)  -15(4) -10(5)  101(7) 
C(56) 69(3)  66(3) 52(2)  -1(2) 4(2)  19(2) 
______________________________________________________________________________  
  
Table 6-9.   Hydrogen coordinates (x 104) and isotropic  displacement parameters (Å2x 103) for 1-59. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1B) 10231 7840 7847 64 
H(2B) 5036 2911 1862 59 
H(1C) 11272 9838 6322 129 
H(1D) 12520 9487 6534 129 
H(2C) 11382 7946 6718 80 
H(4A) 8082 7056 7056 57 
H(5A) 9241 5932 6542 64 
H(5B) 10186 6242 7169 64 
H(6A) 8542 5553 7916 91 
H(6B) 7561 5289 7304 91 
H(7A) 9006 9167 7006 114 
H(7B) 7957 8564 6481 114 
H(7C) 9180 9370 6222 114 
H(8A) 9229 8133 4505 148 
H(8B) 10260 8874 4983 148 
H(8C) 8824 8847 5048 148 
H(9A) 10090 6356 4882 128 
H(9B) 10235 6070 5647 128 
H(9C) 11163 7069 5350 128 
H(10A) 7331 6295 5092 143 
H(10B) 6959 7022 5637 143 
H(10C) 7388 6056 5872 143 
H(11A) 8071 4019 6379 120 
H(12A) 8477 2382 6305 193 
H(13A) 9178 1704 7253 245 
H(14A) 9515 2562 8230 234 
H(15A) 9197 4171 8331 138 
H(17A) 10684 9540 8067 128 
H(18A) 11543 11191 8504 164 
H(19A) 10606 11798 9358 151 
H(20A) 8733 10837 9778 147 
H(21A) 7819 9131 9352 129 
H(23A) 6758 6607 9289 115 
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H(24A) 6970 5680 10260 136 
H(25A) 8909 5498 10576 126 
H(26A) 10668 6331 10010 113 
H(27A) 10519 7276 9062 91 
H(29A) 5512 5854 1490 121 
H(29B) 4005 5372 1584 121 
H(30A) 4346 4361 2382 75 
H(32A) 7090 3543 2731 53 
H(33A) 5616 3656 3626 60 
H(33B) 4546 2964 3146 60 
H(34A) 5455 1622 3189 102 
H(34B) 6665 2315 3570 102 
H(35A) 7216 4622 1557 115 
H(35B) 8181 5042 2164 115 
H(35C) 7446 5765 1826 115 
H(36A) 7497 7450 3333 170 
H(36B) 6617 7138 2680 170 
H(36C) 8020 7057 2669 170 
H(37A) 5619 6067 4184 150 
H(37B) 5023 4901 3975 150 
H(37C) 4698 5775 3545 150 
H(38A) 8281 5779 4133 134 
H(38B) 8782 5407 3456 134 
H(38C) 7781 4618 3890 134 
H(39A) 6329 2934 4774 108 
H(40A) 5580 2335 5830 146 
H(41A) 3926 945 5878 158 
H(42A) 3032 -41 4962 151 
H(43A) 3859 532 3856 120 
H(45A) 3866 920 1831 106 
H(46A) 2823 -698 2149 140 
H(47A) 3902 -1813 2474 130 
H(48A) 6059 -1356 2447 151 
H(49A) 7160 287 2082 123 
H(51A) 5872 3581 802 214 
H(52A) 5608 3692 -371 258 
H(53A) 5726 2330 -1086 189 
H(54A) 6107 856 -629 259 
H(55A) 6370 745 544 227 
________________________________________________________________________________  
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APPENDIX C 
SELECTED 1H AND 13C NMR DATA FOR COMPOUNDS 5-40, 5-53, 5-63, 5-64,      
5-66,  AND 5-69. 
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227
228
9
8
7
6
5
4
3
2
1
ppm 2.240
2.246
2.261
2.271
2.273
2.282
2.294
2.368
2.383
2.391
2.406
2.499
2.521
2.549
2.618
3.072
3.114
3.370
3.591
3.759
4.073
4.080
4.091
4.526
4.539
5.003
5.023
5.142
5.152
5.171
5.177
5.193
5.210
5.226
5.317
5.319
5.321
5.909
5.922
5.924
5.926
5.928
5.939
5.950
5.953
5.955
5.968
7.296
7.308
7.316
7.328
7.345
7.359
7.375
2.94
1.10
1.09
1.03
0.49
0.44
0.64
0.45
1.67
1.40
1.00
1.00
0.57
3.43
0.97
4.71
jp6_024 1H NMR 600 MHz CD2Cl2 rt 10
−1
−07
229
210
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
ppm
40.47
40.55
40.64
41.72
42.26
43.36
45.97
52.61
52.82
53.14
53.32
53.50
53.68
53.86
59.18
59.39
64.67
65.27
67.24
67.50
79.42
80.55
117.51
117.72
127.97
128.01
128.15
128.19
128.45
128.55
135.17
135.27
136.36
154.27
154.85
174.50
174.79
208.14
208.23
jp6_024 13C NMR 150 MHz CD2Cl2 rt 10
−1
−07
230
9
8
7
6
5
4
3
2
1
ppm 1.232
1.243
1.255
2.114
2.133
2.138
2.141
2.158
2.161
2.277
2.289
2.292
2.300
2.306
2.310
2.318
2.324
2.330
2.341
2.384
2.386
2.394
2.403
2.477
2.488
2.493
2.501
2.511
2.519
2.614
2.630
2.638
2.654
3.535
3.692
4.529
4.544
4.591
4.606
4.946
4.966
5.097
5.102
5.124
5.144
7.203
7.221
7.232
7.234
7.247
7.250
7.261
7.273
7.283
7.294
2.93
0.99
1.95
1.08
2.00
1.03
1.05
3.03
1.00
0.99
2.09
5.51
jp8_002 1H NMR 600 MHz CDCl3 5
−6
−08
231
200
180
160
140
120
100
80
60
40
20
p
p
m 14.96
15.23
38.69
40.12
40.20
40.46
40.77
40.92
42.43
43.60
44.26
44.36
52.55
52.69
58.22
58.24
61.30
61.71
67.37
67.72
76.79
77.00
77.21
87.51
88.38
128.09
128.15
128.17
128.31
128.40
128.56
135.68
135.81
153.67
153.80
170.32
170.92
175.61
175.76
205.05
205.08
jp8_002 13C NMR 150 MHz CDCl3 5
−6
−08
232
9.5
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
ppm 1.863
1.881
1.883
1.891
1.894
2.028
2.195
2.237
2.261
2.535
2.537
2.540
2.543
3.009
3.042
3.049
3.375
3.602
3.678
3.775
3.831
3.852
3.863
3.875
3.904
3.943
3.954
3.959
3.962
3.972
3.982
3.992
4.002
4.480
4.497
4.549
4.566
5.024
5.045
5.079
5.100
5.122
5.143
5.205
5.226
7.322
7.334
7.347
7.359
7.373
7.393
7.405
7.415
7.419
7.431
2.56
0.93
1.79
1.35
0.52
0.93
1.77
1.25
1.12
4.34
1.00
1.93
4.36
jp8_016 1H NMR 600 MHz rt DMSO 6
−3
−08
233
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
ppm 13.81
13.83
30.80
30.81
37.09
37.20
37.77
38.25
39.18
39.20
40.03
40.17
40.31
40.45
40.59
40.73
40.87
40.99
43.75
43.77
52.88
52.90
57.61
57.72
62.04
62.36
64.03
64.20
65.16
65.33
67.23
67.29
87.72
88.77
107.74
107.76
128.33
128.71
128.76
128.98
129.28
129.42
137.47
154.05
154.24
171.48
172.06
177.79
177.82
jp8_016 13C NMR 150 MHz rt DMSO 6
−4
−08
234
9
8
7
6
5
4
3
2
1
ppm 0.885
0.889
0.896
0.901
1.047
1.050
1.632
2.064
2.092
2.104
2.113
2.132
2.136
2.141
2.279
3.389
3.584
3.760
3.818
4.006
5.027
5.138
5.201
5.210
7.270
7.301
7.313
7.315
7.329
7.340
7.342
7.353
7.362
7.364
7.373
7.376
7.382
7.383
7.393
7.395
7.405
7.407
7.434
7.435
7.442
7.446
7.450
7.597
7.599
7.608
7.610
7.618
7.620
7.631
7.633
3.11
9.10
4.16
3.13
0.52
0.47
1.00
1.05
1.41
0.49
1.54
0.51
0.55
0.52
1.00
0.50
0.54
1.01
11.02
3.98
jp8_031 1H NMR 600 MHz CDCl3 rt 7
−1
−08
235
210
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
ppm
13.75
13.85
19.14
26.89
35.31
35.42
37.33
37.47
40.96
41.14
41.26
42.08
42.10
43.08
52.65
53.00
59.18
59.49
65.41
66.07
67.04
67.06
67.40
67.73
76.79
77.00
77.21
81.30
82.42
127.77
127.79
128.08
128.11
128.20
128.30
128.45
128.61
129.82
129.88
133.03
133.08
133.14
133.17
135.48
135.86
135.94
154.05
154.93
175.10
175.44
209.73
209.97
jp8_031 13C NMR 150 MHz CDCl3 rt 7
−1
−08
236
9
8
7
6
5
4
3
2
1
ppm 0.864
0.876
0.879
0.891
0.902
0.919
0.931
0.943
1.256
1.261
1.268
1.273
1.280
1.285
1.296
1.361
1.373
2.356
2.365
2.368
2.371
2.412
2.430
2.438
2.442
2.462
2.485
2.493
2.509
2.704
3.536
3.792
4.123
4.135
4.345
4.363
4.585
4.599
5.007
5.069
5.088
5.117
5.146
5.166
5.209
7.270
7.324
7.330
7.336
7.345
7.354
7.365
7.368
7.379
6.49
1.33
0.74
6.43
0.81
1.09
0.92
1.90
1.09
0.68
0.60
0.97
0.32
0.38
3.57
0.34
0.56
5.48
jp8_060 1H NMR 600 MHz CDCl3 rt 9
−17
−08
237
200
180
160
140
120
100
80
60
40
20
0
ppm
13.60
13.83
14.12
14.18
14.19
17.28
17.51
21.06
22.64
26.77
28.26
30.21
30.30
31.38
31.58
38.29
39.71
39.77
39.91
40.11
40.27
44.72
44.88
52.52
52.67
54.57
55.10
57.66
58.20
60.39
66.39
66.65
67.77
68.17
76.79
77.00
77.21
87.06
87.86
116.96
116.99
128.21
128.36
128.53
128.58
128.61
129.00
135.09
135.53
135.71
154.28
155.16
155.52
159.21
163.45
170.01
170.94
171.16
171.59
171.98
173.04
174.11
174.77
175.29
175.33
176.19
176.67
205.61
205.73
jp8_060 13C NMR 150 MHz CDCl3 rt 9
−17
−08
238
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